RÉFÉRENCES (4845 REFERENCES) Philippe Furger, Md, Cc, Cme Éditions D&F Gmbh/Sàrl Depuis 1998

Last update: 3.6.2021 RÉFÉRENCES (4845 REFERENCES) Philippe Furger, md, cc, cme Éditions D&F GmbH/sàrl depuis 1998

Auteur: [email protected] Editeur: Editions D&F GmbH, Switzerland E-mail: [email protected] WEB: www.investimed.ch

SUISSE - SCHWEIZ Deutsch: • SURF-med 2009, 2010, 2013, 2016, 2018 (reprint 2019), 2021 • TURBO-Notfallmedizin 2006, 2012, 2015 • INVESTI-MED© 2007, 2010 • Algo-SURF© 2011 • RED FLAGS© 2013 (bilingue), 2018, 2020 • Labor-SURF© 2013, 2014, 2020 • TURBO-Notfallmedizin & Kardiologie 2019 Français: • SURF 2006, 2009, 2012, 2016 (2x reprint), 2019 • TURBO - Médecine d’urgence 2006, 2012, 2019 • INVESTI-MED© 2007, 2010, 2020 • Labo-SURF© 2009, 2013 • RED FLAGS© 2013 (bilingue), 2018, 2020 • Intoxi-SURF© 2013

Version électronique disponible:

SURFméd© + Labo-SURF© + INVESTI-MÉD© + Intoxi-SURF©

4 en 1

App Store & Plateforme web ▼ ▼ → SURFmed ▼ www.SURFmed.co

1 Scheme used for classification of the evidence son of vasopressin and epinephrine of out-of- M Meta-analysis; use of statisitical methods to hospital cardiopulmonary resuscitation. N Engl combine results from clinical trials J Med 2004; 350: 105-13. Ra Randomized controlled trials; also known as AHA in Collaboration with International Liaison experimental studies Comittee on Resuscitation. Guidelines 2005 for Re Retrospective analyses; also known as case- Cardiopulmonar Resuscitation and Emergency control studies Cardiovascular Care. Circulation 2005; 112: IV- F Prospective study; also known as cohort 1-IV211. sttuides, including historical or prospective Coudray A, Romand J-C, Treggiari M, et al. Fluid follow-up studies reponsiveness in spoontaneously breathing pa- X Cross-sectional survey; also known as pre- tients: a review of indexes used in intensive valence studies cary. Crit Care Med 2005; 33: 2757-62. Pr Previeous review or position statements European Resuscitation Council. ERC Guidelines C Clinical interventions (nonrandomized) for Resuscitation 2005. Resuscitation 2005; 67: 157-341. Holzer M, Bernard SA, Hachimi-Idrissi S, et al. SOINS INTENSIFS Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient Réanimation data meta-analysis. Crit Care Med 2005; 33: Kloeck W, Cummins R, Chamberlain DA, et al. 1449-52. The universal ALS Algorithm: an advisory state- Skowronski GA. Therapeutic Hypothermia After ment by the advanced life support working Cardiac Arrest - Not so Fast. Crit Care Resusc group of the international liaison committee on 2005; 7: 322-4. resuscitation. Resuscitation 1997; 34: 109-11. Aberle J, Kluge S, Prohl J, et al. Hypothermie Walpoth BH, et al. Outcome of survivors of acci- nach Reanimation durch Konduktion und Kon- dental deep hypothermia and circulatory arrest vektion. Intensivmedizin 2006; 43: 37-43. treated with extracorporeal blood warming. N Monnet X, Rienzo N, Osman D et al. Passive leg Engl J Med 1997; 337: 1500-5. raising predicts fluid responsiveness in the criti- Advanced life support working group of the euro- calli ill. Crit Care Med 2006; 341:1402-7. pean resuscitation council. The 1998 european Morrison LJ, Visentin LM, Kiss A, et al. Validation resuscitation council guidelines for advanced of a Rule for Termination of Resuscitation in life support. Resuscitation 1998; 37: 81-90. Out-of-Hospital Cardiac Arrest. N Engl J Med Beveridge R, Ducharme J, Janes L et al. Reliabi- 2006; 355: 478-87. lity of the canadian emergency department Nielsen N, Wetterslev J, Cronberg T et al. Targe- triage and acuity scale: interrater agreement. ted Temperature Management at 33°C versus Ann Emerg Med 1999; 34: 1555-9. 36°C after Cardiac Arrest. N Engl J Med 2013; American Heart Association in collaboration with 369: 2197-206. the International Liaison Committee on Resus- Lima A, Bakker J. Clinical assessment of periphe- citation (ILCOR). International guidelines 2000 ral circulation. Curr Opin Crit Care 2015; 21(3): for cardiolpulmonary resuscitation and emer- 226-31. gency cardiovascular care - A consensus on Soar J, Nolan JP, Böttiger BW et al. European science. Resuscitation 2000; 46: 103-252. Resuscitation Council Guidelines for Resuscita- Cummins RO, Hazinski MF, Baskett PJF, et al. In- tion 2015: Section 3. Adult advanced life sup- troduction to the international guidelines 2000 port. Resuscitation 2015; 95: 100-47. for Cardiopulmonary Resuscitation and Emer- A Truhlář, CD Deakin, J Soar et al. European Re- gency Cardiovascular Care. A consensus on suscitation Council Guidelines for Resuscitation science. Resuscitation 2000; 46: 3-15. 2015: Section 4. Cardiac arrest in special cir- Eisenberg MS, Mengert TJ. Cardiac resuscitation. cumstances. Resuscitation 2015; 95: 148-201. N Engl J Med 2001; 344: 1304-13. Jabre P, Bougouin W, Dumas F, et al. Early Iden- De Latorre F, Nolan J, Robertson C, et al. Euro- tification of Patients With Out-of-Hospital Car- pean resuscitation council guidelines 2000 for diac Arrest With No Chance of Survival and adult advanced life support. Resuscitation Consideration for Organ Donation. Ann Intern 2001; 48: 211-21. Med 2016 6; 165: 770-778. Fumeaux T, Dussoix P, Unger PF. Réanimation Kudenchuk PJ, Brown S.P. , Daya M et al. Amio- cardiopulmonaire en 2001: qu’est-ce qui a darone, Lidocaine, or Placebo in Out-of-Hospi- changé? Med Hyg 2001; 59: 1046-9. tal. Amiodarone, Lidocaine, or Placebo in Bernard SA, Gray TW, Buist MD, et al. Treatment Out-of-Hospital Cardiac Arrest. N Engl J Med of Comatose Survivors of Out-of-Hospital Car- 2016; 374: 1711-22. diac Arrest with Induced Hypothermia. N Engl J Westhall E, Rossetti AO, van Rootselaar AF et al. Med 2002; 346: 557-63. Standardized EEG interpretation accurately Holzer M and The Hypothermia after Cardiac Ar- predicts prognosis after cardiac arrest. Neuro- rest Study Group. Mild Therapeutic Hypother- logy 2016; 86: 1482-90. mia to Improve the Neurologic Outcome after Andersen LW, Granfeldt A, Callaway CW et al. Cardiac Arrest. N Engl J Med 2002; 346: 549- Association Between Tracheal Intubation Du- 56. ring Adult In-Hospital Cardiac Arrest and Survi- Wenzel V, Krismer AC, Arntz HR, et al. A compari- val. JAMA 2017; 317: 494-506. 2 Kragholm K, Wissenberg M, Mortensen RN et al. Schuster DP. A physiologyc approach to initiating, Bystander Efforts and 1-Year Outcomes in Out- maintaining, and withdraw mechanical ventila- of-Hospital Cardiac Arrest. N Engl J Med. 2017; tory support during acute respiratory failure. Am 376: 1737-1747. J Med 1990; 88: 268-78. Merchant RM, Topjian AA, Panchal AR et al. Part Feihl F, Perret C. Permissive hypercapnia. How 1: Executive Summary: 2020 American Heart permissive should we be ? Am J Respir Crit Association Guidelines for Cardiopulmonary Care Med 1994; 150: 1722-37. Resuscitation and Emergency Cardiovascular Slutsky AS. Consensus conference on mechani- Care. Circulation 2020; 142(suppl 2): S337. cal ventilation – January 28-30, 1993 at North- Panchal AR, Bartos JA, Cabañas JG et al. Part brook, Illinois, USA. Part 1. Intensive Care Med 3: Adult Basic and Advanced Life Support: 2020 1994; 20: 64-79. American Heart Association Guidelines for Car- Slutsky AS. Consensus conference on mechani- diopulmonary Resuscitation and Emergency cal ventilation – January 28-30, 1993 at North- Cardiovascular Care. Circulation 2020; 142 brook, Illinois, USA. Part 2. Intensive Care Med (suppl 2): S366. 1994; 20: 150-62. Perkins GD, Graesner JT, Semeraro F et al. Eu- Bernard GR, Artigas A, Brigham KL, et al. The ropean Resuscitation Council Guidelines 2021: american-european consensus conference on Executive summary. Resuscitation 2021;161:1- ARDS: definitions, mecanisms, relevant outco- 60. mes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24. Défibrillation - Kardioversion Corbridge TC, Hall JB. The assessment and ma- Dell'Orfano JT, Naccarelli GV. Update on external nagement of adults with status asthmaticus. Am cardioversion and defibrillation. Curr Opin Car- J Respir Crit Care Med 1995; 151: 1296-1316. diol 2001; 16: 54-7. Kollef MH, Schuster DP. The acute distress syn- Adgey AA, Walsh SJ. Theory and practice of defi- drome. N Engl J Med 1995; 332: 27-37. brillation: (1) Atrial fibrillation and DC conver- Thorens JB, Jolliet P, Ritz M, Chevrolet JC. Ef- sion. Heart 2004; 90: 1493-8. fects of rapid permissive hypercapnia on hemo- Hubner PJ, Gupta S, McClellan I. Simplified car- dynamics, gas exchange, and oxygen transport dioversion service with intravenous midazolam. and consumption in ARDS. Intensive Care Med Heart 2004; 90: 1447-9. 1996; 22: 182-91. Nurmi J, Rosenberg P, Castren M. Adherence to Antonelli M, Conti G, Rocco M, et al. A compari- guidelines when positioning the defibrillation son of nonivasive positive-pressure ventilation electrodes. Resuscitation 2004; 61: 143-7. and conventional mechanical ventilation in pa- Adgey AA, Spence MS, Walsh SJ. Theory and tients with acute respiratory faliure. N Engl J practice of defibrillation: (2) defibrillation for Med 1998; 339: 429-35. ventricular fibrillation. Heart 2005; 91: 118. Amato MBP, Barbas CSV, Medeiros DM, et al. Ef- Stiell IG, Sivilotti MLA, Taljaard M et al. Electrical fect of a protective-ventilation strategy on mor- versus pharmacological cardioversion for emer- tality in the acute respiratory distress syndrome. gency department patients with acute atrial fi- N Engl J Med 1998; 338: 347-54. brillation (RAFF2): a partial factorial randomised Artigas A, Bernard GR, Carlet J, et al. The ameri- trial. Lancet 2020; 395: 339-349. can-european consensus conference on ARDS, Triage part 2. Am J Respir Crit Care Med 1998; 157: 1332-47. http://www.oru-mip.fr/docs/ccmu.pdf Eckert Ph, Burdet L, Liaudet L, et al. Stratégies Gerdtz MF, Bucknall TK. Triage nurses’ clinical ventilatoires actuelles du syndrome de détresse decision making. An observational study of ur- respiratoire aigu. Med Hyg 1998; 56: 1920-4. gency assessment. J Adv Nurs 2001; 34: 550- International Consensus Conferences in Intensive 61. Care Medicine: ventilator-associated lung injury Wuerz R. Emergency severity index triage cate- in ARDS. Am J Respir Crit Care Med 1999; 160: gory is associated with six-month survival. ESI 2118-24. Triage Study Group. Acad Emerg Med 2001; 8: The Acute Respiratory Distress Syndrome Net- 61-4. work. Ventilation with lower tidal volumes as Wuerz RC, Travers D, Gilboy N et al. Implemen- compared with traditional volumes for acute tation and refinement of the emergency severity lung injury and the acute respiratory distress index. Acad Emerg Med 2001; 8: 170-6. syndrome. N Engl J Med 2000; 342: 1301-8. Fishman D, Guyot E, Bertin N et al. Les urgences Ware L, Matthay MA. The acute respiratory dis- prises d’assaut: à qui le tour? Me Hyg 2004; 62: tress syndrome. N Engl J Med 2000; 342: 1334- 1550-3. 49. Tanabe P, Gimbel R, Yarnold PR et al. Reliability Gattinoni L, Tognoni G, Pesenti A, et al. Effect of and validity of scores on The Emergency Seve- prone positioning on the survival of patients rity Index version 3. Acad Emerg Med 2004; 11: with acute respiratory failure. N Engl J Med 59-65. 2001; 345: 568-73. Ventilation mécanique — Tobin MJ. Advances in mechanical ventilation. N SDRA/ARDS Engl J Med 2001; 345: 1986-96. Lodato RF. Oxygen toxicity. Crit Care Clin 1990; Taskforce by the american college of chest physi- 6: 749-65. cians: Evidence-based guidelines for weaning 3 and discontinuing ventilatory support. Chest Denborough M. Malignant hyperthermia. Lancet 2001; 120: Suppl. 375S-395S. 1998; 3; 352:1131-6. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Ali SZ, Taguchi A, Rosenberg H. Malignant hyper- Noninvasive positive-pressure ventilation for thermia. Res Clin Anaesthesiol 2003;17: 519- rspiratory failure after extubation. N Engl J Med 33. 2004; 350: 2452-60. Brûlures Malhotra A. Low-Tidal-Volume Ventilation in the Acute Respiratory Distress Syndrome. N Engl J Scheulen JJ, Munster AM. The Parkland formula Med 2007; 357: 1113-20. in patient with burns and inhalation injury. J Acute Respiratory Distress Syndrome. The Berlin Trauma 1982; 22: 869-71. Definition. The ARDS Definition Task Force. 4ème Conférence de consensus en réanimation JAMA 2012; 307: 2526-2533. et en médecine d’urgence. Choix des produits Claude Guérin C, Reignier J, Richard J-C et al. de remplissage vasculaire pour le traitement Prone Positioning in Severe Acute Respiratory des hypovolémies chez l’adulte. Rean Soins In- Distress Syndrome. N Engl J Med 2013; 368: tens Med Urg 1989; 5: 295-304. 2159-68. Warden GD. Burn shock resuscitation. World J Howell MD, Davis AM. Management of ARDS in Surg 1992; 16: 16-23. Adults. JAMA 2018;319:711-12. Ryan CM, Schoenfeld DA, Thorpe WP, et al. Ob- jective estimates of the probability of death from Intubation en cas de trauma crânien burn injuries. N Engl J Med 1998; 338: 362-6. Grande CM, Stene JK. Airway managment: consi- Bloch A, Merz T. Hämodynamische Instabilität. derations in the trauma patient. Crit Care Clin Schweiz Med Forum 2015; 15: 592-599. 1990; 6: 37-59. Choc Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning Vincent JL, De Backer D. Circulatory Shock. N from mechanical ventilation. N Engl J Med Engl J Med 2013; 369: 1726-34. 1991; 324: 1445-50. Roberts I, Shakur H, Coats T, et al. The CRASH- Walls RM. Rapid-sequence intubation in head 2 trial: a randomised controlled trial and econo- trauma. Ann Emerg Med 1993; 22: 1008-11. mic evaluation of the effects of tranexamic acid Bullock R, Chesnut RM, Clifton G. Guidelines for on death, vascular occlusive events and trans- the management of severe head injury. Eur J fusion requirement in bleeding trauma patients. Emerg Med 1996; 2: 109-27. Health Technol Assess 2013; 17: 1-79. Ely EW, Baker AM, Dunagan DP, et al. Effect on Choc cardiogénique the duration of mechanical ventilation of identi- Scheidt S, Wilner G, Mueller H, et al. Intra-aortic fying patients capable of breathing spontane- ballon counterpulsation in cardiogenic shock: ously. N Engl J Med 1996; 335: 1864-9. report of a co-operative clinical trial. N Engl J Koleff MH. Critical care. In: Ahya SN. et al. (eds.). Med 1973; 288: 979-84. The Washington Manual of medical therapeu- Goldberg RJ, Gore JM, Alpert JS, et al. Cardioge- tics. Lippincott Williams & Wilkins, 2001; p. 195- nic shock after acute myocardial infarction: inci- 216. dence and mortality from a community-wide Moeschler O, Engler A. Un tournus de médecine perspective, 1975 to 1988. N Engl J Med 1991; d’urgence au cours de la formation en anesthé- 325: 1117-22. siologie. Med Hyg 1998; 56: 2368-73. Califf RM, Bengtson JR. Cardiogenic shock. N Hyperthermie Engl J Med 1994; 330: 1724-30. Allen GC. Malignant hyperthermia and associated Follath F, Cleland J, Just H, et al Efficacy and disorders. Curr Opin Rheumatol 1993; 5: 719- safety of intravenous levosimendan compared 24. with dobutamine in severe low-output heart fai- Miranda AD, Donovan LA, Schuster LL, et al. Ma- lure (the LIDO study): a randomised double- lignant hyperthermia. Am J Crit Care 1997; 6: blind trial. Lancet 2002; 360: 196-202. 368-76. Mebazaa A, Nieminen MS, Packer M, et al - Ording H, et al. In vitro contracture test for dia- SURVIVE Investigators. Levosimendan vs do- gnosis of malignant hyperthermia following the butamine for patients with acute decompensa- protocol of the European MH Group. Results of ted heart failure: The SURVIVE Randomized testing patients surviving fulminant MH and un- Trial. JAMA 2007; 297: 1883-1891. related low-risk sujects. The European Mali- Bloch A, Merz T. Hämodynamische Instabilität. gnant Hyperthermia Group. Acta Anaesthesiol Schweiz Med Forum 2015;15:592-599. Scand 1997; 41: 955-66. Choc anaphylactique Denboroughh M. Malignant hyperthermia. Lancet Valentine MD. Insect venom allergy: Diagnosis 1998; 352: 1131-6. and treatment. J Allergy Clin Immunol 1984; 73: Morrison AG, Serpell MG. Malignant hyperther- 299-304. mia during prolonged surgery for tumor resec- Bochner BS, Lichtenstein LM. Anaphylaxis. N tion. Eur J Anaesthesiol 1998; 15: 114-7. Engl J Med 1991; 324: 1785-90. Chastonay P, Bracco D, Freymond D, Ravussin Muller U, Mosbech H, Blaauw P, et al. Emergency P. L’hyperthermie maligne. Rev Med Suisse treatment of allergic reactions to Hymenoptera Rom 1999; 119, 191-202. stings. Clin Exp Allergy 1991; 21: 281-8. 4 Atkinson TP, Kaliner MA. Anaphylaxis. Med Clin 2001; 344: 699-709. Editorial: 2001; 344: 759- North Am 1992; 76: 841-55. 62. Muller U. Adrenaline for emergency kits; EAACI Werdan K. Intravenous immunoglobulin for pro- position paper. Allergy 1995; 50: 783-7. phylaxis and therapy of sepsis. Curr Opin Crit Nicklas R, Bernstein IL, Li JT, et al. The diagnosis Care 2001; 7: 354-61. and management of anaphylaxis. J Allerg Clin Tsuneyoshi I, Yamada H, Kakihana Y, et al. He- Immunol 1998; 101(Suppl.): S465-528. modynamic and metabolic effects of low-dose Project Team of the Resuscitation Council (UK). vasopressin infusions in vasodilatatory septic The emergency treatment of anaphylactic reac- schock. Crit Care Med 2001; 29: 487-93. tions. J Accid Emerg Med 1999; 16: 243-7. Vincent JL. Hemodynamic support in septic shock. Intensive Care Med 2001; 27 Suppl. 1: Sepsis - choc septique S80-S92. Davis JP, Chesney PJ, Want PJ, et al. Toxic- Matthy MA. Severe sepsis - a new treatment with shock syndrome. N Engl J Med 1980; 303: both anticoagulant and antiinflammatory proper- 1429-35. ties. N Engl J Med 2001; 344: 759-62. The ACCP/SCCM Consensus Conference Com- Alejandria MM, Lansang MA, Dans LF, et al. In- mittee: Definitions for sepsis and organ failure travenous immunolglobulin for treating sepsis and guidelines for the use of innovative thera- and septic shock. Cochrane Database Syst Rev pies in sepsis. Crit Care Med 1992; 20: 864-74. 2002; 1: CD001090. Also published in: Chest 1992; 101: 1644-55. Annane D, Sebille V, Charpentier C, et al. Effect Rangel-Fausto MS, Pittet D, et al. The natural hi- of treatment with low doses of hydrocortisone story of the systemic inflamatory response syn- and fludrocotisone on mortality in patients with drome. JAMA 1995; 273:117-23. septic shock. JAMA 2002; 288: 862-71. Vincent JL, Moreno R, Takala J, et al. Working Patel BM, Chittock DR, Russel JA, et al. Benefi- Group on Sepsis-Related Problems of the Euro- cal effects of short-term vasopressin infusion pean Society of Intensive Care Medicine. The during severe septic schock. Anesthesiology SOFA (Sepsis-related Organ Failure Assess- 2002; 96: 576-82. ment) score to describe organ dysfunction/fai- Vincent JL, de Carvahlo FB, De Backer D. Ma- lure. Intensive Care Med 1996; 22: 707-710. nagement of septic shock. Ann Med 2002; 34: Vincent JL, de Mendonça A, Cantraine F, et al. 606-13. Working Group on “Sepsis-Related Problems” Vincent JL, Sun Q, Dubois MJ. Clinical trials of of the European Society of Intensive Care Me- immunomodulatory therapies in severe sepsis dicine. Use of the SOFA score to assess the in- and septic shock. Clin Infect Dis 2002; 34: cidence of organ dysfunction/failure in intensive 1084-93. care units: results of a multicenter, prospective Dhainaut JF, Laterre PF, Janes JM, et al. Drotre- study. Crit Care Med 1998; 26: 1793-1800. cogin alfa (activated) in the treatment of severe Argenziano M, Choudhri AF, Oz MC, et al. A pro- sepsis patients with multiple-organ dysfunction: spective randomized trial of arginine vasopres- data from PROWESS trial. Crit Care 2003; 24 sin in the treatment of vasodilatory schock after april [epub ahead of print] left ventricular assist device placement. Cricula- Hotchkiss RS, Karl IE. The pathophysiology and tion 1997; 96 (Suppl): II-286-90. treatment of sepsis. N Engl J Med 2003; 348: Case definitions for infectious conditions under 138-50. public health surveillance. Morb Mortal Wkly Levy MM, Fink MP, Marshall JC, et al. 2001 Rep 1997; 46: 39. SCCM(ESICM/ACCP/ATS/SIS international Landry DW, Levin HR, Gallant EM, et al. Vaso- sepsis definition conference. Intensive Care pressin deficiency contributes to the vasodilata- Med 2003; 29: 530-8; also published in: Crit tion of septic schock. Circulation 1997; 95: Care Med 2003; 31: 1250-6. 1122-5. Vincent JL, Angus DC, Artigas A, et al. Effects of Zanetti G, Baumgartner JD, Glauser MP. Sepsis drotrecogin alfa (activated) on organ dys- and septic shock. Schweiz Med Wochenschr function in the PROWESS trial. Crit Care Med 1997; 127: 489-99. 2003; 31: 834-40. Practice parameters for hemodynamic support of Levy MM, Fink MP, Marshall JC, et al. 2001 sepsis in adult patients in sepsis. Task Force of SCCM/ESICM/ACCP/ATS/SIS International the American College of Critical Care Medicine, Sepsis Definition Conference. Crit Care Med Society of Critical Care Medicine. Crit Care Med 2003; 31: 1250-6. 1999; 27: 639-60. Dhainaut JF, Laterre PF, Janes JM, et al. Drotre- Abraham E, Matthay MA, Dinarello CA, et al. cogin alfa (activated) in the treatment of severe Consensus conference definitions for sepsis, sepsis patients with multiple-organ dysfunction: septic shock, acute lung injury, and acute respi- data from PROWESS trial. Crit Care 2003; 29: ratory distress syndrome: time for a reevalua- 894-903. tion. Crit Care Med 2000; 28: 232-5. Dellinger RP, Carlet JM, Masur H, et al. Surviving Wheeler AP, Bernard G. Treating patients with se- sepsis guidelines for management of sepsis vere sepsis. N Engl J Med 1999; 340:207-14. and septic shock. Crit Care Med 2004; 32: 858- Bernard GR, Vincent JL, Laterre PF, et al. Effi- 73. cacy and safety of recombinant human acti- Gaieski DF, Mikkelsen ME, Band RA et al. Impact vated protein C for severe sepsis. N Engl J Med of time to antibiotics on survival in patients with 5 severe sepsis or septic shock in whom early Johnson TS, Rock PB. Acute mountain sickness. goal-directed therapy was initiated in the emer- N Engl J Med 1988; 319: 841-5. gency department. Crit Care Med 2010; 38: Levine BD, Yoshimura K, Kobayashi T, et al. De- 1045-53. xamethasone in the treatment of acute moun- Dellinger R, Moreno R, Aitken L et al. Surviving tain sickness. N Engl J Med 1989; 321: sepsis campaign: international guidelines for 1707-13. management of severe sepsis and septic Oelz O, Maggiorini M, Ritter M, et al. Nifedipine shock: 2012. Crit Care Med 2013; 41: 580-637. for high altitude pulmonary edema. Lancet Seymour CW, Liu VX, Iwashyna TJ et al (2016) 1989; 2: 1241-4. Assessment of clinical criteria for sepsis: for the Bärtsch P, Maggiorini M, Ritter M, et al. Preven- Third International Consensus Definitions for tion of high-altitude pulmonary edema by nifedi- Sepsis and Septic Shock (Sepsis-3). JAMA pine. N Engl J Med 1991; 325: 1284-9. 2016; 315:762–74. Sutton JR, Coates G, Huston CS (eds). In: The Singer M, Deutschman CF, Seymour CW et al. Lake Louise Consensus on the definition and The Third International Consensus Definitions qunatification of altitude illness. Queen City for Sepsis and Septic Shock (Sepsis-3). JAMA. Printers, Burlington, Vermount, 1992. 2016; 315: 801-810. Cook S, Duplain H, Egli M, Sartori Claudio, et al. doi:10.1001/jama.2016.0287. Œdème pulmonaire de haute altitude: physio- Rhodes A, Evans LE, Alhazzani W et al. Surviving pathologie et traitement. Med Hyg 2000; 58: Sepsis Campaign: International Guidelines for 1520-3. Management of Sepsis and Septic Shock: Hackett PH, Roach RC. High-altitude illness. N 2016. Intensive Care Med 2017; 43: 304-7. Engl J Med 2001; 345: 107-14. Sartori C, Allemann Y, Duplain H, et al. Salmete- Delir — Delir auf der IPS rol for the prevention of high-altitude pulmonary Samaras N, Chevalley Th, Samaras D, Gold. edema. N Engl J Med 2002; 346: 1631-6. Older Patients in the Emergency Department: A Egli M, Sartori C, Scherrer U. Les maladies ai- Review. Annals of Emergency Medicine 2010; guës liées à la haute altitude. Recommandati- 56:261-9. ons pour leur prise en charge et avancées Siegemund M, Massarotto P, Reuthebuch P et al. expérimentales récentes. Med Hyg 2003; 61: Postoperatives Delirium: Pathophysiologie und 1007-13. Diagnose. Schweiz Med Forum 2011;11: 354- Maggiorini M, Brunner-La Rocca HP, Peth S, et 357. al. Both tadalafil and dexamethasone may re- Toxic shock syndrom duce the incidence of high-altitude pulmonary Centers for Disease Control and Prevention. edema: a randomized trial. Ann Intern Med Case definitions for infectious conditions under 2006 3; 145:497-506. public health surveillance. MMWR Recomm Rhabdomyolyse Rep 1997; 46: 1-55. Grossman RA, Hamilton RW, Morse BM, et al. Oliveira DC, Tomasz A, de Lencastre H. Secrets Nontraumatic rhabdomyolisis and acute renale of success of a human pathogen: molecular failure. N Engl J Med 1974; 291: 807-11. evolution of pandemic clones of methicillin-resi- Schiff HB, MacSearraigh ET, Kallmeier JC. Myo- stant Staphylococcus aureus. Lancet Infect Dis globinuria, rhabdomyolysis and marathon run- 2002; 2: 180-9. ning. Q J Med 1978; 47: 463-72. Coma Lonka L, Pedersen RS. Fatal rhabdomyolysis in Höjer J. Diagnostic utility of flumazenil in coma marathon runner (letter). Lancet 1987; 11: 857- with suspected poisoning: a double blind, ran- 8. domized controlled study. Br Med J 1990; 301: Eiser AR, Neff MS, Slifkin RF. Acute myoglobinu- 1308-11. ric renal failure. A consequence of the neurolep- Geller R. Risks and benefits of therapy with flu- tic malignant syndrome. Arch Intern Med 1982; mazenil in mixed drug intoxications. Eur Neurol 142: 601-3. 1991; 31: 241-50. Knochel JP. Rhabdomyolisis and myoglobinuria. Bates D. The management of medical coma. J Annu Ref Med 1982; 33: 435-43. Neurol Neurosurg Psychiatry 1993; 56: 589-98. Curry SC, Chang D, Connor D. Drug- and toxine- Enrico JF. Le coma non traumatique en pratique induced rhabdomyolysis. Ann Emerg Med 1989; extrahospitalière. Schweizerische Rundschau 18: 1068-84. für Medizin 1995; 45: 1321-30. Naschitz JE, Yeshurun D, Shagrawi I. Rhabdo- Hoffman RS. The poisoned patient with altered myolisis in pneumococcal sepsis. Am J Med consciousness. JAMA 1995; 274: 562-9. 1989; 87: 479-80. Wijdicks EFM, Bamler WR et al. Validation of a Better OS, Stein JH. Early management of shock New Coma Scale: The FOUR Score Ann Neurol and prophylaxis of acute renal failure in trauma- 2005; 58: 585-93. tic rhabdomyolysis. N Engl J Med 1990; 322: 825-9. GLASGOW-Score Shemin D, Cohn PS, Zipin SB. Pheochromocy- Teasdale G, Jennett B. Assessment of coma im- toma presenting as rhabdomyolysis and acute pared consciousness. Lancet 1974; 2: 83. myoglobinuric renal failure. Ach Intern Med 1990; 150: 2384-5. Maladies de haute altitude 6 Tonin P, Lewis P, Servidei S, et al. Metabolic cau- Réadmission hospitalière ses of myoglobinuria. Ann Neurol 1990; 27: Donzé J, Aujesky D, Williams D, et al. Potentially 181-5. avoidable 30-day hospital readmissions in me- Singhal PC, Kumar A, Desroches L, et al. Preva- dical patients: derivation and validation of a lence and predictors of rhabdomyolysis in pa- prediction model. JAMA Intern Med 2013; 173: tients with hypophosphatemia. Am J Med 1992; 632-8. 92: 458-64. Barrett SA, Mourani S, Villareal CA, et al. Rhab- CARDIOLOGIE - Kardiologie domyolysis associated with status asthmaticus. Crit Care Med 1993; 21: 151-3. Aortenaneurysma - Aortendissektion Knochel JP, Moore GE. Rhabdomyolysis in mala- Elliott WJ.Clinical features in the management of ria (letter). N Engl J Med 1993; 329: 1206-7. selected hypertensive emergencies. Prog Car- Pesik MT, Otten EJ. Severe rhabdomyolisis follo- diovasc Dis 2006;48:316-25. wing a viral illness: a case report and review of Suzuki T, Distante A, Zizza A et al. Diagnosis of the literature. J Emerg Med 1996; 14: 425-8. acute aortic dissection by D-dimer: the Interna- Vanholder R, Sever MS, Erek E, et al. Acute renal tional Registry of Acute Aortic Dissection Sub- failure related to the crush syndrome: towards study on Biomarkers (IRAD-Bio) experience. an era of seismo-nephrology? Nephrol Dial Circulation 2009; 119: 2702-7. Transplant 2000; 15: 1517-21. Ranasinghe AM1, Bonser RS. Biomarkers in Bedry R, Baudrimont I, Deffieux G, et al. Wild- acute aortic dissection and other aortic syndro- mushroom intoxication as a cause of rhabdo- mes. J Am Coll Cardiol. 2010; 56: 1535-41. myolysis. N Engl J Med 2001; 345: 798-802. Rogers AM, Hermann LK, Booher AM et al. Sen- Bouchama A, Knochel JP. Heat stroke. N Engl J sitivity of the Aortic Dissection Detection Risk Med 2002; 346: 1978-88. Score, a Novel Guideline-Based Tool for Identi- Syndrome malin des neuroleptiques fication of Acute Aortic Dissection at Initial Pre- Levenson JL. Neuroleptic malignant syndrome. sentation Results From the International Am J Psychiatry 1985; 142: 1137-45. Registry of Acute Aortic Dissection. Circulation Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic 2011;123:2213. malignant syndrome. Am J Psychiatry 2007; Myokardinfarkt → Akutes Koronarsyndrom 164: 870-6. Syndrome coronarien aigu et chronique - Électrisation Maladie coronarienne - KHK DixonGF. The evaluation and management of STEMI - NSTEMI - Angor instable electrical inujuries. Crit Care Med 1983; 11: The MIAMI Trial Research Group. Metoprolol in 384-7. acute myocardial infarction (MIAMI). A randomi- Carleton SC. Cardiac problems associated with sed, placebo-controlled international trial. Eur electrical injury. Cardiol Clin 1995; 13: 263-6. Heart 1985; 6: 199-226. Yusuf S, Peto R, Lewis J, Collins R, et al. Beta Hypothermie blockade during and after myocardial infarction: Danzel F. Accidental hypothermia. N Engl J Med an overview of the randomised trials. Prog Car- 1994; 331: 1756-60. diovasc Dis 1985; 27: 335-71. Handrigan MT, Wright RO, Becker BM, et al. Fac- ISIS-1 Collaborative Group. Randomised trial of tors and mehtodology in achieving ideal deli- intravenous atenolol among 16027 cases of su- very temperatures for intravenous and lavage spected acute myocardial infarction. Lancet fluid in hypothermia. Am J Emerg Med 1997; 1986; ii: 57-66. 15: 350-3. Findings from aspirin component of the ongoing Lazar HL. The treatment of hypothermia. N Engl J Physicians’ Health Study. N Engl J Med 1988; Med 1997; 337: 1545-7. 318: 262-4. Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. ISIS-2 (second International Study of Infarct Sur- Outcome of survivors of accidental deep hypo- vival). Collaborative Group. Randomised trial of thermia and circulatory arrest treated with extra- intravenous streptokinase, oral aspirin, both, or corporeal blood warming. N Engl J Med 1997; neither among 17187 cases of suspected acute 337: 1500-5. myocardial infarction: ISIS-2. Lancet 1988; 2: Goodenberger D. Cold induced illness. In: Ahya 349-60. SN. et al. (eds.). The Washington Manual of The Steering Committee of the Physicians’ Health medical therapeutics. Lippincott Williams & Wil- Study Research Group. Preliminary report. Fin- kins, 2001: 541-3. dings from the aspirin component of the on- Murray P, Hall J. Hypothermia. In: Hall J. et al. going Physicians’ Health Study. N Engl J Med (eds). Principles of Critical Care. McGraw-Hill, 1988; 318: 262-4. 1998: p. 1645-55. Braunwald E. Unstable angina: a classification. Maladie du caisson -- Decompression Circulation 1989; 80: 410-4. ACC/AHA Guidelines for early management of Schröder S, Lier H, Wiese S- Der Tauchunfall. patients with acute myocardial infarction. Circu- Notfallmedizinische Versorgung des schweren lation 1990; 82: 664-707. Tauchunfalls. In: Der Anästhesist. Springer Me- GISSI-2: A factorial randomised trial of alteplase dizin Verlag 2004. versus streptokinase and heparin versus no he- 7 parin among 12490 patients with acute myocar- farction. Circulation 1998; 97: 1195-1206. dial infarction. Lancet 1990; 336: 65-71. Anteman EM, McCabe CH, Gurfinkel EP, et al. ISIS-3: A randomised comparison of streptoki- Enoxaparin prevents death and cardiac ische- nase vs tissue plasminogen activator vs anistre- mic events in unstable angina/non-Q-wave plase and of aspirin plus heparin vs apirin alone myocardial infarction: results of the thromboly- among 41299 cases of suspected acute myo- sis infarction (TIMI) 11 B trial. Circulation 1999; cardial infarction. Lancet 1992; 339: 753-70. 100: 1602-8. Scandinavian Simvastatin Survival Study Group. FRagmin and fast revascularisation during insta- Randomised trial of cholesterol lowering in bility in coronary artery disease investigators. 4444 patients with coronary heart disease: the Invasive compared with non-invasive treatment Scandinavian Simvastatin Survival Study (4S). in unstable coronary-artery disease: FRISC II Lancet 1994; 344: 1383-89. prospective randomised multicentre study. Lan- Gurfinkel EP, Manos EJ, Mejail RI, et al. Low mo- cet 1999; 354: 708-15. lecular weight heparin versus regular heparin or FRAXIS study group. Comparison of two trea- aspirin in the treatment of unstable angina and ment durations (6 days and 14 days) of a low silent ischemia. J Am Coll Cardiol 1995; 26: molecular weight heparin with a 6-day treament 313-8. of unfractionated heparin in the inital manag- White HD et al. (for the GUSTO I Investigators). ment of unstable angina or non-Q-wave myo- Age and outcome with contemporary thrombo- cardial infarction. Eur Heart J 1999; 20: lytic therapy: results from the GUSTO I Trial. 1553-62. Circulation 1996 ,94: 1826-33. The ASSENT-2 Investigators. Single-bolus tenec- Braunwald E, (ed.). Heart disease: a textbook of teplase compared with front-loaded alteplase in cardiovascular medicine. Philadelphia W.B. acute myocardial infacrction: the ASSENT-2 Saunders Company, 1997. double-blind randomised trial. Lancet 1999; Cohen M, Demers Ch, Gurfinkel EP, et al. A com- 354: 716-22. parison of low-molecular-weight heparin with Zijlstra F, Hoorntje JCA, de Boer MJ, et al. Long- unfractionated heparin for unstable coronary ar- term benefit of primary angioplasty as compa- tery diesease. N Engl J Med 1997: 337: 447-52. red with thrombolytic therapy for acute Nguyen KN, Aursnes I, Kjekshus J. Interaction myocardial infarction. N Engl J Med 1999; 341: between enalapril and aspirin on mortality after 1413-9. acute myocardial infarction: subgroup analysis Gan SC, Beaver SK, Houck PM, et al. Treatment of the Cooperative New Scandinavian Enalapril of acute myocardial infarction and 30-day mor- Survival Study II (CONSESUS II). (Abstr.) Am J tality among women and men. N Engl J Med Cardiol 1997; 79: 115-19. 2000; 343: 8-15. The PURSUIT Trial Investigators. Inhibition of Hamm CW, Braunwald E. A classification of uns- platelet glycoprotein IIb/IIIa with eptifibatide in table angina revisited. Circulation 2000; 102: patients with acute coronary syndromes. N Engl 118-22. J Med 1998; 339: 436-43. Monrad ES. Role of low-molecular-weight hepa- The Platelet Receptor Inhibition in Ischemic Syn- rins in the management of patients with unsta- drome Management in Patients Limiting by ble angina pectoris and non-Q-wave acute Unstable Signs and Symptoms (PRISM-PLUS) myocardial infarction. Am J Cardiol 2000; 85: Study Investigators. Inhibition of the platelet gly- 2C-9C. coprotein IIb/IIIa receptor with triofiban in unsta- Scull GS, Martin JS, Weaver WD, et al. Early an- ble angina pectoris and non-Q-wave myocardial giography versus conservative treatment in pa- infarction. N Engl J Med 1998; 338: 1488-97. tients with non-ST elevation acute myocardial [Erratum: N Engl J Med 1998; 339; 414]. infarction: MITI Investigators. Myocardial In- The Platelet Receptor Inhibition in Ischemic Syn- farction Triage and Intervention. J Am Coll Car- drome Management (PRISM) Study Investiga- diol 2000; 35: 895-902. tors. A comparison of aspirin plus tirofiban with Yeghiazarians Y, Braustein JB, Askari A, Stone P. aspirin plus heparin for unstable angina. N Engl Unstable Angina pectoris. N Engl J Med 2000; J Med 1998; 338: 1498-505. 342: 101-14. ASSENT-2 Investigators. Single-bolus tenecte- Yusuf S. et al. Effects of an angiotensin-conver- plase compared with front-loaded alteplase in ting-enzyme inhibitor, Ramipril, on death from acute myocardial infarction: the ASSENT-2 dou- cardiovascular events in high-risk patients. N ble-blind randomised trial. Lancet 1999; 354: Engl J Med 2000; 342,145-53. 716-22. Hamm C, Bertrand M, Braunwald E. Acute coro- Ryan TJ, Antman EM, Brooks NH, et al. 1999 up- nary syndrome without ST elevation: implemen- date: ACC/AHA guidelines for the management tation of new guidelines. Lancet 2001; 358: of patients with acute myocardial infarction: 1533-8. executive summary and recommendations: a Ohman EM, Harrington RA, Cannon CP, et al. In- report of the American College of travenous thrombolysis in acute myocardial in- Cardiology/American Heart Association Task farction. Chest 2001; 119 (Suppl): 253S-277S. Force on Practice Guidelines. J Am Coll Cardiol Schwartz GG, Oliver MF, Ezekowitz MD, et al. Ef- 1999; 34: 890-911. fects of Atorvastatin on early ischemic events in Théroux P, Fuster V. Acute coronary syndromes: acute coronary syndromes: the MIRACL study: unstable angina and non-Q-wave myocardial in- a randomized controlled study. JAMA; 2001; 8 285: 1711-8. Valsartan, Captopril, or both in myocardial in- Simoons ML. Effet of glycoprotein IIb/IIIa receptor farction complicated by heart failure, left ventri- blocker abciximab on outcome in patients with cular dysfunction, or both. N Engl J Med 2003; acute coronary syndromes without early coro- 349: 1893-906. nary revascularisation: the GUSTO IV-ACS ran- Pitt B, Remme W, Zannad F, et al. Eplerenone, a domised trial. Lancet 2001; 357: 1915-24. selective aldosterone blocker, in patients with The ASSENT-3 Investigators. Efficacy and safety left ventricular dysfunction after myocardial in- of tenecteplase in combination with enoxaparin, farction. N Engl J Med 2003; 348: 1309–1321. abciximab or unfractionated heparin: the AS- Van de Werf F, Ardissino D, Betriu A, et al. The SENT-3 randomized trial in acute myocardial in- Task Force of Management of acute myocardial facrtion. Lancet 2001; 358: 605-13. infarction of the european society cardiology. The Clopidogrel in unstable angina to prevent re- Management of acute myocardial infarction in current events trial investigators (CURE). Ef- patients presenting with ST-segment elevation. fects of Clopidogrel in addition to Aspirin in The Task Force on the management of acute patients with acute coronary syndromes without myocardial infarction of the European Society of ST-segment elevation. N Engl J Med 2001; 345: cardiology. Eur Heart J 2003; 24: 28-66. 494-502. Cannon Ch, Braunwald E, McCabe C, et al. Com- Aviles RJ, Askari AT, Lindahl B, et al. Troponin T parison of moderate lipid lowering with statins levels in patients with acute coronary syndro- after acute coronary syndromes. N Engl J Med mes, with or wothout renal dysfunction. N Engl 2004; 350: 1495-504. J Med 2002; 346: 2047-52. Keller KB, Lemberg L. Prinzmetal's angina. Am J Fox KAA, Goodman SG, Klein W, et al. Manage- Crit Care 2004; 13: 350-4. ment of acute coronary syndromes. Variations Jestra JA, Kromhout D, van der Schouw YT et al. on practice and outcome. Eur Heart J 2002; 23: Effect size estimates of lifestyle and dietary 1177-89. changes on all-cause mortality in coronary ar- Bertrand ME, Simoons ML, Fox KAA, et al. Ma- tery disease patients: a systematic review. Cir- nagement of acute coronary syndromes in pa- culation. 2005; 112: 924-34. tients presenting without persistent ST segment Nallamothu BK, Bradley EH, Krumholz HM. Time elevation. The Task Force on the management to Treatment in Primary Percutaneous Coronary of acute coronary syndromes of the European Intervention. N Engl J Med 2007; 357:1631- Society of Cardiology. Eur Heart J 2002 ; 23: 1638. 1809-40. The Task Force on the management of ST-seg- Braunwald E, Antman EM, Beasley JW et al. ment elevation acute myocardial infarction of ACC/AHA 2002 Guideline update for the ma- the European Society of Cardiology. Manage- nagement of patients with unstable angina and ment of acute myocardial infarction in patients non-ST-segment elevation myocardial in- presenting with persistent ST-segment eleva- farction-2002. Circulation 2002; 106: 1893-900 tion. Eur Heart J 2008; 29, 2909-45. (http://www.acc.org/clinical/guidelines/unsta- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor ble/unstable.pdf). versus Clopidogrel in Patients with Acute Coro- Budaj A, Yusuf S, Mehta SR, et al. Clopidogrel in nary Syndromes. N Engl J Med 2009;361: Unstable angina to prevent Recurrent Events 1045-57. (CURE) Trial Investigators. Benefit of clopido- Hamm CW, Bassand JP, Agewall S et al. ESC grel in patients with acute coronary syndromes Guidelines for the management of acute coro- without ST-segment elevation in various risk nary syndromes in patients presenting without groups. Circulation 2002; 106: 1622-6. persistent ST-segment elevation: The Task Steinhubel SR, Berger PB, Mann JF for the Force for the management of acute coronary CREDO Investigators. Early and sustanied dual syndromes (ACS) in patients presenting without oral antiplatelet therapy following percutaneous persistent ST-segment elevation of the Euro- coronary intervention. A randomized controlled pean Society of Cardiology (ESC). Eur Heart J trial. JAMA 2002; 288: 2411-20. 2011; 32: 2999-3054. Andersen HR, Nielsen TT, Rasmussen K, et al. A Zannad F, McMurray JJ, Krum H, et al. Eplere- comparison of coronary angioplastie with fibri- none in patients with systolic heart failure and nolytiqc therapy in acute myocardial infarction. mild symptoms. N Engl J Med 2011; 364: 11-21. N Engl J Med 2003; 349: 733-42. Steg PG, James SK, Atar D et al. ESC Guidelines Brennan M-L, Penn MS, Van Lente F, et al. Pro- for the management of acute myocardial in- gnostic value of myeloperoxidase in patients farction in patients presenting with ST-segment with chest pain. N Engl J Med 2003; .349: elevation. Task Force on the management of 1595-604. ST-segment elevation acute myocardial in- Fox K. The EUROPA trial. Lancet 2003; 362: farction of the European Society of Cardiology 1936-7. (ESC). Eur Heart J 2012; 33: 2569-619. Kinlay S, Schwartz GG, Olsson AG, et al. High- Bonaca MP, Bhatt DL, Braunwald E, et al. Design dose atorvastatin enhances the decline in in- and rationale for the prevention of cardiovascu- flammatory markers in patients with acute lar events in patients with prior heart attack coronary syndromes in the MIRACL study. Cir- using ticagrelor compared to placebo on a culation 2003; 108: 1560-6. background of aspirin-thrombolysis in myocar- Pfeffer MA, McMurray JJV, Velazquez EJ, et al. dial infarction 54 (PEGASUS-TIMI 54) trial. Am 9 Heart J 2014; 167: 437-44.e5. prognosis in patients with suspected stable an- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or gina. Eur Heart J 2018;40:1426-1435. 30 months of dual antiplatelet therapy after Valgimigli M, Bueno H, Byrne RA, et al. 2017 drug-eluting stents. N Engl J Med 2014; 371: ESC focused update on dual antiplatelet the- 2155-66. rapy in coronary artery disease developed in Windecker S, Kolh P, Alfonso F, et al. 2014 collaboration with EACTS: The Task Force for ESC/EACTS guidelines on myocardial revascu- dual antiplatelet therapy in coronary artery larization : The task force on myocardial revas- disease of the European Society of Cardiology cularization of the European Society of (ESC) and of the European Association for Car- Cardiology (ESC) and the European Associa- dio-Thoracic Surgery (EACTS). Eur Heart J tion for Cardio-Thoracic Surgery (EACTS). De- 2018; 39: 213-60. veloped with the special contribution of the Juarez-Orozco LE, Saraste A, Capodanno D, European Association of Percutaneous Cardio- Prescott E, Ballo H, Bax JJ, Wijns W, Knuuti J: vascular Interventions (EAPCI). Eur Heart J Impact of a decreasing pretest probability on 2014;35:2541-619. the performance of diagnostic tests for coronary Bonaca MP, DL Bhatt, Cohen M, et al. Long-Term artery disease. Eur Heart J Cardiovasc Imaging Use of Ticagrelor in Patients with Prior Myocar- 2019; 20: 1198-1207. doi: 10.1093/ehjci/jez054 dial Infarction N Engl J Med 2015; 372: 1791- ÉCG — EKG Elektrokardiogramm 800. Iglesias JF, Monney P, Pascale P et al. Cardiolo- Kossman CE. The normal electrocardiogram. Cir- gie - nouveautés en médecine 2014. Rev Med culation 1953; 8: 929. Suisse 2015; 11: 30-43. Hiss RG, Lamb LE, Allen MF. Electrocardiogra- Koskinas K, Räber L, Zanchin T et al. Clinical im- phic findings in 67'375 asymptomatic patients. pact of gastrointestinal bleeding in patients un- Am J Cardiol 1960; 6: 200. dergoing percutaneous coronary interventions. Wasserburger RH, Alt WJ, Lloyd CJ. The normal Circ Cardiovasc Interv 2015;8:e002053. RS-T segment elevation variant. Am J Cardiol Roffi M, Patrono C, Collet J-P et al. Task Force 1961;8:184. for the Management of Acute Coronary Syndro- Warner RA. Recent advances in the diagnosis of mes in Patients Presenting without Persistent myocardial infarction. Cardiol Clin 1987; 5: 381- ST-Segment Elevation of the European Society 92. of Cardiology (ESC) 2015 ESC guidelines for Wellens HJJ, Conover MB. (eds.). The ECG in the management of acute coronary syndromes emergency decision making. Philadelphia in patients presenting without persistent ST- Saunders 1992. segment elevation. Eur Heart J 2016; 37: 267- Touboul P, Lefkiefre J, Fontaine F, et al. (eds.). In: 315. Les troubles du rythme cardiaque. Editions Ma- Degrauwe S, Iglesisas JF. Double antiagrégation loine 1993. plaquettaire pour le traitement et la prévention Chou T. (ed.). In: Electrocardiography in Clinical secondaire de la maladie coronarienne Indicati- Practice. W.B. Philadelphia Saunders Com- ons, modalités et durées de traitement. Rev pany, 1996. Med Suisse 2016 ; 12 : 1022-34. Scarbossa EB, Pinski SL, Barbagelata A, et al. 2017 ESC Guidelines for the management of Electrocardiographic dianosis of evolving acute acute myocardial infarction in patients presen- myocardial infarction in the presence of left ting with ST-segment elevation: The Task Force bundle-branch block. GUSTO-1 Investigators. N for the management of acute myocardial in- Engl J Med 1996; 334: 481-7. farction in patients presenting with ST-segment Sgarbossa EB. Value of the ECG in suspected elevation of the European Society of Cardiology acute myocardial infarction with left bundle (ESC). Eur Heart J 2018; 39: 119-177. branch block. J Electrocardiol 2000; 33 Suppl: 2020 ESC Guidelines for themanagement of 87-92. acute coronary syndromes in patients presen- Sztajzel J, Urban P. Early and late Q wave re- ting without persistent ST-segment elevation. gression in the setting of acute myocardial in- The Task Force for the management of acute farction. Heart 2000; 83: 708-10. coronary syndromes in patients presenting wit- Lewis GD, Holmes CH, Holmavang G et al. Q 48- hout persistent ST-segment elevation of the Eu- year-old man with chest pain followed by car- ropean Society of Cardiology (ESC). Eur Heart diac arrest. N Engl J Med 2007; 356; 1153-62. J 2020; 00:1-79. Smith SW, et al.Diagnosis of ST-Elevation Myo- cardial Infarction in the Presence of Left Bundle Syndrome coronarien chronique (CCS) Branch Block With the ST-Elevation to S-Wave Foldyna B, Udelson JE, Karady J, et al. Pretest Ratio in a Modified Sgarbossa Rule. Ann Emerg probability for patients with suspected obstruc- Med 2012; 60: 766-76. tive coronary artery disease: re-evaluating Dia- Drezner JA, Fischbach P, Froelicher V et al. Nor- mond-Forrester for the contemporary era and mal electrocardiographic findings: recognising clinical implications: insights from the PRO- physiological adaptations in athletes. Br J MISE trial. Eur Heart J Cardiovasc Imaging Sports Med 2013; 47: 125-136. 2018;20:574-581. Meyers HP et al. Validation of the Modified Sgar- Reeh J, Therming CB, Heitmann M, et al. Predic- bossa Criteria for Acute Cornoary Occlusion in tion of obstructive coronary artery disease and the Setting of Left Bundle Branch Block: A Re- 10 trospective Case-Control Study. Am Heart J Brugada J, Katritsis DG, Arbelo E et al. 2019 ESC 2015; 170: 1255-64. Guidelines for the management of patients with Schindler MJ, Schmied Ch. EKG-Interpretation supraventricular tachycardiaThe Task Force for bei Sportlern – die «Seattle-Kriterien». Méd the management of patients with supraventricu- Cardiovasc 2016; 19: 72-76. lar tachycardia of the European Society of Car- Early repolarisation syndrome diology (ESC). Eur Heart J 2020; 41: 655-720. Syndrome de repolarisation précoce Fibrillation auriculaire - Vorhofflimmern Haissaguerre M, Derval N, Sacher F, et al. Sud- Dunn M, Alexander J, de Silva R, Hildner F. Anti- den cardiac arrest associated with early repo- thrombotic therapy in atrial fibrillation. Chest larization. N Engl J Med 2008; 358: 2016-23. 1989; 95 (Suppl.): 118S-127S. Haissaguerre M, Sacher F, Nogami A, et al. Cha- Petersen P, Boysen G, Godtfredsen J, et al. Pla- racteristics of recurrent ventricular fibrillation as- cebo-controlled, radomized trial of warfarin and sociated with inferolateral early repolarization aspirin for prevention of thromboembolic com- role of drug therapy. J Am Coll Cardiol 2009; plications in chronic atrial fibrillation: the Copen- 53: 612-9. hagen AFASAK Study. Lancet 1989; 1: 175-9. Antzelevitch C, Yan GX. J wave syndromes. Weinberg DM, Mancini J. Anticoagulation for car- Heart Rhythm 2010; 7: 549-58. dioversion of atrial fibrillation. Am J Cardiol Tikkanen JT, Junttila MJ, Anttonen O, et al. Early 1989; 63: 745-6. repolarization : Electrocardiographic phenoty- The Boston Area Anticoagulation Trial for Atrial Fi- pes associated with favorable long-term out- brillation Investigators. The effect of low dose come. Circulation 2011; 123: 2666-73. warfarin on the risk of stroke in patients with Burri H. Repolarisation précoce: quand s’inquié- nonrheumatic atrial fibrillation. N Engl J Med ter? Rev Med Suisse 2015; 11: 553-6. 1990; 323: 1505-11. Echokardiographie Laupacis A, Albers G, Dunn M, et al. Antithrombo- Buck T, Breithardt OA, Faber L et al. Manual zur tic therapy in atrial fibrillation. Chest 1992; 102 Indikation und Durchführung der Echokardio- (Suppl. 4 ): 426S-433S. graphie. Clin Res Cardiol 2009; Suppl 4:3-51. Pritchett ELC. Management of atrial fibrillation. N Hagendorff A, Fehske W, Flachskampf F.A. et al. Engl J Med 1992; 326: 1264-71. Manual zur Indikation und Durchführung der The Stroke Prevention in Atrial Fibrillation Investi- Echokardiographie – Update 2020 der Deut- gators. Predictors of thromoembolism in atrial fi- schen Gesellschaft für Kardiologie. Der Kardio- brillation. In: clinical features of patients at risk. loge 2020; 14: 396-431. Ann Intern Med 1992; 116: 1-5. Tachycardie supraventriculaire - QRS fins Gage BF, Cardinalli AB, Albers GW, et al. Cost-ef- Supraventrikuläre Tachykardien fectiveness of warfarin and aspirin for prophyla- Orejarena LA, Vidaillet H, DeStefano F, et al. Pa- xis of stroke in patients with nonvalvular atrial roxysmal Supraventricular Tachycardia in the fibrillation. JAMA 1995; 274: 1839-45. General Population. Journal of the American Prystowsky EN, Benson Jr DW, Fuster V, et al. College of Cardiology 1998; 31: 150-7. Management of patients with atrial fibrillation. Vohra J. Cardiac Arrhythmia: Mechanisms, Dia- Circulation 1996; 93: 1262-77. gnosis and Management, Second Ed.: Philip J. Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Podrid, Peter R. Kowey (Eds.), Lippincott Wil- Chronic atrial fibrillation. Succes of serial car- liams and Wilkins Publication; 2004. dioversion therapy and safety of oral anticoagu- Link MS. Clinical practice. Evaluation and initial lation. Arch Intern Med 1996; 156: 2585-92. treatment of supraventricular tachycardia. Kaufmann W, (ed.). Internistische Differenzialdia- NEJM 2012; 367: 1438-48. gnostik. Entscheidungsprozesse in Flussdia- Bibas L, Levi M and Essebag V. Diagnosis and grammen. Schattauer, 4. Auflage 1997. management of supraventricular tachycardias. Weigner MJ, Caulfield TA, Danias PG, et al. Risk CMAJ 2016; 188:E466-E473. for clinical thromboembolism associated with Page RL, Joglar JA, Caldwell MA, et al. 3rd, Field conversion to sinus rhythm in patients with atrial ME, Goldberger ZD, Hammill SC, Indik JH, fibrillation lasting less than 48 hours. Ann Intern Lindsay BD, Olshansky B, Russo AM, Shen Med 1997; 126: 615-20. WK, Tracy CM and Al-Khatib SM. 2015 Zimmermann M. Les traitements de la fibrillation ACC/AHA/HRS Guideline for the Management auriculaire. Med Hyg 1997; 55: 445-9. of Adult Patients With Supraventricular Tachy- Benjamin EJ, Wolf PA, D'Agostino RB et al. Im- cardia: Executive Summary: A Report of the pact of atrial fibrillation on the risk of death: the American College of Cardiology/American Framingham Heart Study. Circulation 1998; 98: Heart Association Task Force on Clinical Prac- 946-52. tice Guidelines and the Heart Rhythm Society. J Hart RG, Benavente O, McBride R et al.Anti- Am Coll Cardiol 2016; 67: 1575-623. thrombotic therapy to prevent stroke in patients Lam A, Roten L. Supraventrikuläre Tachykardien. with atrial fibrillation: a meta-analysis. Ann In- Schweiz Med Forum 2018; 18: 1028-36. tern Med 1999; 131: 492-501. Chen YL, Lin YS, Wang HT et al. Clinical outco- Steeds RP, Birchall AS, Smith N, et al. An open mes of solitary atrial flutter patients using anti- label, randomised, crossover study comparing coagulation therapy: a national cohort study. sotalol and atenolol in the treatment of sympto- Europace 2019; 21: 313-21. matic paroxysmal atrial fibrillation. Heart 1999; 11 82: 170-5. Singh BN, Singh SN, Reda DJ, et al. Amiodarone Hart RG, Pearce LA, Rothbart RM et al. Stroke versus Sotalol for Atrial Fibrillation. N Engl J with intermittent atrial fibrillation: incidence and Med 2005; 352: 1861-72. predictors during aspirin therapy. Stroke Pre- Fuster V et al. ACC/AHA/ESC 2006 Guidelines vention in Atrial Fibrillation Investigators. J Am for the Management of Patients with Atrial Fi- Coll Cardiol 2000; 35: 183-7. brillation: Executive Summary. Circulation 2006; Roy D, Talajic M, Dorian P, et al. Amiodaron to 114; 700-52. prevent recurrence of atrial fibrillation. N Engl J Stiell IG, Macle L, CCS Atrial Fibrillation Guideli- Med 2000; 342: 913-20. nes Committee. Canadian Cardiovascular So- Singh S, Zoble RG, Yellen L, et al. Efficacy and ciety atrial fibrillation guidelines 2010: safety on oral dofetilide in converting to and management of recent-onset atrial fibrillation mantaining sinus rhythm in patients with chronic and flutter in the emergency department. Can J atrial fibrillation or atrial flutter: the symptomatic Cardiol 2011; 27: 38-46. atrial firbillation investigative research on dofeti- Camm AJ, Lip GY, De Caterina R et al. 2012 fo- lide (SAFIRE-D) study. Circulation 2000; 102: cused update of the ESC Guidelines for the ma- 2385-90. nagement of atrial fibrillation: an update of the Fuster V, Rydén LE, Asinger RW, et al. Stroke 2010 ESC Guidelines for the management of with intermittent atrial fibrillation: incidence and atrial fibrillation. Developed with the special predictors during aspirin therapy. Stroke Pre- contribution of the European Heart Rhythm As- vention in Atrial Fibrillation Investigators. J Am sociation. Eur Heart J 2012;33:2719. Coll Cardiol 2000; 35: 183-7. January CT, Wann LS, Alpert JS et al. 2014 ACC/AHA/ESC Guidelines for the management AHA/ACC/HRS Guideline for the Management of patients with atrial fibrillation: executive sum- of Patients With Atrial Fibrillation: Executive mary. Eur Heart J 2001; 22: 1852-923. Summary: A Report of the American College of Falk RH. Atrial fibrillation. N Engl J Med 2001; Cardiology/American Heart Association Task 344: 1067-87. Force on Practice Guidelines and the Heart Gage BF, Waterman AD, Shannon W et al. Vali- Rhythm Society. Circulation 2014; 130: 2071- dation of clinical classification schemes for pre- 104.. dicting stroke: results from the National Registry Meier B, Blaauw Y, Khattab AA et al. of Atrial Fibrillation. JAMA 2001; 285: 2864-70. EHRA/EAPCI expert consensus statement on Klein AL, Grimm RA, Murray RD et al. Use of catheter-based left atrial appendage occlusion. transesophageal echocardiography to guide Europace 2014; 16: 1397-416. cardioversion in patients with atrial fibrillation. N Verma A, Cairns JA, Mitchell LB et al. 2014 focu- Engl J Med 2001; 344: 1411-20. sed update of the Canadian Cardiovascular So- The assessment of the safety and efficacy of a ciety Guidelines for the management of atrial new thrombolytic regimen (ASSENT)-3 investi- fibrillation. Can J Cardiol 2014;30:1114-30. gators. Efficacy and safety of tenecteplase in Authors/Task Force Members: Ponikowski P combination with enoxaparin. abciximab, or un- (Chairperson), Voors AA. (Co-Chairperson) fractioneated heparin: the ASSENT-3 randomi- Anker St.D. et al. 2016 ESC Guidelines for the sed trial in acute myocardial infarction. Lancet diagnosis and treatment of acute and chronic 2001; 358: 605-13. heart failure. Eur J Heart Failure (2016) Stewart S, Hart CL, Hole DJ et al. A population- doi:10.1002/ejhf.592 based study of the long-term risks associated Kirchof P, Benussi S et al. 2016 ESC Guidelines with atrial fibrillation: 20-year follow-up of the for the management of atrial fibrillation develo- Renfrew/Paisley study. Am J Med 2002; 113: ped in collaboration with EACTS. Eur Heart J. 359-64. 2016. doi: 10.1093/eurheartj/ehw210. Forthco- Wyse DG, Waldo AL, DiMarco JP et al. A compa- ming rison of rate control and rhythm control in pa- Packer DL, Mark DB, Robb RA, et al. Catheter tients with atrial fibrillation. N Engl J Med 2002; Ablation versus Antiarrhythmic Drug Therapy 347: 1825-33. for Atrial Fibrillation (CABANA) Trial: Study Ra- Levy S, Camm AJ, Saksena S et al. International tionale and Design. Am Heart J 2018; 199: 192- consensus on nomenclature and classification 199. of atrial fibrillation: A collaborative project of the Kirchhof P, Camm AJ, Goette A et al. Early Working Group on Arrhythmias and the Working Rhythm-Control Therapy in Patients with Atrial Group of Cardiac Pacing of the European So- Fibrillation. NEJM 2020; 383:1305-1316 ciety of Cardiology and the North American So- Cardiomyopathie ciety of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 2003; 14: 443-5. Towbin JA, Lorts A, Jefferies JL. Left ventricular Steinberg JS, Sadaniantz A, Kron J, et al. Analy- non-compaction cardiomyopathy. Lancet 2015; sis of cause-specific mortalitiy in the Atrial Fibril- 386: 813-25. lation Follow-up Investigation of Rhythm, Corrado D, Link MS, Calkins H. Arrhythmogenic Management (AFFIRM) study. Circulation 2004; Right Ventricular Cardiomyopathy. N Engl J 109: 1973-80. Med 2017; 376: 61-72. De Denus S. et al. Rate vs. Rhythm Control in Kato K, Lyon AR, Ghadri JR, Templin C. Takot- Patients with Atrial Fibrillation. Arch Intern Med subo syndrome: aetiology, presentation and 2005; 165; 258-262. treatment. Heart 2017; 103: 1461-9. 12 Veselka J, Anavekar NS, Charron Ph. Hypertro- et al. (eds.). Editions Médecine et Hygiène, phic obstructive cardiomyopathy. Lancet 2017; 1997, p: 104-33. 389: 1253-67. Syndrome du QT long (LQTS) Weintraub RG, Christopher Semsarian C, Macdo- nald P. Dilated cardiomyopathy. Lancet 2017; Paavonen K, Swan H, Piippo K, Hokkanen L, Lai- 390: 400-14. tinen P, Viitasalo M, et al. Response of the QT Pereira NL, Grogan M, Dec GW. Spectrum of Re- interval to mental and physical stress in types strictive and Infiltrative Cardiomyopathies: Part LQT1 and LQT2 of the long QT syndrome. 1. J Am Coll Cardiol 2018; 71: 1130-48. Heart 2001; 86: 39-44. Pereira NL, Grogan M, Dec GW. Spectrum of Re- Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, strictive and Infiltrative Cardiomyopathies: Part Shen W-K, Porter CJ. Epinephrine-Induced QT 2 of a 2-Part Series. J Am Coll Cardiol 2018; Interval Prolongation: A Gene-Specific Parado- 71: 1149-66. xical Response in Congenital Long QT Syn- Marcus FI, McKenna WJ, Sherrill D et al. Diagno- drome. Mayo Clin Proc 2002; 77: 413–21. sis of arrhythmogenic right ventricular cardio- Pelliccia A, Fagard R, Bjørnstad H, Anastassakis myopathy/dysplasia: proposed modification of A, Arbustini E, Assanelli D, et al. Recommenda- the Task Force Criteria. Circulation 2010; 31: tions for competitive sports participation in ath- 806-14. letes with cardiovascular diseaseA consensus Ghadri JR, Wittstein IS, Prasad A et al. Internatio- document from the Study Group of Sports Car- nal Expert Consensus Document on Takotsubo diology of the Working Group of Cardiac Reha- Syndrome (Part I): Clinical Characteristics, Dia- bilitation and Exercise Physiology and the gnostic Criteria, and Pathophysiology. Euro- Working Group of Myocardial and Pericardial pean Heart Journal 2018; 39: 2032-46. Diseases of the European Society of Cardio- logy. Eur Heart 2005; 26: 1422-45. Syndrome du takotsubo BJ. Drew, MJ. Ackerman, M Funk, WB Gibler, P Stresskardiomyopathie Kligfield, V Menon, et al. Prevention of Torsade (cardiomyopathie de stress ou transient left ven- de Pointes in Hospital Settings: A Scientific tricular apical ballooning) Statement From the American Heart Associa- Haslett C et al. Davidson Médecine Interne, Prin- tion and the American College of Cardiology cipes et Pratique. Maloine Editions, 2004, 1267 Foundation. Journal of the American College of Miller TH, Kruse JE, Evaluation of syncope. Am Cardiology 2010; 55:934-947. Fam Physician. 2005; 72: 1492-500. Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Bybee KA et al. Systematic review: transient left Kalman JM, Vohra JK, et al. The Response of ventricular apical ballooning: a syndrome that the QT Interval to the Brief Tachycardia Provo- mimics ST-segment elevation myocardial in- ked by Standing A Bedside Test for Diagnosing farction. Ann Intern Med 2004; 141: 858-65. Long QT Syndrome. J Am Coll Cardiol 2010; Wittstein IS et al. Neurohumoral Features of Myo- 55: 1955-61. cardial Stunning due to sudden emotional Schwartz PJ, Crotti L, Insolia R. Long-QT Syn- stress. N Engl J Med 2005; 352: 539-548. drome. Circ Arrhythmia Electrophysiol 2012; 5: Akashi YJ et al. The clinical features of takotsubo 868-77. cardiomyopathy. Q J Med 2003; 96: 563–573. Ackerman MJ, Priori SG, Willems S, Berul C, Bru- Handschin R, Hess N, Rickenbacher P. Tako- gada R, Calkins H, et al. HRS/EHRA Expert Tsubo-Kardiomyopathie: «transient left ventricu- Consensus Statement on the State of Genetic lar apical ballooning». Schweiz Med Forum Testing for the Channelopathies and Cardio- 2004; 4: 147-148. myopathies. Heart Rhythm. 2011; 8: 1308-39. Hurst RT, Askew JW, Reuss CS et al. Transient Schwartz PJ, Crotti L. QTc Behavior During Exer- midventricular ballooning syndrome: a new va- cise and Genetic Testing for the Long-QT Syn- riant. J Am Coll Cardiol. 2006; 48: 579-83. drome. Circulation 2011; 124: 2181-4. Templin C, Ghadri JR, Diekmann J et al. Clinical Priori SG, Blomström-Lundqvist C, Mazzanti A, Features and Outcomes of Takotsubo (Stress) Blom N, Borggrefe M, Camm J, et al. 2015 ESC Cardiomyopathy. NEJM 2015; 373: 929-38.. Guidelines for the management of patients with Arythmies ventricular arrhythmias and the prevention of sudden cardiac death Eur Heart J 2015; 36: Dancy M, Camm AJ. Misdiagnosis of chronic re- 2793-867. current ventricular tachycardia. Lancet 1985; Al-Khatib SM, Stevenson WG, Ackerman MJ, 8450: 320-3. Bryant WJ, Callans DJ, Curtis AB, et al. 2017 Stewart R, et al. Wide complex tachycardia: Mis- AHA/ACC/HRS guideline for management of diagnosis and outcome after emergency the- patients with ventricular arrhythmias and the rapy. Ann Int Med 1986; 104: 766-71. prevention of sudden cardiac death. Heart Griffith MJ, Ward DE, Linker NJ, Camm AJ. Ade- Rhythm 2018;15:e73-189. nosine in the diagnosis of broad complex tachy- Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ, cardia. Lancet 1988; 8587: 672-75. and of on and on and on in and of on Cardio- Wellens HJJ, Brugada P. Treatment of cardiac ar- logy A. Eligibility and Disqualification Recom- rhythmias: When, how and where ? J Am Coll mendations for Competitive Athletes With Cardiol 1989; 14: 1417-28. Cardiovascular Abnormalities: Task Force 10: Adamec R, Conti F, Zimmermann M, et al. Les The Cardiac Channelopathies. Circulation arythmies. In: Urgences Médicales. Restellini A, 13 2015;132:e326–9. phy. Eur J Echocardiogr 2000; 1: 72-9. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Erbel R, Alfonso F, Boileau C, et al. Diagnosis Bloise R, Marino M, et al. Interplay Between and management of aortic dissection. Eur Heart Genetic Substrate, QTc Duration, and Arrhyth- J 2001; 22: 1642-81. mia Risk in Patients With Long QT Syndrome. J Kawahito K, Adachi H, Yamaguchi A, et al. Preo- Am Coll Cardiol 2018; 71: 1663-71. pective risk factors for hospital mortality in acute type A aortic dissection. Ann Thorac Surg Torsade de pointes (voir aussi LQTS) 2001; 71: 1239-43. Vukmir BB. Torsades de pointes: a review. Am J Lederle AF, Wilson SE, Johnson GR, et al. Im- Emerg Med 1991; 9: 250-5. meadiate repair compared with surveillance of Napolitano C, Priori SG, Schwartz PJ. Torsade de small abdominal aortic aneurysms. N Engl J pointes. Mecanisms and management. Drugs Med 2002; 346: 1437-44. 1994; 47: 51-65. Roden DM. A practical approach to torsade de Syndrome de BRUGADA pointes. Clin Cardiol 1997; 20: 285-90. Brugada P, Brugada J. Righ bundle branch block, Viskin S. Long QT syndromes and torsade de persistent ST segment elevation and sudden pointes. Lancet 1999; 354: 1625-33. cardiac death: a distinct clinical and electrocar- Delacretat E. Médicaments et long QT. Forum diographic syndrome. Am J Coll Cardiol 1992; Med Suisse 2007; 7: 814-9. 20: 1391-96. Brugada P, Brugada R, Brugada J. The Brugada Dissection aortique syndrome. Curr Cardiol Rep 2000; 2: 507-14. De Bakey ME, Henly WS, Cooley DA, et al. Sur- Brugada J, Brugada R, Antzelevitch C, et al. gical management of dissecting aneurysms of Long-term follow-up of individuals with the elec- the aorta. J Thorac Cardiovasc 1965; 49: 130- trocardiographic pattern of right bundle-branch 49. block and ST-segment elevation in precodial Daily PO, Trueblood HW, Stinson EB, et al. Ma- leads V1 to V3. Circulation 2002; 105: 73-8. nagement of acute aortic dissections. Ann Tho- Chevallier St, Forclaz A, Tenkorang J, Schlaepfer, rac Surg 1970; 10: 237-47. J, Pruvot E et al. New Electrocardiographic Cri- Slater EE, DeSanctis RW. The clinical recognition teria for Discriminating Between Brugada Types of dissecting aortic aneurysm. Am J Med 1976; 2 and 3 Patterns and Incomplete Right Bundle 60: 625-33. Branch Block. JACC 2011; 58: 2290-8. Smith DC, Jang GC. Radiological diagnosis of Bayés de Luna A, Brugada J, Baranchuk A et al. aortic dissection. In: Doroghazi RM, Slater EE Current electrocardiographic criteria for diagno- (eds.). Aortic dissection. New York: Mc Graw- sis of Brugada pattern: a consensus report. J Hill 1983; 71: 71-132. Electrocardiol 2012; 45: 433-42. Greenwood WR. Robinson MD. Painless dissec- Brugada, J, Campuzano O, Arbelo, E et. Present tion of the thoracic aorta. Am J Emerg Med Status of Brugada Syndrome. JACC State-of- 1986; 4: 330-3. the-Art Review. JACC 2018; 9: 1046-59. DeSanctis RW, Doroghazi RM, Austen WG, et al. Aortic dissection. N Engl J Med 1987; 317: Intervalle QT - Long QT syndrome 1060-7. Sudden death Erbel R, Engberding R, Daniel W, et al. Echocar- Bazett HC. An analysis of the time relations of diography in diagnosis of aortic dissection. Lan- electrocardiograms. Heart 1920; 7: 353-70. cet 1989; 1: 457-61. Hodges M, Salerno D, Erlien D. Bazett’s QT cor- Crawford ES. The diagnosis and management of rection reviewed. Evidence that a linear QT cor- aortic dissection. JAMA 1990; 264: 2537-41. rection for heart ist better [Abstract]. J Am Coll Cheitlin MD, Alpert JS, Armstrong WF, et al. Cardiol 1983; 1: 694. ACC/AHA Guidelines for the clinical application Schwartz PJ. Idiopathic long QT syndrome: proof echocardiography. Circulation 1997; 95; gress and questions. Am Heart J 1985; 109: 1686-1744. 399-411. Elefteriades JA, Lovoulos MA, Tellides G, et al. Campbell CJC, Yusoff K, Moore M, et al. Impor- Management of descending aortic dissection. tance of lead selection in QT interval measure- Ann Thorac Surg 1999; 67: 2002-5; discussion ment. Am J Cardiol 1988; 61: 83-87. 2014-9. Day CP, James OF, Budler TJ, et al. QT prolonga- Juvonen T, Ergin MA, Galla JD, et al. Risk factors tion and sudden cardiac death in patients with for rupture of chronic type B dessections. J alcoholic liver disease. Lancet 1993; 341: 1423- Thorac Cardiovasc Surg 1999; 117: 776-86. 8. Hagan PG, Nienaber CA, Isselbacher EM, et al. Schwartz PJ, Moss AJ, Vincent GM, et al. Dia- The international registry of acute aortic dissec- gnostic criteria for the long QT syndrome. An tion (IRAD). New insights into an old disease. Update. Circulation 1993; 88: 782-4. JAMA 2000; 283: 897-903. Roden DM, Lazzara R, Rosen M, et al. Multiple Pepi M, Campodonico J, Galli C, et al. Rapid dia- mechanisms in the long-QT-syndrome. Current gnosis and management of thoracic aortic dis- knowledge, gaps and future directions. Circula- section and intramural haematoma: a tion 1996; 94: 1996-2012. prospective study of advantages of multiplane Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval vs. bilplane transoesophageal echocardiogra- abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048- 14 52. Atrial fibrillation in the preexcitation syndrome. Delacretat E. Médicaments et long QT. Forum Am J Cardiol 1977; 40: 514-20. Med Suisse 2007; 7: 814-9. Gallagher JJ, Pritchett EL, Sealy WC, Kasell J, Schwartz PJ , Crotti L. QTc Behavior During Exer- Wallace AG: The preexcitation syndromes. Prog cise and Genetic Testing for the Long-QT Syn- Cardiovasc Dis 1978; 20: 285-327. drome. Circulation 2011; 124: 2181-4. Gallagher JJ, Smith WM, Kasell JH, et al. Role of Priori SG, Blomström-Lundqvist C, Mazzanti A et Mahaim fibers in cardiac arrhythmias in man. al. 2015 ESC Guidelines for the management of Circulation 1981; 64: 176-89. patients with ventricular arrhythmias and the Bardy GH, Packer DL, German LD, et al. Preexci- prevention of sudden cardiac death The Task ted reciprocating tachycardia in patients with Force for the Management of Patients with Ven- Wolff-Parkinson -White syndrome: incidence tricular Arrhythmias and the Prevention of Sud- and mechanisms. Circulation 1984; 70: 377-91. den Cardiac Death of the European Society of Guize L, Soria R, Chaouat JC, et al. Prevalence Cardiology (ESC). Eur Heart J 2015; 36: 2793- and course of Wolff-Parkinson-White syndrome 2867. in a population of 138.048 subjects. Ann Med Interne (Paris) 1985; 136: 474-8. Voie veineuse centrale, SWAN-GANZ Waspe LE, Brodman R, Kim SG, et al. Suscepti- O’Quin R, Marini JJ. Pulmonary artey occlusion bility to atrial fibrillation and ventricular tachyar- pressure: clinical physiology, mesurement, and rhythmia in the Wolff-Parkinson-White interpretation. Am Rev Respir Dis 1983; 128: syndrome: role of the accessory pathway. Am 319-26. Heart J 1986;112: 1141-52. Sharkey SW. Beyond the wedge: clinical physio- Jackman WM, Wang XZ, Friday KJ, et al. Cathe- logy and the Swan-Ganz catheter. Am J Med ter ablation of accessory atrioventricular path- 1987; 83: 111-22. ways (Wolff-Parkinson-White syndrome) by Perret C, Tagan D, Feihl F. (eds.). Le cathété- radiofrequency current. N Engl J Med 1991; risme cardiaque droit en soins intensifs. Arnette 324: 1605-11. 1993. Gaita F, Giustetto C, Riccardi R, et al. Wolff-Par- Sandham JD, Hull RD, Brant RF, et al.; Canadian kinson-White syndrome. Identification and ma- Critical Care Clinical Trials Group. A randomi- nagement. Drugs 1992; 43: 185-200. zed, controlled trial of the use of pulmonary-ar- Gallay P, Grolleau R, Nicolai P. Les préexcitations tery catheters in high-risk surgical patients. N ventriculaires. In: Touboul P, et al. (eds.). Les Engl J Med 2003; 348: 5-14. troubles du rythme cardiaque. Paris Editions Tachycardie supraventriculaires Maloine 1993, p: 141-54. Kastor JA. Multifocal atrial tachycardia. N Engl J Munger TM, Packer DL, Hammill SC, et al.: A po- Med 1990; 322: 1713-1717. pulation study of the natural history of Wolff- Murgatroyd FD, Camm AJ. Atrial Fibrillation for Parkinson-White syndrome in Olmsted County, the clinician. In: Camme AJ, (ed.). Clinical ap- Minnesota, 1953-1989. Circulation 1993, 87: proaches to tachyarrhythmias. Volume 4. Fu- 866-73. tura Publishing Company Inc, Armonk, NY, Oren JW IV, Beckman KJ, McClelland JH, et al. A 1995. functional approach to the preexcitation syndro- Schläpfer J, Goy JJ. Urgences rythmiques. Praxis mes. Cardiol Clin 1993; 11: 121-149. 1995; 84: 1314-20. Ganz L, Friedman PL. Supraventricular tachycar- Saoudi N, Cosio F, Waldo A, et al. A classification dia. N Engl J Med 1995; 332: 162-73. of atrial flutter and regular atrial tachycardia ac- Al-Khatib SM, Pritchett EL. Clinical features of cording to electrophysiological mechanisms and Wolff-Parkinson-White syndrome. Am Heart J anatomical bases. European Heart Journal 1999;138:403-13. 2001; 22: 1162-82. Basson CT. A molecular basis for Wolff-Parkin- 2015 ACC/AHA/HRS Guideline for the Manage- son-White Syndrome. N Engl J Med 2001; 344: ment of Adult Patients With Supraventricular Ta- 1861-4. chycardia: A Report of the American College of Fitzsimmons PJ, McWhirter PD, Peterson DW, Cardiology/American Heart Association Task Kruyer WB. The natural history of Wolff-Parkin- Force on Clinical Practice Guidelines and the son-White syndrome in 228 military aviators: a Heart Rhythm Society. Page RL, Joglar JA, long-term follow-up of 22 years. Am Heart J Caldwell MA, Calkins H, Conti JB, Deal BJ, 2001; 142:530-6. Estes NA 3rd, Field ME, Goldberger ZD, Ham- Gollob MH, Green MS, Tang ASL, et al. Identifi- mill SC, Indik JH, Lindsay BD, Olshansky B, caiton of a gene responsible for familias Wolff- Russo AM, Shen WK, Tracy CM, Al-Khatib SM; Parkinson-White Syndrome. N Engl J Med Evidence Review Committee Chair. Circulation 2001; 344: 1823-31. 2016; 133: e506-74. Pappone C, Santinelli V, Manguso F, et al. A randomized of prophylactic catheter ablation in Syndromes de préexcitation - WPW asymptomatic patients with the Wolff-Parkin- Wolff L, Parkinson J, White PD. Bundle-branch son-White syndrome. N Enlg J Med 2003; 349: block with short P-R interval in healthy young 1803-11. people prone to paroxysmal tachycardia. Am Pediatric and Congenital Electrophysiology So- Heart J 1930; 5: 685-704. ciety (PACES) et al. PACES/HRS expert con- Campbell RW, Smith RA, Gallagher JJ, et al. sensus statement on the management of the 15 asymptomatic young patient with a Wolff-Par- 1990; 8: 411-42. kinson-White (WPW, ventricular preexcitation) Brugada P, Brugada J, Mont L, Smeets J, Andries electrocardiographic pattern: developed in part- EW. A new approach to the differentiai diagno- nership between the Pediatric and Congenital sis of a regular tachycardia with a wide QRS Electrophysiology Society (PACES) and the complex. Circulation 1991; 83: 1649-59. Heart Rhythm Society (HRS). Endorsed by the Wyse DG. Pharmacologic therapy in patients with governing bodies of PACES, HRS, the Ameri- ventricular tachyarrhythmias. Cardiol Clin 1993; can College of Cardiology Foundation (ACCF), 11:65-83. the American Heart Association (AHA), the Antunes E, Brugada J, Steurer G, Andries E, Bru- American Academy of Pediatrics (AAP), and the gada P The differential diagnosis of a regul ta- Canadian Heart Rhythm Society (CHRS). Heart chycarw ith a wide QRS complex on the Rhythm 2012; 9: 1006-24. 12-lead ECG: ventricular tachycardia, supra- Brugada J, Katritsis DG, Arbelo E et al. 2019 ESC ventricular tachycardia with aberrant intraventri- Guidelines for the management of patients with cular conduction, and supraventricular supraventricular tachycardiaThe Task Force for tachycardia with anterograde conduction over the management of patients with supraventricu- an accessor pathway.Pacin Clin Electrophysiol lar tachycardia of the European Society of Car- 1994: 17; 1515-24. diology (ESC). Eur Heart J 2020;41: 655-720. Ganz LI,. Friedmann P. Supraventricular tachycardia. N Engl J Med 1995; 332: 162-73. Tachycardie ventriculaire, QRS larges Vukmir RB. Cardiac arrhythmia therapy. Am J Breitkomplextachykardien Emerg Med 1995; 13: 459-70. Lewis T. Clinical Electrocardiography. Clinical Vereckei A, Duray G, Szénási G, Altemose GT, Electrocardiography. 5th Edition. Auricular fibril- Miller JM. Application of a new algorithm in the lation Shaw and Sons 1931: 87–100. differential diagnosis of wide QRS complex ta- Sandler IA, Marriott HJL.The differential morpho- chycardia. Eur Heart J 2007; 28: 598-600. logy of anomalous ventricular complexes of Vereckei A, Duray G, Szénási G, Altemose GT, RBBB type in V1. Ventricular ectopy versus Miller JM. New algorithm using only lead aVR aberration. Circulation 1965; 31: 551-6. for differential diagnosis of wide QRS complex Marriott HJL,Sandler IA. Criteria, old and new, for tachycardia. Heart Rhythm 2008; 5: 89-98. differentiating between ectopic ventricular beat Issa F, Miller JM, Zipes DP. Clinical arrhythmo- and aberrant ventricular conduction in the pre- logy and electrophysiology 2nd Edition.Ap- sence of atrial fibrillation. Prog Cardiovasc Dis proach towide QRS complex tachycardias. 1966; 9:18-2 Elsevier, Saunders 2012: 499-511. Swanick EJ, LaCamera F, Marriott HJL.Morpholo- Vereckei A. Current Algorithms for the Diagnosis gic features of right ventricular ectopic beats. of wide QRS Complex Tachycardias. Curr Car- Am J Cardiol 1972; 30:888-91. diol Rev 2014;10: 262-76. Wellens HJJ, Bar FW, Lie KL The value of the Priori SG, Blomström-Lundqvist C, Mazzanti A et electrocardiogramsin the differential diagnosis al. 2015 ESC Guidelines for the Management of of tachycardia with a widened QRS Patients With Ventricular Arrhythmias and the complex.Am J Med 1978; 64:27-33. Prevention of Sudden Cardiac Death: The Task Wellens HJJ, Bar FW, Vanagt FJ, et al. The diffe- Force for the Management of Patients With rentiation between ventricular tachycardia and Ventricular Arrhythmias and the Prevention of supraventricular tachycardia with aberrant con- Sudden Cardiac Death of the European Society duction: the value of the 12-lead electrocardio- of Cardiology (ESC). Endorsed By: Association gram. In: Wellens HJJ, Kulbertus HE (eds). for European Paediatric and Congenital Cardio- What’s New in Electrocardiography. Boston: logy (AEPC). Eur Heart J 2015;3 6: 2793-2867. Nijhoff 1981, p: 184-99. Al-Khatib SM, Stevenson WG, Ackerman MJ, et Coumel P, Leclercq JF, Attuel P, Maisonblanche al. 2017 AHA/ACC/HRS Guideline for Manage- P.The QRS morphology in post myocardial in- ment of Patients With Ventricular Arrhythmias farction ventricular tachycardia. A study of 100 and the Prevention of Sudden Cardiac Death: A tracings compared with 70 cases of idiopathic Report of the American College of ventricular tachycardia. Eur Heart J 1984; Cardiology/American Heart Association Task 5:792-805. Force on Clinical Practice Guidelines and the Wellens HJJ, Brugada P. Diagnosis of ventricular Heart Rhythm Society. J Am Coll Cardiol 2018; tachycardia from the 12-lead electrocardiogram. 72:e91 Cardiol Clin 1987; 5: 511-25. Tchou P, Young P, Mahmud R, et al. Useful clini- Bloc atrio-ventriculaire cal criteria for the diagnosis of ventricular tachy- Wagner GS, Waugh RA, Ramo NW. (eds.). In: cardia. Am J Med 1988; 84: 53-6. Cardiac arrhythmias. Churchill Livingstone Kindwall KE, Browns J, Josephson ME. Electro- 1983, p: 217-30. cardiographic criteria for ventricular tachycardia Wagner GS. (ed.). In: Marriot’s Practical electro- in wide complex left bundle branch block mor- cardiography. 9th ed. Williams & Wilkins 1994, phology tachycardias. AM J. Cardiol 1988; 61: p: 388-94. 1279-83. Josephson ME, Wellens HJJ. Differential diagno- Péricardite/Myocardite et tamponnade sis of supraventricular tachycardia. Cardiol Clin Spodick DH. Differential diagnosis of acute peri- 16 carditis. Prog Cardiovasc Dis 1971; 14: 192- 486-9. 209. Bernard C, de Moerloose P. Anticorps anticardioli- Marini PV, Hull AR. Uremic pericarditis: a review pine et thromboses. Med Hyg 1990; 48: 166-9. of incidence and management. Kidney Int Suppl Bounameaux H, Chevrolet JC. Le rôle de la 1975; 2: 163-6. thrombolyse dans le traitement de l’embolie pul- Spodick DH. Arrythmias and pericardial disease. monaire. Schweiz Med Wschr 1991; 121: 1654- Am J Cardiol 1984; 53: 265. 7. Spodick DH. Pericarditis, pericardial effusion, car- Stein PD, Perrin ML, Hales CA, et al. Clinical, la- diac tamponade and constriction. Crit Care Clin boratory, roentgenographic, and electrocardio- 1989; 5: 455-76. graphic findings in patients with acute Battle RW, Le Winter MM. The evaluation and pulmonary embolism and no pre-existing car- management of pericardial disease. Curr Opin diac or pulmonary disease. Chest 1991; 10: Cardiol 1990; 5: 331-9. 598-603. Spodick DH. Pericardial disease. Mayo Clin Proc. Lutter K, Kerr T, Roedersheimer L, et al. Superfi- 1992; 67: 201-2. cial thrombophlebitis diangosed by duplex Zayas R, Anguita M, Torres F, et al. Incidence of scanning. Surgery 1991; 10: 42-6. specific etiology and role of methods for specific Raschke RA, Reilly BM, Guidry JR, Fontana JR, etiologic diagnosis of primary acute pericarditis. Srinivas S. The weight-based heparin dosing Am J Cardiol 1995; 75: 378-82. nomogram compared with a "standard care" no- Marinella MA. Acute pericarditis. Am Fam Phys mogram. A randomized controlled trial. Ann In- 1998; 57: 702-4. tern Med 1993;119:874-81. Adler Y, Finkelstein Y, Guindo J, et al. Colchicine Perrier A, Bounameau H, Morabia A, et al. Contri- treatment for recurrent pericarditis. A decade of bution of Plasma D-dimer and lower limb ve- experience. Circulation 1998; 97: 2183-5. nous ultrasound to the diagnosis pf pulmonary Longo M, Jaffe CC. Electric alternans. N Engl J embolism: a decision analysis. Am Heart J Med 1999; 341: 2060. 1994; 127: 624-35. Spodick DH. Acute cardiac tamponade. N Engl J Svensson PJ, Dahlbäck B. Resistance to acti- Med 2003; 349: 684-90. vated protein C as a basis for venous thrombo- Lange RA, Hillis LD. Clinical practice. Acute peri- sis. N Engl J Med 1994; 330: 518-22. carditis. N Engl J Med 2004; 351:2195. Ginsberg JS, Wells PhS, Brill-Edwards P, et al. Maisch B, Seferovic PM, Ristic AD, et al. Guideli- Antiphospholipid antibodies and venous throm- nes on the diagnosis and management of peri- boembolism. Blood 1995; 86: 3685-91. cardial disease: The task force on the diagnosis Lensing AWA, Prins MH, Davidson BL, Hirsh J. and management of pericardial disease of the Treatment of deep venous thrombosis with low- European Society of Cardiology. European molecular-weight heparins. Arch Intern Med Heart Journal 2004; 25:587. 1995; 155: 601-7. Imazio M, Bobbio M, Cecchi Enrico et al. Colchi- Bounameaux H, de Moerloose Ph, Sarasin FP. cine in addition to conventional therapy for Optimal duration of oral anticoagulation therapy acute pericarditis. Results of the Cochicine for following deep vein thrombosis of lower limbs. acute PEricarditis (COPE) trial. Circulation Blood Coag Fibrinol 1996; 7: 507-14. 2005; 112: 2012-2016. Cavenagh JD, Colvin BT. Guidelines for the ma- Imazio M, Bobbio M, Cecchi Enrico et al. Colchi- nagement of thrombophilia. Postgrad Med J cine as first-choice therapy for recurrent peri- 1996; 72: 87-94. carditi; results of the CORE (Colchicine for Ginsberg JS. Management of venous thrombo- REcurrent perocarditis) trial. Arch Intern Med. embolism. N Engl J Med 1996; 335; 1816-28. 2005; 165: 1987-1991. Levine M, Gent M, Hirsh J, et al. A comparison of Imazio M, Trinchero R. Myopericarditis: etiology, low-molecular-weight heparin administered pri- management, and prognosis. Intern J Cardiol marily at home with unfractionated heparin ad- 2008; 127: 17-26. mistered in the hospital for proximal deep-vein Imazio M, Gaita F. Diagnosis and treatment of pe- thrombosis. NEJM 1996; 334: 677-81. ricarditis. Heart 2015; 101: 1159-68. Hirsh J, Hoak J. Management of deep vein throm- Mansoor AM, Karlapudi SP. Kussmaul’s Sign. bosis and pulmonary embolism. A statement for NEJM 2015;372: e3 healthcare professionals. Council on Thrombo- Hessulf F, Ljungberg J, Johansson PA, et al. sis (in consultation with the Council on Cardio- Campylobacter jejuni-associated perimyocardi- vascular Radiology), American Heart tis: two case reports and review of the literature. Association. Circulation 1996; 93: 2212-45. BMC Infections Disease 2016; 16: 289-95. Perrier A, Bounameaux H, Morabia A, et al. Dia- Maladie thromboembolique veineuse gnosis of pulmonary embolism by a decision MTEV (thrombose veinsues profonde, analysis-based strategy including clinical proba- embolie pulmonaire)- Lungenembolie, bility D-dimer levels, and ultrasonography: a Tiefe Venenthrombose management study. Arch Intern Med 1996; 156: Hughes GRV. Thrombosis, abortion, cerebral 531-6. disease and the lupus anti-coagulant. BMJ Büller HR, Gent M, Gallus AS, et al. Low-molecu- 1983; 287: 1088-9. lar-weight heparin in the treatment of patients Hughes GRV, Harris EN, Gharavi AE. The anti- with venous thromboembolism. N Engl J Med cardiolipine syndrome. J Rheumatol 1986; 13: 1997; 337: 657-62. 17 Dalen JE, Alpert JA. Thrombolytic therapy for pul- Lee AY, Levine MN. Venous thromboembolism monary embolism: is it effective ? is it safe ? and cancer: risks and outcomes. Circulation Arch Intern Med 1997; 157: 2550-6. 2003; 1072 Suppl. 1: I17 21. Daniels LB, Parker JA, Patel SR, et al. Relation of Ridker PM, Goldhaber SZ, Danielson E, et al. duration of symptoms with response to throm- Long-term, low-intensity warfarin therapy for the bolytic therapy in pulmonary embolism. Am J prevention of recurrent venous thromboembo- Cardiol 1997; 80: 184-88 lism. N Engl J Med 2003; 348: 1425-34. Schulman S, et al. The duration of oral anticoagu- Kearon C, Ginsberg JS, Kovacs M, et al. Compa- lant therapy after a second episode of venous rison of low-intensity warfarin therapy with con- thromboembolism. N Engl J Med 1997; 336: ventional-intensity warfarin therapy for 393-8. long-term prevention of recurrent venous throm- Wells PS, Anderson DR, Bormanis J, et al. Value boembolism. N Engl J Med 2003; 349: 631-9. of assessment of pretest probability of deep- Crowther MA, Ginsberg JS, Math JJ, et al. A com- vein thrombosis in clinical management. Lancet parison of two intensitiesof warfarin for the pre- 1997; 350: 1795-8. vention of recurrent thrombosis in patients with Büller H, ten Cate JW. Primary venous thrombo- antiphospholipid antibody syndrome. N Engl J embolism and cancer screening. N Engl J Med Med 2003; 349: 1133-8. 1998; 338: 1221-2. Fedullo PF, Tapson VF. The evaulation of suspec- Hyers TN, Agnelli G, Hull RD, et al. Antithrombo- ted pulmonary embolism. N Engl J Med 2003; tic therapy for venous thromboembolic disease. 349: 1247-56. Chest 1998; 114(Suppl.): 561S-78S. Superficial thrombophlebitis treated by enoxapa- Sorensen HT, Mellemkjaer L, Steffensen FH, et rin Study Group. A pilot randomised double- al. The risk of a diagnosis of cancer after pri- blind compraison of a low-molecular-weight mary deep venous thrombosis or pulmonary heparin, a nonsteroidal anti-inflammatory agent, embolism. N Engl J Med 1998; 338: 1169-74. and placebo in the treatment of superficial vein Bouneameaux H, Beer J, Blättler W, et al. Le trai- thrombosis. Arch Intern Med 2003; 163: 1657- tement ambulatoire de la thrombose veineuse 63. profonde: prise de position d’un comité d’ex- Wells PA, Anderson DR, Rodger M, et al. Evalua- perts. Bull Med Suisses 1999; 80: 405-6. tion of d-dimer in the diangosis of suspected Huisman MV, Rosendaal RF. Thrombophilia. Curr deep-vein thrombosis. N Engl J Med 2003; 349: Opin Hematol 1999; 6: 291-7. 1227-35. Perrier A, Desmarais S, Miron MJ, et al. Non-in- The Matisse Investigators. Subcutaneous Fonda- vasive diagnosis of venous thromboembolism in parinux versus intravenous unfractionated he- outpatients including clinical probability, D- parin in the initial treatment of pulmonary dimer and ultrasonography. Lancet 1999; 353: embolism. N Engl J Med 2003; 349: 1695-702. 190-5. Bates SM, Ginsberg JS. Treatment of deep-vein Wells PS, Anderson DR, Ginsberg J. Assessment thrombosis. N Engl J Med 2004; 351: 268-77. of deep vein thrombosis or pulmonary embo- Kyrle P, Minar E, Bialonczyk C et al. The rist of lism by the combined use of clinical model and recurrent venous thromboembolism in men and nonivasive diagnostic tests. Semin Thromb He- woman. N Engl J Med 2004; 350: 2558-63. most 2000; 26: 643-56. Antithrombotische und thrombolytische Behand- Bounameaux H, de Moerloose Ph, Perrier A. Dia- lung: Internationale EBM-Guidelines, kommen- gnostic de la thrombose veineuse profonde et tiert von Schweizer Experten. The 7th ACCP de l’embolie pulmonaire. Med Hyg 2000; 58: Conference on Antithombotic and thromboytic 161-9. therapy. Swiss Med Forum 2005 (Suppl 27):1- Wells PS, Anderson DR, Rodger M, et al. Deriva- 48S. tion of a simple clinical model to categorize pa- Aujesky D, Obrosky DS, Stone RA, Auble TE, tients probability of pulmonary embolism: Perrier A, Cornuz J, Roy PM, Fine MJ. Deriva- increasing the models utility with the SimpliRED tion and validation of a prognostic model for D-dimer. Thromb Haemost 2000; 83: 416-420. pulmonary embolism. Am J Respir Crit Care Perrier A, Bounameaux H. Cost-effective diagno- Med 2005;172:1041-1046. sis of deep vein thrombosis and pulmonary em- Perrier A, Roy P.-M, Sanchez O, et al. Multidetec- bolism. Thromb Haemost 2001; 86: 475-87. tor-Row Computed Tomography in Suspected Sixth ACCP Consensus Conference on anti- Pulmonary Embolism. N Engl J Med 2005; 352: thrombotic therapy. Chest 2001; 119 (Suppl. 1): 1760-8. 1S-336S. Traitement antithrombotique et thromboyltique: Wicki J, Perneger TV, Junod AV, et al. Assessing Commentaires des experts suisses concentrant clinical probability of pulmonary embolism in the les «EBM-guidelines» internationales. 7th Con- emergency ward: a simple score. Arch Intern ference on antithrombotic and thrombolytic the- Med 2001; 161: 92-7. rapy. Swiss Med Forum 2005 (Suppl 28): Goldhaber SZ. Thrombolysis for pulmonary em- 1-48S. bolism. N Engl J Med 2002; 347: 1131-2. Jeanneret Ch, Baldi Th, Jenelten R. Die ober- Konstantinides S, Geibel A, Heusel G. Heparin flächliche Thrombophlebitis: ein Überblick. plus Alteplase compared with heparin alone in Schweiz Med For 2006; 6: 190-195. patients with submassive pulmonary embolism. The van Gogh Investigators. Idraparinux versus N Engl J Med 2002; 347: 1143-50. Standard Therapy for Venous Thromboembolic 18 Disease. N Engl J Med 2007: 357: 1094-1104. Guidelines. Chest 2012 ;141 (2 Suppl):e419S- The van Gogh Investigators. Extended Prophyla- 94S. xis of Venous Thromboembolism with Idrapari- Prins MH, Lensing A.WA, Bauersachs R et al. nux. N Engl J Med 2007: 357: 1105-12. Oral rivaroxaban versus standard therapy for Antithrombotic and thrombolytic therayp: Ameri- the treatment of symptomatic venous thrombo- can College of Chest Physicians Evidence- embolism: a pooled analysis of the EINSTEIN- based clinical practice guidelines (8th Editions). DVT and PE randomized studies. Thromb J Chest 2008; 133 (suppl): 1-968S. 2013, 11: 21. Carrier M, et al. Systematic review: the Trous- Fontana P, Goldhaber SZ, Bounameaux H. Direct seau syndrome revisited: should we screen ex- oral anticoagulants in the treatment and long- tensively for cancer in patients with venous term prevention of venous thrombo-embolism. thromboembolism? Ann Intern Med 2008; 149: Eur Heart J 2014; 35: 1836-43. 323-33. Meyer G, Vicaut E, Danays T et al. PEITHO Inve- Gibson NS, Sohne M, Kruip MJHA, et al.; Christo- stigators. Fibrinolysis for Patients with Interme- pher study investigators. Further validation and diate-Risk Pulmonary Embolism. N Engl J Med simplification of the Wells clinical decision rule 2014; 370:1402-11. in pulmonary embolism. Thromb Haemost Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s 2008; 99: 229-234. Choice - efficacy and safety of the new oral an- Guyatt GH, Oxman, AD, Vist GE et al. for the ticoagulants dabigatran, rivaroxaban, apixaban, GRADE working group. GRADE: an emerging and edoxaban in the treatment and secondary consensuss on rating quality of evidence and prevention of venous thromboembolism: a sy- strength oh recommendations. BMJ 2008; 336: stematic review and meta-analysis of phase III 924-6. trials. Eur J Vasc Endovasc Surg 2014; 48: 565- Kahn SR, Shrier I, Julian JA, et al. Determinants 75. and time course of the postthrombotic syn- Righini M, Van Es J, Den Exter PL et al. Age-ad- drome after acute deep venous thrombosis. justed D-dimer cutoff levels to rule out pulmo- Ann Intern Med 2008;149:698-707. nary embolism: the ADJUST-PE study. JAMA. Righini M, Perrier A, De Moerloise P, et al. D- 2014; 311: 1117-24. doi: Dimer for venous thromboembolism diagnosis: 10.1001/jama.2014.2135. 20 years later. J Thromb Haemost 2008; 6: The Task Force for the Diagnosis and Manage- 1059- 71. ment of Acute Pulmonary Embolism of the Eu- Weitz JI, Hirsh J, Samama MM. New antithrom- ropean Society of Cardiology (ESC). 2014 ESC botic drugs: American College of Chest Physici- Guidelines on the diagnosis and management ans Evidence-based clinical practice guidelines of acute pulmonary embolism. European Heart (8th Edition). Cherst 2008; 133 (Suppl):234- Journal 2014; 35: 3033-80. 56.S. Bates SH, Greer IA, Middeldorp S et al. VTE, Eklof B, Perrin M, Delis KT, et al. Updated termi- Thrombophilia, Antithrombotic Therapy, and nology of chronic venous disorders: The VEIN- Pregnancy Antithrombotic Therapy and Preven- TERM transatlantic interdisciplinary consensus tion of Thrombosis, 9th ed: American College of document. J Vasc Surg 2009;49:498-501. Chest Physicians Evidence-Based Clinical Jiménez D, Aujesky D, Moores L, Gomez V, Lobo Practice Guidelines. CHEST 2012; JL, Uresandi F, Otero R, Monreal M, Muriel A, 141(2)(Suppl):e691S–e736S. Yusen RD; RIETE Investigators. Simplification National Clinical Guideline, National Institute for of the pulmonary embolism severity index for Health and Clinical Excellence: Guidance, in prognostication in patients with acute sympto- Venous Thromboembolic Diseases: The Ma- matic pulmonary embolism. Arch Intern Med nagement of Venous Thromboem bolic Disea- 2010;170:1383-1389. ses and the Role of Thrombophilia Testing. Karthikesalingam A, Young EL, Hinchliffe RJ, et Londres: Royal College of Physicians (UK) Na- al. A systematic review of percutaneous mecha- tional Clinical Guideline Centre, 2012. nical thrombectomy in the treatment of deep ve- Fahrni J, Engelberger RP, Kucher N, et al. Cathe- nous thrombosis. Eur J Vasc Endovasc Surg ter-based treatment of ilio-femoral deep vein 2011; 41: 554-65. thrombosis – an update on current evidence. Pollack CV, Schreiber D, Goldhaber SZ, et al. Cli- Vasa 2013; 42: 161-7. nical characteristics, management, and outco- Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s mes of patients diagnosed with acute Choice - efficacy and safety of the new oral an- pulmonary embolism in the emergency depart- ticoagulants dabigatran, rivaroxaban, apixaban, ment: initial report of EMPEROR (Multicenter Emergency and edoxaban in the treatment and secondary Medicine Pulmonary Embolism in the Real World Regi- prevention of venous thromboembolism: a sy- stry). J Am Coll Cardiol 2011; 57: 700-706. stematic review and meta-analysis of phase III Zondag W, Mos IC, Creemers-Schild D et al. Outpatient trials. Eur J Vasc Endovasc Surg 2014; 48: 565- treatment in patients with acute pulmonary embolism: 575. the Hestia Study. J Thromb Haemost 2011;9:1500-7. Engelberger RP, Alatri A, Qanadli SD et al. Traite- Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy ment percutané de la thrombose veineuse pro- for VTE disease: Antithrombotic Therapy and Prevention fonde aiguë. Rev Med Suisse 2015; 11 : of Thrombosis, 9th ed: American College of Chest 348-51. Physicians Evidence-Based Clinical Practice Kearon C, Elien K, Ornelas J et al. Antithrombotic 19 Therapy for VTE Disease. CHEST Guideline patients with isolatet systolic hypertension. Sy- and Expert Panel Report. Chest 2016; 149: stolic Hypertension in the Elderly Program Co- 315-352. operative Research Group. JAMA 1996; 276: Klok FA, Hosel V, Clemens A, et al. Prediction of 1886-92. bleeding events in patients with venous throm- Elliott J. ALLHAT: The largest and most important boembolism on stable anticoagulation treat- clinical trial in hypertension ever done in the ment. Eur Respir J 2016; 48: 1369-76. USA. Antihypertensive and lipid lowering treat- Jara-Palomares L, et al. Development of a risk ment to prevent heart attack trial. Am J Hyper- prediction score for occult cancer in patients tension 1996; 9: 409-11. with VTE. Chest 2017; 151: 564-71. Pitt B, Segal R, Martinez FA, et al. Randomised Klok FA, Barco S, Konstantinides SV. External trial of losartan versus captopril in patients over validation of the VTE-BLEED score for predic- 65 with heart failure (Evaluation of Losartan in ting major bleeding in stable anticoagulated pa- the Elderly Study, ELITE). Lancet 1997; 349: tients with venous thromboembolism. Thromb 747-52. Haemost 2017; 117: 1164-70. The Sixth Report of the Joint National Committee Carcaterra A, Serratrice J, Righinin, et al. Maladie on Detection, Evaluation, and Diagnosis of High thromboembolique veineuse idiopathique : faut- Blood Pressure. Arch Intern Med 1997; 157: il rechercher un cancer occulte? Rev Med 2413-46. Suisse 2018 ; 14 : 1840-3. Estacio RO, Jeffers BW, Hiatt WR, et al. The ef- Konstantinides SV, Meyer G, Becattini C et al. fect of nisoldipine as compared with enalapril The Task Force for the diagnosis and manage- on cardiovascular outcomes in patients with ment of acute pulmonary embolism of the Euro- non-insulin-dependent diabetes and hyperten- pean Society of Cardiology (ESC). 2019 ESC sion. N Engl J Med 1998; 338: 645-52. Guidelines for the diagnosis and management Frishman WH, Nalamati J. Carvedilol: a new of acute pulmonaryembolism developed in col- alpha- and beta-adrenergic blocker for heart fai- laboration with the European Respiratory So- lure and hypertension. N Engl J Med 1998; 339: ciety (ERS): supplementary data. Eur Heart J 1759-65. 2019; 00:1-19. Hansson L, Zanchetti A, Carruthers SG, et al. Ef- Konstantinides SV, Meyer G, Becattini C et al. fects of intensive blood-pressure lowering and The Task Force for the diagnosis and manage- low-dose aspirin in patients with hypertension: ment of acute pulmonary embolism of the Euro- Principal results of the hypertension optimal pean Society of Cardiology (ESC). 2019 ESC treatment (HOT) randomised trial. Lancet 1998; Guidelines for the diagnosis and management 351: 1755-62. of acute pulmonaryembolism developed in col- Recommendations of the Second Joint Task laboration with the European Respiratory So- Force of European and other Societies on coro- ciety (ERS). Eur Heart J 2020; 41: 543-603 nary Prevention. Eur Heart J 1998; 19: 1434- 1503. Hypertension artérielle (HTA) Tati P, Pahor M, Byington RP, et al. Fosinopril WEB - Canada (mise à jour: Luc Lanthier, Sher- Amlodipine Cardiovascular Events Trial. Out- brooke): come results of the Fosinopril versus Amlodi- www.hypertension.qc.ca pine Cardiovascular Events Randomised trial WEB - Suisse: www.swisshypertension.ch (FACET) in patients with hypertension and Strandgaard S, Olesen J, Skinhoj E, et al. Autore- NIDDM. Diabetes Care 1998; 21: 597-603. gulation of brain circulation in severe arterial hy- UK Prospective Diabetes Study Group. Tight pertension. BMJ 1973; 1: 507-10. blood pressure control and risk of macrovascu- Messerli FH, Ventura HO, Amodeo C. Osler’s ma- lar and microvascular complications in type 2 neuver and pseudohypertension. N Engl J Med diabetes: UKPDS 38. BMJ 1998; 317: 703-13. 1985; 312: 1548-51. UK Prospective Diabetes Study Group. Efficacy Dahlhof B, Lindholm LH, Hansson L, et al. Morbi- of atenolol and captopril in reducing risk of ma- dity and mortality in Swedish Trial in Old Pa- crovascular and microvascular complications in tients with Hypertension (STOP-Hypertension). type 2 diabetes: UKPDS 39. BMJ 1998; 317: Lancet 1991; 338: 1281-5. 713-20. Melburne Diabetic Nephropathy Study Group: Hansson L, Lindholm LH, Ekbom T, et al. Rando- comparison between perindopril and nifedipine mised trial of old and new antihypertensive in hypertensive and normotensive diabetic pa- drugs in elderly patients: cardiovascular morta- tients with microalbuminuria. BMJ 1991; 302: lity and morbidity in the Swedish Trial in Old Pa- 210-6. tients with Hypertension-2 study. Lancet 1999; Phillips SJ. Pathophysiology and management of 354: 1751-6. hypertension in acute Hansson L, Lindholm LH, Niskanen L, et al. Effect ischemic stroke. Hypertension 1994; 23: 131-6. of angiotensin-converting-enzyme inhibition Laragh JH, Brenner BM (eds.). In: Hypertension: compared with conventional therapy on cardio- Pathophysiology, diagnosis, and management. vascular morbidity and mortality in hyperten- New York: Raven Press, 1995. sion: the Captopril Prevention Project (CAPPP) Curb JD, Pressel SL, Cutler JA, et al. Effect of di- randomised trial. Lancet 1999; 353: 611-6. uretic-based antihypertensive treatment on car- Ramsay LE, Williams B, Johnston D, et al. British diovascular disease risk in older diabetic Hypertension Society guidelines for hyperten- 20 sion management 1999: summary. BMJ 1999; Cohn JN, Tognoni G, et al. A randomized trial of 319: 630-5. the angiotensin-receptor blocker Valsartan in Tuomilenhto J, Rastenyte D, Birkenhäger WH, et chronic heart failure. N Engl J Med 2001; 345: al. Effects of calcium-channel blockade in older 1667-75. patients with diabetes and systolic hyperten- Lewis EJ, Hunsicker LG, Clarke WR, et al. Reno- sion. N Engl J Med 1999; 340: 677-84. protective effect of the angiotensin-receptor ant- 1999 World Health Organization-International So- agonist Irbesartan in patients with nephropathy ciety of Hypertension. Guidelines for the ma- due to type 2 diabetes. N Engl J Med 2001; nagement of hypertension . J Hypertens 1999; 345: 851-60. 17: 905-83. Parving HH, Lehnert H, Brochner-Mortensen J, et Campbell NR, McKay DW. Accurate blood pres- al. The effect of Irbesartan on the development sure measurement: why does it matter? Can of diabetic nephropathy in patients with type 2 Med Assoc 1999; 161: 277-8. diabetes. N Engl J Med 2001; 345: 870-8. Dickerson JEFC, Hingorani HG, Ashby MJ, et al. PROGRESS Collaborative Group. Randomised Optimisation of antihypertensive treatment by trial of perindopril-based blood-pressure-lowe- crossover rotation of four major classes. Lancet ring regimen among 6,105 individuals with pre- 1999; 353: 2008-13. vious stroke or transient ischaemic attack. ALLHAT Collaborative Research Group. Major Lancet 2001; 358: 1033-41. cardiovascular events in hypertensive patients Sacks FM, Svetkey LP, Vollmer WM, et al. Effects randomized to doxazosine vs chlorthalidone: on blood pressure of reduced dietary sodium the antihypertensive and lipid-lowering treat- and Dietary Approaches to Stop Hypertension ment to prevent heart attack trial (ALLHAT). (DASH) diet. N Engl J Med 2001; 344: 3-10. JAMA 2000; 283: 1967-75. Sanmuganathan PS, Ghahramani P, Jackson PR, Brown MJ, Palmer CR, Castaigne A, et al. Morbi- et al. Aspirin for primary prevention of coronary tidy and mortality in patients radomised to dou- heart disease: safety and absolute benefit rela- ble-blind treatment with a long-acting ted to coronary risk derived from meta-analysis calcium-chanel blocker or diuretic in the Inter- of randomised trials. Heart 2001; 85: 265-71. national Nifedipine GITS study: Intervention as The canadian recommendations for the manage- a Goal in Hypertension Treatment (INSIGHT). ment of hypertension: Part 1 - Therapy. Can J Lancet 2000; 356: 366-72. Cardiol 2001; 17: 543-59. Hansson L, Hedner T, Lund-Johansen P, et al. The canadian recommendations for the manage- Randomised trial of effects of calcium antago- ment of hypertension: Part 2 - Diagnosis and nists compared with diuretics and beta-blockers assessment of people with high blood pressure. on cardiovascular morbidity and mortality in hy- Can J Cardiol 2001; 17: 1249-63. pertension: the Nordic Diltiazem (NORDIL) Vasan RS, Larson MG, Leip EP, et al. Impact of study. Lancet 2000; 356: 359-65. high-normal blood pressure one the risk of car- Mogensen CE, Neldam S, Tikkanen I, et al. Ran- diovascular disease. N Engl J Med 2001; 345: domised controlled trial of dual blockade of 1291-7. renin-angiotensin system in patients with hyper- American Diabetes Association: clinical practice tension, microalbuminuria, and non-microalbu- recommendations 2002. Diabetes Care 2002; minuria (CALM) study. BMJ 2000; 321: 1440-4. 25 (Suppl.1): S1-S147. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of Antithrombotic Trialists’ Collaboration. Collabora- losartan compared with captopril on mortality in tive meta-analysis of randomised trials of anti- patients with symptomatic heart failure: rando- platelet therapy for prevention of death, mised trial - the Losartan Heart Failure Survival myocardial infarction, and stroke in high risk pa- Study ELITE II. Lancet 2000; 355: 1582-7. tients. BMJ 2002; 324: 71-86. The Heart Outcomes Prevention Evaluation Dahlof B, Devereux RB, Kjeldsen SE, et al. Car- Study Investigators. Effects of an angiotensin- diovascular morbidity and mortality in the Losar- converting-enzyme inhibitor, ramipril, on cardio- tan Intervention For Endpoint reduction in vascular events in high risk patients. N Engl J hypertension study (LIFE): a randomised trial Med 2000; 342: 145-53. against atenolol. Lancet 2002; 359: 995-1003. Van den Hoogen PCW, Feskens EJM, Nagel- Kjeldsen SE, Dahlof B, Devereux RB, et al. Ef- kerke NJD, et al. The relation betwenn blood fects of Losartan on cardiovascular morbidity pressure and mortality due to coronary heart and mortality in patients with isolated systolic disease among men in different parts of the hypertension and left ventricular hypertrophy. A world. N Engl J Med 2000; 342: 1-8. Losartan Intervention For Endpoint Reduction American Diabetes Association. Aspirin therapy in (LIFE) Substudy. JAMA 2002; 288: 1491-8. diabetes. Position statement. Diabetes Care Lauer MS. Aspirin for primary prevention of coro- 2001; 24: S62-S63. nary events. N Engl J Med 2002; 346: 1468-74. Brenner BM, Cooper ME, de Zeeuw D, et al. Ef- Lindholm LH, Ibsen H,, Dahlof B, et al. Cardio- fects of Losartan on renal and cardiovascular vascular morbidity and mortality in patients with outcomes in patients with type 2 diabetes and diabetes in the Losartan Intervention For End- nephropathy. N Engl J Med 2001; 345: 861-9. point Reduction in hypertension study (LIFE): a Brown M. Hypertension: Matching the right drug randomised trial against atenolol. Lancet 2002; to the right patient in essential hypertension. 359: 1004-10. Heart 2001; 86: 113-120. McAlister FA, Zarnke KB, Campbell NR, et al. 21 The 2001 canadian recommendations for ther sure Overrides the Benefits of Heart Rate Lo- management of hypertensio: Part 2- therapy. wering. J Am Coll Cardiol 2016; 68: 754-62. Can J Cardiol 2002; 18: 625-41. Rimoldi SF, Messerli FH, Cerny D et al. Selective Wallis EJ, Ramsay LE, Jackson PR. Cardiovas- Heart Rate Reduction With Ivabradine Increa- cular and coronary risk estimation in hyperten- ses Central Blood Pressure in Stable Coronary sion management. Heart 2002; 88: 306-12. Artery Disease. Hypertension 2016; 67: 1205- Société québecoise de l’hypertension artérielle. 10. Guide thérapeutique 2002 (ISBN 2-9806257-1- Sorbets E, Greenlaw N, Ferrari R, et CLARIFY In- X); mise à jour: www.hypertension.qc.ca vestigators. Rationale, design, and baseline The ALLHAT officers and coordinators for the characteristics of the CLARIFY registry of out- ALLHAT collaborative research group. Major patients with stable coronary artery disease. outcomes in high-risk hypertensive patients ran- Clin Cardiol 2017;40:797-806. domized to angiontensin-converting enzyme in- Messerli FH, Rimoldi SF, Bangalore S. Changing hibitor or calcium channel blocker vs diuretic: definition of hypertension in guidelines: how in- the antihypertensive and lipid-lowering treat- nocent a number game? Eur Heart J 2018; 39: ment to prevent heart attack trial (ALLHAT). 2241-42. JAMA 2002; 289: 30-309-42. Whelton PK, Carey RM, Aronow WS et al. 2017 Chobanian AV, Bakris GL, Black HR, et al. The ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ seventh report of the Joint National Committee ASPC/NMA/PCNA Guideline for the Prevention, on Prevention, Detection, Evaluation, and treat- Detection, Evaluation, and Management of High ment of higt blood pressure. JAMA 2003; 289: Blood Pressure in Adults: A Report of the Ameri- 2560-72. can College of Cardiology/American Heart As- U.S. Preventive Services Task Force (Chair: Berg sociation Task Force on Clinical Practice AO). Aspirin for the prevention of cardiovascular Guidelines. Hypertension 2018; 71: 1269-1324. events: recommendation and rationale. Ann In- Williams B, Mancia G, Spiering W, et al. 2018 tern Med 2002; 136: 157-60. ESC/ESH Guidelines for the management of ar- August P. Initial treatment of hypertension. N Engl terial hypertension. Eur Heart J 2018; 39: 3021- J Med 2003; 348: 610-17. 3104. Imoberdorf R. Tous les diabétiques devraient-ils Urgence hypertensive prendre de l’aspririne? Forum Med Suisse 2003; 7: 149-54. McGregor E, Isles CG, Jay JL, et al. Retinal Wing LMH, Reid CM, Ryan PH, et al. (ANBP2). A changes in malignant hypertension. Br Med J comparison of outcomes with angiotensin-con- 1986; 292: 233-4. verting-enzyme inhibitors and diuretics for hy- O’Mailia JJ, Sander GE, Giles TD. Nifedipine-as- pertension in the elderly. N Engl J Med 2003; sociated myocardial ischemia or infarction in 348: 583-92. the treatment of hypertensive urgencies. Ann Sever PS, Dahlof B, Poulter NR, et al. Prevention Intern Med 1987; 107: 185-6. of coronary and stroke events with atorvastatin Emergency Cardiac care Committee and sub- in hypertensive patients who have average or committees, Amercican Heart Association. Gui- lower-the-average cholesterol concentrations, delines for cardiopulmonary resuscitation and in the Anglo-Scandinavian Cardiac Outcomes emergency cardiac care: Part IV. special resus- Trial-Lipid Lowering Arm (ASCOT-LLA): a multi- citation situations: stroke. JAMA 1992; 268: centre randomised controlled trial. Lancet 2003; 2242-50. 361: 1149-58. Kaplan NM. (ed.) Hypertensive crisis. In: clinical Adrogué HJ, Madias NE. Sodium and potassium Hypertension. Baltimore: Wiliams & Wilkins, in the pathogenesis of hypertension. N Engl J 1994, p: 281-97. Med 2007; 356: 1966-78. Kaplan NM. Management of hypertensive emer- Mancia G et al. 2013 ESH/ESC Guidelines for the gencies. Lancet 1994; 344: 1335-8. management of arterial hypertension: The Task Hirschl MM. Guidelines for the drug treatment of Force for the management of arterial hyperten- hypertensive crises. Drugs 1995; 50: 991-1000. sion of the European Society of Hypertension Ram CVS. Immediate management of severe hy- (ESH) and of the European Society of Cardio- pertension. Cardiol Clin 1995; 13: 579-91. logy (ESC). J Hypertens 2013; 31: 1281-357 Varon J, Marik PE. The diagnosis and manage- and Eur Heart J 2013; 34: 2159-219. ment of hypertensive crises. Chest 2000; 118: Cloutier L, Poirier L. éd. Prise en charge systé- 214-27. matisée des personnes atteintes d’hypertension Vaughan CJ, Delanty N. Hypertensive emergen- artérielle. Montréal, Canada Société québé- cies. Lancet 2000; 356: 411-7. coise d'hypertension artérielle, 2015; 1-101. Vidt DG. Emergency room management of hyper- Daskalopoulou SS, Rabi DM, Zarnke KB et al. tensive urgencies and emergencies. J Clin Hy- The 2015 Canadian Hypertension Education pertens 201; 3: 158-64. Program Recommendations for Blood Pressure Elliott WJ. Hypertensive emergencies. Crit Care Measurement, Diagnosis, Assessment of Risk, Clin 2001 ;17: 435-51. Prevention, and Treatment of Hypertension. Elliot WJ. Clinical features and management of Can J Cardiol 2015; 3: 549-68. selected hypertensive emergencies. J Clin Hy- Franz H. Messerli FH, Rimoldi SF, Bangalore S et pertens (Greenwich) 2004; 6: 587-92. al. When an Increase in Central Systolic Pres- Messerli FH, Rimoldi SF, Bangalore S. Changing 22 definition of hypertension in guidelines: how in- Linzer M, Yang EH, et al. Diagnosing syncope nocent a number game? Eur Heart J 2018; 39: Part 2. Unexplained syncope. Ann Intern Med 2241-2242. 1997; 127: 76-86. Jeong HOH, Hanusa BH, Kapoor WN. Do sym- Hypotension orthostatique ptoms predict cardiac arrhythmias and mortality Orthostatische Hypotonie in patients with syncope ? Arch Intern Med Shy GM, Drager GA. A neurological syndrome as- 1999; 159: 375-80. sociated with orthostatic hypotension: a clinical- Pruvot E, Vasallei G, Kappenberger L. De l’appro- pathologic study. Arch Nerurol 1960; 2: 511-27. che diagnostic au traitement de la syncope. Thomas JE, Schirger A, Fealey RD, Sheps SG. Med Hyg 1999; 57: 1182-9. Orthostatic hypotension. Mayo Clin Proc 1981; Kapoor WN. Syncope. N Engl J Med 2000; 343: 56: 117-25. 1856-62. Weidmann P. Orthostatic hypotension. Schweiz Brignole M, Alboni P, Benditt D, et al. Task force Med Wochenschr 1984; 114: 246-60. on syncope, European Society of Cardiology. Lipsitz LA. Orthostatic hypotension in the elderly. Part 1. The initial evaluation of patients with N Engl J Med 1989; 321: 952-7. syncope. Europace 2001; 3: 253-60. Freistuhler M, et al. The Shy-Drager syndrome. Brignole M, Alboni P, Benditt D, et al. Task force Dtsch Med Wochenschr 1992; 117: 1146-8. on syncope, European Society of Cardiology. Rutan GH, Hermanson B, Bild DE, Kittner SJ, Part 2. Diagnostic tests and treatment: sum- LaBaw F, Tell GS. Orthostatic hypotension in mary of recommendations. Europace 2001; 3: older adults. The Cardiovascular Health Study. 261-8. CHS Collaborative Research Group Hyperten- Brignole M, Alboni P, Benditt D, et al. Guidelines sion 1992; 19: 508-19. on management (diagnosis and treatment) of Bula C. Orthostatic hypotension in the elderly. syncope. Eur Heart J. 2001; 22: 1256-1306. Schweiz Rundsch Med Prax 1996; 85: 145-9. Sarasin FP, Louis-Simonet M, Carballo D, et al. Consensus statement. The definition of orthosta- Prospective evaluation of patients with syn- tic hypotension, pure autonomic failure, and cope: a population-based study. Am J Med multiple system atrophy. J Auton Nervous Syst 2001; 111: 177-84. 1996; 58: 123-4. Sarasin FP, Louis-Simonet M, Carballo D, et al. Freeman R, Landsberg L, Young J. The treatment Prevalence of orthostatic hypotension amoung of neurogenic orthostatic hypotension with 3,4- patients presentingwith syncope in the ED. A J DL-threo-dihydroxyphenylserine. A randomised, Emerg Med 2002; 20: 497-501. placebo-controlled, crossover trial. Neuro- Sarasin FP, Junod AV, Carballo D, et al. Role of logy1999; 53: 2151-7. echocardiography in the evaluation of syncope: Fagard RH, De Cort P. Orthostatic hypotension is a prospective study. Heart 2002; 88: 363-7. a more robust predictor of cardiovascular Kapoor WN. Current evaluation and manageme- events than nighttime reverse dipping in elderly. net of syncope. Circulation 2002; 106: 1606-9. Hypertension 2010; 56: 56-61. Bringole M, Alboni P, Benditt DG, et al. Guidelines Freeman R, Wieling W, Axelrod FB et al. Consen- on management (diagnosis and treatment) of sus statement on the definition of orthostatic hy- syncope - Update 2004. Eur Heart J 2004; 25: potension, neurally mediated syncope and the 2054-72. postural tachycardia syndrome. Clin Auton Res Sarasin FP, Pruvot E, Louis-Simonet M, et al. 2011; 21: 69-72. Stepwise evaluation of syncope: A prospective Ricci F, De Caterina R, Fedorowski A. Orthostatic population-based controlled study. Int J Cardiol hypotension: epidemiology, prognosis, and 2008; 127: 103-11. treatment. J Am Coll Cardiol 2015 ;66: 848-860. Freeman R, Wieling W, Axelrod FB et al. Consen- Syncope - Synkope sus statement on the definition of orthostatic hy- Franke H. Über das Karotissinus-Syndrom und potension, neurally mediated syncope and the den sogenannten hyperaktiven Karotissinus- postural tachycardia syndrome. Clin Auton Res Reflex. Stuttgart: Schlatter-Verlag, 1963: 149. 2011; 21: 69-72. Kapoor WN, et al. A prospective evaluation and Thiruganasambandamoorthy V, Stiell IG, Wells follow-up of patients with syncope. N Engl J GA et al. Outcomes in presyncope patients: a Med 1983; 309: 197-204. prospective cohort study. Ann Emerg Med Hoefnagels WAJ, Padberg GW, Overweg J, et al. 2015; 65: 268-276.e6. Transient loss of consciousness: the value of Brignole M, Moya A, de Lange FJ, et al. 2018 the history for distinguishing seizure from syn- ESC Guidelines for the diagnosis and manage- cope. J Neurol 1991; 238: 39-43. ment of syncope. Eur Heart J 2018; 39:1883- Sra JS, Jazayeri MR, Avitall B, et al. Comparison 48. of cardiac pacing with drug therapy in the treat- Insuffisance cardiaque, OAP ment of neurocardiogenic (vasovagal) syncope Herzinsuffizienz und akutes Lungenödem with bradycardia or asystole. N Engl J Med Criteria Committee, New York Heart Association. 1993; 328: 1085-90. Diseases of the heart and blood vessels. No- Linzer M, Yang EH, Estes NA, et al. Diagnosing menclature and criteria for diagnosis. 6th ed. syncope Part 1. Value of history, physical ex- Boston, Little Brown and Co. 1964, p: 114. amination, and electrocardiography. Ann Intern Killip T, et al. Am J Cardiol 1967; 20: 257-64. Med 1997; 126: 989-96. 23 Campeau L. Grading of angina pectoris. Circula- Packer M, Bristow MR, Cohn JN, et al. The effect tion 1975; 54: 522. of carvedilol on morbidity and mortality in pa- Constant J. (ed.). The jugular pulse. In: Bedside tients with chronic heart failure. N Engl J Med Cardiology. Little Brown and Company; 1976; p. 1996; 334: 1349-55. 69-75. Packer M, O'Connor CM, Ghali JK, et al. Effect of The CONSENSUS Trial Study Group. Effect of amlodipine on morbidity and mortality in severe enalapril on mortality in severe congestive heart chronic heart failure. N Engl J Med 1996; 335: failure: results of the Cooperative North Scandi- 1107-14. navian Enalapril Survival Study (CONSEN- The RALES Investigators. Effectiveness of spiro- SUS). N Engl J Med 1987; 316: 1429-35. nolactone added to an angiotensin-converting Francis GS, Benedict C, Johnstone DE, et al. enzyme inhibitor and a loop diuretic for severe Comparison of neuroendocrine activation in pa- chronic congestive heart failure (The Randomi- tients with left ventricular dysfunction with and zed Aldactone Evaluation Study [RALES]). Am without congestive heart failure. A substudy of J Cardiol 1996; 78: 902-7. the Studies of Left Ventricular Dysfunction Cohn JN, Ziesche S, Smith R, et al. Effect of the (SOLVD). Circulation 1990; 82: 1724-9. calcium antagonist felodipine as supplementary Cohn JN, Johnson G, Ziesche S, et al. A compari- vasodilator therapy in patients with chronic son of enalapril with hydralazine-isosorbide di- heart failure treated with enalapril: V-Heft III. nitrate in the treatment of chronic congestive Circulation 1997; 96: 856-63. heart failure. N Engl J Med 1991; 325: 303-10. Pitt B, Segal R, Martinez FA, et al. Randomised Effect of enalapril on survival in patients with re- trial of losartan versus captopril in patients over duced left ventricular ejection fractions and con- 65 with heart failure (Evaluation of Losartan in gestive heart failure. The SOLVD Investigators. the Elderly Study, ELITE). Lancet 1997; 349: N Engl J Med 1991; 325: 293-302. 747-52. Effect of enalapril on mortality and the develop- The Digitalis Investigation Group. The efffect of ment of heart failure in asymptomatic patients digoxin on mortality and morbidity in patients with reduced left ventricular ejection fractions. with heart failure. N Engl J Med 1997; 336: 525- The SOLVD Investigators. N Engl J Med 1992; 33. 327: 685-91. Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combina- Pfeffer MA, Braunwald E, Moy LA, et al. Effect of tion neurohormonal blockade with ACE inhibi- captopril on mortality and morbidity in patients tors, angiotensine II antagonists and with left ventricular dysfunction after myocardial beta-blockers in patients with congestive heart infarction: results of the survival and ventricular failure: design of the Randomized Evaluation of enlargement trial: N Engl J Med 1992; 327: Strategies for Left Ventricular Dysfunction (RE- 669-77. SOLVD) Pilot Study. Can J Cardiol 1997; 13: Goldsmith SR, Dick C. Differentiating systolic 1166-74. from diastolic heart failure: Pathophysiologic European study group on diastolic heart failure. and therapeutic considerations. Am J Med How to diagnose diastolic heart failure. Eur 1993; 95: 645-55. Heart J 1998; 19: 990-1003. Ho KK, Anderson KM, Kannel WB, et al. Survival Recommendations of the Second Joint Task after the onset of congestive heart failure in Force of European and other Societies on coro- Framingham Heart Study subject. Cirulation nary Prevention. Prevention of coronary heart 1993; 88: 107-15. disease in clinical practice. Eur Heart J 1998; ACC/AHA Task Force Report. Guidelines for the 19: 1434-1503. evaluation and management of heart failure. Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et Circulation.1995; 92: 2764-84. al. High- versus low-dose ACE inhibition in Dickstein K, Chang P, Willenheimer R, et al. chronic heart failure. J Am Coll Cardiol 1998; Comparison of the effects of losartan and ena- 32: 1811-8. lapril on clinical status and exercise perfor- Whelton PK, Appel LJ, Espeland MA, et al. So- mance in patients with moderate or severe dium reduction and weight loss in the treatment chronic heart failure. J Am Coll Cardiol 1995; of hypertension in older persons. JAMA 1998; 26: 438-45. 279: 839-46. Garg R, Yusuf S. Overview of randomized trials of Bart BA, Ertl G, Held P, et al. Contemporary ma- angiotensin-converting enzyme inhibitors on nagement of patients with left ventricular systo- mortality and morbidity in patients with heart fai- lic dysfunction. Results from the Study of lure. Collaborative Group on ACE Inhibitor Tri- Patients Intolerant of Converting Enzyme Inhibi- als. JAMA 1995; 273: 1450-6. tors (SPICE) Registry. Eur Heart J 1999; 20: Singh SN, Fletcher RD, Fisher SG, et al. Amioda- 1182-90. rone in patients with congestive heart failure Baruch L, Anand I, Cohen IS, et al. Augmented and asymptomatic ventricular arrhythmias. N short- and long-term hemodynamic and hormo- Engl J Med 1995; 333: 77-82. nal effects of an angiotensin receptor blocker Bristow MR, Gilbert EM, Abraham WT, et al. Car- added to angiotensin converting enzyme inhibi- vedilol produces dose-related improvements in tor therapy in patients with heart failure. Vasodi- left ventricular function and survival in subjects lator Heart Failure Trial (V-HeFT) Study Group. with chronic heart failure. Circulation 1996; 94: Circulation 1999; 99: 2658-64. 2807-16. Brunner-La Rocca HP, Weilenmann D, Kiowski 24 W, et al. Within-patient comparison of effects of the diagnosis of diastolic heart failure? Circula- different dosages of enalapril on functional cation 2001; 104: 779-82. pacity and neurohormone levels in patients with Cosin J, Diez J. Torasemide in chronic heart fai- chronic heart failure. Am Heart J 1999; 138: lure: results of the TORIC study. Eur J Heart 654-62. Fail 2002;4:507-13. Packer M, Cohn JN. Consensus recommendati- Faris R, Flather M, Purcell H, Henein M, Poole- ons for the management of chronic heart fai- Wilson P, Coats A. Current evidence supporting lure. Am J Cardiol 1999; 83: 1-38. the role of diuretics in heart failure: a meta ana- Packer M, Poole-Wilson PA, Armstrong PW, et al. lysis of randomised controlled trials. Int J Car- Comparative effects of low and high doses of diol 2002; 82: 149-158. the angiotensin-converting enzyme inhibitor, li- Hess OM (Arbeitsgruppe für Herzinsuffizienz der sinopril, on morbidity and mortality in chronic schweizerischen Gesellschaft für Kardiologie). heart failure. ATLAS Study Group. Circulation Empfehlungen zur Diagnose und Behandlung 1999; 100: 2312-8. der chronischen Herzinsuffizienz. Schweizeri- Stevenson LW. Tailored therapy to hemodynamic sche Ärztezeitung 2002; 83: 1233-42. goals for advanced heart failure. Eur J Heart Kjeldsen SE, Dahlof B, Devereux RB, et al. Ef- Failure 1999; 1: 251-7. fects of losartan on cardiovascluar mobidity and Swedberg K, Pfeffer M, Granger C, et al. Candes- mortality in patients with isolated systolic hyper- artan in heart failure-assessment of reduction in tension and left ventricular hypertrophy: a Los- mortality and morbidity (CHARM): rationale and artan Intertevention for Endpoint Reduction design. Charm-Programme Investigators. J (LIFE) substudy. JAMA 2002; 288: 1491-8. Card Fail 1999;5:276-82. Lubien E, DeMaria A, Krishnaswamy P, Clopton De Vries RJ, van Veldhuisen DJ, Dunselman PH. P, et al. Utility of B-natriuretic peptide in detec- Efficacy and safety of calcium channel blockers ting diastolic dysfunction: comparison with in heart failure: focus on recent trials with se- doppler velocity recordings. Circulation 2002; cond-generation dihydropyridines. Am Heart J 105: 595-601. 2000; 139: 185-94. Zile MR, Brutsaert DL. New concepts in diastolic Pitt B, Poole-Wilson PA, Segal R, et al. Effect of dysfunction and diastolic heart failure: Part I: losartan compared with captopril on mortality in diagnosis, prognosis, and mesurements of dia- patients with symptomatic heart failure: rando- stolic function. Circulation 2002; 105: 1387-93. mised trial - the Losartan Heart Failure Survival Zile MR, Brutsaert DL. New concepts in diastolic Study ELITE II. Lancet 2000; 355: 1582-7. dysfunction and diastolic heart failure: Part II: Suter TM, Eberli FR, Hess OM. Herzinsuffizienz causal mechanisms and treament. Circulation im neuen Millennium – welche Rolle spielen die 2002; 105: 1503-8. Angiotensin-II-Antagonisten? Kardiovasc Med Funder JW. The role of mineralocorticoid receptor 2000;3:467-75. antagonists in the treatment of cardiac failure. Vasan RS, Levy D. Defining diastolic heart failure: Expert Opin Investig Drugs 2003; 12: 1963-9. a call for standardized diagnostic criteria. Circu- Granger CB, McMurray JJV, Yusuf S, et al. Ef- lation 2000; 105: 1503-08. fects of candesartan in patients with chronic Yusuf S, Sleight P, Pogue J, et al. Effect on agio- heart failure and reduced left-ventricular systolic tensin-converting-enzyme inhibitor, ramipril, on function intolerant to angiotensin-converting-en- cardiovascular events in high-risk patients. The zyme inhibitors: the CHARM-Alternative trial. Heart Outcomes Prevention Evaluation Study Lancet 2003; 362: 772-776. Investigators. N Engl Med 2000; 342: 145-53. Jessup M, Brozena S. Heart failure. N Engl J Med ACC/AHA Guidelines for the evaluation and ma- 2003; 348: 2007-18. nagement of chronic heart failure in the adult: Nohria A, Tsang SW, Fang JC, Stevenson LW. executive summary. A report of the american Clinical assessment identifies hemodynamic college of cardiology/american heart associa- profiles that predict outcomes in patients admit- tion task force on practice guidelines. Circula- ted with heart failure. J Am Coll Cardiol tion 2001; 104: 2996-3007. Also published in: J 2003;41:1797-1804. Am Coll Cardiol 2001; 38: 2101-13. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Cohn JN, Tognoni G, et al. A randomized trial of Valsartan, Captopril, or both in myocardial in- the angiotensin-receptor blocker Valsartan in farction complicated by heart failure, left ventri- chronic heart failure. N Engl J Med 2001; 345: cular dysfunction, or both. N Engl J Med 2003; 1667-75. 349: 1893-906. Packer M, Coats AJS, Fowler MB, et al. Effects of Pfeffer M, Swedberg K, Granger C, et al. Effect of Carvedilol on survival in severe chronic heart Candesartan on mortality and morbidity in pa- failure. N Engl J Med 2001; 344: 1651-8. tients with chronic heart faliure. The CHARM- Remme WJ, Swedberg K. Guidelines for diagno- Overall Programme. Lancet 2003; 362: 759-66. sis and treatment of chronic heart failure. Task Yusuf S, Pfeffer M, Swedberg K et al. Effects of Force for the diagnosis and treatment of chronic Candesartan in patients with chronic heart fai- heart failure, European Society of Cardiology. lure and preserved lef-ventricular ejaction frac- Eur Heart J 2001; 22: 1527-60. tion: the CHARM-Preserved Trial. Lancet 2003; Zile MR, Gaasch WH, Carroll JD, et al. Heart fai- 362: 777-81. lure with a normal ejection fraction: is measure- Bristow MR, Saxon LA, Boehmer J, et al. Car- ment of diastolic function necessary to make diac-resynchronization therapy with or without 25 implantable defibrillator in advanced chronic Savarese G, Perrone-Filardi P, D’Amore C, et al. heart failure. N Engl J Med 2004; 350: 2140-50. Cardiovascular effects of dipeptidyl peptidase-4 Zile MR, Baicu CF, Gaasch WH. Diastolic heart inhibitors in diabetic patients: a meta-analysis. failure - abnormalities in active relaxation and Int J Cardiol 2015;181:239–244. passive stiffness of the left ventricle. N Engl J Zinman B, Wanner C, Lachin JM, et al. EMPA- Med 2004; 350: 1953-9. REG OUTCOME Investigators. Empagliflozin, Palmer BF. Managing hyperkalemia caused by in- cardiovascular outcomes, and mortality in type hibitors of the renin-angiotensin-aldosterone sy- 2 diabetes. N Engl J Med 2015;373:2117-28. stem. N Engl J Med 2004; 351: 585-92. Authors/Task Force Members: Ponikowski P Stevenson LW. Design of therapy for advanced (Chairperson), Voors AA. (Co-Chairperson) heart failure. Eur J Heart Fail 2005; 7: 323-31. Anker St.D. et al. 2016 ESC Guidelines for the Kjekshus J., Apetrei E, Barrios V et al. Rosuva- diagnosis and treatment of acute and chronic statin in Older Patients with Systolic Heart Fai- heart failure. Eur J Heart Failure (2016) lure. N Engl J Med 2007; 357: 2248-61. doi:10.1002/ejhf.592 Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac- Kirchof P, Benussi S et al. 2016 ESC Guidelines Resynchronization Therapy in Heart Failure for the management of atrial fibrillation develo- with Narrow QRS Complexes. N Engl J Med ped in collaboration with EACTS. Eur Heart J. 2007; 357: 2461-71. 2016. doi: 10.1093/eurheartj/ehw210. Forthco- Massie BM, Carson PE, McMurray JJ, et al. Irbe- ming sartan in patients with heart failure and preser- Køber L, Thune JJ, Nielsen JJ et al. Defibrillator ved ejection fraction. N Engl J Med 2008; 359: Implantation in Patients with Nonischemic Sy- 2456-2467. stolic Heart Failure N Engl J Med 2016; 375: Moya A, Sutton R, Ammirati F, et al. Guidelines 1221-30. for de diagnosis and management of syncope Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC (2009). Eur Heart J 2009 ; 30: 2631-71. Guidelines for the management of atrial fibrilla- De Backer D, Biston P, Devriendt J, et al. Compa- tion developed in collaboration with EACTS. rison of dopamine and norepinephrine in the Eur Heart J 2016; 37: 2893-2962. treatment of shock. N Engl J Med McMurray JJ, Krum H, Abraham WT et al. Aliski- 2010;362:779-789. ren, Enalapril, or Aliskiren and Enalapril in Heart Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltra- Failure. N Engl J Med 2016; 374: 1521-32. tion in decompensated heart failure with cardio- Eikelboom JW, Connolly SJ, Bosch J et al. Riva- renal syndrome. N Engl J Med 2012;367: roxaban with or without Aspirin in Stable Car- 2296-2304. diovascular Disease. N Engl J Med 2017; 377: ESC guidelines for the diagnosis and treatment of 1319–1330. acute and chronic heart failure 2012: The Task Neal B, Perkovic V, Mahaffey KW et al. Canagli- Force for the Diagnosis and Treatment of Acute flozin and Cardiovascular and Renal Events in and Chronic Heart Failure 2012 of the Euro- Type 2 Diabetes. NEJM 2017;377:644-657. pean Society of Cardiology. Developed in colla- Núñez J, Bayés-Genís A, Zannad F et al. Long- boration with the Heart Failure Association Term Potassium Monitoring and Dynamics in (HFA) of the ESC. McMurray JJ, Adamopoulos Heart Failure and Risk of Mortality. Circulation S, Anker SD et al. Eur J Heart Fail 2012; 14: 2018; 137: 1320-30. 803-69. Cardiomyopathie - Kardiomyopathie Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev Abelmann WH. Classification and natural history 2012; 2: CD003838. of primary myocardial disease. Prog Cardiovasc Jankowska EA, von Haehling S, Anker SD et al. Dis 1984; 27: 73-94. Iron deficiency and heart failure: diagnostic di- Packer DL, Bardy GH, Worley SJ, et al. Tachycar- lemmas and therapeutic perspectives. Eur dia-induced cardiomyopahty: a reversible form Heart J 2013;34:816-26. of left ventricular dysfunction. Am J Cardiol McMurray J, Packer M, Desai A, et al. Angioten- 1986; 57: 563-70. sin-neprilysin inhibition versus enalapril in heart Lampert MB, Lang RM. Peripartum cardiomyopa- failure. N Engl J Med 2014; 371: 993-1004. thy. Am Heart J 1995; 130: 860-70. Pitt B, Pfeffer MA, Assmann SF et al. Spironolac- Manolio TA, Baughman KL, Rodeheffer R, et al. tone for heart failure with preserved ejection Prevalence and etiology of idiopathic dilateted fraction. N Engl J Med. 2014; 370: 1383-92. cardiomyopathy. Am J Cardiol 1992; 69: 1458- Felker GM, Mentz RJ, Teerlink JR, Vet al. Serial 66. high sensitivity cardiac troponin T measurement Dec GW, Fuster V. Idiopathic dilatated cardio- in acute heart failure: insights from the RELAX- myopathy. N Engl J Med 1994; 331: 1564-75. AHF study. Eur J Heart Fail 2015;17:1262-70. Richardson R, McKenna W, Bristow M, et al. Re- Mebazaa A, Yilmaz MB, Levy P, et al. Recom- port of the 1995 World Health Organization/In- mendations on pre-hospital and early hospital ternational Society and Federation of management of acute heart failure: a consen- Cardiology Task Force on the definition and sus paper from the HFA of the ESC, the Euro- classification of the cardiomyopathy. Circulation pean Society of emergency Medicine and the 1996; 93: 841-2. Society of Academic Emergency Medicine. Eur Felker CM, Thompson RE, Hare JM, et al. Under- J Heart Fail 2015;17:544-58. lying causes and long-term survival in patients 26 with initially unexplained cardiomyopathy. N Folland ED, Kriegel BJ, Hernderson WG, et al. Engl J Med 2000; 342: 1077-84. Implication of third heart sounds in patients with Nagueh SF, Ommen SR, Lakkis NM, et al. Com- valvular heart disease. N Engl J Med 1992; parison of ethanol septal reduction therapy with 327: 458-62. surgical myectomy for the treatment of hyper- Carabello BA, Crawford FA. Valvular heart trophic obstructive cardiomyopathy. J Am Coll disease. N Engl J Med 1997; 337: 32-41. Cardiol 2001; 15: 1701-6. ACC/AHA Guidelines for Management of Patients Frustaci A, Cuoco L, Chimenti C, et al. Celiac With Valvular Heart Disease. JACC disease assiciated with autoimmune myocardi- 1998;32:1486-588. tis. Circulation 2002; 105: 2611-8. Bonow RO et al. ACC/AHA guidelines for the ma- Felker GM, Thompson RE, Joshua M, et al. Un- nagement of patients with valvular heart derlying causes and long-term survival in pa- disease. Circulation 1998; 98: 1949-84. Also tients with initially unexplained cardiomyopahty. published in: J Heart Valve Dis 1998 ; 7: 672- N Engl J Med 2000; 342: 1077-84. 707 and JACC 1998; 32: 1486-588. Bhagwandeen R, Woo A, Ross J, et al. Septal Quinones MA. Management of mitral regurgita- ethanol ablation for hypertrophic obstructive tion. Cardiology Clinics 1998; 16: 421-35. cardiomyopathy: early and intermediate results Braunwald E, Zipes DP, Libby P. (eds.). Valvular of a Canadian referral center. Can J Cardiol heart disease. In: Heart disease: a textbook of 2003; 19: 912-7. cardiovascular medicine. W.B. Saunders Com- Nielsen CD, Killip D, Spencer WH 3rd. Nonsurgi- pany. 2001; p. 1643-1704. cal septal reduction therapy for hypertrophic ob- Khot UN, Novaro GM, Popovic Z, et al. Nitroprus- structive cardiomyopathy; short-term results in siate in critically ill patients with left ventricuolar 50 consecutive procedures. Clin Cardiol 2003; dysfunction and aortic stenosis. N Engl J Med 26: 275-9. 2003; 348: 1756-63. Bristow MR, Saxon LA, Boehmer J, et al. Car- Christen T., Lercha R., Trindadea PT. Die Aorten- diac-resynchronization therapy with or without klappenstenose beim Erwachsenen. Schweiz implantable defibrillator in advanced chronic Med Forum 2006;6:647–651. heart failure. N Engl J Med 2004; 350: 2140-50. Leon MB, Smith CR, Mack M et al. Transcatheter Kadish A, Dyer A, Dauber JP, et al. Prophylactic aortic-valve implantation for aortic stenosis in defibrillator implantation in patients with noni- patients who cannot undergo surgery. NEJM schemic dilatated cardiomyopathy. N Engl J 2010; 363: 1597-607. Med 2004; 350: 2151-8. Joint Task Force on the Management of Valvular Templin C, Ghadri JR, Diekmann J, et al. Clinical Heart Disease of the European Society of Car- Features and Outcomes of Takotsubo (Stress) diology (ESC). Guidelines on the management Cardiomyopathy. NEJM 2015; 373: 929-38. of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96. Stimulateur cardiaque - Pacemaker Nishimura RA, Otto CM, Bonow RO et al. 2014 Javier RP, Maramba LC, Hildner FJ, et al. Tempo- AHA/ACC Guideline for the Management of Pa- rary cardiac pacing: technique and indications. tients With Valvular Heart Disease: Executive Chest 1971; 59: 498-500. Summary A Report of the American College of Goy JJ. La stimulation cardiaque: indication et Cardiology/American Heart Association Task évolution actuelle. Rev Med Suisse Rom 1986; Force on Practice Guidelines. Circulation 106: 359-63. 2014;129:2440-92. ACC/AHA Guidelines for early management of Baumgartner H, Falk V, Bax JJ et al. 2017 patients with acute myocardial infarction. Circu- ESC/EACTS Guidelines for the management of lation 1990; 82: 664-707. valvular heart disease. Eur Heart J 2017; 38: Dreifus LS, Fisch C, Griffin JC, et al. Guidelines 2739-2791. for implantation of cardiac pacemakers and an- Kang DH, Park SJ, Lee SA et al. Early surgery tiarrhythmia devices. Circulation 1991; 84: 455- versus conservative care for asymptomatic aor- 67. tic stenosis. NEJM 2020; 382: 111-119. Jafri SM, Kruse JA. Temporary transvenous cardiac pacing. Crit Care Clin 1992; 8: 713-25. Auscultation cardiaque - Herzauskultation Report of the joint American College of Cardio- Folland ED, Kriegel BJ, Hernderson WG, et al. logy/ American Heart Association task force on Implication of third heart sounds in patients with assessment of cardiovascular procedures (sub- valvular heart disease. N Engl J Med 1992; committee on pacemaker implantation): Guideli- 327: 458-62. nes for permanent cardiac pacemaker Carabello BA, Crawford FA. Valvular heart implantation. JACC 1994; 4: 433-42. disease. N Engl J Med 1997; 337: 32-41. Kusumoto FM, Goldschlager N. Cardiac pacing. Etchells E, Bell C, Robb K. Does this patient have N Engl J Med 1996; 332: 89-98. an abnormal systolic murmur? JAMA 1997; Committee on pacemaker implantation. ACC/ 277: 564-71. AHA Guidelines for implantation of cardiac Shry EA. Auscultation versus echography in a he- pacemakers and antiarrhythmia devices: execu- althy population with precordial murmur. Am J tive summary. Circulation 1998; 97: 1325-35. Cardiol 2001; 87:1428-30. Shub C. Echography or auscultation. Can Fam Valvulopathie - Klappenvitien Phys 2003; 49: 163-7. 27 Bouchardy J, Schlueter L. Souffle cardiaque et in- pervised exercise versus primary stenting for dications à l'échocardiographie. Rev Med claudication resulting from aortoiliac peripheral Suisse 2005; 21: 1400-2, 1405. artery disease: six-month outcomes from the claudication: exercise versus endoluminal re- Insuffisance artérielle -AOMI - PAVK vascularization (CLEVER) study. Circulation. Cranley JJ. Ischemic rest pain. Arch Surg 2012; 125: 130-9. 1969;98: 187-8. Becker F, Robert-Ebadi H. Diagnostic clinique de Spittell JA. Recognition and management of chro- l’ischémie critique chronique de membre infé- nic atherosclerotic occlusive peripheral arterial rieur. Rev Med Suisse 2013;302-305. disease. Mod Concepts Cardiovasc Dis Rooke TW, Hirsch AT, Misra S et al. Management 1981;50:19-23. of patients with peripheral artery disease (com- Jamieson C. The definition of critical ischaemia of pilation of 2005 and 2011 ACCF/AHA Guideline a limb. Br J Surg 1982;69(Suppl.):S1. Recommendations): a report of the American Second European consensus document on chro- College of Cardiology Foundation/American nic critical leg ischemia. Circulation Heart Association Task Force on Practice Gui- 1991;84:IV1-26. delines. J Am Coll Cardiol 2013; 61: 1555-70. Pentecost MJ, Criqui MH, Dorros G, et al. Guide- lines for peripheral percutaneous transluminal Pouls angioplasty of the abdominal aorta and lower Spodick DH. Acute cardiac tamponade: patholo- extremity vessels. A statement for health pro- gic physiology, diagnosis and management. fessionals from a special writing group of the Prog Cardiovasc Dis 1967; 10: 64-96. Councils on Cardiovascular Radiology, Arter- Gubermann BA, Fowler NO, Engel PJ, et al. Car- iosclerosis, Cardio-Thoracic and Vascular Sur- diac tamponade in medical patients. Circulation gery, Clinical Cardiology, and Epidemiology and 1982; 64: 633-40. Prevention, the American Heart Association. Anticoagulation Circulation 1994;89: 511-31. Pahlsson HI, Wahlberg E, Olofsson P, Sweden- Sixth ACCP Consensus Conference on anti- borg J. The toe pole test for evaluation of arte- thrombotic therapy. Chest 2001; 119 (Suppl. 1): rial insufficiency in diabetic patients. Eur J Vasc 1S-336S. Endovasc Surg 1999;18: 133-7. The Warfarin Antiplatelet Vascular Evaluation Hankey GJ, Norman PE, Eikelboom JW. Medical Trial Investigators. Oral Anticoagulant and Anti- treatment of peripheral arterial disease. JAMA platelet Therapy and Peripheral Arterial 2006; 295: 547-53. Disease. N Engl J Med 2007; 357: 217-27. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Stratific. risque périop. coronarien 2005 Practice guidelines for the management of Palda VA, Detsky AS. Perioperative assessment patients with peripheral arterial disease (lower and management of risk from coronary artery extremity, renal, mesenteric, and abdominal disease. Ann Intern Med 1997; 127: 131-28. aortic). Circulation 2006;113:e463-654. Fleisher LA, Eagle K. Lowering cardiac risk in Khan NA, Rahim SA, Anand SS, Simel DL, Panju noncardiac surgery. N Engl J Med 2001; 345: A. Does the clinical examination predict lower 1677-82. extremity peripheral arterial disease ? JAMA 2006;295:536-46. Voie veineuse centrale Burrows, C., et al. Best practice recommendati- http://content.nejm.org/cgi/content/short/357/24/e ons for the prevention and treatment of venous 26?query=TOC leg ulcers: Update 2006. Wound Care Canada 2006: 4: 45-55. PNEUMOLOGIE Paraskevas N, Ayari R, Malikov S, et al. «Pole test» measurements in critical leg ischaemia. Dypnoe — Dyspnée Eur J Vasc Endovasc Surg 2006;31:253-7. Lavanchy AS, Bahri Ksouri A, Garcia W, Ribordy Norgren L, Hiatt WR, Dormandy JA, et al. Inter- V. Dyspnée haute chez l’adulte. Rev Med society consensus for the management of peri- Suisse 2015; 11: 1486-90. pheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl.1):S1-75. Lungenauskultation Fowkes FG, Price JF, Stewart MC et al. Aspirin Auscultation pulmonaire for prevention of cardiovascular events in a ge- Forcas P. (ed.). Lung sounds. Baillüre Tindall, neral population screened for a low ankle bra- 1978. chial index: a randomized controlled trial. JAMA Zellweger JP. Anamnesis and physical examina- 2010; 303: 841-8. tion in pneumology. Praxis 1992; 81: 278-81. Varu VN, Hogg ME, Kibbe MR. Critical limb ische- Maitre B, Similowski T, Derenne JP, et al. Physi- mia. J Vasc Surg 2010;51:230-41. cal examination of the adult patient with respira- Becker F, Robert-Ebadi H, Ricco JB, et al. ESVS tory diseases: inspection and palpation. Eur guidelines for critical limb ischemia and diabetic Respir J 1995; 8: 1584-93. foot. Chapter I : Definitions, epidemiology, clini- Marquet P. Les bruits d’origine ventilatoire. Rev cal presentation and prognosis. Eur J Vasc En- Mal Resp 1995; 12: 87-101. dovasc Surg 2011;42 (Suppl.2):S4-12. Meslier N, Charbonneau G, Racineux JL, et al. Murphy TP, Cutlip DE, Regensteiner JG et al. Su- Wheezes. Eur Respir J 1995; 8: 1942-8. 28 Sharma OP. Symptoms and signs in pulmonary 6. medicine: old observations and new interpretati- Medical Research Council. Definition and classifi- ons. Disease-A-Month 1995; 41: 577-638. cation of chronic bronchitis for clinical and epi- Breitenstein E, Aubert JD. Signes cliniques en demiological purposes. Lancet 1965; i: 775-9. pneumologie: faut-il encore les rechercher ? Nocturnal Oxygen Therapy Trial Group. Conti- Med Hyg 1996; 54: 2231-3. nous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Asthme Med 1980; 93: 391-8. NET: www.ginasthma.com Medical Research Council. Long term domiciliary McFadden ER, Lyons HA. Arterial blood gas ten- oxygen therapy in chronic hypoxic cor pulmo- sion in asthma. N Engl J Med 1968; 278: 1027- nale complicating chronic bronchitis and em- 32. physema. Lancet 1981; 1: 681-6. McFadden ER, Gilbert IA. Asthma. N Engl J Med Anthonisen NR, Manfreda J, Warren CPW, et al. 1992; 327: 1928-37. Antibiotic therapy in exacerbations of chronic Corbridge TC, Hall JB. The assessment and ma- obstructive pulmonary disease. Ann Intern Med nagement of adults with status asthmaticus. Am 1987; 106: 196-204. J Respir Crit Care Med 1995; 151: 1296-1316. American Thoracic Society. Lung function testing: McFadden ER, Hejal R. Asthma. Lancet 1995; selection of reference values and interpretative 345: 1215-20. strategies. Am Rev Respir Dis 1991; 144: 1202- Schaller MD, Tagan D, Perret C. Asthme aigu 18. grave. Encycl Med Chir (Elsevier, Paris), Anes- Callahan CM, Dittus RS, Katz BP. Oral corticoste- thesie-reanimation, 36-970-A-10, 1996. roid therapy for patients with stable chronic ob- Evans DJ, Taylor DA, Zetterstrom O, et al. A com- structive pulmonary disease. A meta-analysis. parison of low-dose inhaled budesonide plus Ann Intern Med 1991; 114: 216-23. theophylline and high-dose inhaled budesonide Murphy TF, Sethi S. Bacterial infection in chronic for moderate asthma. N Engl J Med 1997; 337: obstructive pulmonary disease. Am Rev Respir 1412-8. Dis 1992; 146: 1067-83. O’Byrne PM, Israel E, Drazen JM. Antileucotrie- Curtis JR, et al. Emergent assessment and ma- nes in the treatment of asthma. Ann Intern Med nagement of acute respiratory failure in COPD. 1997; 127: 472-80. Clin in Chest Med 1994; 3: 481-500. The British Thoracic Society. Guidelines and American Thoracic Society. Standards for the dia- asthma management. Thorax 1997; 52 gnosis and care of patients with chronic ob- (Suppl.1): S1-S21. structive pulmonary disease. Am J Resp Crit Van der Molen T, et al. Effects of the long acting Care Med 1995; 152: 77-120. b-agonist formoterol on asthma control in Brochard L, Manecebo J, Wysocky M, et al. No- asthmatic patients using inhaled corticosteroids. ninvasivie ventilation for acute exacerbations of Thorax 1997; 52: 535-9. chronic obstructive pulmonary disease. N Engl Leff JA, Busse WW, Pearlman D, et al. Montelu- J Med 1995; 333: 817-22. kast, a leukotriene-receptor antagonist, for the Kramer N, Meyer TJ, Meharg J, et al. Randomi- treatment of mild asthma and exercise-induced zed, prospective trial of noninvasive positive bronchoconstriction. N Engl J Med, 1998; 339: pressure ventilation in acute respiratory failure. 147-52. Am J Respir Crit Care Med 1995; 151: 1799- Li JT, et al. Algorithm for the diagnosis and ma- 1806. nagement of asthma: a practice parameter up- Saint S, Bent S, Vittinghoff E, et al. Antibiotics in date: Joint Task Force on Practice Parameters, chronic obstructive pulmonary diseases exacer- representing the American Academy of Allergy, bations. A meta-analysis. JAMA 1995; 273: 957- Asthma and Immunology, the American College 60. of Allergy, Asthma and Immunology, and the Siafakas NM, Vermeire P, Pride NB, et al. Optimal Joint Council of Allergy, Asthma and Immuno- assessment and management of chronic ob- logy. Ann Allergy Asthma Immunol 1998; 81: structive pulmonray disease (COPD). The Euro- 415-20. pean Respiratory Society Task Force. Eur Nelson JA, Strauss LS, et al. Effect of long-term Respir J 1995; 8: 1398-1420. salmeterol treatment on exercise-induced Tarpy SP, Celli BR. Long-term oxygen therapy. N asthma. N Engl J Med 1998; 339: 141-6. Engl J Med 1995; 333: 710-4. Pralong G, Leuenberger Ph. Les bêta-2 stimu- Aboussouan LS. Acute exacerbations of chronic lants à longue duree d’action dans le traitement bronchitis. Postgrad Med 1996; 99: 89-103. de l’asthme: utiles ou dangereux ? Med Hyg Leuenberger Ph, Anderhub HP, Brändli O, et al. 1998; 56: 2322-6. Management 1997 of chronic obstructive pul- BPCO - COPD - MPOC monary disease. Schweiz Med Wochenschr 1997; 127: 766-82. Fletcher CM, Elmes PC, Fairbairn MB, et al. The McEvoy CE, Niewoehner DE. Adverse effects of significance of respiratory symptoms and the coricosteroid therapy for COPD. A critical re- diagnosis of chronic bronchitis in a working po- view. Chest 1997; 111: 732-43. pulation. Br Med J 1959;2:257-266. O’Donohue WJ. Home oxygen therapy. Clin Mahler DA, Wells CK. Evaluation of clinical me- Chest Med 1997; 18: 535-45. thods for rating dyspnea. Chest 1988; 93: 580- Maurer JR, Frost AE, Estenne M, et al. Internatio- 29 nal guidelines for the selection of lung trans- 2679-81. plant candidates. The international society for National Emphysema Treatment Trial Research heart and lung transplantation, the american Group. A randomized trial comparing lung-vo- thoracic society. Transplantation 1998; 66: 951- lume-reduction surgery with medical therapy for 6. severe emphysema. N Engl J Med 2003; 348: Davies L, Angus RM, Calverley PMA. Oral corti- 2059-73. costeroids in patients admitted to hospital with Celli BR, Cote CG, Marin JM, et. al. The body- exacerabations of chronic obstructive pulmo- mass index, airflow obstruction, dyspnea and nary disease: a prospective randomised con- exercise capacity index in chronic obstructive trolled trial. Lancet 1999; 354: 456-60. pulmonary disease. N Engl J Med. 2004; 350: Niewoehner DE, Erbland ML, Deupree RH, et al. 1005-12. Effect of systemic glucocorticoids on exacerba- Løkke A, Lange P, Vestbo J, et al. Developing tions of chronic obstructive pulmonary disease. COPD--25 years follow-up study of the general N Engl J Med 1999: 340: 1941-7. population. Thorax 2006; 61: 935-9. Vincken W, Greefhorst APM, Westbroek J, et al. O zalevli S, Ozden A, Itil O, Akkoclu A: Compari- Once daily tiotropium is more efficacious than son of the Sit-to-Stand Test with 6 min walk test q.i.d. ipratropium as maintenance treatment of in patients with chronic obstructive pulmonary COPD. Eur Resp J 1999; 14 (Suppl. 30): 520S. disease. Respir Med 2007; 101: 286-93. Barnes PJ. Chronic obstructive pulmonary Tashkin DP, Celli B, Senn S, et al. UPLIFT Study disease. N Engl J Med 2000; 343: 269-80. Investigators. A 4-Year Trial of Tiotropium in Lancaster T, Stead L, Silagy C, et al. Effective- Chronic Obstructive Pulmonary Disease. N ness of interventions to help people stop smo- Engl J Med 2008; 359: 1543-54. king: findings from the Cochrane Library. BMJ Leuppi JD, Schuetz P, Bingisser R et al. Short- 2000; 321: 355-8. term vs conventional glucocorticoid therapy in Niewoehner DE, Collins D, Erbland ML. Relation acute exacerbations of chronic obstructive pul- of FEV1 to clinical outcomes during exacerbati- monary disease: the REDUCE randomized cli- ons of chronic obstructive pulmonary disease. nical trial. JAMA 2013; 5; 309(21):2223-31. doi: Am J Respir Crit Care Med 2000; 161: 1201-5. 10.1001/jama.2013.5023. Rice KL, Rubins JB, Lebahn F, et al. Withdrawl of García-Sidro P, Naval E, Martinez Rivera C et a. chronic systemic corticosteroids in patients with The CAT (COPD Assessment Test) question- COPD; a randomized trial. Am J Respir Crit naire as a predictor of theevolution of severe Care Med 2000; 162: 174-8. COPD exacerbations. Resp Med 2015; 109: Fitting JW, Rochat Th. Corticostéroïdes dans la 1546-52. broncho-pneumopathie obstructive chronique. Weill D, Benden C, Corris PA et al. A consensus Réhabilitation respiratoire. Med Hyg 2000; 58: document for the selection of lung transplant 60-4. candidates: 2014 - an update from the Pulmo- McCrory DC, Brown C, Gelfand SE, et al. Ma- nary Transplantation Council of the International nagement of acute exacerbations of COPD. Society for Heart and Lung Transplantation. J Chest 2001;119: 1190-1209. Heart Lung Transplant 2015; 34: 1-15. Pauwels RA, Buist AS, Calverley PM, et al. Glo- Vogelmeier CF, Criner GJ, Martinez FJ et al. Glo- bal strategy for the diagnosis, management, bal Strategy for the Diagnosis, Management, and prevention of chronic obstructive pulmo- and Prevention of Chronic Obstructive Lung nary diseases. NHLBI/WHO Global Initiative for Disease 2017 Report. GOLD Executive Sum- Chronic Obstructive Lung Disease (GOLD) mary. Am J Respir Crit Care Med 2017; 195: Workshop summary. Am J Respir Crit Care 557-82. 2001; 163: 1256-76. Fonction pulmonaire, spirométrie, ERF Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacer- Weinberger SE. Principals of pulmonary medi- bations of COPD: clinical practice guideline. cine. Philiadelphia, Saunders, 1986. Chest 2001; 119: 1185-9. West JB. (ed.). Physiologie respiratoire. 2ème Donohue JA, van Noord JA, Batemen ED, et al. A édition. MEDSI, Paris, 1986. 6-month placebo-controlled study comparing Gold WM, Boushey HA. Pulmonay function te- lung function and health status changes in sting. Murray JF, Nadel JA (eds.). In: Textbook COPD patients treated with tiotropium or salme- of respiratory medicine. Philadelphia, Saunders, terol. Chest 2002; 122: 47-55. 1988, p: 611-82. Casburi R, Mahler DA, Jones PW, et al. A long- Altose MD. Practical aspects of pulmonary term evaluation of once-daily inhaled tiotropium function testing. In: Baum GL, Wolirsky E. in chronic obstructive pulmonary disease. Eur (eds.). Textbook of Pulmonary Disease. Little Respir J 2002; 19: 217-24. Brown and Company, 1989; p. 101-3. Aron SD, Vandemheen KL, Hebert P, et al. Out- Clausen JL. Pulmonary testing. In: Kelly WN, et patient oral prednisone after emergency treat- al. (eds.). Textbook of Internal Medicine, Phil- ment of chronic obstructive pulmonary diseas. adelphia, JB. Lippincott, 1992, p: 182. N Engl J Med 2003; 348: 2618-25. Débit de pointe (Peak flow) Irwin RS, Madison M. Systemic corticosteroids for Gregg I, Nunn AJ. Peak expiratory flow on normal acute exacerbations of chronic pbstructive plu- subjects. BMJ 1973; 3: 282-4. monary disease. N Engl J Med 2003; 348: Nunn AJ, Gregg I. New regression equations for 30 predicting peak expiratory flow in adults. BMJ pneumothorax. Chest 2014; 145: 688-94. 1989; 298: 1068-70. Roberts DJ, Leigh-Smith S, Faris PD, Blackmore Regan EA, Lynch DA, Curran-Everett D et al. Cli- C et al. Clinical Presentation of Patients With nical and Radiologic Disease in Smokers With Tension Pneumothorax: A Systematic Review. Normal Spirometry. JAMA Intern Med 2015; Ann Surg 2015; 261: 1068-78. 175: 1539-49. Chang SH, Kang YN, Chiu HY et al. A Systematic Review and Meta-Analysis Comparing Pigtail Pleuraerguss Catheter and Chest Tube as the Initial Treat- Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral ment for Pneumothorax. Chest 2018; 153: pleural effusions with more than one apparent 1201-1212. etiology. A prospective observational study. Ann Am Thorac Soc 2016; 13: 1050-6. Test aux stéroïdes - Steroidtest Jany B, Welte T. Pleuraerguss des Erwachsenen Leuenberger Ph, Anderhub HP, Brändli O, et al. – Ursachen, Diagnostik und Therapie Deut- Management 1997 of chronic obstructive pul- sches Ärzteblatt 2019; 116: 377-386. monary disease. Schweiz Med Wochenschr 1997; 127: 766-82. Pneumothorax Fitting JW, Rochat Th. Corticosteroïdes dans la Miller AC, Harvey JE on behalf of Standards of broncho-pneumopathie obstructive chronique. Care Committee, British Thoracic Society. Gui- Rehabilitation respiratoire. Med Hyg 2000; 58: delines for the management of spontaneous 60-4. pneumothorax. Br Med J 1993; 307: 114-6. Jantz MA, Pierson DJ. Pneumothorax and baro- Pneumonie trauma. Clin Chest Med 1994; 15: 75-91. Guidelines for the management of community-ac- Light RW. Tension pneumothorax. Intensive Care quired pneumonia in adults admitted to hospital. Med 1994; 20: 468-9. British J Hosp Med 1993; 49: 346-50. Light RW. Pleural diseases. 3rd edition. Balti- Marrie TJ. Community-acquired pneumonia. Clin more, Williams and Wilkins 1995. Infect Dis 1994; 18: 501-15. Wyser C, Ullmer E, Bolliger CT. Pneumothorax. American Thoracic Society. Hospital-acquired Bulletin des Médecins Suisses. 1998; 79: 28- pneumonia in adults: diagnosis, assessment of 31. severity, initial antimicrobial therapy, and pre- Sahn SA, Heffner JE. Spontaneous pneumotho- ventive strategies. Am J Respir Crit Care Med rax. N Engl J Med 2000; 342: 868-74. 1996; 153: 1711-25. Baumann HM, Strange C, Heffner HE, et al. Ma- Fine MJ, Smith MA, Carson CA, et al. Prognosis nagement of spontaneous pneumothorax: an and outcome of patients with community-acqui- American College of Chest Physician Delphi red pneumonia. A meta-analysis. JAMA 1996; consensus statement. Chest 2001; 119: 590- 275: 134-41. 602. Fine JM, Auble TE, Yealy DM, Hanusa BH, et al. Noppen M, Alexander P, Driesen P, et al. Manual A prediction rule to identify low-risk patients with aspiration versus chest tube drainage in first community-acquired pneumonia. N Engl J Med episodes of primary spontaneous pneumotho- 1997; 336: 243-50. rax: a multicentre, prospective, randomized pilot Metlay JP, Kapoor WN, Fine JM. Does this pa- study. Am Respir Crit Care Med 2002; 165: tient have community-acquired pneumonia ? 1202-3. JAMA 1997; 278: 1440-5. Henry M, Arnold T, Harvey J, et al. BTS guideli- Bartlett JG, Breiman RF, Mandell LA, File TM. nes for the managment of spontaneous pneu- Guidelines from the infectious diseases society mothorax. Thorax 2003; 58 (Suppl. II): ii39-ii52. of America. Community-acquired pneumonia in Dev SP, Nascimiento B Jr, Simone C, Chien V. Vi- adults: guidelines for management. Clin Infect deos in clinical medicine. Chest-tube insertion. Dis 1998; 26: 811-38. N Engl J Med 2007; 357(15): e15. ESOCAP committee: management of adult com- Dev SP, Nascimiento B Jr, Simone C, Chien V. Vi- munity-acquired lower respiratory tract infecti- deos in clinical medicine. Chest-tube insertion. ons. Eur Respir J 1998; 61: 391-426. N Engl J Med 2007; 357(15): e15. Halm EA, Fine MJ, Marrie TJ, et al. Time to clini- MacDuff A, Arnold A, Harvey J. BTS Pleural Disease Guideline Group. cal stability in patients hospitalised with commu- Management of spontaneous pneumothorax: British Thoracic So- nity-acquired pneumonia. Implications for ciety Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2: practice guidelines. JAMA 1998; 279: 1452-7. ii18-31. Nathwani D. Sequential switch therapy for lower Ho KK, Ong ME, Koh MS, et al. A randomized respiratory tract infections. Chest 1998; 113: controlled trial comparing minichest tube and 211S-218S. needle aspiration in outpatient management of Fine MJ, Stone RA, Singer DE, et al. Process and primary spontaneous pneumothorax. Am J outcomes of care for patients with community- Emerg Med 2011; 29: 1152-7. acquired pneumonia. Arch Intern Med 1999; Lai SM, Tee AK. Outpatient treatment of primary 159: 970-80. spontaneous pneumothorax using a small-bore Lamy O, Zanetti G, Bille J, et al. Diagnostic et chest drain with a Heimlich valve: the experi- traitement de la pneumonie acquise à domicile ence of a Singapore emergency department. de l’adulte. Rev Suisse Rom 1999; 119: 403-27. Eur J Emerg Med 2012; 19: 400-4. Mandell LA, Marrie TJ, Grossman RF, et al. Sum- Hu X, Cowl CT, Baqir M, Ryu JH. Air travel and 31 mary of canadian guidelines for the initial ma- in pleural fluid: TB or not TB? SAfr Med J 1980; nagement of community-acquired pneumonia: 57: 937-39. an evidence-based update by the canadian in- Ocana IM, et al. Adenosine deaminase in pleural fectious disease and the canadian thoracic so- fluids. Chest 1983; 84: 51-53. ciety. Can Respir J 2000; 7: 371-82. Seneff MG, et al. Complications associated with Guthrie R. Community-acquired lower respiratory thoracocentesis. Chest 1986; 90: 97-100. tract infections. Etiology and treatment. Chest Rodríguez-Panadero, Lopez Mejías J. Low glu- 2001; 120: 2021-34. cose and pH levels in malignant pleural effusi- McCory DC, Brown C, Gelfand SE, et al. Ma- ons. Am Rev Respir 1989; 139: 663-7. nagement of acute exacerbation of COPD. Light RW. Pleural diseases. 3rd ed. Baltimore, Chest 2001; 119: 1190-1209. Williams and Wilkins 1995. Halm EA, Teirstein AS. Managemenet of commu- Marel M, et al. Diagnosis of pleural effusions. nity-acquired pneumonia. N Engl J Med 2002; Chest 1995; 107: 1598-1603. 347: 2039-45. Hamm H, Light RW. Parapneumonic effusion and Lim WS, van der Eerden MM, Laing R et al. Defi- empyema. Eur Respir J 1997; 10: 1150-6. ning community acquired pneumonia severity Light RW. Diagnostic principles in pleural on presentation to hospital: an international de- disease. Eur Respir J 1997; 10: 476-81. rivation and validation study. Thorax 2003; 58: Trachiotis GD, Vricella LA, Aaron BL, et al. Reex- 377-82. pansion pulmonaray edema. Ann Thorac Surg Woodhead M1, Blasi F, Ewig S et al. Guidelines 1997; 63: 1206-7. for the management of adult lower respiratory Nicod LP. Epanchement parapneumoniques: eva- tract infections. Clin Microbiol Infect 2011; 17 luation et traitement. Med Hyg 1997; 55: 2312- (Suppl 6):E1-59. 5. Aleman C. Alegre J, Armadans L, et al. The value Pneumonie acquise en communauté (PAC) of chest roentgenography in the diagnosis of Erworbene Pneumonie (CAP) pneumothorax after thoracentesis. Am J Med Ferreira-Gonzalez I, Permanyer-Miralda G, Busse 1999; 107: 340-3. JW, et al. Methodologic discussions for using Light RW. Pleural effusion. N Engl J Med 2002; and interpreting composite endpoints are limi- 346: 1971-7. ted, but still identify major concerns. J Clin Epi- Thomsen TW, DeLaPena J, Setnik GS. Thora- demiol 2007; 60: 651-57. centesis. N Engl J Med 2007; 355: e16. Ewig S, Birkner N, Strauss R et al. New perspec- Havelock T, Teoh R, Laws D et al. Pleural proce- tives on community-acquired pneumonia in 388 dures and thoracic ultrasound: British Thoracic 406 patients. Results from a nationwide manda- Society pleural disease guideline 2010. Thorax tory performance measurement programme in 2010; 65(Suppl 2): ii61eii76. healthcare quality. Thorax 2009; 64: 1062-9. Rahman NM, Maskell NA, West A et al. Intrapleu- Hemkens LG, Grouven U, Bender R, Sawicki PT. ral Use of Tissue Plasminogen Activator and Insuffi cient evaluation of adverse events is not DNase in Pleural Infection. N Engl J Med 2011; a proof of safety. Diabetologia 2010; 53: 790- 365; 518-26. 92. Denkinger CM, Schumacher SG, Boehme CC et Hirata Y, Tomioka H, Sekiya R, et al. Association al. Xpert MTB/RIF assay for the diagnosis of of hyperglycemia on admission and during hos- extrapulmonary tuberculosis: a systematic re- pitalization with mortality in diabetic patients ad- view and meta-analysis. Eur Respir J 2014; 44: mitted for pneumonia. Intern Med 2013; 52: 435-46. 2431-38. Garin N, Genné D, Carballo S et al. β-Lactam Pneumopathies interstitielles monotherapy vs β-lactam-macrolide combina- Dunkalek E. Interstitielle (diffuse) Lungernerkran- tion treatment in moderately severe community- kungen. In: Kaufmann W. (ed.).Internistische acquired pneumonia: a randomized Differenzialdiagnostik. Schattauer Verlag, 1997, noninferiority trial. JAMA Intern Med 2014; 174: p. 580-99. 1894-901. Siegenthaler W, Kaufmann W, Hornbostel H, et al Annane D. Corticosteroids and pneumonia: time (eds.). In: Lehrbuch der inneren Medizin. to change practice. Lancet 2015; 385: 1484-85. Thieme, 1997. Claudine Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with commu- Fibrose pulmonaire idiopathique nity-acquired pneumonia: a multicentre, double- Katzenstein ALA, Myers JL. Idiopathic pulmonary blind, randomised, placebo-controlled trial. fibrosis - clinical relevance of pathologic classifi- Lancet 2015; 385: 1511-18. cation. Am J Respir Crit care Med 1998; 157: 1301-15. Épanchement pleural Mason RJ, Schwarz MI, Hunninghake GW, et al. Yam LT. Diagnostic significance of lymphocytes in Pharmacological therapy for idiopathic pulmo- pleural effusions. Ann Intern Med 1967; 66: nary fibrosis: past, present, future. Am J Respir 972-82. Crit Care Med 1999; 160: 1771-7. Light RW, et al. Pleural effusions: the diagnostic King TE, Costabel U, Cordier JE, et al. ATS/ETS. separation of transudates and exudates. Ann Idiopathic pulmonary fibrosis: Diagnosis and Intern Med 1972; 77: 507-13. treatment. Am J Respir Crit Care Med 2000; Hurwitz S, Leiman G, Shapiro C. Mesothelial cells 32 161: 646-64. 334: 296-301. Idiopathic pulmonary fibrosis: diagnosis and treat- Gaine SP, Rubin LJ. Primary pulmonary hyper- ment: international consensus statement. Am J tension. Lancet; 1998; 352: 719-25. Respir Crit Care Med 2000; 161: 646-64. Rich S, (ed). Primary pulmonary hypertension: Gross TG, Hunninghake GW. Idiopathic pulmo- executive summary from the world symposium. nary fibrosis. N Engl J Med 2001; 345: 517-25. Geneva: World Health Organization, 1998. Travis WE, King TE, Bateman ED, et al. ATS/ETS Benigni A, Ramuzzi G. Endothelin antagonists. international multidisciplinary consensus classi- Lancet 1999; 353: 133-8. ficatin of idiopathic interstitial pneumonias. Ge- Sanchez O, Humbert M, Sitbon O, et al. Treat- neral principles ansd recommendations. Am J ment of pulmonary hypertension secondary to Respir Crit Care Med 2002; 165: 277-304. connective tissue disease. Thorax 1999; 54: Noble P, Albera C, Bradford WZ, et al. Pirfeni- 274-7. done in patients with idiopathic pulmonary fibro- Hoeper MM, Schwarze M, Ehlerding St, et al. sis (CAPACITY): two randomized trials. Lancet Long-term treatment of primary pulmonary hy- 2011; 377: 1760-9. pertension with aeroslized iloprost, a prostacy- Richeldi L, Costabel U, Selman M, et al. Efficacy clin analogue. N Engl J Med 2000; 342: of a tyrosine kinase inhibitor in idiopathic pul- 1866-70. monary fibrosis. N Engl J Med 2011; 365: 1079- Channick RN, Simonneau G, Sitbon O, et al. Ef- 87. fects of the dual endothelin-receptor antagonist King TE, Bradford WZ, CastroBernardini S, et al. bosentan in patients with pulmonary hyperten- A phase 3 trial of pirfenidone in patients with sion: a randomised placebo-controlled study. idiopathic pulmonary fibrosis (ASCEND). N Lancet 2001; 358: 1119-23. Engl J Med 2014; 370: 2083-92. Hoeper MM, Galie N, Simonneau G, et al. New Richeldi L, du Bois R, Raghu G, et al. Efficacy treatments for pulmonary arterial hypertension. and safety of nintedanib in idiopathic pulmonary Am J Respir Crit Care Med 2002; 165: 1209-16. fibrosis (INPULSIS). N Engl J Med 2014; 370: Kim NHS, Rubin LJ. Endothelin in health and 2071-82. disease: endothelin receptor antagonist in the Travis WD, Costabel U, Hansell DM et al. An offi- management of pulmonary artery hypertension. cial American Thoracic Society/European Re- J Cardiovasc Pharmacol Therapeut 2002; 7: 9- spiratory Society statement: Update of the 19. international multidisciplinary classification of Prakash A, Perry CM. Bosentan. Am J Cardio- the idiopathic interstitial pneumonias. Am J Re- vasc Drugs 2002; 2: 335-42. spir Crit Care Med 2013; 188: 733-48. Olschewski H, G Simonneau, Galie N, et al. Inha- led Iloprost for severe pulmonary hypertension. Hypertension pulmonaire (HP) N Engl J Med 2002; 347: 322-9. Rich S, Dantzker DR, Ayres SM, et al. Primary Rubin LJ. Therapy of pulmonary hypertension: pulmonary hypertension. Ann Intern Med 1987; the evolution from vasodilatators to antiprolife- 107: 216-23. rative agents. Am J Respir Crit Care 2002; 166: Rich S, Chomka E, Hasara L, et al. The preva- 1308-9. lence of pulmonary hypertension in the United Rubin LJ, Badesch DB, Barst R, et al. Bosentan States. Adult population estimates obtained therapy for pulmonary arterial hypertension. N from measurements of chest roentgenograms Engl J Med 2002; 346: 896-903. from the NHANES II Survey. Chest 1989; 96: Barst RJ, McGoon M, McLaughlin V, et al. Bera- 236-41. prost therapy for pulmonary arterial hyperten- Speich R, Jenni R, Opravil M, et al. Primary pul- sion. J Am Coll Cardiol 2003; 41: 2119-25. monary hypertension in HIV infection. Chest Widlitz A, Barst RJ. Pulmonary arterial hyperten- 1991; 100:1268-71. sion in children. Eur Respir J 2003; 21: 155-76. Rich S, Kaufmann E, Levy PS. The effect of high Barst RJ, McGoon M, Torbicki A, et al. Diagnosis doses of calcium-channel blockers on sirvival in and differential assessment of pulmonry arterial primary pulmonary hypertension. N Engl J Med hypertension. J Am Coll Cardiol 2004; 43 (12 1992; 327: 76-81. Suppl): S40-7. Rubin LJ. ACCP consensus statement: primary Pietra GG, Capron F, Stewart S, et al. Pathologic pulmonary hypertension. Chest 1993; 104: 236- assessment of vasculopathies in pulmonary hy- 50. pertension. J Am Coll Cardiol 2004; 43 (12 Rich S, Kaufmann P, Lew PS. The effect of high Suppl): S25-32. doses of calcium-channel blockers on survival Simonneau G, Galie N, Rubin LJ, et al. Clinical in primary pulmonary hypertension. N Engl J classification of pulmonary hypertension. J Am Med 1992; 327: 76-81. Coll Cardiol 2004; 43 (12 Suppl): S5-12. Abenhaim L, Moride Y, Brenot F, et al. Appetite- Pengo V, Lensing AWA, Prins MH, et al. Inci- suppressant drugs and the risk of primary pul- dence of chronic thromboembolic pulmonary monary hypertension. N Engl J Med 1996; 335: hypertension after pulmonary embolism. N Engl 609-16. J Med 2004; 350: 2257-64. Barst RJ, Rubin LJ, Long WA, et al. A comparison Humbert M, Sitbon O, Chaouat A, et al. Pulmo- of continous intravenous epoprostenol (prosta- nary arterial hypertension in France : Results cyclin) with conventional therapy for primary from a national registry. Am J Respir Crit Care pulmonary hypertension. N Engl J Med 1996; Med 2006; 173: 1023-30. 33 Task Force for Diagnosis and Treatment of Pul- Taimeh Z, Hertz MI, Shumway S, Pritzker M: monary Hypertension of European Society of Lung transplantation for pulmonary sarcoidosis. Cardiology (ESC); European Respiratory So- Twenty-five years of experience in the USA. ciety (ERS); International Society of Heart and Thorax 2016; 71: 378-9. Lung Transplantation (ISHLT), Galiè N, Hoeper Rhinite — Rhinitis MM, Humbert M, Torbicki A, Vachiery JL, Bar- bera JA, Beghetti M, Corris P, Gaine S, Gibbs Laursen LC, Faurschou P, Pals H, et al. Intramus- JS, Gomez-Sanchez MA, Jondeau G, Klepetko cular betamethasone dipropionate vs. oral pred- W, Opitz C, Peacock A, Rubin L, Zellweger M, nisolone in hay feverpatients. Allergy 1987; 42: Simonneau G. Guidelines for the diagnosis and 168-72. treatment of pulmonary hypertension. Eur Re- Brogden RN, McTavish D. Acrivastine. A review of spir J 2009; 34: 1219-63. its pharmacological properties and therapeutic Taichman DB, McGoon MD, Harhay MO, et al. efficacy in allergic rhinitis, urticaria and related Wide variation in clinicians’ assessment of New disorders. Ann Allergy 1991; 67: 541-7. York Heart Association/World Health Organiza- Naclerio RM. Allergic rhinitis. N Engl J Med 1991; tion functional class in patients with pulmonary 325: 860-9. arterial hypertension. Mayo Clin Proc 2009; 84: Brooks CD, Karl KJ, Francom SF. Oral methyl- 586-592. prednisolone acetate (Medrol tablets) for seaso- Benza RL, Gomberg-Maitland M, Miller DP et al. nal rhinitis: examination of dose and symptom The REVEAL Registry risk score calculator in response. J Clin Pharmacol 1993; 33: 816-22. patients newly diagnosed with pulmonary arte- International Rhinitis Management Working rial hypertension. Chest 2012; 141: 354-362. Group. International consensus report on the Hoeper MM, Bogaard HJ, Condliffe R et al. Defi- diagnosis and management of rhinitis. Allergy nitions and diagnosis of pulmonary hyperten- 1994; 49 (Suppl. 9): S5-S34. sion. J Am Coll Cardiol 2013; 62(25 Suppl): Abramson MJ, Puy RM, Weiner JM. Is allergen D42-50. immunotherapy effective in asthma? A meta- Simonneau G, Gatzoulis MA, Adatia I et al. Up- analysis of randomized controlled trials. Am J dated clinical classification of pulmonary hyper- Respir Crit Care Med 1995; 151: 969-74. tension. J Am Coll Cardiol 2013; 62 (25 Suppl): Bernstein IL, Storm WW. Practice parameters for D34-41. allergy diagnostic testing. Joint tasc force on Galiè N, Humbert M, Vachiery J-L et al. 2015 practice parameters for the diagnosis and treat- ESC/ERS Guidelines for the diagnosis and ment of asthma. The american academy of al- treatment of pulmonary hypertension. Eur Re- lergy, asthma and immunology. Ann Alllergy spir J 2015; 46: 903-75. Asthma Immunol 1995; 75: 43-625. Desager JP, Horsmans Y. Pharmacokinetic-phar- Sarcoïdose — Sarkoidose macodynamic relationships of H1-antihistami- Panel of th world association of sarcoidosis and nes. Clin Pharmacokinet 1995; 28: 419-32. other granulomatous disease. Consensus con- Small P, Hule PA, et al. A comparison of triamci- ference: activity of sarcoidosis. Eur Resp J nolone acetonide nasal aerosol spray and fluti- 1994; 7: 624-7. casone propionate aqueous solution spray in Peckham DG, Spiteri MA. Sarcoidosis. Postgrad the treatment of spring allergic rhinitis. J Allergy Med J 1996; 72: 196-200. Clin Immunol 1997; 100: 592-5. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Stern MA, Dahl R, et al. A comparison of aqueous Engl J Med 1997; 336: 1224-34. suspensions of budesonide nasal spray and flu- American Thoracic Society, European Respira- ticasone propionate nasal spray in the treat- tory Society, World Association of Sarcoidosis ment of adult patiens with seasonal allergic and other Granulomatous Disorders. Statement rhinitis. Am J Rhinol 1997; 11: 323-30. on sarcoidosis. Am J Respir Crit Care Med Bousquet J, Lockey R, Malling HJ, et al. Allergen 1999; 160: 736-55. immunotherapy: therapeutic vaccines for aller- Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoido- gic diseases. A WHO position paper. J Allery sis. N Engl J Med 2007; 357: 2153-65. Clin Immunol 1998; 102: 558-562. Mostard RL, Voo S, van Kroonenburgh MJ, et al.: Dykewicz MS, et al. Joint Task Force Algorithm Inflammatory activity assessment by F18 FDG- and Annotations for Diagnosis and Manage- PET/CT in persistent symptomatic sarcoidosis. ment of Rhinitis. Ann Allergy Asthma Immunol Respir Med 2011; 105: 1917-24. 1998; 81: 469-73. Mostard RL, Verschakelen JA, van Kroonenburgh Dykewicz MS, et al. Joint Task Force summary MJ, et al.: Severity of pulmonary involvement statements on Diagnosis and Management of and (18)F-FDG PET activity in sarcoidosis. Re- Rhinitis. Ann Allergy Asthma Immunol 1998; 81: spir Med 2013; 107: 439-47. 463-8, et 474-7. Baughman RP, Judson MA: Relapses of sarcoi- Dykewicz MS, et al. Diagnosis and management dosis: what are they and can we predict who of rhinitis: complete guidelines of the Joint Task will get them? Eur Respir J 2014; 43: 337–9. Force on Practice Parameters in Allergy, Kandolin R, Lehtonen J, Airaksinen J, et al.: Car- Asthma and Immunology. American Academy of diac sarcoidosis: epidemiology, characteristics, Allergy, Asthma, and Immunology. Ann Allergy and outcome over 25 years in a nationwide Asthma Immunol 1998; 81: 478-518. study. Circulation 2015; 131: 624-32 Lundbäck B. Epidemiology of rhinitis and asthma. 34 Clin Exp Allerg 1998; 28: 3-10. Questionnaire (LCQ). Thorax 2003; 58:339-43. Durham SR, Walker SM, Varga EM, et al. Long- Morice AH, Fontana GA, Sovijarvi AR, et al. The term clinical efficacy of grass-pollen immunodiagnosis and management of chronic cough. therapy. N Engl J Med 1999; 341: 468-75. Eur Respir J 2004; 24:481-92. Howarth PH. A comparison of the anti-inflamma- Jeyakumar A, Brickman TM, Haben M. Effective- tory properties of intranasal corticosteroids and ness of amitriptyline versus cough suppres- antihistamines in allergic thinitis. Allergy 2000; sants in the treatment of chronic cough 62: 6-11. resulting from postviral vagal neuropathy. La- Van Cauwenberge P, Bachert P, Passalacqua G, ryngoscope 2006; 116: 2108-12. et al. Consensus statement on the treatment of Morice AH, McGarvey L, Pavord I, British Thora- allergic rhinitis. European academy of allergo- cic Society Cough Guideline G. Recommendati- logy and clinical immunology. Allergy 2000; 55: ons for the management of cough in adults. 116-34. Thorax 2006; 61 Suppl 1: i1-24. Bousquet J, can Cauwenberger P, Khaltaev N. Irwin RS, Baumann MH, Bolser DC, et al. Diagno- Allergic rhinitis and its impact pm asthma. J Al- sis and management of cough executive sum- lergy Clin Immunol 2001; 101 (Supp. 5): S147- mary: ACCP evidence-based clinical practice S334. guidelines. Chest 2006; 129(1 Suppl): 1S-23S Kaszuba SM, Baroody FM, deTineo M, et al. Su- Kastelik JA, Aziz I, Ojoo JC et al. Investigation periority of an intranasal corticoid compared and management of chronic cough using a pro- with an oral antihistamine in the as-needed bability-based algorithm. Eur Respir J 2005; 25: treatment of seasonal allergic rhinitis. Arch In- 235-43. tern Med 2001; 161: 2581-7. Chung KF, Pavord ID. Prevalence, pathogenesis, Pullerits T, Praks L, Ristioja V, et al. Comparison and causes of chronic cough. Lancet 2008; of a nasal glucocorticoid, antileukotriene, and a 371: 1364-74. combination of antileukotriene and antihista- Birring SS. Controversies in the evaluation and mine in the treatment of seasonal allergic rhini- management of chronic cough. Am J Respir Crit tis. J Allergy Clin Immunol 2002; 109: 949-55. Care Med 2011; 183:708-15. Ryan NM, Birring SS, Gibson PG. Gabapentin for Toux refractory chronic cough: a randomised, double- Pratter MR, Bartter Th, Akers St, et al. An algo- blind, placebo-controlled trial. Lancet 2012; rithmic approach to chronic cough. Ann Intern 380: 1583-9. Med 1993; 119: 977-83. Keller D, Nicod L. La toux chez l’adulte. Forum O’Connell F, Thomas VE, Pride NB, et al. Capsai- Med Suisse 2015; 15: 702-708. cin cough sensitivity decreases with successful Wei W, Liu R, ZhangTong Y, Qiu Z. The efficacy treatment of chronic cough. Am J Respir Crit of specific neuromodulators on human refrac- Care Med 1994; 150: 374-80. tory chronic cough: a systematic review and Patrick H, Patrick F. Chronic cough. Med Clin meta-analysis. J Thorac Dis 2016; 8: 2942- North Am 1995; 79: 361-72. 2951. Chung KF, Lalloo UG. Diagnosis and manage- Gibson P, Wang G, McGarvey L et al. Treatment ment of chronic persistent dry cough. Postgrad of Unexplained Chronic Cough: CHEST Guide- Med J 1996; 72: 594-8. line and Expert Panel Report. Chest 2016; 149: Lawler WR. An office approach to the diagnosis 27-44. of chronic cough. Am Family Physician 1998; Vertigan AE, Kapela SL, Ryan NM et al. Pregaba- 58: 2015-22. lin and Speech Pathology Combination Therapy Smyrnios NA, Irwin RS, Curley FJ, et al. From a for Refractory Chronic Cough: A Randomized prospective study of chronic cough. Arch Intern Controlled Trial. Chest 2016; 149: 639-48. Med 1998; 158: 1222-8. Palombini BC, Villanova CAC, Araújo E, et al. A Hoquet chronique pathogenic triad in chronic cough. Chest 1999; Kolodzki PW, Eilers MA. Hiccups (singultus): re- 116: 279-84. view and approach to management. Ann Emerg Pratter MR, Bartter Th, Lotano R. The role of Med. 1991; 20: 565-73. sinus imaging in the treatment of chronic cough Launois S, Bizec JL, Whitelow WA, et al. Hiccup in adults. Chest 1999; 116: 1287-91. in adults: an overview. Eur Respir J. 1993; 6: Irwin RS, Madison JM. The diagnosis and treat- 563-75. ment of cough. N Engl J Med 2000; 343: 1715- Friedgood CE, Ripstein CB. Chlorpromazine 21. (Thorazine) in the treatment of intractable hic- Irwin RS, Madison JM. Diagnosis and treatment cups. JAMA 1995;157:309-10. of chronic cough due to gastro-esophageal re- Friedman NL. Hiccups: a treatment review. Phar- flux disease and postnasal drip syndrome. Pulm macotherapy. 1996; 16: 986-95. Pharmacol Ther 2002; 15: 261-6. Federspil PA, Zenk J. Singultus. HNO. 1999; 47: Madison JM, Irwin RS. Pharmacotherapy of chro- 867-75. nic cough. Expert Opin Pharmacother 2003; 4: Schlafapnoesyndrom (SAS) 1039-48. Syndrome de l’apnée du sommeil Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for Rosenow F, McCarthy V, Caruso AC. Sleep ap- patients with chronic cough: Leicester Cough noea in endoctrine disease. J Sleep Res 1998; 7: 3-11. 35 American Thoracic Society: Indications and stan- 7. dards for cardiopulmonary sleep studies. Am Young T, Skatrud J, Peppard PE: Risk factors for Rev Respir Dis 1989; 139: 559-68. obstructive sleep apnea in adults. JAMA 2004; Johns MW. A new method for measuring daytime 291: 2013-6. sleepiness: the Epworth sleepiness sclae. Brack Th. Therapie der Cheyne-Stokes-Atmung Sleep 1991; 14: 540-5. bei Herzinsuffizienz. Schweiz Med Forum 2006; Bradley TD, Phillipson EA. Central sleep apnea. 6: 1092-6. Clin Chest Med 1992; 13: 493-505. Collop NA, Anderson WM, Boehlecke B et al. Cli- Douglas N, Thomas S, Jan M. Clinical value of nical guidelines for the use of unattended porta- polysomnography. Lancet 1992; 339: 347-50. ble monitors in the diagnosis of obstructive Guilleminault C, Stoohs R, Clerk A, et al. A cause sleep apnea in adult patients. Portable Monito- excessive daytime sleepiness. The upper air- ring Task Force of the American Academy of way resistance syndrome. Chest 1993; 104: Sleep Medicine. J Clin Sleep Med. 2007; 3: 781-7. 737-47. McNamara SG, Grunstein RR, Sullivan CE. Ob- Javaheri S, Smith J, Chung E. The prevalence structive sleep apnoea. Thorax 1993; 48: 754- and natural history of complex sleep apnea. J 64. Clin Sleep Med 2009; 5: 205-11. Young T, Palta M, Dempsey J, et al. The occur- Gottlieb DJ, Yenokyan G, Newman AB, et al. Pro- rence of sleep-disordered breathing amoung spective study of obstructive sleep apnea and middle-aged adults. N Engl J Med 1993; 328: incident coronary heart disease and heart fai- 1230-5. lure: the sleep heart health study. Circulation Flemons WW, Whitelaw WA, Brant R, et al. Likeli- 2010; 122: 352-60. hood ratios for a sleep apnea clinical prediction Berry RB et al. Update from 2007 des guidelines rule. Am J Respir Crit Care Med 1994; 150: AASM. J Clin Sleep Med 2012; 8:597-619. 1279-85. Sateia MJ. International classification of sleep Meurice JC, Marc I, Series F. Efficacy of auto- disorders-third edition: highlights and modificati- CPAP in the treatment of obstructive sleep ons. Chest 2014; 146: 1387-1394. apnea/hypopnea syndrome. Am J Respir Crit Heinzer R, Vat S, Marques-Vidal P et al. Preva- Care Med 1996: 153: 794-8. lence of sleep-disordered breathing in the gene- Series F. Auto CPAP in the treatment of sleep ral population: the HypnoLaus study. Lancet apnea hypopnea syndrome. Sleep 1996; 19 (10 Respir Med 2015;3:310-8. Suppl): S281-3. Marti-Soler H, Hirotsu C, Marques-Vidal P et al. Young T, Peppard P, Palta M, et al. Population- The NoSAS score for screening of sleep-disor- based study of sleep-disordered breathing as a dered breathing: a derivation and validation risk factor for hypertension. Arch Intern Med study. Lancet Respir Med 2016; 4: 742-748. 1997; 157: 1746-52. Turnheer R. Das obstruktive (und zentrale) Naughton MT. Heart failure and central apnea. Schlafapnoesyndrom. Schweiz Med Forum Reviews. Sleep Medeicine 1998; 2: 105-16. 2018; 18: 482-88. Worsnop CJ, Naughton MT, Barter CE, et. al. The Piqûre d’insecte prevalence of obstructive sleep apnea in hyper- tensives. Am J Respir Crit Care Med 1998; 157: Valentine MD. Insect venom allergy: Diagnosis 111-5. and treatment. J Allergy Clin Immunol 1984; 73: Sleep-related breathing disorders in adults: re- 299-304. commendations for syndrome definition and Reisman RE. Natural history of insect sting al- measurement techniques in clinical research. lergy. J Allergy Clin Immunol 1992; 90: 335-9. The report of an american academy of sleep Mosbech H. Hymenoptera immunotherapy. Al- medicine task force. Sleep 1999; 22: 667-89. lergy 1997; 52: 1-3. Peppard PE, Young T, Palta M, et al. Prospective Golden DB, Demain J, Freeman T, et al. Stinging study of the association between sleep-disorde- insect hypersensitivity: A practice parameter up- red breathing and hypertension. N Engl J Med date 2016. Ann Allergy Asthma Immunol 2017; 2000; 342: 1378-84. 118: 28-54. Logan AG, Perlikowski SM, Mente A, et al. High Urticaire prevalence of unrecognized sleep apnoea in Sibbald RG, Cheema AS, Lozinski A, et al. Chro- drug-resistant hypertension. J Hypertens 2001; nic urticaria: evaluation of the role of physical, 19: 2271-7. immunologic, and other contributory factors. Int Kohnlein T, Welte T, Tan LB et al. Central sleep J Dermatol 1991; 30: 381-6. apnoea syndrome in patients with chronic heart Charlesworth EN. Urticaria and angioedema: a disease: a critical review of the current literau- clinical spectrum. Ann Allergy Asthma Immunol tre. Thorax 2002; 57: 547-54 1996; 76: 484-99. Series F. Interpretation of home oxymetry tra- Tharp MD. Chronic urticaria. Pathophysiology cings. Chest 2002; 121: 1006-7. and treatment approaches. J Allergy Clin Immu- Young T, Peppard PE, Gottlieb DJ: Epidemiology nol 1996; 98: 325-30. of obstructive sleep apnea. Am J Respir Crit Golkar L, Bernhard JD. Mastocytosis. Lancet Care Med 2002; 165: 1217-39. 1997; 349: 1379- 85. Bottini P, Tantucci C. Sleep apnea syndrome in Tong LJ, Balakrishnan G, Kochan JP, et al. As- endocrine diseases. Respiration 2003; 70: 320- 36 sessment of autoimmunity in patients with chro- Allergic bronchopulmonary aspergillosis. Natu- nic urticaria. J Allergy Clin Immunol 1997; 99: ral history and classification of early disease y 461-5. serologic and roentgenographic studies. Arch Montureux P, Leaute-Labreze C, Legranin-Lifer- Intern med 1986; 146: 916-8. mann V, et al. Acute urticaria in infancy and Denning DW, Van Wye JE, Lewiston, et al. Ad- early childhood. Arch Dermatol 1998; 134: 319- junctive therapy of allergic bronchopulmonary 23. aspergillosis with itraconazole. Chest 1991; Lee EE, Maibach HI. Treatment of urticaria. An 100: 813-9. evidence-based evaluation of antihistamines. Wardlaw A, Geddes DM. Allergic bronchopulmo- Am J Clin Dermatol 2001; 2: 27-32 nary aspergillosis. J RoySoc Med 1992; 85: Negro-Alvarez JM, Miralles-Lopez JC. Chronic 747-51. idiopathic urticaria treatment. Allergol Immuno- Greenberger PA. Diagnosis and management of pathol (Madr) 2001; 29 :129-32. allergic bronchopulmonary aspergillosis. Allerg Kaplan AP. Chronic urticaria. N Engl J Med 2002; Proc 1994; 15: 335-9. 346: 175-9. Seaton A, Seaton RA, Wightman AJ. Manage- Doutre MS, Joly P. Prise en charg de l’urticaire ment of allergic bronchopulmonary aspergillosis chronique: recommandations de la conférence without maintenance oral corticosteroids: a fif- de consensus. La Revue de Médecine interne teen-year follow-up. QJMed 1994; 87: 529-37. 2004; 24: 637-9. Salez F, Brichet A, Desurmont S, et al. Effects of Kozel MA, Sabroe RA. Chronic urticaria. Drugs itraconazole therapy in allergic bronchopulmo- 2004; 64: 2515-36. nary aspergillosis. Chest 1999; 116: 1665-8. Zuberbier T, Asero R, Bindslev-Jensen C et al. Al- Stevens DA, Schwartz HJ, Lee JY, et al. A rando- lergy 2009; 64: 1417-26. mized trial of itraconazole in allergic broncho- EAACI/GA(2)LEN/EDF/WAO guideline: defini- pulmonary aspergillosis. tion, classification and diagnosis of urticaria. Agarwal R, Chakrabarti A, Shah A et al. Allergic Viswanathan RK, Moss MH, Mathur SK. Retro- bronchopulmonary aspergillosis: review of lite- spective analysis of the efficacy of omalizumab rature and proposal of new diagnostic and clas- in chronic refractory urticaria. Allergy Asthma sification criteria. Clin Exp Allergy 2013; 43: Proc. 2013; 34: 446-52. 850-73. Maurer M, Magerl M, Metz M et al. Revisions to Maladie de WIDAL the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Derma- Samter M, Beers RF. Concerning the nature of intol Ges 2013; 11: 971-7. tolerance to aspirin. J Allergy 1967; 40: 281. Maurer M, Rosén K, Hsieh HJ et al. Omalizumab Zeitz HJ. Bronchial asthma, nasal polyps, and for the treatment of chronic idiopathic or sponta- aspirin sensitivity: Sampter’s syndrome. Clin neous urticaria. NEJM 2013; 368: 924-35. Chest Med 1988; 9: 567-76. Spoerl D, Harr T, Seebach JD. Allergologie Oma- Israel E, Fischer AR, Rosenberg MA, et al. The lizumab dans le traitement de l’urticaire chroni- pivotal role of 5 lipoxygenase products in the re- que: quoi de neuf en 2013? Rev Med Suisse action of aspirin-sensitive asthmatics to aspirin. 2014; 10: 18-23. Am Rev Respir Dis 1993; 144: 1447-51. Zuberbier T, Aberer W, Asero R et al. The Leimgruber A. La triade de Widal: une anomalie EAACI/GA²LEN/EDF/WAO Guideline for the du métabolisme inflammatoire. Med Rev Suisse Definition, Classification, Diagnosis and Ma- 2005; 1: 15-8. nagement of Urticaria. The 2017 Revision and Mucoviscidose - Fibrose kystique / CF Update. Allergy. 2018 Jan 15. doi: www.genet.sickkids.on.ca/cftr/app 10.1111/all.13397. https://www.cftr2.org/ ABPA (Allergic bronchopulmonary Rosenstein BJ. What is a cystic fibrosis diagno- aspergillosis) sis? Clin Chest Med 1998;19:423-41. Rosenberg M, Patterson R, Mintzer RA, et al. Cli- Rosenstein BJ, Cutting GR. The diagnosis of cy- nical and immunological criteria for the diagnostic fibrosis: a consensus statement. Cystic Fi- sis of ABPA. Am J Int Med 1977; 86: 405-14. brosis Foundation Consensus Panel. J Pediatr Patterson R, Greenberger PA, Radin RC, et al. 1998;132:589-95. Allergic bronchopulmonary aspergillosis: sta- Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, ging as an aid to management. Ann Intern Med Cutting GR. Variant cystic fibrosis phenotypes 1982; 96: 286-91. in the absence of CFTR mutations. N Engl J Ricketti AJ, Greenberger PA, Patterson R. Serum Med 2002;347:401-7. IgE as an important aid in management of aller- Borowitz D. Use of fecal Elastase 1 to classify gic bronchopulmonary aspergillosis. J Allergy pancreatic status in patients with cystic fibrosis. Clin Immunol 1984; 74: 68-77. J Pediat 2004; 145: 322-6. Greenberger PA. Allergic bronchopulmonary as- Mishra A, Greaves R, Massie J. The relevance of pergillosis. J Allergy Clin Immunol 1984; 74: sweat testing for the diagnosis of cystic fibrosis 645-53. in the genomic era. Clin Biochem Rev Greenberger PA, Patterson R. Diagnosis and ma- 2005;26:135-53. nagement of allergic bronchopulmonary asper- De Boeck K, Wilschanski M, Castellani C, et al. gillosis. Ann Allergy 1986; 56: 444-8. Cystic fibrosis: terminology and diagnostic algo- Patterson R, Greenberger PA, Halwig JM, et al. 37 rithms. Thorax 2006; 61: 627-35. consensus guidelines from the cystic fibrosis LeGrys VA, Yankaskas JR, Quittell LM, Marshall foundation. J Pediatr 2017; 181: Suppl S4-15. BC, Mogayzel PJ, Jr. Diagnostic sweat testing: Leung DH, Narkewicz MR. Cystic fibrosis – rela- the Cystic Fibrosis Foundation guidelines. J Pe- ted cirrhosis. J Cyst Fibros 2017; 16 Suppl 2: diatr 2007;151:85-9. S50-S61. Wallis C. Diagnosis of cystic fibrosis. Cystic fibro- Jung A. La mucoviscidose aujourd’hui. Swiss sis Edited by MHodson, DGeddes, ABush (CRC Med Forum 2017; 17: 514–522. Press, 3rd Edition) 2007:101. Jung A. Zystische Fibrose heute: Diagnose, Ma- Farrell PM, Rosenstein BJ, White TB, et al. Gui- nagement und Therapie. Schweiz Med Forum delines for diagnosis of cystic fibrosis in 2017; 17: 514-522 newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr GASTROENTEROLOGIE 2008;153:S4-S14. Dequeker E, Stuhrmann M, Morris MA, et al. Best Douleur abdominale - Bauchschmerzen practice guidelines for molecular genetic dia- Oulhaci de Saussure E. Andereggen Quand réfé- gnosis of cystic fibrosis and CFTR-related dis- rer aux urgences un patient présentant des orders--updated European recommendations. douleurs abdominales? Rev Med Suisse 2010; Eur J Hum Genet 2009;17:51-65. 6: 1546-49. Flume PA. Cystic fibrosis pulmonary guidelines Bates B. Abdomen, chapitre 11. Guide de l’ex- Treatment of pulmonary exacerbations. amen clinique, édition 17 2014. AJRCCM 2009; 180: 802-8. Fitzgibbons RA. Forse Clinical Practice. Groin Derichs N, Sanz J, Von Kanel T, et al. Intestinal hernias in adults. NEJM 2015; 372: 756-63. current measurement for diagnostic classifica- Piqueres S, Staeger Ph, Pasche O. Examen de tion of patients with questionable cystic fibrosis: l’abdomen : et si nous refaisions nos gammes? validation and reference data. Thorax Rev Med Suisse 2016; 12:1866-72. 2010;65:594-9. Oesophagite toxique induite par des Flume PA. Cystic fibrosis pulmonary guidelines médicaments ;pulmonary complications. Hemoptysis and pneumothorax . AJRCCM 2010; 182: 298-306. Vãlean S, Petrescu M, Cãtinean A, et al. Pill eso- Bombieri C, Claustres M, De Boeck K, et al. Re- phagitis. Rom J Gastroenterol 2005; 14: 159- commendations for the classification of disea- 63. ses as CFTR-related disorders. Journal of Becker B, Zimmermann D, Borovicka J. Dabiga- cystic fibrosis : official journal of the European tran-induzierte exfoliative Ösophagitis. Schweiz Cystic Fibrosis Society 2011;10 Suppl 2:S86- Med Forum 2014; 14: 802-4. 102. Dağ MS, Öztürk ZA, Akin I et al. Drug-induced Ramsey BW. A CFTR potentiator in patients with esophageal ulcers: Case series and the review cystic fibrosis and the G551D mutation. NEJM of the Literature. Turk J Gastroenterol 2014; 25: 2011; 365:1663-72. 180-4. Ooi CY, Dupuis A, Ellis L, et al. Comparing the Muhammed SD et al. Drug-induced esophageal American and European diagnostic guidelines ulcers: Case series and the review of the litera- for cystic fibrosis: same disease, different ture. Turk J Gastroenterol 2014; 25: 180-4. language? Thorax 2012;67:618-24. Rottenstreich M, Rottenstreich M, Shapira S. Mogayzel PJ. Cystic fibrosis pulmonary guideli- Doxycycline induced oesophageal ulcers in a nes: chronic medications for maintenance of navy ship crewmember. Int Marit Health 2015; lung health AJRCCM 2013; 187: 680-9. 66: 181-3. Rueegg CS, Kuehni CE, Gallati S, et al. One-year Brown IS, Bettington M. Doxycycline induced oe- evaluation of a neonatal screening program for sophagitis: five cases highlighting a distinctive cystic fibrosis in Switzerland. Deutsches Arzte- pattern of injury. Pathology 2017; 49: 90-2. blatt international 2013;110:356-63. Senna JD, Bauerfeindb P; Hubera LC. Schluck- Bagheri-Hanson A, Nedwed S, Rueckes-Nilges schmerzen nach Zeckenstich. Schweiz Med C, Naehrlich L. Intestinal current measurement Forum 2019; 19: 423-25. versus nasal potential difference measurements Insuffisance hépatocellulaire for diagnosis of cystic fibrosis: a case-control Trey C, Burns DG, Saunders SJ. Treatment of study. BMC Pulm Med 2014;14:156. hepatic coma by exchange blood transfusion. N Guglani L, Stabel D, Weiner JD. False-positive Engl J Med 1966; 274: 473-81. and false-negative sweat tests: systematic re- Trey C, Davidson CS. The management of fulmi- view of the evidence. Pediatr Allergy Immunol nant hepatic failure. Prog Liver Dis 1970;3:282- Pulmonol 2015;28:198-211. 298. Wainwright CE. Lumacaftor-ivacaftor in patients Pugh RNH, Murray-Lyon IM, Dawson JL, et al. with cystic fibrosis homozygous for Phe508del Transection of the oesophagus for bleeding oe- CFTR. NEJM 2015; 373: 1783-4. sophageal varices. Brit J Surg 1973; 60: 646-9. Boudreau V. Sensitivity and specificity of cystic fi- Bernuau J, Rueff B, Benhamou JP. Fulminant and brosis –related diabetes screening methods: subfulminant liver failure: definitions and cau- which test should be the reference method ? J ses. Semin Liver Dis. 1986;6:97-106. Pediatr Endocrinol Metab 2017; 30: 885-887. Starzl TE, Demetris AJ, Van Thiel D. Liver trans- Farrell Ph.M et all. Diagnosis of cystic fibrosis: plantation. N Engl J Med 1989; 321: 1014-22 et 38 1092-9. Burroughs AK. Pharmacological treatment of Chapman RW, Forman D, Peto R, Smallwood R. acute variceal bleeding. Digestion 1998; 59 Liver transplantation for acute hepatic failure ? (Suppl. 2): 28-36. Lancet 1990; 1: 32-5. D’Amico G, Pagliaro L, Bosch J. Phamacological Caraceni P, van Thiel DH. Acute liver failure. Lan- treatment of portal hypertension: an evidence- cet 1995; 345: 163-9. based approach. Semin Liver Dis 1999; 19: Giostra E, Mentha G, Malè PJ, et al. Insuffisance 475-505. hépatocellulaire (IHC) aiguë et hépatite fulmi- Hébert PC, Wells F, Blajchman MA, et al. A multi- nante. In: Urgences Médicales, Restellini A et center, randomized, controlled clinical trial of al. (eds.). Editions Médecine et Hygiène, 1997, transfusion requirements in critical care. N Engl p: 278-83. J Med 1999; 340: 409-17. Lebrec D. Pharmacological treatment of portal hy- Schiff ER, Sorrell MF, Maddrey WC. In: Diseases pertension: present and future. J Hepatol 1998; of the liver. 8th ed. Philadelphia, Lippincott- 28: 869-907. Raven Publishers, 1999. O'Grady JG. Acute liver failure. Postgrad Med J Fishman D, Burnand D, Dorta G, et al. Hémorra- 2005;81: 148-154. gie digestive haute. Med Hyg 2000; 58: 1685. GÖR — Reflux — GERD Lau YJ, Sung JJ, Lee KK, et al. Effect of intrave- Sami, SS, et al. The Los Angeles classification of nous omeprazol on recurrents bleeding after gastroesophageal reflux disease. Video journal endoscopic treatment of bleeding peptic ulcers. and encyclopedia of GI Endoscopy 2013; 1: N Engl J Med 2000; 343: 310-6. 103-104. Schmassmann A, Di Nicola A. Prophylaxe und Vakil N, Van Zanten SV, Kahrilas P et al. The Therapie der Ösophagusvarizen. Forum Med Montreal Definition and Classification of Ga- Suisse 2001; 12: 313-9. stroesophageal Reflux Disease: A Global Evi- Sharara AI, Rockey DC. Gastroesophageal vari- dence-Based Consensus. Am J Gastroenterol ceal hemorrhage. N Engl J Med 2001; 345: 2006; 101: 1900-20. 669-81. Villanueva C, Minana J, Ortiz J, et al. Endoscopic Hémorragie gastro-intestinale, ligation compared with combined treatment with varices oesophagienes Nadolol and Isosorbid Mononitrate to prevent Graham DY, Smith JL. The course of patients recurrent variceal bleeding. N Engl J Med 2001; after variceal haemorrhage. Gastroenterology 345: 647-55. 1981; 80: 800-9. Burroughs AK, McCormick PA, Hughes MD, et al. Thrombose portale (veine porte) Randomized, double-blind, placebo-controlled Meuwly J-Y, Saverot-Chevalier A-L, Sgourdos G. trial of somatostatin for variceal bleeding. Ga- Thrombose veineuse porte. Forum Med Suisse stroenterology 1990; 99: 1388-95. 2012; 12: 119-25. Morrissey JF, Reichelderfer M. Gastrointestinal Garcia –Pagán J-C et al. Directives de pratiques endoscopy. N Engl J Med 1991; 325: 1142-9. cliniques EASL : les pathologies vasculaires du Poynard T, Cales P, Pasta L, et al. Beta-adrener- foie. Journal of Hepatology 2016: 64: 179-202. gic-antagonist drugs in the prevention of ga- Deleve Laurie D., Valla D-C, Garcia-Tsao G. Vas- strointestinal bleeding in patients with cirrhosis cular Disorders of the Liver. Hepatology 2009: and esophageal varices. N Engl J Med 1991; 1729-1764. 324: 1532-8. Diverticulite - Divertikulitis Daneshmend TK, Hawkey CJ, Langman MJ, et al. Omeprazole versus placebo for acute upper Brodribb AJM. Treatment of symptomatic diverti- gastrointestinal bleeding: randomized double cular disease with a high fibre diet. Lancet blind controlled study. BMJ 1992; 304: 143-7. 1977; 1: 664-5. Blaise M, Pateron D, Trinchet JC, et al. Systemic Almy TP, Howel DA. Diverticular disease of the antibiotic therapy prevents bacterial infection in colon. N Engl J Med 1980; 302: 324-31. cirrhotic patients with gastrointestinal hemor- Konvolinka CW. Acute diverticulitis under age of rage. Hepatology 1994; 20: 34-8. forty. Am J Surg 1994; 167: 562-5. Lin HJ, Wang K, Perng CL, et al. Early or delayed Roberts PL, Veidemheimer MC. Current mange- endoscopy for patients with peptic ulcer blee- ment of diverticulitis. Adv Surg 1994; 27: 189- ding. A prospective randomized study. J Clin 208 Gastroenterol 1996; 22: 267-71. Vignati PV, Welch JP, Cohen JL. Long-term ma- Rockall TA, Logan RF, Devlin HB, et al. Risk as- nagement of diverticulitis in young patients. Dis sessment after acute upper gastrointestinal ha- Colon Rectum 1995; 38: 627-9. emorrhage. Gut 1996; 38: 316-21. Ambrosetti P, Grossholz M, Becker C, et al. Com- Bernard R, Lebrec D, Mathurin P, et al. Beta- puted tomography in acute left colonic diverticu- adrenergic antagonists in the prevention of ga- litis. Br J Surg 1997; 84: 532-4. strointestinal rebleeding in patiets with cirrhosis: Cunningham MA, Davis JW, Kaups KL. Medical a meta-analysis. Hepatology 1997; 25: 63-70. versus surgical management of diverticulitis in Burroughs AK, Planas R, Svoboda P. Optimizing patients under age 40. Am J Surg 1997; 174: emergency care of upper gastointestinal blee- 733-6. ding in cirrhotic patients. Scand J Gastroenterol Stollman NH, Raskin JB. Diagnosis and manage- 1998; 226: (Suppl) 14-24. ment of diverticular disease of the colon in 39 adults. Am J Gastroenterol 1999; 94: 3110-21. Rambaud JC. Diarrhée chronique: orientation dia- Jacobs DO. Diverticulitis. N Engl J Med 2007; gnostique et conduite à tenir. Rev Prat (Paris) 357: 2057-66. 1989; 39: 1809-16. Unlü C, de Korte N, Daniels L et al. A multicenter Descos L. Diarrhée chronique sans malabsorp- randomized clinical trial investigating the cost- tion intestinale du grêle. Etiologie, diagnostic, effectiveness of treatment strategies with or wit- évolution et pronostic, principes de traitement. hout antibiotics for uncomplicated acute Rev du Prat 1990; 9: 846-8. diverticulitis (DIABOLO trial). BMC Surg 2010; Greenberger NJ. Diagnostic approach to the pa- 20;10:23. tient with a chronic diarrhea disorder. Dis Mon Strate LL, Modi R, Cohen E, Spiegel BM. Diverti- 1990; 36: 131-79. cular disease as a chronic illness: evolving epi- Cerf M. Stratégie diagnostique devant une diar- demiologic and clinical insights. Am J rhée chronique de l'adulte. Gastroenterol Clin Gastroenterol 2012; 107:1486. Biol 1992; 16: T12-T21. Shahedi K, Fuller G, Bolus R, et al. Long-term Donowitz M, Kokke FT, Saidi R. Evaluation of pa- risk of acute diverticulitis among patients with tients with chronic diarrhea. N Engl J Med 1995; incidental diverticulosis found during colonos- 332: 725-9. copy. Clin Gastroenterol Hepatol 2013; 11:1609. Fine KD. Diarrhea. In: Feldman M, et al. (eds.). Hall J, Hardiman K, Lee S et al. The American Sleisenger and Fordtran's Gastrointestinal and Society of Colon and Rectal Surgeons Clinical hepatic disease: pathophysiology, diagnosis, Practice Guidelines for the Treatment of Left- management. Philadelphia: Saunders WB Sided Colonic Diverticulitis. Dis Colon Rectum 1998, p: 128-52. 2020; 63: 728-747. Marteau Ph. Les diarrhées chroniques. Gastroen- terol Clin Biol 1999; 23: 73-95. Cholezystitis Fine KD, Schiller LR. American Gastroenterologi- Dyrhovden R., Øvrebø K.K., Nordahl M.V., Ny- cal Association Medical position statement: Gui- gaard R.M., Ulvestad E., Kommedal Ø. Bacteria delines for the evaluation and management of and fungi in acute cholecystitis. A prospective chronic diarrhea. Gastroenterology 1999; 116: study comparing next generation sequencing to 1461-3. culture. J Infect 2020;80:16-23 Binder HJ. Causes of Chronic Diarrhea. N Engl J Akute Diarrhö — Diarrhées aiguës Med 2006; 355: 236-9.5 Fine KD et al. In: Sleienger MH, Fordtran JS, Ga- Schiller LR, Pardi DS, Spiller R, et al. Gastro strointestinal Disease 1989; p: 290-316. 2013 APDW/WCOG Shanghai Working Party Bandres JC, DuPont H. Approach to the patient Report: Chronic diarrhea: Definition, classifica- with diarrhea. In: Gorbach SL, et al. (eds.). In- tion, diagnosis. J Gastroenterol Hepatol 2014; fectious Diseases. Philadelphia: Saunders, 29: 6-25. 1992; p: 572-575. Arasaradnam RP, Brown S, Forbes A et al. Gui- Kelly CP, Pothoulakis C, LaMont JT. Clostridium delines for the investigation of chronic diarrhoea difficile colitis. N Engl J Med 1994; 330: 257-62. in adults: British Society of Gastroenterology, Praz JO, Stalder H. Les diarrhées aiguës. Med 3rd edition. Gut 2018;0:1-20. Hyg 1996; 54: 1719-22. Laktosemalabsorption - Laktoseintoleranz DuPont HL. Guidelines on acute infections diar- Misselwitz B, Butter M, Verbeke K et al. Update rhea in adults. The practice parameters commit- on lactose malabsorption and intolerance: pa- tee of the American College of thogenesis, diagnosis and clinical management. Gastro-enterology. Am J Gastroenterol 1997; Gut 2019; 68: 2080-91. 92: 1962-75. DuPont HL. Guidelines on acute infectious diar- Giardiase lambliase rhea in adults. The Practice Parameters Com- Greig JD, Michel P, Wilson JB et al. A descriptive mittee of the American College of analysis of giardiasis cases reported in Ontario, Gastroenterology. Am J Gastroenterol 1997; 92: 1990-1998. Can J Public Health. 2001; 92: 361- 1962-75. 5. Aranda-Michel J,Giannella RA. Acute diarrhea: a Cavallo JD, Garrabé E. Infectious aetiologies of practical review. Am J Med 1999; 106: 670-7. travelers’ diarrhea. Med Mal Infect 2007; 37: Guerrant RL, Van Gilder T, Steiner TS et al. Prac- 722-7. tice guidelines for the management of infectious Gétaz L, Chappuis F, Loutan L. Parasitoses inte- diarrhea. Clin Infect Dis 2001; 32: 331-51. stinales et hépatiques: diagnostic et traitement. Haque R, Huston C, Hughes M, et al. Amebiais. Rev Med Suisse 2007; 3: 1254-8. N Engl J Med 2003; 348: 1565-73. Escobedo AA, Cimerman S. Giardiasis: A phar- Vallière S, Pasche O, Cornuz J, Felley Chr. Diar- macotherapy review. Expert Opin Pharmacot- rhées aiguës : propositions de prise en charge her 2007; 8: 1885-902. ambulatoire. Rev Med Suisse 2008; 181: 2586- Morken MH, Lind RA, Valeur J et al. Subjective- 90. health complaints and quality of lifein patients Truninger: Diarrhoe beim älteren Patienten. In: with irritable bowel syndromefollowing Giardia Therapeutische Umschau. Band 71, Nummer 9, lambliainfection: a case control study. Scand J 2014. Gastroenterol 2009; 44: 308-13. Stensvold CR, Smith HV, Nagel R et al. Eradica- Chronische Diarrhö - Diarhées chroniques 40 tion of Blastocystis carriage with antimicrobials : tite aiguë. In: Urgences Médicales, Restellini A Reality or delusion? J Clin Gastroenterol 2010; et al. (eds.). Médecine et Hygiène, 1997, p: 44: 85-90. 267-72. Chappuis F, Gétaz L. Parasitoses digestives d’ici Bassi C, Falconi M, Talamini G, et al. Controlled et d’ailleurs. Rev Med Suisse 2011; 279: 200- clinical trial of pefloxacin versus imipenem in 202. severe acute pancreatitis. Gastroenterology 1998; 115: 1513-7. Clostrioidium difficile - C. difficile Pitchumoni CS. Chronic pancreatitis, pathogene- Kelly CP, LaMont JT. Clostridium difficile--more sis and management of pain. J Clin Gastroente- difficult than ever. N Engl J Med 2008; rol 1998; 27: 101-7. 359:1932. Etemad B, Whitcomb DC: Chronic pancreatitis: You DM, Franzos MA, Holman RP. Successful diagnosis, classification, and new genetic deve- treatment of fulminant Clostridium difficile infec- lopments. Gastroenterology 2001; 120: 682- tion with fecal bacteriotherapy. Ann Intern Med 707. 2008; 148:632. Nathens AB, Curtis R, Beale RJ, et al. Manage- Cohen SH, Gerding DN, Johnson S, et al. Clinical ment of the critically ill patient with severe acute practice guidelines for Clostridium difficile infec- pancreatitis. Crit Care Med 2004; 32: 2524-36. tion in adults: 2010 update by the society for Michel Biour M, Daoud H, Ben Salem C. Pan- healthcare epidemiology of America (SHEA) créatotoxicité des médicaments. Seconde mise and the infectious diseases society of America à jour du fichier bibliographique des atteintes (IDSA). Infect Control Hosp Epidemiol 2010; pancréatiques et des médicaments responsab- 31:431. les. Gastroenterol Clin Biol 2005; 29: 353-359. Trubiano JA, Gardiner B, Kwong JC, et al. Faecal Frossard JL, Nicolet Th. Pancréatite chronique et microbiota transplantation for severe Clostri- insuffisance pancréatique. Forum Med Suisse dium difficile infection in the intensive care unit. 2007; 7: 75-80. Eur J Gastroenterol Hepatol 2013; 25:255. Catalano MF, Sahai A, Levy M, Romagnuolo J et Bagdasarian N, Rao K, Malani PN. Diagnosis and al. EUS-based criteria for the diagnosis of chro- treatment of Clostridium difficile in adults: a sy- nic pancreatitis: the Rosemont classification. stematic review. JAMA 2015; 313:398. Gastrointest Endosc 2009; 69: 1251-61. Pankreatitis — Pancréatite Banks PA, Bollen TL, Dervenis C et al. Classifica- Knaus WA, Draper EA, Wagner DP et al. APA- tion of acute pancreatitis--2012: revision of the CHE II: a severity of disease classification sy- Atlanta classification and definitions by interna- stem. Critical Care Medicine 1985; 13: 818-29. tional consensus. Gut 2013; 62: 102-11. Ranson JHC et al. Computed tomography and Nadkarni NA, Khanna S, Vege SS. Splanchnic the prediction of pancreatic abscess in acute venous thrombosis and pancreatitis. Pancreas pancreatitis. Ann Surg 1985; 201: 656-65. 2013; 42: 924-31. Reynaert MS, Dugernier T, Kestens PJ. Current Working Group IAP/APA Acute Pancreatitis Gui- therapeutic strategies in severe acute pancrea- delines. IAP/APA evidence-based guidelines for titis. Intensive Care Med 1990; 16: 352-62. the management of acute pancreatitis. Pan- Ros E, Navarro S, Bru C, et al. Occult microlithia- creatology 2013; 13(4 Suppl 2): e1-15. sis in " idiopathic " acute pancreatitis: preven- Cholangite biliaire primitive (CBP) tion of relapses by cholecystectomy or Primär biliäre Cholangitis (PBC) ursodeoxycholic acid therapy. Gastroenterology Angulo P, Lindor KD. Primary biliary cirrhosis and 1991; 101: 1701-9. primary sclerosing cholangitis. Clin Liver Dis Tenner SM, Steinberg W. The admission serum li- 1999; 3: 529-70. pase: amylase ratio differentiates alcoholic from Leuschner M, Maier KP, Schlichtling J, et al. Oral nonalcoholic acute pancreatitis. Am J Gastroen- budesonide and orsodeoxycholic acid treatment terol 1992; 12: 1755-8. of primary biliary cirrhosis: results of o prospec- Steinberg W, Tenner S. Acute Pancreatitis. N tive double-blind trial. Gastroenterology 1999; Engl J Med 1994; 330: 1198-1210. 117: 918-25. Grangé JD, Biour M. Pancréatites aiguës médi- Heathcotge EJ. Management of primary biliary camenteuses. Gastroenterol Clin Biol 1995; 19: cirrhosis. The American Association for the B67-B70. study of liver diseases practice guidelines. He- Delcenserie R, Yzet T, Ducroix JP. Prophylactic patology 2000; 31: 1005-13 antibiotics in treatment of severe acute alcoho- Holtmeier J, Leuschner U. Medical treatment of lic pancreatitis. Pancreas 1996; 13: 198-201. primary biliar cirrhosis and primary sclerosing Sainio V, Kemppanien E, Poulakkainen P et al. cholangitis. Digestion 2001; 64: 137-50. Early antibiotic treatment in acute necrotising Floreani A. Preventive therapy in primary biliary pancreatitis. Lancet 1995; 346 :663-7. cirrhosis. Clin Liver Dis 2003; 7: 911-21. Brown A, Hugues M, Tenner S, Banks P. Does Levy C, Lindor KD. Management of primary bi- pancreatic enzyme supplementation reduce liary cirrhosis. Curr Treat Options Gastroenterol pain in patients with chronic pancreatitis: a 2003; 6: 493-8. meta-analysis. Am J Gastroenterol 1997; 92: Talwalker JA, Lindor KD. Primary biliary cirrhosis. 2032-5. Lancet 2003; 362: 53-61. Gaillard Ph, Restellini A, Malè PJ, et al. Pancréa- Pares A, Cisneros L, Salmeron JM, et al. Extra- 41 corporeal albumin dialysis: a procedure for pro- Strassburg CP, Manns MP. Autoantibodies and longed relief of intractable pruritus in patients autoimmune hepatitis. Semin Liver dis 2002 with primary biliary cirrhosis. Am J Gastroente- 2002; 22: 339-52. rol 2004; 99: 1105-10. Hennes EM, Zeniya M, Czaja AJ et al. Simplified Bressler B, Pinto R, El-Ashry D, Heathcote EJ. criteria for the diagnosis of autoimmune hepati- Which patients with primary biliary cirrhosis or tis. Hepatology 2008; 48: 169-76. primary sclerosing cholangitis should undergo Björnsson E, Talwalkar J, Treeprasertsuk S et al. endoscopic screening for oesophageal varices Patients with typical laboratory features of auto- detection? Gut 2005; 54: 407-10. immune hepatitis rarely need a liver biopsy for Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. diagnosis. Clin Gastroenterol Hepatol 2011; 9: Primary Biliary Cholangitis: 2018 Practice Gui- 57-63. dance from the American Association for the NASH (nonalcoholic steatohépatite) Study of Liver Diseases. Hepatology 2019; 69: 394-419 Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. Can J Gastroen- Cholangite sclérosante primitive (CSP) terol 2000; 14: 321-6. Primär sklerosierende Cholangitis (PSC) Farrell GC. Drugs ans steatohepatitis. Semin Stiehl A, Benz C, Sauer P. Primary sclerosing Liver Dis 2002; 22: 185-94. cholangitis. Can J Gastroenterol 2000; 14: 311- Brunt EM. Nonalcoholic steatohepatitis. Semin 5. Liver Dis 2004; 24: 3-20. Holtmeier J, Leuschner U. Medical treatment of primary biliar cirrhosis and primary sclerosing Cirrhose hépatique - Ascite cholangitis. Digestion 2001; 64: 137-50. Goldberg BB, Goodman GA, Clearfield HR. Eva- Zein CO, Lindor KD. Primary sclerosing cholangi- luation of ascittes by ultrasound. Radiology tis. Semin Gastrointest Dis 2001; 12: 103-12. 1970; 96: 15-22. Rocco VK, Ware AJ. Cirrhotic ascites: Pathophy- Foetor ex ore siology, diagnosis and management. Ann Intern Rosenberg M, Kozlovsky A, Gelernter I, et al. Med 1986; 105: 573-85. Self-estimation of oral malodor. J Dent Res Runyon BA. Low protein-concentration ascitic 1995; 74: 1577-82. fluid is predisposed to spontaneous bacterial Rosenberg M. Clinical assessment of bad breath: peritonitis. Gastroenterology 1986; 91: 1343-6. currents concepts. J Am Dent Assoc 1996; 127: Ariza J, Xiol X, Esteve M, et al. Aztreonam vs. ce- 475-82. fotaxime in the treatment of gram-negative Rosenberg M. The science of bad breath. Sci Am spontaneous peritonitis in cirrhotic patients. He- 2002; 286: 72-9. patology 1991;14: 91-8. Quiryenen M, Zhao H, van Steenberghe D. Re- Gines P, Arroyo V, et al. Paracentesis with intra- view of the treatment strategies for oral malo- venous infusion of albumin compared with peri- dour. Clin Oral Invest 2002; 6: 1-10. toneovenous shunting in cirrhosis with Filippi A, Meyer J. Haltinosis - Ursachen, Dia- refractory ascites. N Engl J Med 1991; 325: gnose, Therapie. Schweiz Med Forum 2004; 4: 829-35. 585-9. Garcia-Pagan JC, et al. Effects of low-sodium diet Hépatite auto-immune (HAI) and spironolactone on portal pressure in pa- Autoimmunhepatitis (AIH) tients with compensated cirrhosis. Hepatology 1994; 19: 1095-99. Bieri-Tehovnik S, Marbert U, Bertschinger P. Au- Runyon BA. Care of patients with ascites. N Engl toimmune hepatitis in Switzerland. Schweiz J Med 1994; 330: 337-42. Med Wochenschr 1998; 128: 850-2. Arroyo V, Gines P, Gerbes AL, et al. Definition Alvarez F, Berg PA, Bianchi L, et al. International and diagnostic criteria of refractory ascites and autoimmune hepatitis group report: review of hepatorenal syndrome in cirrhosis. Hepatology criteria for diagnosis of autoimmune hepatitis. J 1996; 23: 164-76. Hepatol 1999; 31: 929-38. Gines A, Fernández-Esparrach G, Monescillo A, Manns MP. Autoantibodies to soluble liver anti- et al. Randomized trial comparing albumin, gen: specific marker of autoimmune hepatitis. J Dextran-70 plus polygeline in cirrhotic patients Hepatol 2000; 33: 326-8. with ascites treated with paracentesis. Gastro- Al-Khalidi JA, Czaja AJ. Current concepts in the enterol 1996; 111: 1002-10. diagnosis, pathology, and treatment of autoim- Bataller R, Gines P, Arroyo V. Practical recom- mune hepatitis. Mayo Clin Proc 2001; 76: 1237- mendations for the treatment of ascites and its 52. complications. Drugs 1997; 54: 571-80. Czaja AJ. Autoimmune hepatitis. Clin Liver Dis Gines P, Fernandez-Esparrach G, Arroyo V, et al. 2002; 6: xi-xii. Pathogenesis of ascites in cirrhosis. Semin Czaja AJ, Freese DK; American Association for Liver Dis 1997; 17: 175-89. the sutdy of Liver Diesease. Diagnosis and Arroyo V, Cardenas A. TIPS in the treatment of treatment of autoimmune hepatitis. Hepatology refractory ascites. In: Arroyo V. et a. (ed.). 2002; 36: 479-97. Treatment of liver diseases. 1999, Masson. McFarlane IG. Autoimmune hepatitis: diagnostic Akriviadis E, Botla R, Briggs W, et. al. Pentoxi- criteria, subclassifications, and clinical features. phylline improves short-terme survival in severe Clin Liver dis 2002; 6: 317-33. 42 acute alcoholic hepatitis: a double-blind, pla- Curr Opin Gastroenterol 2004; 20: 386-90. cebo-controlled trial. Gastroenterelogy 2000; Syndrome hépatorénal 119: 1637-48. Cardenas A, Bataller R, Arroyo V. Mechanisms of Arroyo A, Ginès P, Gerbes AL, et al. Definition ascites formation. Clin Liver Dis 2000; 4: 447- and diagnostic criteria of refractory ascites and 65. hepatorenal syndrome in cirrhosis. Hepatology Rössle M, Ochs A, Veit G, et al. A comparison of 1996; 23: 164-73. paracentesis and transjugular intrahepatic por- Angeli P, Volpin R, Gerunda G, et al. Reversal of tosystemic shunting in patients with ascites. N type 1 hepatorenal syndrome with the admini- Engl J Med 2000; 342: 1701-7. stration of midodrine and octreotide. Hepato- Ginès P, Cárdenas A, Arroyo V, Rodés J. Ma- logy 1999; 29: 1690-7. nagement of Cirrhosis and Ascites. N Engl J Cardenas A, Uriz J, Gines P et al. Hepatorenal Med 2004; 350:1646-54. syndrome. Liver Transpl 2000; 6 (4 Suppl. 1): Sigal SH, Stanca CM, Fernandez J, et al. Restric- S63-71. ted use of albumin for spontaneous bacterial Uriz J, Gines P, Cardenas A, et al. Terlipressin peritonitis.Gut 2007; 56: 597-9. plus albumin infusion: an effective and safe the- European Association for the Study of the Liver. rapy of hepatorenal syndrome. J Hepatol 2000; EASL clinical practice guidelines on the ma- 33: 43-8. nagement of ascites, spontaneous bacterial pe- Bataller R, Ginès P, Arroyo V et al. Hepatorenal ritonitis, and hepatorenalsyndrome in cirrhosis. syndrome. Clin Liver Dis 2000; 4: 487-507. J of Hepatol 2010; 53: 397-417. Insuffisance hépatocellulaire Runyon BA . The American Association for the Trey C, Burns DG, Saunders SJ. Treatment of Study of Liver Diseases (AASLD). Introduction hepatic coma by exchange blood transfusion. N to the revised American Association for the Engl J Med 1966; 274: 473-81. Study of Liver Diseases Practice Guideline ma- Pugh RNH, Murray-Lyon IM, Dawson JL, et al. nagement of adult patients with ascites due to Transection of the oesophagus for bleeding oe- cirrhosis 2012. Hepatology 2013; 57: 1651-3. sophageal varices. Brit J Surg 1973; 60: 646-9. Bureau C, Adebayo D, de Rieu MC et al. Alfa- Starzl TE, Demetris AJ, Van Thiel D. Liver trans- pump System vs. Large Volume Paracentesis plantation. N Engl J Med 1989; 321: 1014-22 et for Refractory Ascites: A Multicenter Randomi- 1092-9. zed Controlled Study. J Hepatol 2017; 67: 940- Chapman RW, Forman D, Peto R, Smallwood R. 949. Liver transplantation for acute hepatic failure ? Péritonite bactérienne spontanée Lancet 1990; 1: 32-5. Runyon BA, Hoefs JC. Culture-negative neutrocy- Caraceni P, van Thiel DH. Acute liver failure. Lan- tic ascites: a variant of spontaneous bacterial cet 1995; 345: 163-9. peritonitis. Hepatology 1984; 4: 1209-11. Giostra E, Mentha G, Malè PJ, et al. Insuffisance Yang CY, Liaw YF, Chu CM, et al. White count, hépatocellulaire (IHC) aiguë et hépatite fulmi- pH and lactate in ascites in the diagnosis of nante. In: Urgences Médicales, Restellini A et spontneous bacterial peritonitis. Hepatology al. (eds.). Editions Médecine et Hygiène, 1997, 1985; 5: 85-90. p: 278-83. Titó L, Rimola A, Ginès P, et al. Recurrence of Lebrec D. Pharmacological treatment of portal hy- spontaneous bacterial peritonitis in cirrhosis: pertension: present and future. J Hepatol 1998; frequency and predictive factors. Hepatology 28: 869-907. 1988; 8: 27-31. Ictère Ginès P, Rimola A, Planas R, et al. Norfloxacin Zimmermann HJ, Deschner KW. Differencial dia- prevents spontaneous bacterial peritonitis re- gnosis of jaundice. Hosp Practice (Off Ed) currence in cirrhosis: results of a double-blind 1987; 22: 99-103. placebo-controlled trial. Hepatology 1990; 12: Reisman Y, Gips CH, Lavelle SM, Wilson JHP. 716-24. Clinical presentation of (subclinical) jaundice. Arroyo V, Navasa M, Rimola A. Spontaneous The Euricterus project in the Netherlandp. He- bacterial peritonitis in liver cirrhosis: treatment pato-Gastroenterology 1996; 43: 1190-5. and prophylaxis. Infection 1994; 22 (Suppl.3): S1-8. Insuffisance pancréatique exocrine Gilbert JA, Kamath PS. Spontaneous bacterial Steer ML, Waxman I, Feedman S. Chronic pan- peritonitis: An update. Mayo Clin Proc 1995; 70: creatitis. N Engl J Med 1995; 332: 1482-90. 365-70. Pitchumoni CS. Chronic pancreatitis, pathogene- Ginès P, Navasa M. Antibiotic prophylaxis for sis and management of pain. J Clin Gastroente- spontaneous bacterial peritonitis: how and rol 1998; 27: 101-7. whom ?. J Hepatology 1998; 29: 490-94. Hepatitis - Hépatites: A, B, C. Vaccins Rimola A, García-Tsao G, Navasa M, et al. (and the International Ascites Club). Diagnosis, treat- Bernuau J, Goudeau A, Poynard T, et al. Multiva- ment and prophylaxis of spontaneous bacterial riate analysis of prognostic factors in fulminant peritonitis: a consensus document. J Hepatol hepatitis B. Hepatology 1986; 6: 648-51. 2000; 32: 142-53. Bismuth H, Samuel D, Gugenheim J, et al. Emer- Wu JC, Chan FK. Esophageal bleeding disorders. gency liver transplantation for fulminant hepati- 43 tis. Ann Int Med 1987; 107: 337-41. Jack AD, Hall AJ, Maine N, et al. What level of Malè PJ. Hépatites virales. Rev Med Suisse Rom hepatitis B antibody is protective? J Infect Dis 1989; 109: 889-99. 1999; 179: 489-92. Tormans G, Van Damme P, Van Doorslaer E. Re- Marcellin P. Hepatitis C: the clinical spectrum of commendations for prevention of hepatitis A the disease. J Hepatol 1999; 31 (Suppl.1): 9-16. based on a effeciveness analysis. J Travel Med Sobesky R, Mathurin P, Charlotte F, et al. Mode- 1994; 1: 127-135. ling the impact of interferon alfa treatment on Béguelin Ch, Fall F, Seydi M, Wandeler G. The liver fibrosis progression in chronic hepatitis C: current situation and challenges of screening a dynamic view. Gastroenterology 1999; 116: for and treating hepatitis B in sub-Saharan 378-86. Africa. Expert Rev Gastroenterol Hepatol 2018; Jaeckel E, Cornberg M, Wedmeyer H, et al. 12:537-546. Treatment of acute hepatitis C with Interferon The French METAVIR Cooperative Study Group. alpha 2b. N Engl J Med 2001; 345: 1452-7. Intraobserver and interobserver variations in Lauer GM, Walker BD. Hepatitis C virus infection. liver biopsy interpretation in patients with chro- N Engl J Med 2001; 345: 41-52. nic hepatitis C. Hepatology 1994; 29 :15. Perillo R, Schiff ER, Yoshida E, et al. Adefovir di- Swiss Association for the Study of the Liver; pivoxil for the tratment of lamivudine-resistant Groupe d’Experts Suisses pour les Hépatites hepatitis B mutants. Hepatology 2000 , 32: 129- Virales; Société Suisse de Gastro-entérologie 34. et d’Hépatologie. Recommandations pour le Lok AS, McMahon BJ. Chronic hepatitis B. Hepa- traitement par l’interféron de l’hépatite C chroni- tology 2001; 34: 1225-41. que. Bulletin des Médecins Suisses 1996; 43: Alberti A, Boccato S, Vario A, et al. Therapy of 1746-7. acute hepatitis C. Hepatology 2002; 36 (suppl Bedossa P, Poynard T. An algorithm for the gra- 1): S195-S200. ding of activity in chronic hepatitis C. The ME- Conjeevaram HS, Lok AS. Management of chro- TAVIR Cooperative Study Group. Hepatology nic hepatitis B. J Hepatol 2003;38 Suppl 1:S90- 1996; 24:289. 103. Erratum in: J Hepatol. 2003; 38: 876. Lee WM. Hepatits B virus infection. N Engl J Med Gerlach JT, Diepolder HM, Zachoval R, et al. 1997; 337: 1733-44. Acute hepatitis C: high rate of both spontane- Hoofnagle JH, Di Bisceglie AM. The treatment of ous and treatment-induced viral clearance. Ga- chronic hepatits. N Engl J Med 1997; 336: 347- troenterlogy 2003; 125: 80-88. 56. Hadziyannis SJ, Tassoipoulos NC, Heathcote EJ, Poynard T, Bedossa P, Opolon P, et al . Natural et al. Adefovir dipivoxil for the treatment of he- history of liver fibrosis progression with chronic patitis B e antigen-negative chronic hepatitis B. hepatitis C. Lancet 1997; 349: 825-32. N Engl J Med 2003; 348: 800-7. Koff RS. Hepatitis A. Lancet 1998; 351: 1643-9. Lok AS, Lai CL, Leung N, et al. Long-term safety Lai CL, Chien RN, Leung NW, et al. A one-year of lamivudine treatment in patients with chronic trial of lamivudine of chronic hepatits B. N Engl hepatitis B. Gastroenterology 2003; 125: 1714- J Med 1998; 339: 61-8. 22. Davis GL, Esteban-Mur R, Rustgi V, et al. Interfe- Marcellin P, Chang TT, Lim SG, et al. Adefovir di- ron alfa-2b alone or in combination with ribava- pivoxil for the treatment of hepatitis B e antigen- rin for the treatment of relapse of chronic posisitiv chronic hepatitis B. N Engl JMed 2003; hepatits C. N Engl J Med 1998; 339: 1493-9. 348: 808-16. McHutchinson JG, Gordon SC, Schiff ER, et al. Lin KW, Kirchner JT. Hepatitis B. Am Fam Physi- Interferon alfa-2b alone or in combination with cian 2004; 69: 75-82. ribavarin as initial treatment for chronic hepatitis Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et C. N Engl J Med 1998; 339: 1485-92. al. Peginterferon alfa-2a plus Ribavarin for Niederau C, Lange S, Heintges T, et al. Prognosis chronic hepatitis C virus infection in HIV-infec- of chronic hepatits C: results of a large prospec- ted patients. N Engl J Med 2004; 351: 438-50. tive cohort study. Hepatology 1998; 28: 1687- Wiegand J, Jeckel E, Cornberg M, et al. Long- 95. term follow-up agfer successful interferon the- Resti M, Azzari C, Mannelli F, et al. Mother to rapy of acute hepatitis C. Hepatology 2004; 40: child tranmission of hepatitis C virus: prospec- 98-107. tive study of risk factors and timing of infection Lok AS. New treatment of chronic hepatitis B. in children born to women seronegative for HIV- Semin Liver Dis. 2004;24 Suppl 1:77-82. 1- BMJ 1998; 317: 437-40. Lok AS, McMahon BJ. Practice Guidelines Com- Vento S, Garofano T, Renzini C, et al. Fulminant mittee, American Association for the Study of hepatitis associated with hepatitis A virus supe- Liver Diseases (AASLD). Chronic hepatitis B: rinfection in patients with chronic hepatitis C. N update of recommendations. Hepatology 2004; Engl J Med 1998; 338: 286-90. 39: 857-61. Dienstag JL, Schiff ER, Wright TL, el al. Lamivu- Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. dine as initial tratment for chronic hepatitis B in Peginterferon alfa-2a and ribavirin in patients the United States. N Engl J Med 1999; 341: with chronic hepatitis C who have failed prior 1256-63. treatment. Gastroenterology 2004; 126: 1015- EASL International Consensus Conference on 23. Hepatitis C. J Hepatol 1999; 31 (Suppl.1): 3-8. 44 Hépatite alcoolique tion Test (AUDIT). Addiction 1993; 88: 791-804. Maddrey WC, Boitnott JK, Bedine MS, et al. Cor- Steinweg DL, Worth H. Alcoholism: The keys of ticosteroid therapy of alcolholic hepatitis. Ga- the CAGE. Am J Med 1993; 94: 520-523. stroenterol 1978; 75: 193-9. Mayo-Smith MF. Pharmacological Management Carithers RL, Herlong HF, Diehl AM, et al. Methyl- of Alcohol Withdrawal. A Meta-analysis and Evi- prednisolone therapy in patients with severe al- dence-Based Practice Guideline. American So- coholic hepatitis. Ann Intern Med 1989; 110: ciety of Addiction Medicine Working Group on 685-90. Pharmacological Management of Alcohol With- Ramond MJ, Poynard T, Rueff B, et al. A rando- drawal. JAMA 1997; 278: 144-51. mized trial of prednisolone in patients with se- Gache P, Siegrist G. Les traitements medicamen- vere alcoholic hepatitis. N Engl J Med 1992; teux de l’alcoolo-dependance. Rev Med Suisse 326: 507-12. romande 1998; 118: 767-769. Salaspuro M. Biological state makers of alcohol Yersin B, Pilet F. Syndrome de sevrage alcooli- abuse. Alcolhol Health Res World 1994; 18: que : Prise en charge ambulatoire par le mede- 131-5. cin praticien. Rev Med Suisse romande 1998; Lieber CS. Medical disorders of alcoholism. M 118: 777-781. Engl J Med 1995; 333: 1058 –65. Daeppen JB, Gache P, Landry U, et al. Symptom- Stauber RE, Stepan V, Trauner M, et al. Evalua- triggered vs fixed-schedule doses of benzodia- tion of carbohydrate-deficient transferrin for de- zepine for alcohol withdrawal: a randomized tection of alcohol abuse in patients with liver treatment trial. Arch Intern Med 2002; 162: dysfunction. Alcohol Alcohol 1995; 30: 171-6. 1117-21. Lesch OM, Walter H. A new " state " marker for Mukamal KJ, Conigrave KM, Mittelmann MA, et the detection of alcoholism. Alcohol Alcohol al. Roles of drinking pattern and type of alcohol 1996; 31 (Suppl.1): 59-62. consumed in coronary heart disease in men. N Mathurin P, Duchatelle V, Ramond MJ, et al. Sur- Engl J Med 2003; 348: 109-18. vival and prognostic factors in patients with se- Mayo-Smith MF, Beecher LH, Fischer TL, et al. vere alcoholic hepatitis treated with Management of Alcohol Withdrawal Delirium. prednisolone. Gastroenterol 1996; 110: 1847- An Evidence-Based Practice Guideline. Arch In- 53. tern Med 2004; 164: 2068 and Arch Intern Med Naveau S. Les indications de la ponction-biopsie 2004; 164: 1405-12. hépatique chez les sujets alcooliques. Hepato Schlueter V, Narring F, Münsch U, et al. Trends in Gastro 1999; 1: 11-5. violent deaths among young people 10-24 Spahr L, Burckhardt B, Hadengue A. La maladie years old in Switzerland, 1969-1997. Eur J Epi- alcoolique du foie. Med Hyg 2000; 8: 262-6. demiol 2004; 19: 291-7. Louvet A, Naveau S, Abdelnour M et al. The Lille Saitz R et al., Unhealthy alcohol use, clinical model: a new tool for therapeutic strategy in pa- practice, N Engl J Med 2005; 352: 596-607. tients with severe alcoholic hepatitis treated Broers B, Humair JP, Haaz S, et al. Dépister with steroids. Hepatology 2007; 45: 1348-54. l’usage de substances psychoactives: pourquoi, Thursz MR, Forrest EH, Ryder S; STOPAH inve- comment, et ensuite ? Rev Med Suisse 2007; stigators. Prednisolone or Pentoxifylline for Al- 3: 2157-61. coholic Hepatitis.NEJM 2015; 373: 282-3. ISPA (2009). Chiffres calcules sur la base de l'En- quete suisse sur la santé 2007. Encéphlopathie hépatique Seitz HK, Becker P. Alcohol metabolism and can- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic En- cer risk. Alcohol Res Health 2007; 30: 38-47. cephalopathy in Chronic Liver Disease: 2014 Schukit MA. Alcohol-use disorders. Lancet 2009; Practice Guideline by the American Association 373: 492-501. for the Study of Liver Diseases and the Euro- Smith PC, Schmidt SM, Allensworth-Davies D, et pean Association for the Study of the Liver. He- al. Primary care validation of a single question patology 2014; 60:715. alcool screening test. J Gen Intern Med 2009; 24: 881-3. Alcool Jürgen R, Taylor B, Mohapatra S, et al. Alcohol as Prochaska JO, Di Clemente CC. Stages and pro- a risk factor for liver cirrhosis : A systematic re- cesses of self change in smoking towards an in- view and meta-analysis. Drug Alcohol Rev tegrative model of change. J Consulting and 2010; 29: 437-45. Clinical Psychology 1983; 51: 390-95. Righetti V, Favrod-Coune T. Questionnaires de Sullivan JT, Sykora K, Schneiderman J, et al. As- dépistage et d’évaluation des consommations sesment of alcohol withdrawal: the revised clini- de substances psychoactives. Rev Med Suisse cal institute withdrawal assessement for alcohol 2010; 6: 1821-5. scale (CIWA-Ar). Br J Addict 1989; 84: 1353-7. Chen WY, Rosner B, Hankinson SE, et al. Mode- Classification Internationale des Maladies. CIM- rate alcohol consumption during adult life, drin- 10/ICD-10. OMS 1992. Paris: Masson. king patterns, and breast cancer risk. JAMA Krahenbuhl B. La force de l’autre. Ou l’entretien 2011; 306: 1884-90. de motivation avec la personne alcoolique. Med Rehm J, Kehoe T, Gmel G, et al. Alcohol attribu- et Hyg 1993; 51: 2263-6. table burden of incidence of cancer in eight Eu- Saunders JB, Aasland OG, Babor TF, et al. Deve- ropean countries based on results from lopment of the Alcohol Use Disorders Identifica- prospective cohort study. BMJ 2011; 342: 45 d1584. 5S-11S. Ronksley PE, Brien SE, Turner BJ, et al. Associa- Isaacs D, Fitzgerald D. Seven alternatives to evi- tion of alcohol consumption with selected car- dence based medicine. BMJ 1999; 319: 1618. diovascular disease outcomes : A systematic Thompson WG. Irritable bowel syndrome: a ma- review and meta-analysis. BMJ 2011; 342: nagement strategy. Baillière's clinical Gastroen- d671. terology 1999; 13: 453-60. Pasche S, Broers B, Favrod-Coune Th. Comment Drossmann DA. The functional gastrointestinal y voir clair face à toutes les recommandations disorders, their diagnosis, and the Rome II pro- relatives à la consommation d’alcool? Rev Med cess. In: Drossmann DA, Corazziari E, Talley Suisse 2012;1831-1835. NJ, et al. (eds.). Rome II. The functional ga- Wood E, MD, Albarqouni L, Tkachuk S et al. Will strointestinal disorders: diagnosis, pathophysio- This Hospitalized Patient Develop Severe Alco- logy and treatment: a multinational consensus. holWithdrawal Syndrome? The Rational Clinical McLean VA: Degnon Associates, 2000: 1-36. Examination Systematic Review. JAMA 2018; De Ponti F, Tonini M. Irritable bowel syndrome: 320: 825-33. new agents targeting serotonin receptor subty- pes. Drugs 2001; 61: 317-32. TFI - Côlon irritable - Reizdarmsyndrom Camilleri M. Management of the irritable bowel Manning AP, Thompson WG, Heaton KW, Morris syndrome. Gastroenterology 2001; 120: 652- AF. Towards positive diagnosis of the irritable 68. bowel. BMJ 1978; 2: 653-4. Spiller RC. Postinfectious irritable bowel syn- Lennard-Jones JE. Functional gastrointestinal drome. Gastroenterology 2003; 124: 1662-71. disorders. N Engl J Med 1983; 308: 431-5. Mearin F, Perez-Oliveras M, Perello A, et al. Dys- Otte JJ, Larsen L, Anderson JR. Irritable bowel pepsia and irritable bowel syndrome after a Sal- syndrome and symptomatic diverticular monella gastroenteritis outbreak : One-year disease-different diseases ? Am J Gastroente- follow-up cohort study. Gastroenterology 2005; rol 1986; 81: 529-31. 129: 98-104. Camilleri M, Prather CM. The irritable bowel syn- Drossmann DA. The functional gastrointestinal drome: mechanisms and a practical approach disorders and the Rome III process. Gastroen- to management. Ann lntern Med 1992; 116: terology 2006; 130: 1377-90. 1001-8. Longstreth GF, Thompson WG, Chey WD, et al. Cullingfort GL, Coffey JF, Carr-Locke DL. Irritable Functional bowel disorders. Gastroenterology bowel syndrome: can the patient's response co- 2006; 130: 1480. loscopy help with diagnosis. Digestion 1992; Track J,. Talley NJ, Camilleri M, et al. Functional 52: 209-13. gastroduodenal disorders. Gastroenterology Accarino AM, Azpiroz F, Malagelada JR. Selective 2006; 130: 1466-79. dysfunction of mechanosensitive intestinal affe- Chey WD, Kurlander J, Eswaran S. Irritable rents in irritable bowel syndrome. Gastroentero- bowel syndrome: a clinical review. JAMA 2015; logy 1995; 108: 636-43. 313: 949-958. Agréus L, Svärdsudd K, Nyren O, et al. Irritable Drossmann DA. Functional Gastrointestinal Dis- bowel syndrome and dyspepsia in the general orders: History, Pathophysiology, Clinical Featu- population: overlap and lock of stability over res, and Rome IV. Gastroenterology 2016; 150: time. Gastroenterology 1995; 109: 671-80. 1262-1279.e2 Delvaux M, Denis P, Allemand H. Sexual abuse is Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero more frequently reported by IBS patients than Santiago M et al. Fecal Calprotectin as Predic- by patients with organic digestive diseases or tor of Relapse in Patients With Inflammatory controls. Results of a multicentre inquiry. Bowel Disease Under Maintenance Infliximab French Club of Digestive Motility. Eur J Gastro- Therapy. J Clin Gastroenterol 2016; 50:147-51. enterol Hepatol 1997; 9: 345-52. Mearin F, Lacy BE, Chang L, et al. Bowel Disor- Drossmann DA, Whitehead WE, Camilleri M. Irri- ders. Gastroenterology 2016 Feb 18. pii: table bowel syndrome: a technical review for S0016-5085(16)00222-5. doi: practice guideline development. Gastroentero- 10.1053/j.gastro.2016.02.031. logy 1997; 112: 2120-37. Heinrich H, Schwizer, W. Das Reizdarm Syn- Aziz A, Thompson DG. Brain-gut axis in health drom. Der informierte arzt 2017; 7(8): 22-24. and disease. Gastroenterol 1998; 114: 559-78. Kostas A, Siakavellas SI, Kosmidis C et al. Fecal Farthing JMG. New drugs in the management of calprotectin measurement is a marker of short- the irritable bowel syndrome. Drugs 1998; 56: term clinical outcome and presence of mucosal 11-21. healing in patients with inflammatory bowel Camilleri M. Review article: clinical evidence to diseas. World J Gastroenterol 2017; 23: 7387- support therapies of irritable bowel syndrome. 7396. Aliment Pharmacol Therap Ther 1999; 13: 48- 53. Cholélithiase - Cholécystite Drossmann DA. The functional gastrointestinal Everhart JE, Khare M, Hill M, Maurer KR. Preva- disorders and the Rome II process. Gut 1999; lence and ethnic differences in gallbladder 45: 1-5. disease in the United States. Gastroenterology. Hammer J, Talley NJ. Diagnostic criteria for the ir- 1999; 117: 632-9. ritable bowel syndrome. Am J Med 1999; 107: Warttig S, Ward S, Rogers G, Guideline Develop- 46 ment Group. Diagnosis and management of Colite microscopique gallstone disease: summary of NICE guidance. Burgel N, Bojarski C, Mankertz J, et al. Mecha- BMJ 2014; 349: g6241. nisms of diarrhea in collagenous colitis. Gastro- Intolérance au lactose enterology 2002; 123: 433-43. Bayless TM. et al. A racial difference in incidence Shaz BH, Reddy SI, Ayata G, et al. Sequential cli- of lactase deficiency: a survey of milk intole- nical and histopathological changes in collage- rance and lactase deficiency in healthy adult nous and lymphocytic colitis over time. Mod males. JAMA 1966; 197: 968-72. Pathol 2004; 17: 1475- 1485. Bayless TM. et al. Lactose and milk intolerance: Wildt S, Nordgaard-Lassen I, Bendtsen F, Ru- clinical implications. N Engl J Med 1975; 292: messen JJ.. Metabolic and inflammatory faecal 1156-9. markers in collagenous colitis. Eur J Gastroen- Newcomer AD, McGill DB, Thomas PJ, et al. Pro- terol Hepatol 2007; 19: 567-74. spective comparison of indirect methods for de- Chande N, MacDonald JK, MacDonald JW.. Inter- tecting lactase deficiency. N Engl J Med 1975; ventions for treating microscopic colitis : A 293: 1232-6. Cochrane inflammatory bowel disease and Rosade JL, Solomons NW. Sensitivity and speci- function bowel disorder review group systema- ficity of the hydrogen breath-analysis test for tic review of randomized trials. Am J Gastroen- detecting malabsorption of physological doses terol 2009; 104: 235-41. of lactose. Clin Chem 1983; 29: 545-8. Nyhlin N, Montgomery SM, Wickbom A, et al. Hammer HF, Petrisch W, Pristautz H et al. As- Symptom burden in collagenous and lymphocy- sessment of the influence of hydrogen nonexre- tic colitis compared to a matched control group. tion on the usefulness of thd hydrogen breath Gut 2009; 58(Suppl. II): A309. test and lactose tolerance test. Wien Klin Wo- Stewart MJ, Seow CH, Storr MA.. Prednisolone chenschr 1996; 108: 137-41. and budesonide for short- and long-term treat- Shaw AD, Davies GJ. Lactose intolerace: pro- ment of microscopic colitis : Systematic review blems in diagnosis and treatment. J Clin Ga- and meta-analysis. Clin Gastroenterol Hepatol stroenterol 1999; 28: 208-16. 2011; 9: 881-90. Högenauer C, Hammer HF, Mellitzer K et al. Eva- Vigren L, Sjoberg K, Benoni C, et al. Is smoking a lutation of a new DNA test compared with the risk factor for collagenous colitis. Scand J Ga- lactose hydrogen breath test for the diagnosis stroenterol 2011; 46: 1334-9. of lactase non-persistence. Eur J Gastroenterol Münch A, Aust D, Bohr J, et al. Microscopic colitis Hepatol 2004; 17: 371-6. : Current status, present und future challenges Kubli M, Tuitan R, Fried M et al. Chronische Diar- – Statements of the European Microscopic Coli- rhoe - Fallgrube Laktasemangel. Forum Med tis Club. J Crohns Colitis 2012; 6: 932-45. Schweiz 2007; 7: 422-4. Burgmann K, Fraga M, Yan P, et al. Colites mi- croscopiques – quoi de neuf? Rev Med Suisse Maladie de WHIPPLE 2014; 440: 1586-1590. Galperin C, Gershwin ME. Immunopathogenesis Coeliakie / Sprue / Zöliakie Glutenintoleranz of gastrointestinal and hepatobiliary diseases. JAMA 1997; 278: 1946-55. Trier JS. Celiac sprue and refractory sprue. Ga- Feldman M, Scharschmidt BF, Sleisenger MH stroenterology 1978; 75: 307-16. (eds.). In: Sleisenger and Fordtran’s gastrointe- Revised criteria for diagnosis of coeliac disease: stinal and liver diseases. W Saunders Com- report of working group of european society of pany,1998. paediatric gastroenterology and nutrition. Arch André R, Ehresmann B, Stirnemann J et al. Mala- Dis Child 1990; 65: 909-11. die de Whipple : un diagnostic différentiel de po- Dietrich W, Ehnis T, Bauer M, et al. Identification lyarthrite à ne pas oublier. Rev Med Suisse of tissue transglutaminase as the autoantigen of 2015;448:1582-1586. celiac disease. Nat Med 1997; 3: 797-801. Cunningham S, Maulucci F, Zufferey P et al. Ma- Greco L, Romino R, Coto I et al. Ther fist large ladie de Whipple: quand y penser? Rev Med population based twin study of coelica disease. Suisse 2015; 11: 1582-6. Gut 2002; 50: 624-8. Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med Malabsorption 2001 , 346: 180-8. De la Morena ES, Chantar R. Malabsorción inte- Green PHR, Cellier Ch. Celiac Disease. N Engl J stinal. In: Rodés J, et al. (eds.). El Manual de Med 2007; 357: 1731-43. Medicina. Masson, S.A, 1993, p: 539-61. Leffler DA, Schuppan D. Update on serologic te- Falk R, Comenzo RL, Skinner M. The systemic sting in celiac disease. Am J Gastroenterol amyloidoses. N Engl J Med 1997; 337: 898- 2010; 105: 2520-4. 909. Rashid M. Tests sérologiques dans la maladie Feldman M, Scharschmidt BF, Sleisenger MH cœliaque Guide pratique à l’usage des clini- (eds). Sleisenger and Fordtran’s gastrointesti- ciens. Can Fam Physician 2016; 62: e11-e17. nal and liver diseases. W. Saunders Company, Maladie de CROHN 1998. Furness BW, Beach MJ, Roberts JM. Giardiasis Best WR, Becktel JM, Singleton JW, et al. Deve- surveillance - United States. 1992-1997. lopment of a Crohn’s disease activity index: Na- MMWR CDC Surveill Summ 2000; 49: 1-13. tional Cooperative Crohn’s Disease Study. 47 Gastroenterology 1976; 70: 439-44. Hanauer SB. Inflammatory bowel disease. N Engl Best WR, Becktel JM, Singleton JW, et al. Rederi- J Med 1996; 334: 841-8. ved values of the eight coefficients of the Guyot J, Hess J, Fasel J. Maladies inflammatoi- Crohn’s disease activity index (CDAI). Gastro- res intestinales. Med Hyg 1999; 57: 199-206. enterology 1979; 77: 843-6. Podolsky DK. Inflammatory bowel disease. N Hodgson HJF, Mazlam MZ. Assessment of drug Engl J Med 2002; 347: 417-29. therapy in inflammatory bowel disease. Aliment Silverberg MS, Satsangi J, Ahmad T, et al. To- Pharmacol Ther 1991; 5: 555-84. ward an integrated clinical, molecular and sero- Rutgeerts P, Lofberg R, Malchow H, et al. A com- logical classification of inflammatory bowel parison of budenoside with prednisolone for ac- disease: Report of a Working Party of the 2005 tive Crohn’s disase. N Engl J Med 1994; 331: Montreal World Congress of Gastroenterology. 842-5. Can J Gastroenterol 2005;19(suppl A):5-36. Pearson DC, May GR, Fick GH, et al. Azathio- Magro F, Gionchetti P, Eliakim R, et al. Third Eu- prine and 6-mercaptopurine in Crohn’s disease: ropean evidence-based consensus on diagno- a meta-analysis. Ann Intern Med 1995; 123: sis and management of ulcerative colitis. Part 1: 132-42. definitions, diagnosis, extra-intestinal manife- Hanauer SB. Inflammatory bowel disease. N Engl stations, pregnancy, cancer surveillance, sur- J Med 1996; 334: 841-8. gery, and ileo-anal pouch disorders. J Crohns Guyot J, Hess J, Fasel J. Maladies inflammatoi- Colitis 2017; 11: 649-70. res intestinales. Med Hyg 1999; 57: 199-206. Moschouri E., Hessler R., Pittet V., et al. Mise au Pimentel M, Chang M, Chow EJ et al. Identifica- point sur la rectocolite ulcéro-hémorragique en tion of a prodromal period in Crohn's disease 2017. Rev Med Suisse 2017; 13: 1480-6. but not ulcerative colitis. Am J Gastroenterol. Constipation 2000; 95: 3458-62. Tibble JA, Sigthorsson G, Bridger S, et al. Surro- Thompson WG, Longstreth GF, Drossman DA, et gate markers of intestinal inflammation are pre- al. Functional bowel disorders and functional dictive of relapse in patients with inflammatory abdominal pain. Gut 1999; 45: 43-7. bowel disease. Gastroenterology 2000; 119: 15- Lembo A, Camilleri M. Chronic constipation. N 22. Engl J Med 2003; 349: 1360-8. Podolsky DK. Inflammatory bowel disease. N Reflux gastro-oesophagien (RGO) Engl J Med 2002; 347: 417-29. Oesophagite Best WR. Predicting the Crohn's disease activity Monnier P, Savary M. Contribution of endoscopy index from the Harvey-Bradshaw Index. In- to gastroesophageal reflux disease. Scand J flamm Bowel Dis 2006; 12: 304-10. Gastroenterol 1984; 19(Suppl 106): 26. Sandborn WJ, Feagan BG, Stoinov S et al. Certo- Rockall TA, Logan RF, Devlin HB, et al. Incidence lizumab Pegol for the Treatment of Crohn's of and mortality from acute upper gastrointesti- Disease. N Engl J Med 2007; 357: 228-38. nal haemorrhage in the United Kingdom. Stee- Schreiber S, Khaliq-Kareemi M, Lawrance IC et ring Committee and members of the National al. Maintenance Therapy with Certolizumab Audit of Acute Upper Gastrointestinal Haemor- Pegol for Crohn's Disease. N Engl J Med 2007; rhage. BMJ 1995; 311: 222-6. 357: 239-50. El-Serag HB, Sonnenberg A. Associations bet- Van Rheenen PF, Van de Vijver E, Fidler V. Fae- ween different forms of gastro-oesophageal re- cal calprotectin for screening of patients with flux disease. Gut 1997; 41: 594-9. suspected inflammatory bowel disease: Diagno- Ferraris R, Bonelli L, Conio M, et al. Incidence of stic meta-analysis. BMJ 2010; 341: c3369. Barrett’s adenocarcinoma in an Italian popula- Fraga M, Godat S, Nydegger A et al. Calprotec- tion: an endoscopic surveillance programme. tine fécale: outil diagnostique dans les maladies Eur J Gastroenterol Hepatol 1997; 9: 881-5. inflammatoires chroniques de l’intestin. Rev Dent J. Gastro-oesophageal reflux disease. Dige- Med Suisse 2012; 8: 1669-73. stion 1998; 59: 433-45. Lagergren J, Bergström R, Lingren A, Nyrén O. Toxischer Megakolon - Mégacôlon toxique Symptomatic gastroesophageal reflux as a risk Jalan KN, Sircus W, Card WI, Falconer CW, factor for esophageal adenocarcinoma. N Engl Bruce CB, Crean GP, McManus JP, Small WP, J Med 1999; 340: 825-31. Smith AN (1969) An experience of ulcerative Jornod Ph, Blum AL, Armstrong D. Oesophagite colitis. I. Toxic dilation in 55 cases. Gastroente- par reflux: classification. In: Dupas JL, Fléjou rology 1969; 57: 68-82. (eds.). Maladies de l’œsophage, de l’estomac Autenrieth DM, Baumgart DC. Toxic megacolon. et du duodénum. Editions Arnette, 1999. Inflamm Bowel Dis 2012; 18: 584-91. Jornod Ph, Vouillamoz D, Blum AL. Oesophagite Rectocolite ulcéro-hémorragique (RCUH) peptique. Med Hyg 2000; 58: 209-15. - Colitis ulcerosa Hilton D, Iman N, Burke GJ et al. Absence of ab- Truelove SC, Witts LJ. Cortisone in ulcerative co- dominal pain in older persons with endoscopic litis; preliminary report on a therapeutic trial. Br ulcers: a prospective study. Am J Gastroenterol Med J 1954; 2: 375-378. 2001; 96: 380-4. Truelove SC, Witts LJ. Cortisone in ulcerative co- Spechler SJ. Barrett’s esophagus. N Engl J Med litis: final report on a therapeutic trial. BMJ 2002; 2002: 346: 836-42. 1955; 2: 1041-8. Behrman SW. Management of complicated peptic 48 ulcer disease. Arch Surg 2005; 140: 201-8. acter pylori Infection: An Update for the Internist Vakil N, van Zanten SV, Kahrilas P, et al. Global in the Age of Increasing Global Antibiotic Resi- Consensus Group. The Montreal definition and stance. Am J Med 2018; 131: 473-479. classification of gastroesophageal reflux Gressot P, Frossard JL, Grosgurin O et al. Traite- disease: a global evidence-based consensus. ment d’éradication d’Helicobacter pylori en Am J Gastroenterol 2006; 101: 1900-20; quiz 2019. Rev Med Suisse 2019; 15: 1854-8. 1943. ZOLLINGER-ELLISON Syndrome Burri E, Meier R. Ulcères peptiques – mise à jour 2011. Forum Med Suisse 2011; 11: 897–906. Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hyper- Helicobacter pylori (Hp) secretion and the gastrinom . JAMA 1994; 271: NIH Consensus development conference. Helic- 1429-35. obacter pylori in peptic ulcer disease. JAMA Meko JB, Norton JA. Management of patients 1994; 272: 65-9. with Zollinger-Ellison syndrome. Ann Rev Med Lind T, et al. Eradication of helicobacter pylori 1995; 46: 395-411. using one-week triple therapies combining ome- Wolfe MM, Jensen RT. Zollinger-Ellison syn- prazole with two antimicrobials: the Mach I drome. Current concepts in diagnosis and ma- study. Helicobacter 1996; 1: 138-44. nagement. N Engl J Med 1997 ;317: 1200-9. Soll AH. Medical treatment of peptic ulcer Norton JA, Fraker DL Surgery, Alexander R, et al. disease. Practice guidelines. JAMA 1996; 275: Surgery to cure the Zollinger-Ellison syndrome. 622-9. [Erratum: JAMA 1996; 275: 1314]. N Engl J Med 1999; 341: 635-44. Dominguez-Munoz, et al. A citric acid solution is Wells SA, Jr. Surgery for the Zollinger-Ellison an optimal test drink in the 13C-urea breath test syndrome. N Engl J Med 1999; 341: 689-90. for the diagnosis of Helicobacter pylori infection. Dumping syndrome Gut 1997; 40: 459-62. The European Helicobacter Pylori Study Group Lev-Ran A, Anderson RW. The diagnosis of post- (EHPSG). Current European concepts in the prandial hypoglycemia. Diabetes 1981; 30: 996- management of H. pylori infection. The Maas- 9. tricht concensus report. Gut 1997; 41: 8-13. Parardi J, Havrankova J, Lepage R, et al. Blood HuntRH, Thompson ABR. Canadian helicobacter glucose measurement during symptomatic epi- pylory consensus conference. Can J Gastroen- sodes in patints with suspected postprandial hy- terol 1998; 12: 31-41. poglycemia. N Engl J Med 1989; 321: 1421-5. Hunt RH, Fallone CA, Thomson AB. Canadian helicobacter pylori consensus conference up- NEUROLOGIE date: infections in adults. Can J Gastroenterol Hémorragie cérébrale 1999; 13: 213-7. Viani F, Blum AL, Koelz HR, Pantoflickova D. He- Anderson CS, Heeley E, Huang Y, et al. INTER- licobacter pylori, ulcère gastro-duodénal et ACT2 Investigators. Rapid blood-pressure lo- AINS. Med Hyg 2000; 58: 216-24. wering in patients with acute intracerebral Harris A, Misiewicz JJ. ABC of the upper gastroin- hemorrhage. N Engl J Med 2013; 368: 2355-65. testional tract. Management of helicobacter py- Hirnschlag — Schlaganfall — Iktus — Ictus lori infection. BMJ 2001; 323: 1047-50. CVI — Accident cérébro-vasculaire (AVC) Uemura N, Okamoto S, Yamamoto S, et al. Helic- Goldstein M, Bolis CL, (eds.). Cerebrovascular obacter pylori infection and the development of disorders: a clinical and research classification. gastric cancer. N Engl J Med 2001; 345: 784-9. Geneva: World Health Organization, 1978. Vuillamoz D, Viani F, Jornod P, et al. Maladies (WHO offset publication no 43.) peptiques. Rev Med Suisse 2005; 1: 200-8. Bogousslavsky J. Embolies cérébrales d’origine Chey WD, Wong BC, Practice Parameters Com- cardiaque: quand anticoaguler ? Schweiz Med mittee of the American College of Gastroentero- Wschr 1985; 115: 1381-6. logy. American College of Gastroenterology Garcia JH, et al. Physiopathology of cerebral guideline on the management of Helicobacter ischemia. Crit Rev Neurobiol 1989; 4: 303-24. pylori infection. Am J Gastroenterol 2007; Farrell B, et al. The United Kingdom transient 102:1808-25. ischaemic attack (UK-TIA) aspirin trial: final re- Malfertheiner P, Megraud F, O’Morain CA et al. sults. J Neurol Neurosurg Psychiatry 1991; 54: Management of Helicobacter pylori infection— 1044-54. the Maastricht V/Florence Consensus Report. North american symptomatic carotid endarterec- Gut 2017; 66: 6-30. tomy trial collaborators. Beneficial effect of ca- Fallone CA, Chiba N, van Zanten SV et al. The rotid endarterectomy in symptomatic patients Toronto Consensus for the Treatment of Helic- with high-grade carotid stenosis. N Engl J Med obacter pylori Infection in Adults. Gastroentero- 1991; 325: 445-53. logy 2016; 151: 51-69. Stroke Prevention in Atrial Fibrillation Investiga- Moayyedi PM, Lacy BE, Andrews CN, Enns RA, tors. Stroke prevention in atrial fibrillation study. Howden CW, Vakil N. ACG and CAG clinical Final results. Circulation 1991; 84: 527-39. guideline: management of dyspepsia. Am J The Dutch TIA Trial Study Group. A comparison Gastroenterol. 2017;112:988-1013. of two doses of aspirin (30 mg vs. 283 mg a Siddique O, Ovalle A, Siddique AS et al. Helicob- day) in patients after a transient ischemic attack 49 or minor ischemic stroke. N Engl J Med 1991; Barnett HJM, Taylor DW, Eliasziw M, et al. for the 325: 1261-6. North American Symptomatic Carotid-Endarter- Sieber FE, Traystman RJ. Special issues: glu- ectomy Trial Collaborators (NASCET). Benefit cose and brain. Crit Care Med 1992; 20: 104- of carotid endarterctomy in patients with sym- 14. ptomatic moderate to severe stenosis. N Engl J European Atrial Fibrillation Trial Study Group. Se- Med 1998; 339: 1415-25. condary prevention in non-rheumatic atrial fibril- Christ M, Diener HC, Kurth T, et al. Sekundärprä- lation after transient ischaemic attack or minor vention atherosklerotischer Erkrankungen in der stroke. Lancet 1993; 342: 1255-62. täglichen Praxis. Internist 1998; 39: 1080-97. Powers WJ. Acute hypertension after stroke. European Carotid Surgery Triallists’ Cooperative Neurology 1993; 43: 461-7. Group. Randomised trial of endarterectomy for Adams HPJ, Brott TG, Crowell RM, et al. Guideli- recently symptomatic carotid stenosis: final re- nes for the management of patients with acute sults of the MRC European Carotid Surgery ischemic stroke. A statement for healthcare pro- Trial (ECST). Lancet 1998; 351: 1379-87. fessionals from a special writing group of the Kidwell CS, Saver JL, Schubert GB, et al. Design Stroke Council, American Heart Association. and retrospective analysis of the Los Angeles Stroke 1994; 25: 1901-14. prehospital stroke screen (LAPSS). Prehosp Feinberg WM, Albers GW, Barnett HJM, et al. Emerg Care 1998; 2: 267-73. Guidelines for the management of transient Schrader J, Rothenmeyer M, Luders s, et al. Hy- ischemic attacks. Stroke 1994; 25; 1320-35. pertension and stroke - rationale behind the AC- Matchar DB, McCrory DC, Barnett HJM, et al. CESS trial. Acute candesartan cilexetil Guidelines for medical treatment for stroke pre- evaluation in stroke survivors. Bas Res Cardiol vention. Ann Intern Med 1994; 121: 54-5. 1998; 93 (Suppl. 2): 69-78. Blecic S, Bogousslavsky J. General management Broderick JP et al. Am.Stroke Assoc. Guidelines of patients with ischemic stroke: Clinical featu- for intracerebral hemorrhage: Stroke 1999; res and epidemiology. Curr Opinion Neurol 30:905-15. 1995; 8: 30-7. Kappelle LJ, Eliasziw M, Fox AJ, et al. for the Bronner LL, Kanter DS, Manson JE. Primary pre- North American Symptomatic Carotid-Endarter- vention of stroke. N Engl J Med 1995; 333: ectomy Trial Group. Importance of intracranial 1392-1400. atherosclerotic disease in patients with sympto- Executive Committee for the Asymptomatic Caro- matic stenosis of the internal carotid artery. tid Atherosclerosis Study. Endarterectomy for Stroke 1999; 30: 282-6. asymptomatic carotid artery stenosis. JAMA Kothari RU, Panciolo A, Liu T, et al. Cincinnati 1995; 273: 1421-8. Prehospital Stroke Scale: reproducibility and Hacke W, Kaste M, Fieschi C, et al. Intravenous validity. Ann Emerg Med 1999; 33: 373-8. thrombolysis with recombinant tissue plasmino- Brott Th, Bogousslavsky J. Treatment of acute gen activator for acute hemispheric stroke. The ischemic stroke. N Engl J Med 2000; 343: 710- European cooperative acute stroke study 22. (ECASS). JAMA 1995; 274: 1017-25. Inzitari D, Eliasziw M, Gates P, et al. The causes The National Institute of Neurological Disorders and risk of stroke in patients with asymptomatic and Stroke rt-PA Stroke Study Group. Tissue internal-carotid-artery stenosis. N Engl J Med plasminogen activator for actue ischemic 2000; 342: 1693-700. stroke. N Engl J Med 1995; 333: 1581-7. Kidwell CS, Starkman S, Eckstein M, et al. Identi- Berger JP. Petits debits cerebraux, attaques fying stroke in the field: prospective validation of d’ischemie transitoire et syncopes. Rev Med the Los Angeles Prehospital Stroke Screen Suisse Rom. 1996; 116: 597-604. (LAPSS). Stroke 2000; 31: 71-6. CAPRIE Steering Committee. A randomized, blin- Kistler JP, Furie KL. Carotid endarterectomy revi- ded, trial of clopidogrel versus aspirin in pa- sited. N Engl J Med 2000; 342: 1743-45. tients at risk of ischemic events. Lancet 1996; Steiner Th, Hennes HJ, Kretz R, et al. Akute klini- 348: 1329-39. sche Schlaganfallbehandlung. Anaesthesist Dewarrat A, Bogousslavsky J. Antithrombotiques 2000; 49: 2-8. et prevention des accidents vasculaires cere- Zerebrovaskuläre Arbeitsgruppe der Schweiz braux. Rev Med Suisse Rom 1996; 116: 629- (ZAS) und Schweizerische Herzstiftung (SHS). 34. Sekundärprävention nach ischämischem Fisher M, Garcia JH. Evolving stroke and the Schlaganfall. Schweiz Aerztezeitung 2000; 81: ischemic penumbra. Neurology 1996; 47: 884- 1105-15. 8. Albers GW, Amarenco P, Easton JD, et al. Anti- CAST Collaborative Group. CAST: Randomized thrombotic and thrombolytic therapy for ische- placebo-controlled trial of early aspirin use in mic stroke. Sixth ACCP Consensus Conference 20000 patients with acute ischemic stroke. Lan- on antithrombotic therapy. Chest 2001; 119 cet 1997; 349: 1641-9. (Suppl. 1): 300S-320S. International Stroke Trial Collaborative Group. Goldstein LB, Adams R, Becker K, et al. Primary The International Stroke Trial (IST): a randomi- prevention of ischemic Stroke. A statement for sed trial of aspirin, subcutaneous heparin, both, healthcare professionals from the stroke council or neither among 19435 patients with acute of the american heart association. Stroke 2001; ischemic stroke. Lancet 1997; 349: 1569-81. 32: 280-99. Or in: Circulation 2001; 103: 163- 50 82. Study. Stroke 2011; 42(4): 1021-9. Sacco RL. Extracranial carotid stenosis. N Engl J Booth JN 3rd, Levitan EB, Brown TM, et al. Effect Med 2001; 345: 1113-8. of sustaining lifestyle modifications (nonsmo- Barnett HJM, Meldrum HE, Eliasziw M, et al. The king, weight reduction, physical activity, and appropriate use of carotid endarterectomy. Mediterranean diet) after healing of myocardial CMAJ 2002; 166: 1169-79. infarction, percutaneous intervention, or coro- Schrader J, Luders S, Kulschewski A, et al. AC- nary bypass (from the REasons for Geographic CESS study: Acute Candesartan Cilexetil Eva- and Racial Differences in Stroke study). Am J luation in Stroke Survivors [Abstract]. Am J Cardiol 2014;113:1933-40. Hypertension 2002; 15: 17A. Pérez de la Ossa N, Carrera D, Gorchs M et al. Adams HP et al. Am.Stroke Assoc. Guidelines for Design and validation of a prehospital stroke ischemic stroke. Stroke 2003; 34: 1056-83. scale to predict large arterial occlusion: the Diener HC, Bogousslavsky J, Brass LM et al. rapid arterial occlusion evaluation scale. Stroke Aspirin and clopidogrel compared with clopido- 2014; 45: 87-91. (RACE) grel alone after recent ischaemic stroke or tran- Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. sient ischaemic attack in high-risk patients Consumption of nuts and legumes and risk of (MATCH): randomised, double-blind, placebo- incident ischemic heart disease, stroke, and controlled trial. Lancet 2004; 364: 331–37. diabetes: a systematic review and meta-analy- Toni D et al. European Stroke Initiative recom- sis. Am J Clin Nutr 2014;100:278-88. mendations. Cerebrovasc Dis 2004;17 Suppl David Carrera R, Campbell BCV, Cortés J et al. 2:30-46. Predictive Value of Modifications of the Prehos- Adams H, Adams R, del Zoppo G, et al. Guideli- pital Rapid Arterial Occlusion Evaluation Scale nes for the early management of patients with for Large Vessel Occlusion in Patients with ischemic stroke: 2005 guidelines update: Acute Stroke. J Stroke Cerebrovasc Dis 2017; AHA/ASA. Stroke 2005; 36: 916-32. 26: 74-77. AHA Part 9: Adult Stroke. Circulation 2005; 112: GBD 2017 Diet Collaborators. Health effects of 111-20. dietary risks in 195 countries, 1990–2017: a sy- Rothwell PM, Giles MF, Flossmann E et al. A sim- stematic analysis for the Global Burden of ple score (ABCD) to identify individuals at high Disease Study 2017. Lancet 2019; 393: 1958- early risk of stroke after transient ischaemic at- 72. tack. Lancet 2005; 366: 29-36. Johnston SC, Easton JD, Farrant M et al. Clopi- Johnston SC, Nguyen-Huynh MN, Schwarz ME, dogrel and Aspirin in Acute Ischemic Stroke and et al. National Stroke Association guidelines for High-Risk TIA. NEJM 2018; 379: 215-25. the management of transient ischemic attacks. Schnabel RB, Haeusler KG, Healey JS et al. Se- Ann Neurol 2006; 60: 301-13. arching for Atrial Fibrillation Poststroke A White Adams HP, del Zoppo G, Alberts MJ, et al. Guide- Paper of the AF-SCREEN International Collabo- lines for the early management of adults with ration. Circulation 2019;140:1834-185. ischemic stroke (AHA). Stroke 2007: 386: 1655- Thrombolyse de l’AVC 711 (Erratum Stroke 2007; 38: e38). Bart von der Worp H, Gijn J. Acute ischemic The national institute of neurological disorders stroke. N Engl J Med 2007; 357: 572-9. and stroke, rt-PA stroke study group. Tissue Johnston SC, Rothwell PM, Huynh-Huynh MN, et plasminogen activator for acute ischemic al. Validation and refinement of scores to pre- stroke. N Engl J Med 1995; 333: 1581-7. dict very early stroke risk after transient ische- Bogousslavsky J. Thrombolysis in acute stroke. mic attack. Lancet 2007; 369: 283-92. BMJ 1996; 313: 640-1. Paciaroni M, Agnelli G, Micheli S, et al, Efficacy Bogousslavsky J, Buettner UW, Hess K, et al. and safety of anticoagulation treamtment in Thrombolyse intraveineuse par rt-PA (recombi- acute cardioembolic stroke; a meta-analysis of nant tissue plasminogen activator) dans le trai- randomized controlled trials. Stroke 2007; 38: tement aiguë des accidents vasculaires 423-30. cérébraux. Bull Médecins Suisses 1998; 79: Easton JD, Saver JL, Albers GW et al. Definition 114-5. and evaluation of transient ischemic attack : a Fifth consensus conference on antithrombotic scientific statement for healthcare professio- therapy (1998): summary recommendations. nals. Stroke 2009; 40: 2276-93. Chest 1998; 114 (Suppl.): 439S-769S. Giles MF, Rothwell PM. Transient ischaemic at- Hacke W, Kaste M, Fieschi C, et al. Randomised tack: clinical relevance, risk prediction and ur- double-blind placebo-controlled trial of thrombo- gency of secondary prevention. Curr Opin lytic therapy with intravenous alteplase in acute Neurol 2009; 22: 46-53. ischaemic stroke (ECASS II). Second Euro- Amarenco P, Lareuche J, Lavallée PC et al. Does pean-Australian Acute Stroke Study Investiga- ABCD2 score below 4 allow more time to eva- tors. Lancet 1998; 352: 1245-51. luate patients with a transient ischemic attack? Norris JW, Buchman A, Cote, et al. Canadian gui- Stroke 2009; 40: 3091-5. delines for intravenous thrombolytic treatment Ní Chróinín D, Callaly EL, Duggan J, et al. Asso- in acute stroke. Can J Neurol Sci 1998; 25 ciation between acute statin therapy, survival, .257-9. and improved functional outcome after ischemic Clark WM, Wissman S, Albers GW, et al. Recom- stroke: the North Dublin Population Stroke binant tissue-type plasminogen activator (Alte- 51 plase) for ischemic stroke 3 to 5 hours after Marschen D, Fahn S. (eds.). Mouvement disor- symptom onset. The ATLANTIS Study: a rando- ders 1, 2, 3. Butterworth Heinnemann, 1996. mized controlled trial. Alteplase Thrombolysis Van Harten P, Hoek HW, Kahn RS. Acute dysto- for Acute Noninterventional Therapy in Ischemic nia induced by drug treatment. BMJ 1999; 319: Stroke. JAMA 1999; 282: 2019-26. 623-6. Furlan A et al. Intra-arterial prourokinase for acute Céphalée, migraine ischemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in acute cere- NET: http://www.ihs-classification.org/ Bruyn GW. Intracranial arteriovenous malforma- bral thromboembolism. JAMA 1999; 282: tion and migraine. Cephalalgia 1984; 4:191- 2003-11. 207. Hallan S et al. A decision analysis of thrombolytic Mitchell CS, Osborn RE, Grosskreutz SR. Com- therapy compared with standard therapy in puted tomography in the headache patient: is acute ischemic stroke. J Intern Med 1999; 246: routine evaluation really necessary? Headache 549-59. 1993; 33:82-86. Ueda T et al. Multivariable analysis of predictive Frishberg BM. The utility of neuroimaging in the factors related to outcome at 6 month after evaluation of headache in patients with normal intra-arterial thrombolysis for acute ischemic neurologic examinations. Neurology 1994; stroke. Stroke 1999; 30: 2360-5. 44:1191-1197. Brott Th, Bogousslavsky J. Treatment of ischemic Akpek S, Arac M, Atilla S, Onal B, Yucel C, Isik S. stroke. N Engl J Med 2000; 343: 710-22. Cost-effectiveness of computed tomography in Albers GW, Amarenco P, Easton JD, et al. Anti- the evaluation of patients with headache. Head- thrombotic and thrombolytic therapy for ische- ache 1995; 35:228-230. mic stroke. Chest 2001; 119 (Suppl.): Weiller C, May A, Limmroth V, Juptner M, Kaube 300S-320S. H, Schayck RV, Coenen HH, Diener HC. Brain ANAES Recommandations pour la pratique clini- stem activation in spontaneous human migraine que. Prise en charge initiale des patients adul- attacks. Nat Med 1995; 1:658-660. tes atteints d’accident vasculaire cérébral. Dde Bruijn SF, Stam J, Kappelle LJ. Thunderclap Aspects médicaux. Septembre 2002, p. 1.127. headache as first symptom of cerebral venous AHA Part 9: Adult Stroke. Circulation 2005; 112: sinus thrombosis. CVST Study Group. Lancet 111-20. 1996; 348:1623-1625. Reversibles zerebrales Ophoff RA, Terwindt GM, Vergouwe MN, et al. Vasokonstriktionssyndrom (RCVS) Familial hemiplegic migraine and episodic ata- Beerle N, Hader Cl, Kleger GR et al. Das reversi- xia type-2 are caused by mutations in the Ca2+ ble zerebrale Vasokonstriktionssyndrom. Swiss channel gene CACNL1A4. Cell 1996; 87:543- Med Forum 2019; 19: 232-236. 552. Frishberg BM. Neuroimaging in presumed pri- Aphasie mary headache disorders. Semin Neurol 1997; Geschwind N. Aphasia. N Engl J Med 1971; 284: 17:373-382. 654-6. Morgenstern LB, Luna-Gonzales H, Huber JC, Damasio AR. Aphasia. N Engl J Med 1992; 326: Jr., Wong SS, Uthman MO, Gurian JH, Castillo 531-8. PR, Shaw SG, Frankowski RF, Grotta JC. Mesulam MM. Primary progressive aphasia - a Worst headache and subarachnoid hemor- language-based dementia. N Engl J Med 2003; rhage: prospective, modern computed tomogra- 349: 1535-42. phy and spinal fluid analysis. Ann Emerg Med Trombose veineuse cérébrale 1998; 32:297-304. Newman LC, Lipton RB. Emergency department Hirnvenenthrombosen - Sinusvenenthrombose evaluation of headache. Neurol Clin 1998; 16:285-303. Stam J. Thrombosis of the Cerebral Veins and Si- Sommer-Bühler J, Sztajzel R, Le Floch-Rohr J, et nuses. N Engl J Med 2004; 352: 1791-8. al. Les cephalées. Med Hyg 2000; 58: 788-96. Silvis SM, Middeldorp S, Zuurbier SM et al. Risk Bahra A, Matharu MS, Buchel C, Frackowiak RS, Factors for Cerebral Venous Thrombosis. Goadsby PJ. Brainstem activation specific to Semin Thromb Hemost 2016; 42: 622-31. migraine headache. Lancet 2001; 357:1016- FOP - Foramen ovale perméable 1017. Kent DM, Thaler DE. The Risk of Paradoxical Goadsby PJ. Neuroimaging in headache. Microsc Embolism (RoPE) study: developing risk mo- Res Tech 2001; 53:179-187. dels for application to ongoing randomized trials Morgenstern LB, Huber JC, Luna-Gonzales H, of percutaneous patent foramen ovale closure Saldin KR, Grotta JC, Shaw SG, Knudson L, for cryptogenic stroke. Trials. 2011; 12: 185- Frankowski RF. Headache in the emergency 194. department. Headache 2001; 41:537-541. Van GJ, Rinkel GJ. Subarachnoid haemorrhage: Dystonie aiguë - Dyskinésies tardives diagnosis, causes and management. Brain De Gowin EL, De Gowin RL (eds.). Diagnostic au 2001; 124:249-278. lit du malade. Doin Editions-Paris, 1980, p: 808- Dodick DW. Thunderclap headache. Headache 18. 2002; 42:309-315. 52 Ekbom K, Hardebo JE. Cluster Headache aetio- and the elderly. Epilepsia 1992; 33 (Suppl.4): logy, diagnosis and management. Durgs 2002; S15- S25. 62: 61-9. Greenberg MK, Barsan WG, Starkman S. Neuroi- Goadsby PJ. Pathophysiology of cluster head- maging in the emergency patient prensenting ache: a trigeminal autonomic cephalgia. Lancet with seizure. Neurology 1996; 47: 26-32. Neurol 2002; 1:251-257. Despland PA, Foletti G. Strategies therapeutiques Goadsby PJ, Lipton RB, Ferrari MD, et al. Mi- dans l’etat de mal epileptique. Les urgences graine - current understunding and treatment. N neurologiques. Les 60 premières minutes. Med Engl J Med 2002; 346: 257-70. Hyg 1997; 55: 1073-7. Mattle HP, Sturzenegger M, Meyer C. Céphalée Marson AG, Kadir ZA, Hutton JL, Chadwick DW. symptomatiques. Forum Med Suisse 2002; 5: The new antiepileptic drugs: A systematic re- 93-9. view of their efficacy and tolerability. Epilepsia Medina LS, D'Souza B, Vasconcellos E. Adults 1997; 38: 859-80. and children with headache: evidence-based Lowenstein DH, Alldredge BK. Status epilepticus. diagnostic evaluation. Neuroimaging Clin N Am N Engl J Med 1998; 338: 970-6. 2003; 13:225-235. Markand ON. Epilepsis in adults. In: Biller J. (ed.). Ramadan, N. M. Headache update. Headache Practical Neurology. Lippincott-Raven Publis- update. Continuum lifelong learning in neuro- hers 1997, pages 418-36. logy from the american academy of neurology Bleck TP. Management approaches to prolonged 9, 9-24. 2003. Lippincott, Williams, Wilkins. seizures and status epilepticus. Epilepsia 1999; Cortelli P, Cevoli S, Nonino F, Baronciani D, Ma- 40: Suppl. 1:S59-S63. grini N, Re G, De BG, Manzoni GC, Querzani P, Alldredge BK, Gelb AM, Isaacs SM, et al. A com- Vandelli A. Evidence-based diagnosis of non- parison of Lorazepam, Diazepam and placebo traumatic headache in the emergency depart- for the treatment of out-of-hospital status epi- ment: a consensus statement on four clinical lepticus. N Engl J Med 2001; 345: 631-7. scenarios. Headache 2004; 44:587-595. Browne TR, Holmes GL. Epilepsy. N Engl J Med Headache Classification Committee of the Inter- 2001; 344: 1145-51. national Headache Society. Classification and Chang BS, Lowenstein DH. Epilepsy. N Engl J diagnostic criteria criteria for headache disor- Med 2003; 349: 1257-66. ders, cranial neuroalgias, and facial pain. Ce- Leppert D, Stöckli HR, Fuhr P. Directives pour le phalalgia Suppl 1, S1-S160. 2004. traitement de l’état de mal épileptique. Schweiz Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Ärtzezeitung 2005; 86: 1-14. Erratum: Schweiz Olesen J. Classification of primary headaches. Ärtzezeitung 2007; 88: 39 Neurology 2004; 63:427-435. Mort cérébrale, test d’apnée Olesen J, Lipton RB. Headache classification update 2004. Curr Opin Neurol 2004; 17:275-282. The Ad Hoc Commettee of the Harvard Medical Swartz RH, Kern RZ. Migraine is associated with School to examine the definition of brain death. magnetic resonance imaging white matter ab- A definition of irreversible coma. JAMA 1968; normalities: a meta-analysis. Arch Neurol 2004; 205: 337-40. 61:1366-1368. Black PM. Brain death (first of two parts). N Engl Sempere A, Porta-Etessam J, Medrano V, Gar- J Med 1978; 299: 338-44. cia-Morales I, Concepcion L, Ramos A, Floren- Black PM. Brain death (second of two parts). N cio I, Bermejo F, Botella C. Neuroimaging in the Engl J Med 1978; 299: 393-401. evaluation of patients with non-acute headache. Brain death task force: guideline for the diagnosis Cephalalgia 2005; 25:30-35. of brain death. Can Med Assoc J 1987; 136: Headache Classification Committee of the Inter- 200A-200B. national Headache Society (IHS). The Interna- Benzel EC, Gross CD, Hadden TA, et al. The tional Classification of Headache Disorders, 3rd apnea test for the determination of brain death. edition (beta version). Cephalalgia 2013; 33: J Neurosurg 1989; 71: 191-194. 629-808. Asbury AK, McKhann GM, McDonald WI. (eds.). Headache Classification Committee of the Inter- Neurologic manifestation of systemic diseases. national Headache Society (IHS) The Interna- In: Diseases of the nervous system clinical neu- tional Classification of Headache Disorders, 3rd robiology. W.B. Saunders Company , 1992. edition. Cephalalgia 2018; 38:1-211. Academie Suisse des Sciences Medicales: Direc- tives pour la definition et le diagnostic de la Épilepsie mort en vue d’une transplantation d’organes. Commission on Classification and Terminology of Bulletin des medecins suisses 1996; 77: 1821- the International League Against Epilepsy. Pro- 9. posal for revised clinical classification and elec- Favre J. Brain stem death. In: Palmer JD (ed.) troencephalographic classification of epileptic Manual of Neurosurgery. New York, Churchill seizures. Epilepsia 1981; 22: 489-501. Lvingstone 1996; chapter 118: 573-81. Commission on Classification and Terminology of Favre J. La mort cerebrale. Rev Med Suisse Rom the International League Against Epilepsy. Pro- 1998; 118: 531-6. posal for revised clinical classification and epi- Canadian Neurocritical Care Group. Guidelines leptic syndromes. Epilepsia 1989; 30: 389-99. for the diagnosis of brain death. Can J Neurol De Lorenzo. Status epilepticus in children, adult Sci 1999; 26: 64-66. (www.canjneurolsci.org) 53 Wijdicks EFM. The diagnosis of brain death. N nerve. In: Dyck PJ (ed.). Peripheral Neuropathy. Engl J Med 2001; 344: 1215-21. Philadelphia, Saunders, 1984 Berg K, Wood- Meier N, Duner P., Sturzenegger M. Der Kopf- Dauphinee S, Williams JI, Gayton D: Measuring schmerzpatient in der Hausarztpraxis. Schweiz balance in the elderly: Preliminary development Med Forum 2015; 15: 420-4. of an instrument. Physiotherapy Canada, 41:304-311, 1989. Encéphalite - Méningoencéphalite :1266-99. von Arx S, Leib SL, Sturzenegger M, Sendi P. In- Adour KK, Ruboyianes JM, Von Doersten PG, et fektionen des zentralen Nervensystems – Teil 1: al. Bell’s palsy treatment with acyclovir and Meningitis bei Erwachsenen. Schweiz Med prednisone compared with prednisone alone: a Forum 2017; 17: 464-70. double-blind, randomized, controlled trial. Ann von Arx S, Leib SL, Sturzenegger M, Sendi P. In- Otol Rhinol Laryngol 1996; 105: 371-78. fektionen des zentralen Nervensystems – Teil 2: Murakami S, Nakashiro Y, Doi T, et al. Bell palsy Enzephalitis beim Erwachsenen. Schweiz Med and herpes simplex virus: identification of viral Forum 2017; 17: 492-98. DNA in endoneural fluid and muscle. Ann Intern Dermatomes Med 1996; 124: 27-30. International standards for neurological and Robb G, Fazekas F, Hartung HP. Peripheral facial functional classification of spinal cord injury. palsy: etiology, diagnosis and treatment. Eur Chapter II: Neurological Assessment: the sen- Neurol 1999; 41: 3-6. sory examination, 1996: 5-14 Ramsey MJ, DerSimonian R, Hotel MR, et al. www.sci-queri.research.med.va.gov/Registry.htm Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis. Laryngoscope Locked-in-syndrome (LIS) 2000; 110: 335-41. Virgile RS (1984) Locked-in syndrome. Case and Sullivan FM, Swan RC, Donnan PT et al. Early literature review. Clin Neurol Neurosurg 1984; Treatment with Prednisolone or Acyclovir in 86: 275–9. Bell's Palsy. N Engl J Med 2007; 357: 1598- Patterson JR, Grabois M. Locked-in syndrome: a 1607. review of 139 cases. Stroke 1986; 17: 758–64. GUILLAIN-BARRE, MILLER-FISHER Malm J, Kristensen B, Carlberg B, et al. Clinical features and prognosis in young adults with in- Hurwitz E, Schonberger L, Nelson D, et al. Guil- fratentorial infarcts. Cerebrovasc Dis 1999; 9: lain-Barré Syndrome and the 1978-79 influenza 282-9. vaccine. N Engl J Med 1981; 304: 1557-61. Raaba A, Sandner E. Ein Betreuungskonzept für Asbury AK, Cornblath DR. Assessment of current Betroffene mit Locked-in-Syndrom. Schweiz diagnostic criteria for Guillain-Barré syndrome. Med For 2015; 15: 106-110. Ann Neurol 1990; 27 (Suppl.): 1123-1129. Ropper A. Guillain-Barré syndrome. N Engl J Med Neuropathie 1992; 326: 1130-6. Adour KK, Wingerd JW, Doty HE. Prevalence of Van der Meche F, Schmitz P. A randomized trial concurrent diabetes mellitus and idiopathic fa- comparing intravenous immune globuline and cial paralysis (Bell’s palsy). Diabetes 1975; 24: plasma excahange in Guillain-Barré syndrome. 449-51. Dutch Guillain Barré Study Group. N Engl J Raskin NH, Fishman RA. Neurologic disorders in Med 1992; 326: 1123-9. renal failure (first of two parts). N Engl J Med Bolton CF. The changing of concepts of Guillain- 1976; 294: 143-8. Barré Syndrome. N Engl J Med 1995; 333: Pirart J. Diabetes mellitus and its degenerative 1415-7. complications: a prospective study of 4.400 pa- Hughes RA, Hadden RD, Gregson NA, et al. Pa- tiens observed between 1947 and 1973. Dia- thogenesis of Guillain-Barre syndrome. J Neu- bete Care 1978; 1: 168-188. roimmunol 1999; 100: 74-97. Pecket P, Schatter A. Concurrent Bell’s palsy and Willison HJ, O’Hanlon GM. The immunopathoge- diabetes mellitus: a diabetic mononeuropathy? nesis of Miller Fisher syndrome. J Neuroimmu- J Neurol Neurosurg Psychiatry 1982; 45: 652-5. nol 1999; 100: 3-12. Wall PD, Melzack R. (eds.). Peripheral neuropa- Mori M, Kuwabara S, Fukutate T, et al. Clinical thies. In: Textbook of Pain. Churchill Livingstone features and prognosis of Miller Fisher syn- 1989. drome. Neurology 2001; 56: 1104-6. Ropper AH. The Guillain-Barré syndrome. N Engl Van der Meche FG, Van Doorn PA, Meulstee J, et J Med 1992; 326: 1130-6. al. Diagnostic and classification criteria for the Dyck PJ, Kratz KM, Carnes JL et al. The preva- Guillain-Barré syndrome. Eur Neurol 2001; 45: lence by staged severity of varous types of dia- 133-9. betic neuropathy, retinopathy, and nephropathy Yuki N, Hartung HP. Guillain-Barré syndrome. N in a population-based cohort: the Rochester Engl J Med 2012; 366: 2294. Diabetic Neuropathy Study. Neurology 1993; Hypertension intracrânienne, 43: 817-24. [Erratum Neurology 1993; 43: 2345. Oedème cérébral Barohn RJ. Approach to peripheral neuropathy Bruns FJ, Fraley DS, Haigh J, et al. Control of and neuronopathy. Semin 1998; 18: 7-18. organ blood flow. In: Snyder JV, Pinsky MR Parésie faciale — Gesichtslähmung (eds.). Oxygen transport in the critically ill. Chi- Karnes WE. Diseases of the seventh cranial cago: Year Book Medical Publishers 1987; 87- 54 124. 48-53. Drummond JC, Shapiro HM. Cerebral physiology. Marmarou A, Black P, Bergsneider M, et al. Gui- In: Miller RD (ed.). Anesthesia. Churchill Living- delines for management of idiopathic normal stone, 1990, p: 625. pressure hydrocephalus: progress to date. Acta Lang EW, Chesnut RM. Intracranial pressure and Neurochir Suppl. 2005; 95: 237-40. cerebral perfusion pressure in severe head in- Relkin N, Marmarou A, Klinge P, Bergsneider M, jury. New Horiz 1995; 3: 400-9. Black PM. Diagnosing idiopathic normal-pres- Levy MH. Pharmacologic treatment of cancer sure hydrocephalus. Neurosurgery 2005; 57: 4- pain. N Engl J Med 1996; 335: 1124-32. 16; discussion ii-v. Chesnut RM. The management of severe trauma- Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I tic brain injury. Emerg Med Clin North Am 1997; and Wikkelso C. Prevalence of idiopathic nor- 15: 581-604. mal-pressure hydrocephalus. Neurology 2014; Lam CH, Villemure JG. Comparison between 82: 1449-54. ventriculoatrial and ventriculoperitoneal shun- McGirt MJ, Woodworth G, Coon AL et al. Diagno- ting in the adult population. Br J Neurosurg sis, treatment, and analysis of long-term outco- 1997; 11: 43-8. mes in idiopathic normal-pressure Corkill RG, Cadoux-Hudson TA. Normal pressure hydrocephalus. Neurosurgery 2005; 57: 699- hydrocephalus: developments in determining 705; discussion 699-705. surgical prognosis. Curr Opin Neurol 1999; 12: Lemcke J, Meier U, Muller C, et al. Safety and ef- 671-7. ficacy of gravitational shunt valves in patients Zemack G, Romner B. Seven years of clinical ex- with idiopathic normal pressure hydrocephalus: perience with the programmable Codman a pragmatic, randomised, open label, multicen- Hakim valve: a retrospective study of 583 pa- tre trial (SVASONA). J of Neurology, Neurosur- tients. J Neurosurg 2000; 92: 941-8. gery, and psychiatry 2013;84:850-7. Jahn K, Zwergal A. Normaldruckhydrozephalus. Hydrocéphalie à pression normale (NPH) In: Diener HC, Gerloff C, Dieterich M, editors. Adams RD, Fisher CM, Hakim S, Ojemann RG, Therapie und Verlauf neurologischer Erkran- Sweet WH. Symptomatic Occult Hydrocephalus kungen. Stuttgart: Kohlhammer. 2017. with «Normal» Cerebrospinal-Fluid Pressure.A Fichtnera J, Hänia L, Raabea A et al. Normal- Treatable Syndrome. NEJM 1965; 273: 117-26. druck-Hydrozephalus. Schweiz Med Forum Hakim S, Adams RD. The special clinical problem 2019; 19: 476-80. of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on ce- Syndrome lombo-vertébral aigu rebrospinal fluid hydrodynamics. J Neurol Calin A, Porta J, Fries JF, et al. Clinical history as Sciences 1965; 2: 307-27. a screening test for ankylosing spondylitis. Berg K, Wood-Dauphinee S, Williams JI, Maki, B: JAMA 1977; 237: 2613-4. Measuring balance in the elderly: Validation of Weber H. Lumbar disc herniation. A controlled, an instrument. Can. J. Pub. Health 1992; Suppl. prospective study with ten years of observation. 2: S7-11. Spine 1983; 8: 131-40. Berg K, Wood-Dauphinee S, Williams JI: The Ba- Deyo RA, Tsui-Wu JY. Descriptive epidemiology lance Scale: Reliability assessment for elderly of low-back pain and its related care in the Uni- residents and patients with an acute stroke. ted States. Spine 1987; 12: 264-8. Scand J Rehab Med 1995; 27: 27-36. Kosteljanetz M, Bang F, Schmidt-Olsen S. The Wood-Dauphinee S, Berg K, Bravo G, Williams clinical significance of straight-leg-raising (Lase- JI: The Balance Scale: Responding to clinically gue’s sign) in the diagnosis of prolapsed lumbar meaningful changes. Canadian Journal of Re- disc. Spine 1988; 13: 393-5. habilitation 1997; 10: 35-50. McCombe PF, Fairbank JCT, Cockersole BC, et Hebb AO, Cusimano MD. Idiopathic normal pres- al. Reproductibility of physical signs in low-back sure hydrocephalus: a systematic review of dia- pain. Spine 1989; 14: 908-18. gnosis and outcome. Neurosurgery 2001; 49: Boden SD, Davis DO, Dina TS, et al. Abnormal 1166-86. magnetic resonance scans of the lumbar spine Momjian S, Owler BK, Czosnyka Z, et al. Pattern in asymptomatic subjects. J Bone Joint Surg of white matter regional cerebral blood flow and Am 1990; 72: 403-8. autoregulation in normal pressure hydrocepha- Deyo RA, Rainville J, Kent DL. What can the hi- lus. Brain 2004; 127:9 65-72. story and the physical examination tell us about Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et low back pain ? JAMA 1992; 268: 760-5. al. The Montreal Cognitive Assessment, MoCA: Leuba Manueddu B, Stalder H. Lombalgie aiguë. a brief screening tool for mild cognitive impair- Med Hyg 1995; 54: 1745-9. ment. J Am Geriatr Soc 2005; 53: 695-699. Malmivaara A, Häkkinen U, Aro T, et al. The treat- Kahlon B, Sjunnesson J, Rehncrona S. Long- ment of acute low back pain – bedrest, exerci- term outcome in patients with suspected normal ses, or ordinary activity. N Engl J Med 1995; pressure hydrocephalus. Neurosurgery 332: 351-5. 2007;60:327-32; discussion 32. Syndromes extrapyramidal, Brean A, Eide PK. Prevalence of probable idiopa- pyramidal, cérébellaire. Réflexes thic normal pressure hydrocephalus in a Norwe- Babinski J, tournay A. Symptômes des maladies gian population. Acta Neurol Scand 2008; 118: du cervelet. Rev Neurol 1993; 18: 306-22. 55 De Gowin EL, De Gowin RL (eds.). Diagnostic au diagnosis of essential tremor. Neurology 2000; lit du malade. Doin Editions-Paris, 1980, p: 808- 54 (Suppl. 4): S7 18. Habib-ur-Rehman. Diagnosis and management of Marschen D, Fahn S. (eds.). Mouvement disor- tremor. Arch Intern Med 2000; 160: 2438-44. ders 1, 2, 3. Butterworth Heinnemann, 1996. Sullivan KL, Hauser RA, Zesiewicz TA. Essentiel Syndrome d’impatience des membres tremor. Epidemiology, diagnosis, and treatment. inférieurs à l’éveil Neurologist 2004; 10: 250-8. Restless legs syndrome (RLS) Practice parameter. Therapies for Essential Tre- Walters AS. Toward a better definition of the rest- mor. Neurology 2005; 64: 2008-20. less legs syndrome: the international restless Wenning GK, Kiechl S, Seppi K, et al. Prevalence legs syndrome study group. Mov Disord 1995; of movement disorders in men and women 10: 634-42. aged 50-89 years (Bruneck Study cohort): a po- Rothdach AJ, Trenkwalder C, Haberstock J, et al. pulation-based study. Lancet Neurol 2005; 4: Prevalence and risk factors of RLS in an elderly 815-20. population. Neurology 2000; 54: 1064-8. Rodrigues JP, Edwards DJ, Walters SE et al. Blin- Mathis J. Das restless legs Syndrom und periodi- ded placebo crossover study of gabapentin in sche Beinbewegungen im Schlaf. Med Hyg primary orthostatic tremor. Mov Disord 2006; 2003; 61: 106-7. 21: 900-905. Comella CL. Restless legs syndrome: treatment Louis ED, Ferreira JJ. How common is the most with dopaminergic agents. Neurology 2002; 58 common adult movement disorder? Update on (Suppl. 4): S87-S92. the worldwide prevalence of essential tremor. Odin P, Mrowka M, Shing M. Restless legs syn- Mov Disord 2010; 25: 534-41. doi: drome. Eur J Neurol 2002; 9 (Suppl 3): S59- 10.1002/mds.22838. S67. Deuschl G, Raethjen J, Hellriegel H et al. Treat- Stiasny K, OPertel WH, Trenkwalder C. Clinical ment of patients with essential tremor. Lancet symptomatology and treatment of restless legs Neurol 2011; 10: 148-161. syndrome and periodic limb mouvement disor- Parkinsonisme — M. PARKINSON der. Sleep Med Rev 2002; 6: 253-65. Calne DB. Treatment of parkinson’s disease. N Mathis J. Das Restless Legs Syndrom in der Pra- Engl J Med 1993; 329: 1021-7. xis. Swiss Medical Forum 2002; 4: 67-71. Ghika J, Regli F. Nouvelles acquisitions therapeu- Allen RP, Walters AS, Montplaisir J, Hening W, tiques dans la maladie de Parkinson. Med Hyg Myers A, Bell TJ, et al. Restless legs syndrome 1995; 53: 32-6. prevalence and impact: REST general popula- Dooley M, Markham A. Pramipexole. A review of tion study. Archs Intern Med 2005;165:1286-92. its use in the management of early and advan- Garcia-Borreguero D et.al,. The long-term treat- ced Parkinson‘s disease. Drugs & Aging 1998; ment of restless legs syndrome/Willis-Ekbom 12: 495-514. disease: evidence-based guidelines and clinical Groupe de travail de la commission de therapie consensus best practice guidance: a report de la Societe suisse de neurologie (SNN). Re- from the International Restless Legs Syndrome commandations pour le traitement du syndrome Study Group. Sleep Med 2013; 14: 675-684. de Parkinson idiopathique. Bulletin des Mede- Allen RP, Picchietti DL, Garcia-Borreguero D et cins Suisses 1998; 79: 425-7. al. Restless legs syndrome/Willis-Ekbom Lang AE, Lozano AM. Parkinson's disease, first of disease diagnostic criteria: updated Internatio- two parts. N Eng J Med 1998; 339: 1044-53. nal Restless Legs Syndrome Study Group Lang AE, Lozano AM. Parkinson's disease, se- (IRLSSG) consensus criteria--history, rationale, cond of two parts. N Eng J Med 1998; 339: description, and significance. Sleep Med 2014; 1130-43. 15: 860-73. doi: 10.1016/j.sleep.2014.03.025 Dewey RB Jr, Hutton JT, LeWitt PA, et al. A ran- Sateia MJ. International classification of sleep domized, double-blind, placebo-controlled trial disorders-third edition: highlights and modificati- of subcutaneously injected apomorphine for ons. Chest 2014; 146: 1387-94. parkinsonian off-state events. Arch Neurol Mathis J. Langzeittherapie beim Restless-Legs 2001; 58: 1385-92. Syndrom. Rev Med Suisse 2015; 11: 268-70. Krack P, Batir A, Van Blercom N, et al. Five-year Tremblement - Trémor follow-up of bilateral stimulation of the subthala- Elbe RJ, Koller WC. Tremor. Johns Hopkins Uni- mic nucleus in advanced Parkinson’s disease. versity Press, Baltimore 1990. N Engl J Med 2003; 349: 1925.34. Ghika J, Küntzer R, Regli F. Les tremblements. Groupe de travail de la commission de thérapie Revue Suisse de medecins (Praxis). 1993; 82: de la Société suisse de neurologie. Archives de 759-68. Suisses de Neurologie et de Psychiatrie 2004; Deuschl G, Bain P, Brin M. Consensus statement 155: 74-8. of the Movement Disorder Society on Tremor. Burkhard PR, Villemure JG, Vingerhoets FJG. Ad Hoc Scientific Committee. Mov Disord 1998; Traitement actuel de la maladie de Parkinson: 13 (Suppl. 3): 2-23. difficultés et controverses. Rev Med Suisse Findly LJ, Koller WC. (eds.). Handbook of tremor 2005; 1: 1214-9. disorders. Marcel Dekker, 1999. Nutt JG, Wooen GF. Diagnosis and initial ma- Bain P, Brin M, Deuschl G et al. Criteria for the nagement of Parkinson’s Disease. N Engl J 56 Med 2005; 353: 1021-7. ron Diseases/Amyotrophic Lateral Sclerosis of the World Ferderation of Neurology Research FRIEDREICH Ataxie Group on Neuromuscular Diseases and the El Bürk K. Friedreich Ataxia: current status and fu- Escorial «Clinical limits of amyotrophic lateral ture prospects. Cerebellum Ataxias 2017; 4:4. sclerosis» workshop contributors. J Neurol Sci Drop attack 1994; 124, Suppl.: 96-107 Brust JCM, Plank CR, Healton EB, et al. The pa- Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral thology of drop attacks: a case report. Neuro- sclerosis: current issues in classification, pathology 1979; 29: 786-790. genesis and molecular pathology. Neuropathol Lipsitz LA. The drop attack: a common geriatric Appl Neurobiol 1998; 24: 104-17. symptom. J Am Geriatric So c 1983; 31: 617- Brooks BR, Miller RG, Swash M et al. Revised 20. Criteria for the Diagnosis of Amyotrophic Lateral Meissner I, Wiebers DO, Swanson JW, et al. The Sclerosis. A Consensus Conference held at Air- natural history of drop attacks. Neurology 1986; lie House, Warrenton, Virginia April 2-4, 1998. 36: 1029-34. Brooks BR,Miller RG, Swash M,Munsat TL. World Baloh RW, Jacobson K, Winder T. Drop attacks Federation of Neurology Research Group on with Meniere’s syndrome. Ann Neurol 1990; 28: Motor Neuron Diseases (2000) El Escorial revi- 384-7. sed: Revised criteria for the diagnosis of amyo- Morillo CA, Villar JC. Neurocardiology. Neuroge- trophic lateral sclerosis. Amyotroph Lateral nic syncope. Baillieres Clin Neurol 1997; 6: Scler Other Motor Neuron Disord 2000; 1: 293- 357-80. 9. Shaw FE, Kenny RA. The overlap between syn- De Carvalho M, Dengler R, Eisen A, et al. Elec- cope and falls in the elderly. Postgrad Med J trodiagnostic criteria for diagnosis of ALS. Clin 1997; 73: 635-9. Neurophysiol 2008; 119: 497-503. Ludolph A, Drory V, Hardiman O et al. A revision Encépalopathie de (GAYET)- of the El Escorial criteria - 2015. Amyotroph La- WERNICKE, KORSAKOFF teral Scler Frontotemporal Degener 2015; 16: Reuler JB, Girard DE, Cooney TG. Wernicke’s 291-2. encephalopathy. N Engl J Med 1985; 312: 1035-9. Restless legs syndrome - RLS Syndrome des impatiences des jambes Lindberg MC, Oyler RA. Wernicke's encephalopathy. Am Fam Physician 1990; 41: 1205-9. Walters AS1, LeBrocq C, Dhar A et al Validation Heye N, Terstegge K, Sirtl C, et al. Wernicke's en- of the International Restless Legs Syndrome cephalopathy - causes to consider. Intensive Study Group rating scale for restless legs syn- Care Med 1994; 20: 282-6. drome. Sleep Med 2003; 4: 121-32. Kril JJ. Neuropathology of thiamine deficiency Sclérose en plaque - SEP - MS disorders. Metab Brain Dis 1996; 11: 9-17. Polman CH, Reingold SC, Edan G et al. Diagno- Preuss UW, Soyka M. Wernicke-Korsakoff syn- stic criteria for multiple sclerosis: 2005 revisions drome: clinical aspects, pathophysiology and to the "McDonald Criteria". Ann Neurol 2005; therapeutic approaches. Fortschr Neurol Psych- 58: 840-6. iatr 1997; 65: 413-20. Ransohoff RM. Natalizumab for Multiple Sclero- Zubaran C, Fernandes JG, Rodnight R. Wer- sis. N Engl J Med 2007; 356: 2622-9. nicke-Korsakoff syndrome. Postgrad Med J Polman CH, Reingold SC, Banwell B et al. Dia- 1997; 73: 27-31. gnostic criteria for multiple sclerosis: 2010 revi- Ponction lombaire, LCR sions to the McDonald criteria. Ann Neurol Kuntz KM, Kokmen E, Stevens JC, et al. Post- 2011; 69: 292-302. lumbar puncture headaches: experience in 501 Christian P. Kamm CP, Uitdehaag BM, Polman consecutive procedures. Neurology 1992; 42: CH et al. Multiple Sclerosis: Current Knowledge 1884-7. and Future Outlook Eur Neurol 2014; 72: 132- Broadley SA, Fuller GN. Lumbar puncture needn’t 41. be a headache. Use blunt needles and no bed Khanna D, Distler JHW, Sandner P, Distler O. rest. BMJ 1997; 315: 1324-5. Emerging strategies for treatment of systemic Hasbun R, Abrahams J, Jekel J, et al. Computed sclerosis. Journal of Scleroderma and Related tomography of the head before lumbar puncture Disorders 2016; 1: 186-93. in adults with suspected meningits. N Engl J Da D. Sclérose systémique. Forum Médical Med 2001; 345: 1727-33. Suisse 2017; 17: 808-15. Kowal-Bielecka O, Fransen J, Avouac J e al. Up- Amyotrophe Lateralsklerose (ALS) date of EULAR recommendations for the treat- Sclérose latérale amyotrophiante (SLA) ment of systemic sclerosis. Ann Rheum Dis Swash M, Leish N. Criteria for diagnosis of fami- 2017; 76: 1327-39. lial amyotrophic lateral sclerosis: European Thompson AJ, Banwell BL, Barkhof F et al. Dia- FALS Collaborative Group. Neuromuscul Disord gnosis of multiple sclerosis: 2017 revisions of 1992; 2: 7-9. the McDonald criteria. Lancet Neurol 2017. pii: Brooks BR. El Escorial World Federation of Neu- S1474-4422(17)30470-2. rology criteria for the diagnosis of amyotrophic Thompson AJ, Banwell BL, Barkhof F, et al. Dia- lateral sclerosis.Subcommittee on Motor Neu- gnosis of multiple sclerosis: 2017 revisions of 57 the McDonald criteria. Lancet Neurol 2018; 17: systematic review and Bayesian meta-analysis. 162-173. Intensive Care Med 2017; 43: 785-94.Ehrmann S, Quartin A, Hobbs BP et al. Contrast-associa- Sturz im Alter ted acute kidney injury in the critically ill: syste- Sloan JP. Protocols in primary care geriatrics. 2d matic review and Bayesian meta-analysis. ed. New York: Springer, 1997 Intensive Care Med 2017; 43: 785-94. Levey AS, James MT. Acute Kidney Injury. Ann NÉPHROLOGIE Intern Med 2017; 167: ITC66-ITC80. Claudio Ronco C, Bellomo R, Kellum JA. Acute Insuffisance rénale aiguë kidney injury. Lancet 2019; 394: 1949-64. Akute Niereninsuffizienz Ellison DH. Clinical Pharmacology in Diuretic Espinel CH. The FENa test: use in the differential Use. Clin J Am Soc Nephrol 2019; 14: 1248- diagnosis of acuterenal failure. JAMA 1976; 1257. 236: 579-81. Miller TR, Anderson RJ, Linas SL et al. Urinary IRA sur produit de contraste diagnostic indices in acute renal failure: a pro- Kontrastmittelinduzierte Nephropathie spective study. Ann Intern Med 1978; 89: 47-50. Barrett BJ. Contrast nephrotoxicity. J Am Soc Ne- Humes HD. Aminoglycosides nephrotoxicity. Kid- phrol 1994; 5: 25-37. ney Int 1988; 33: 900-8. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, et Solomon R, Werner C, Mann D, et al. Effects of al. Determinants of serum creatinine trajectory saline, mannitol, and furosemide to prevent de- in acute contrast nephropathy. J Interv Cardiol creases in renal function induced by radiocon- 2002; 15: 349-54. trast agents. N Engl J Med 1994; 331:1416-20. Barrett BJ, Parfrey S. Preventing Nephropathy In- Brady HR, Singer GG. Acute renal failure. Lancet duced by Contrast Medium. N Engl J Med 1995; 346: 1533-40. 2006; 354:379-86. Thadani R, Pascual M, Bonventre JV. Acute renal Marenzi G, Assanelli E, Marana I, et al. N-Acetyl- failure. N Engl J Med 1996; 334: 1448-60. cysteine and Contrast-Induced Nephropathy in Mindell JA, Chertow GM. A practical approach to Primary Angioplasty. N Engl J Med 2006; 354: acute renal failure. Med Clin North Am 1997; 2773-82. 81: 731-48. Dialyse NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Gillum DM, Dixon BS, Yanover MJ, et al. The role Am J Kidney Dis. 1997; 30 (Suppl 2): S15-66. of intensive dialysis in acute renal failure. Clin Schrier RW, Gottschalk CW (eds). Diseases of Nephrol 1986; 25: 249-55. the kidney. 6th edition, Little Brown & Co 1997. Conger JD. Interventions in clinical acute renal Halperin ML, Goldstein MB, (ed). Fluid, electro- failure: what are the data? Am J Kidney Dis lyte, and acid-base physiology: a problem- 1995; 26:565-76. based-approach, 3rd edition. W.B. Saunders Clark WR, Mueller BA, Kraus MA, Macias WL. Company, 1999. Extracorporeal therapy requirements for pa- Tepel M, Van der Giet M, Schwarzfeld C, et al. tients with acute renal failure. J Am Soc Nephrol Prevention of radiographic-contrast-agent-indu- 1997; 8:804-12. ced reductions in renal function by acetylcy- Insuffisance surrénalienne steine. N Engl J Med 2000; 343: 180-4. Nebenniereninsuffizienz - ADDISON Kellum JA, Decker JM. Use of dopamine in acute Werbel SS, Ober KP. Acute adrenal insufficiency. renal failure: a metaanalysis. Crit Care Med Endocrinol Metab Clin North Am 1993; 22: 303- 2001; 29: 1526-31. 28. Hoste EAJ, Clermont G , Kersten A et al. RIFLE Howlett TA. An assessment of optimal hydrocorti- criteria for acute kidney injury are associated sone replacement therapy. Clin Endocrinol with hospital mortality in critically ill patients: a 1997; 46: 263-8. cohort analysis. Crit Care 2006; 10: R73. Cooper MS, Stewart PM. Corticosteroid insuffi- Kidney Disease Improuving Outcomes (KDIGO) ciency in acutely ill patients. N Engl J Med Acute Kidney Injury Work Group. KDIGO Clini- 2003; 348: 727-34. cal Practice Guidelines for Acute Kidney Injury. Hamrahian AH, Oseni TS, Arafah BM. Measure- Kidney Inter. supp 2012; 2:1-138. ments of Serum Free Cortisol in Critically Ill Pa- McClave SA, Taylor BE, Martindale RG et al. Gui- tients. N Engl J Med 2004; 350: 1629-38. delines for the Provision and Assessment of Prete A, Taylor AE, Bancos I et al. Prevention of Nutrition Support Therapy in the Adult Critically Adrenal Crisis: Cortisol Responses to Major Ill Patient: Society of Critical Care Medicine Stress Compared to Stress Dose Hydrocorti- (SCCM) and American Society for Parenteral sone Delivery. J Clin Endocrinol Metab 2020; and Enteral Nutrition (A.S.P.E.N.). JPEN J Pa- 105: 2262–74. renter Enteral Nutr 2016; 40 : 159-211. Ostermann M, Joannidis M. Acute kidney injury Colique néphrétique, néphrolithiase 2016: diagnosis and diagnostic workup. Crit Ettinger B, Tang A, Citron JT, et al. Randomized Care 2016; 20: 299. trial of allopurinol in the prevention of calcium Ehrmann S, Quartin A, Hobbs BP et al. Contrast- oxalat calculi. N Engl J Med 1986; 315: 1386-9. associated acute kidney injury in the critically ill: Consensus Conference. Prevention and treat- 58 ment of kidney stones. JAMA 1988; 260: 977- Cohn JN, Kowey PR, Whelton PK, et al. New 81. Guidelines for potassium replacement in clinical Coe FL, Parks JH, Asplin JR. The pathogenesis practice. Arch Intern Med 2000; 160: 2429-36. and treatment of kidney stones. N Engl J Med Calcium et magnésium 1992; 327: 1141-52. Curhan GC, Willet WC, Speizer FE, et al. Beve- Reinhard RA, Desbien NA. Hypomagnesemia in rage use and risk for kidney stones in women. patients entering the ICU. Crit Care Med 1985; Ann Intern Med 1998; 128: 534-40. 13: 506-7. Dobbins JM, Rao PM, Novelline RA, Bush JA. Whang R. Management deficiency: pathogenesis, Unenhanced helical computed tomography for prevalence, and clinical implications. Am J Med suspected urinary tract stones: current state of 1987; 82: 24-9. the art. Em Radiol 1998; 5: 97-102. Arrambide K, Toto RD. Tumor lysis syndrome. Hess B, Jost C, Zipperle L, et al. High calcium in- Semin Nephrol 1993; 13: 273-80. take abolishes hyperoxaluria and reduces uri- Wallach J, (ed.). Interpretation of Diagnostic nary cristallization during a 20-fold normal Tests. Little Brown, 1996. oxalate load in humans. Nephrol Dial Trans- Rose BD, Post TW, (ed). Clinical physiology of plant 1998; 13: 2241-7. acid-base and electrolyte disorders. 5th edition, Borghi L, Schianchi T, Meschi T, et al. Compari- McGraw-Hill, New York, 2001. son of two diets for the prevention of recurrent Singer GG. Fluid and electrolyte management. In: stones in idiopathic hypercalicuria. N Engl J Ahya SN. et al. (eds.). The Washington Manual Med 2001; 346: 77-84. of medical therapeutics. Lippincott Williams & Wilkins, 2001; p. 43-75. Sodium Phosphate Berl T, Schrier RW. Water metabolism and the hypo-osmolar syndrome. In: Brenner BM, Stein Newman JH, Neff TA, Ziporen P. Acute respira- JH (eds). Sodium and Water Homeastasis. tory failure associated with hypophosphatemia. Churchil Livingstone, New York, 1978. N Engl J Med 1977; 296: 1101-3. Ayus JC, Krothapalli RK, Arieff AI. Changing con- Kingston M, Badawi Al-Siba’i M. Treatment of se- cepts in treatment of severe symptomatic hypo- vere hypopohosphatemia. Crit Care Med 1985; natremia. Am J Med 1985; 78: 897-902. 13: 16-8. Rose BD. New approach to disturbances in the Knochel JP. Hypophosphatemia and rhabdomyo- plasma sodium concentration. Am J Med 1986; lysis. Am J Med 1992; 92: 455-7. 81: 1033-40. Brooks MJ, Melnik G. The refeeding syndrome: Weisberg LS. Pseudohyponatremia. Am J Med an approach to understanding its complications 1989; 86: 315-18. and preventing its occurrence. Pharmacothe- Clutimans FHM, Meinders AE. Management of rapy 1995; 15: 713-26. severe hyponatremia: rapid or slow correction ? Weisinger JR, Bellorin-Font E. Magnesium and Am J Med 1990; 88: 161-6. phosphorus. Lancet 1998; 352: 391-6. Schrier RW, Briner A. The differential diagnosis of Subramanian R, Khadori R. Severe hypophos- hyponatremia. Hosp Pract 1990; 30: 29-37. phatemia. Medicine (Baltimore) 2000; 79: 1-8. Lauriat SM, Berl T. The hyponatremic patients: Crook MA, Hally V, Pantelli JV. The importance f Practical focus on therapy. J Am Soc Nephrol the refeeding syndrome. Nutrition 2001; 17: 1997; 8: 1599-1607. 632-7. Kumar S, Berl T. Sodium. Lancet 1998; 352: 220- Syndrome de renutrition 8. Refeeding syndrome Adrogué HJ, Madias NE. Hypernatremia. N Engl Brooks MJ, Melnik G. The refeeding syndrome: J Med 2000; 342; 1493-9. an approach to understanding its complications Adrogué HJ, Madias NE. Hyponatremia. N Engl J and preventing its occurrence. Pharmacothe- Med 2000; 342; 1581-9. rapy 1995; 15: 713-26. Singer GG. Fluid and electrolyte management. In: Crook MA, Hally V, Pantelli JV. The importance f Ahya SN. et al. (eds.). The Washington Manual the refeeding syndrome. Nutrition 2001; 17: of medical therapeutics. Lippincott Williams & 632-7. Wilkins, 2001; p. 43-75. National Institute for Health and Clinical Excel- lence (NICE). Oral nutrition support, enteral Potassium tube feeding and parenteral nutrition. Clinical Milne FJ, Gear JS, Laidley L, Ritchie M, et. al. Guideline. London: National Health Service; Spot urinary electrolyte concentrations and 24 2006. Report No. 32. hour excretion. Lancet 1980; 2: 1135. Stanga Z, Brunner A, Leuenberger M, et al. Nutri- Blumberg A, Weidmann P, Ferrari P. Effect of pro- tion in clinical practice-the refeeding syndrome: longed intravenous bicarbonate administration illustrative cases and guidelines for prevention on plasma potassium in terminal renal failure. and treatment. Eur J Clin Nutr 2008; 62: 687- Kidney Int 1992; 41: 369-74. 94. Wallach J, (ed.) Interpretation of Diagnostic Tests. Do L, Ballmer PE, Rühlin M. Die Komplexität des Little Brown, 1996. Refeeding-Syndroms. Swiss Med Forum 2017; Gennari FJ. Hypokalemia. N Engl J Med 1998; 17: 523-528. 339: 451-8. Insuffisance rénale chronique 59 Urémie Cameron J, Greger R. Renal function and testing NET (Adaptations des posologies en cas d’IR) of function, in AM Davidson, JS Cameron, JP www.med.uni- Grunfeld, et al., Oxford texbook of clinical ne- heidelberg.de/med/klinpharm/Nierebck.htm phrology. Oxford University Press Oxford 1998, Smith HW. The kidney: structure and function in 39-69. health and disease. Oxford University Press, New Gallieni M. Iron in the treatment of anemia in dia- York 1951, 231-238. lysis patients: an important support to erythro- Berlyne G. Endogenous creatinine clearance and poietin. Int J Artifi Organe 1998; 21: 681-6. glomerular filtration rate. Lancet 1964; II: 874-6. Walser M.- Assessing renal function from creati- Lubowitz H, Slatopolsky E, Shankel S, et al. Glo- nine measurements in adults with chronic renal merular filtration rate. Determination in patients failure. Am J Kidney Dis 1998; 32: 23-31. with chronic renal disease. JAMA 1967; 199: Rahn KH, Heidenreich S, Bruckner D. How to as- 252-6. sess glomerular function and damage in hu- Cockcroft DW, Gault MH. Prediction of creatinine mans. J Hypertens 1999: p. 309-317. clearance from serum creatinine. Nephron Halabi G, Vogel G, Wauters JP. Hypertparathyroï- 1976; 16: 31-41. die secondaire: Prévention et traitement. Med Brenner B, Meyer T, Hostetter T. Dietary protein Hyg 1999; 57: 432-6. intake and the progressive nature of kidney Levey AS, Bosch JP, Lewis JB, et al.- A more ac- disease: the role of hemodynamically mediated curate method to estimate glomerular filtration glomerlar injury in the pathogenenis of progres- rate from serum creatinine: a new prediction sive glomerular sclerosis in aging, renal abla- equation. Modification of Diet in Renal Disease tion, and intrinsic renal disease. N Engl J Med Study Group. Ann Intern Med 1999; 130 , 461- 1982; 307: 652-9. 70. Fine LG. El sindrome uremico: mecanismos de Rahn KH, Heidenreich S, Bruckner D. How to as- adaptacion y tratamiento. Hosp Pract (Ed Espa- sess glomerular function and damage in hu- gno); 1988: 3: 9-19. mans. J Hypertens 1999; 309-17. Caravaca F, Santos I, Cubero JJ. Calcium ace- Working Party for European Management of tate versus calcium carbonate as phosphate Anaemia in patients with chronic renal failure. binders in hemodialysis patients. Nephron European best practice guidelines for the ma- 1992; 60:423-7. nagement of anaemia in patients with chronic Perrone RD, Madias NE, Levey AS.- Serum crea- renal failure. Nephrol Dial Transplant 1999; 14 tinine as an index of renal function: new insights (Suppl. 5): 1-50. into old concepts. Clin Chem 1992; 38: 1933- Ruedin P. Nouvelles recommandations du traite- 53. ment de l’anémie au cours de l’insuffisance ré- Van Acker BA, Koomen GC, Koopman MG, et al. nale chronique. Med Hyg 2001; 59: 495-9. Creatinine clearance during cimetidine admini- Eknoyan G, Levin NW, Eschbach JW, et al. Conti- stration for measurement of glomerular filtration nuous quality improvement: DOQI becomes rate. Lancet 1992; 340: 1326-9. K/DOQI and is updated. National kidney foun- Klahr S, Levey AS, Beck GJ, et al. The effect of dation’s dialysis outcomes quality initiative. Am dietary protein restriction and blood-pressure J Kidney dis 2001; 37: 179-94. control on the progression of chronic renal Eknoyan G, Levin NW. Impact of the new K/DOQI disease. N Engl J Med 1994; 330: 877-84. guidelines. Blood Purif 2002; 20: 103-8. Llach F. Secondary hyperparathyroidism in renal K/DOQI. Clinical practice guidelines for chronic failure the trade-off hypothesis revisited. Am J kidney disease: evaluation, classification, and Kidney Dis 1995; 25: 663-79. stratification. Kidney Disease Outcome Quality Peterson JC, Adler S, Burkart JM, et al.: MDRD Initiative. Am J Kidney Dis, 2002; 39 , 1-246. Group: Blood pressure control, proteinuria, and National Kidney Foundation (NFK) Kidney the progression of renal disease: The modifica- Disease Outcome Quality Initiative (K/DOQI) tion of Diet in Renal Disease Study. Ann Intern Advisory Board. K/DOQI clinical practice guide- Med 1995; 123: 754-62. lines for chronic kidney disease: evaluation, Klahr S. Role of dietary protein and blood pres- classification, and stratification. Am J Kidney sure in the progression of renal disease. Kidney Dis 2002; 39 (Suppl. 2): S1-S246. Int 1996; 49: 1783-6. Vervoort G, Willems HL, Wetzels JF. Assessment Kopple JD, Levey AS, Greene T, et al. Effect of of glomerular filtration rate in healthy subjects dietary protein restriction on nutritional status in and normoalbuminuric diabetic patients: validity the modification of diet in renal disease study. of a new (MDRD) prediction equation. Nephrol Kidney Int 1997; 52: 778-91. Dial Transplant 2002; 17: 1909-13. NKF-DOQI clinical practice guidelines for the Darbepoetin alfa: new preparation. Just a me-too: treatment of anemia of chronic renal failure. Na- no advantage in anaemia of chronic renal fai- tional Kidney Foundation-Dialysis Outcomes lure. Prescrire Int 2003; 12: 14-6. Quality Initiative. Am J Kidney Dis 1997; 30 Meyer TW, Hostetter TH. Uremia. N Engl J Med (Suppl.3): S192-S240. 2007; 357: 1316-1325. The Sixth Report of the Joint National Coimmittee Brück K, Stel VS, Gambaro G et al. CKD Preva- on Detection, Evaluation, and Diagnosis of High lence Varies across the European General Po- Blood Pressure (JNC VI). Arch Intern Med pulation. J Am Soc Nephrol 2016; 27: 2135-47. 1997; 157: 2413-46. 60 Urine: pH, protéine, «spot» diction equation. Ann Intern Med 1999; 130: Harrington JT, Cohen JJ. Measurement of urinary 461-70. electroytes - indications and limitations. N Engl Kaene WF. Proteinuria: its clinical importance J Med 1975; 293: 1241-43. and the role in progressive renal disease. Am J Glassock RJ. Postural (orthostatic) proteinuria: no Kidney Dis 2000; 35 (Suppl. 1): S97-105. cause for concern. N Engl J Med 1981; 305: David S, Wauters JP. Fonction rénale et protéinu- 639-41. rie: nouveaux concepts pour vieux dosages. Lenke RR, Van Dorsten JP. The efficacy of the ni- Med Hyg 2001; 59: 471-81. trate test and microscopic urinanalysis in pre- NFK-K/DOQI Clinical practice guidelines for ane- dicting urine culture test. Am J Obstet Gynec mia of chronic kidney disease Update 2000. Am 1981; 140: 427-9. Kidney Dis 2001;37 (Suppl 1) :S182-238. Abuelo JG. Proteinuria: diagnostic principles and Syndrome néphrotique procedures. Ann Intern Med 1983; 98: 186-91. Syndrome néphritique Ginsberg J, et al. Use of single voided urine sam- Cameron JS, Glassock RJ (eds.). In: The nephro- ples to estimate quantitative proteinuria. N Engl tic syndrome. New York, Dekker, 1988. J Med 1983; 309: 1543-6. Brenner BM (ed.). The Kidney. W.B. Saunders Shaw AB, Risdon P, Lewis-Jackson JD. Protein Company, 1996. creatinine index and albustix in assessment of Couser WG. Glomerulonephritis. Lancet 1999; proteinuria. Brit Med J 1983; 287: 929-32. 353: 1509-15. Dufel SE. Urinary electrolytes. Emerg Med Clin Nolin L. Courteau M. Management of IgA nephro- North Am 1986; 4: 185-92. pathy: evidence-based recommendations. Kid- Elseviers MM, Verpooten GA, DeBroe ME. Inter- ney Int Suppl 1999; 70: S56-62. pretation of creatinine clearance. Lancet 1987; Savage CO. ANCA-associated renal vasculitis. 1: 457. Kidney Int 2001; 60: 1614-27. Nathan DM, Rosenbaum C, Protasowicki D. Sin- Hématurie microscopique gle-void urine samples can be used to estimate Froom P, Ribak J, Benbassat J. Significance of quantitative microalbuminuira. Diabetes Care microhaematuria in young adults. Br Med J 1987; 10: 414-18. 1984; 288: 20-2. De Torrenté A. Analyse d’urine au cabinet médi- Mohr DN, Offord KP, Owen RA, et al. Asympto- cal: méthodes et interprétation. Ther Umsch matic microhematuria and urologic disease. A 1988; 45: 528-34. population-based study. JAMA 1986; 256: 224- De Torrenté A. Protéinurie isolée. Schweiz Med 9. Wschr 1989; 119: 851-3. Copley JB, Hasbargen JA. Idiopathic hematuria. Kamel SK, Ethier JH, Richardson RMA, et al. Arch Intern Med 1987 147: 434-7. Urine electrolytes and osmolality: when and Corwin HL, Silverstein MD. The diagnosis of neo- how to use them. Am J Nephrol 1990; 10: 89- plasia in patients with asymptomatic microsco- 102. pic hematuria: a decision analysis. J Urol 1988; Watts GF, Kubal C, Chinn S. Long-term variation 139: 1002-6. of urinary albumin excretion in insulin-depen- Andres A, Praga M, Bello I, et al. Hematuria due dent diabetes mellitus: some practical recomm- to hypercalcemia and hyperuricosuria in adult mendations for monitoring micro-albuminuria. patients. Int Kidney 1989; 36: 96-9. Diabetes Res Clin Pract 1990; 9: 169-77. Woolhandler S, Pels RJ, Bor DH, et al. Dipstick Pappas PG. Laboratory in the diagnosis and ma- urinanalysis screening of asymptomatic adults nagement of urinary tract infections. Med Clin for urinary tract disorders. I. Hematuria and pro- North Am 1991; 75: 313-25. teinuira. JAMA 1989; 262: 1214-9. Haldimann B. Electrolytes urinaires: indications et Murakami S, Igarashi T, Hara S, et al. Strategies interprétation. Rev Med Suisse Rom 1993; 113: for asymptomatic microscopic hematuria: a pro- 1035-38. spective study of 1,034 patients. J Urol 1990; Peterson JC, Adler S, Burkart JM, et al.: MDRD 144: 99-101. Group: Blood pressure control, proteinuria, and Culclasure TF, Bray VJ, Hasbargen JA. The signi- the progression of renal disease: The modifica- ficance of hematuria in the anticoagulant pa- tion of Diet in Renal Disease Study. Ann Intern tient. Arch Intern Med 1994; 154: 649-52. Med 1995; 123: 754-762. Schröder FH. Microscopic haematuria. BMJ Parving HH, Osterby R, Anderson PW, et al. Dia- 1994; 309: 70-2. betic nephropathy. In: Brenner BM (ed.). The Fogazzi GB, Ponticelli C. Microscopic hematuria Kidney. W.B. Saunders Company, 1996, p: diagnosis and management. Nephron 1996; 72: 1864 ff. 125-34. Kaene WF, Eknoyan G. Proteinuria, albuminuria, Cohen RA, Brown RS. Microscopic hematuria. N risk. assessment, detection, elimination (PA- Engl J Med 2003; 248: 2330-8. RADE); a postion paper of the National Kidney Yanagihara T, Hamada R, Ishikura K et al. Uri- Foundation. Am J Kidney Dis 1999; 33: 1001- nary screening and urinary abnormalities in 3- 10. year-old children in Japan. Pediatr Int 2015; 57: Levey AS, Bosch JP, Breyer Lewis J, et al. A 354-8. more accurate method to estimate glomerular filtration rate from serum creatinin: a new pre- Gaz artériel 61 Goldberg M, Green SB, Moss ML, et al. Compu- stration of losartan and enalapril exerts additive ter-based instruction and diagnosis of acid-base antiproteinuire effect in IgA nephropathy. Am J disorders. JAMA 1973; 223: 269. Kidney Dis 2001; 38: 18-25. Guinand O. Interprétation de la gazométrie. Med Appel AB, Glassock RJ et al. Syllbus. Glomerular, Hyg 1984; 42: 334-8. vascular, tubulointerstitial, and genetic disea- Fauci A, Braunwald E, (eds.) et al. In: Harrison: ses. Nephrology Self-Assessment program Principles of Internal Medicine, 1998 Mc Graw 2002; 1: 12-19. Hill. Donadio JV, Grande JP. IgA nephropathy. N Engl Hall JB, Schmidt GA, Wood LDH. (eds). Princi- J Med 2002; 347: 738-49. ples of critical care. McGraw-Hill, 1998. ENDOCRINOLOGIE Équilibre acido-basique Textbook: Rose BD, Post TW, (ed). Clinical phy- Diabète mellitus / Hyperglycémie / Insuline siology of acid-base and electrolyte disorders. The Diabetes Control and Complications Trial Re- 5th edition, McGraw-Hill, New York, 2001. search Group. The effect of intensive treatment Baldwin Ef, Cournand A, Richards DW. Pulmo- of diabetes on the development and progres- nary insufficiency III. A study of 122 cases of sion of long-term complications in insulin-de- chronic pulmonary emphysema. Medicine 1948; pendent diabetes mellitus. N Engl J Med 1993; 28; 201-37. 329: 977-86. Oh MS, Caroll HJ. The anion gap. N Engl J Med Philippe J, Marini M, Pometta D. Le diabète. 1977; 297: 814-7. Guide du praticien. Editions Médecine et Hy- Van Dixhorn J, Duivenvoorden HJ. Efficacy of giène, 1994. Nijmegen questionnaire in recognition of hyper- Peters AL, Davidson MB, Schriger DL, et al. A cli- ventilation syndrome. J Psychosomatic Re- nical approach for the diagnosis of diabetes search 1985; 29: 199-206. mellitus. An analysis using glycosylated hemo- Batlle DC, Hizon M, Cohen E, et al. The use of globin levels. JAMA, 1996; 276: 1246-52. the urinary anion gap in the diagnosis of hyper- Expert Committee on the Diagnosis and Classifi- chloremic metabolic acidosis. N Engl J Med cation of Diabetes Mellitus. Report of the Expert 1988; 318: 594-9. Committee on the Diagnosis and Classification Winter SD, Pearson JR, Gabow PA, et al. The fall of Diabetes Mellitus. Diabetes Care 1997; 20: of the serum anion gap. Arch Intern Med 1990; 1183-97. 150: 311-3. A desktop guide to type 2 diabets mellitus. Euro- Paillard M, Borensztein P, Houillier P, et. al. Les pean Diabetes Policy Group 1999. Diabet Med désordres de la balance acido-baisque. Med 1999; 116: 716-30. Hyg 1991; 49: 794-807. Americcan Diabetes Association. Aspirin therapy Shapiro JI, Kaehny WD. Pathogenesis and ma- in diabetes. Diabetes Care 19999; 22, Suppl 1: nagement of metabolic acidosis and alcalosis. S60-61. In: Schrier RW (ed). Renal and Electrolyte Dis- Bolli GB, Di Marchi RD, Park GD et al. Insulin orders. Little Brown 1992. p: 161-210. analogues and their potential in the manage- Hanson CW 3rd, Marshall BE, Frasch HF, et al. ment of diabetes mellitus. Diabetologia 1999; Causes of hypercarbia with oxygen therapy in 42: 1151-67. patients with chronic obstructive pulmonaray De Fronzo RA. Pharmacologic therapy for type 2 disease. Crit Care Med 1996; 24: 23-8. diabetes mellitus. Ann Intern Med 1999; 131: Adrogué HJ, Madias NE. Management of life- 281-303. threatening acid-base disorders. N Engl J Med Makoto T, et al. Impaired glucose tolerance is a 1998; 338: 26-34. risk factor for cardiovascular disease, but not Néphropathie IgA impaired fasting glucose: the funagata diabetes Cattran DC, Greenwood C, Ritchie S. Long-term study. Diabetes Care 1999; 22: 920-4. benefit of angiotensin-converting enzyme inhibi- UKPDS Group. Effect of intensive blood-glucose tor therapy in patients with severe immunoglo- control with Metformin on complcations on over- bulin A nephropathy: a comparison to patients weight patients with type 2 diabetes. Lancet receiving treatment with other antihypertensive 1999; 352: 1557. agents and to patients receiving no therapy. Am Horton ES, Clinkinbeard C, Gatlin M, et al. Nate- J Kidney Dis 1994; 23: 247-54. glinid alone and in combination with Metformin Nolin L, Courteau M. Management of IgA-nephro- improves glycemic control by reducing meal- pathy: evidence-based recommandations. Kid- time glukose levels in type 2 diabetes. Diabetes ney International 1999; 55 (Suppl 70): S56-S62. Care 2000; 23: 1660-5. Pozzi C, Bolasco PG, Folazzi GB, et al. Cortico- Recommandation de l’association suisse du dia- steroids in IgA nephropathy: a randomised con- bète. Groupe de travail SSE/ASD, 2000. trolled trial. Lancet 1999; 353: 883-7. Ruiz J, Keller U, Buillard C et al. Prévention et D’Amico G. Natural history of idiopathic IgA ne- dépistage de la maladie coronarienne chez le phropathy: role of clinical and histological pro- patient diabétique. Bulletin des Médecins Suis- gnositic factors. Am J Kidney Dis 2000; 36: ses 2000; 81: 2596-2600. 227-37. Troisi RJ, Cowie CC, Harris MI. Diurnal variation Russo D, Minutolo R, Pisani A, et al. Coadmini- in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the 62 afternoon. JAMA 2000; 284: 3157-9. of Incretin Therapy in Type 2 Diabetes Syste- Bonvin JL. Insulinothérapie dans le diabète de matic Review and Meta-analysis. JAMA 2007; type 2. Med Hyg 2001; 59: 1321-5. 298: 194-206. Van den Berghe G, Wouters P, Weekers F, et al. Larsen CM, Faulenbach M, Vaag A, et al. Inter- Intensive insulin therapy in critically ill patients. leukin-1–Receptor Antagonist in Type 2 Diabe- N Engl J Med 2001; 345: 1359-67. tes Mellitus. N Engl J Med 2007; 356: 1517-26. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril Holman RR, Thorne KI Farmer AJ et al. Addition and the development of diabetes. JAMA 2001; of Biphasic, Prandial, or Basal Insulin to Oral 286: 1882-5. Therapy in Type 2 Diabetes. N Engl J Med American Diabetes Association: Standards of me- 2007; 357: 1716-30. dical care for patients with diabetes mellitus Diagnosis and Classiﬁcation of Diabetes Mellitus. (Position Statement). Diabetes Care 2001; 24 Diabetes Care 2014; 37 (Suppl 1); S81-S90. (Suppl.1): S33-S43. Deletre S, Coutaz M. Diabète: cibles glycémiques American Diabetes Association: clinical practice au grand âge et surtraitement. Rev Med Suisse recommendations 2002. Diabetes Care 2002; 2016; 12: 461-466. 25 (Suppl. 1): S1-S147. Lamine F, Lalubin F, Pitteloud N et al. Chronic American Diabetes Association and National In- kidney disease in type 2 diabetic patients follo- stitute of Diabetes, Digestive and Kidney wed-up by primary care physicians in Switzer- Disease. The prevention or delay of type 2 dia- land: prevalence and prescription of antidiabetic betes (Position statement). Diabetes Care drugs. Swiss Med Wkly 2016;146:w14282. 2002; 25: 724-9. Standards of Medical Care in Diabetes-2016: Buchanan TA, Xiang AH, Peters RK, et al. Pre- Summary of Revisions. Diabetes Care 2016; 39 servation of pancreatic beta-cell function and Suppl 1:S4-5. prevention of type 2 diabetes by pharmacologi- Classification and Diagnosis of Diabetes. Diabe- cal treatment of insulin resistance in high-risk tes Care 2017; 40(Suppl 1): S11-S24. hispanic women. Diabetes 2002; 51: 2796-803. Matthew C. Riddle, MD et al. American Diabetes Chiasson JL. Josse RG, Gomis R et al. STOP- Association Standards of Medical Care in Dia- NIDDM Trial Research Group. Acarbose for betes - 2018. Diabetes Care 2018; 41, Suppl 1: prevention of type 2 diabetes mellitus. The S1-S159. STOP-NIDDM randomised trial. Lancet 2002; Qaseem A, Wilt TJ, Kansagara D et al. Hemoglo- 359: 2072-7. bin A1c Targets for Glycemic Control With Phar- Diabetes Preventive Program Research Group. macologic Therapy for Nonpregnant Adults With Reduction in the incidence of type 2 diabetes Type 2 Diabetes Mellitus: A Guidance State- with lifestyle intervention or metformin. N Engl J ment Update From the American College of Med 2002; 346: 393-403. Physicians. Ann Intern Med 2018; 168:569-76. Nathan DM. Initial management of glycemia in Cosentino F, Grant PJ, Aboyans V et al. The Task type 2 diabetes mellitus. N Engl J Med 2002; Force for diabetes, pre-diabetes, and cardio- 347: 1342-9. vascular diseases of the European Society of American Diabetes Association: Aspirin therapy in Cardiology (ESC) and the European Associa- diabetes (Position Statement). Diabetes Care tion for the Study of Diabetes (EASD). 2019 2003; 26 (Suppl. 1): S87-S88. ESC Guidelines on diabetes, pre-diabetes, and American Diabetes Association: Diabetic nephro- cardiovascular diseases developed in collabo- pathy (Position Statement). Diabetes Care ration with the EASD. European Heart Journal 2003; 26 (Suppl. 1): S94-S98. 2020; 41: 255-323. American Diabetes Association: Management of Diabète gestationnel dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 2003; 26 (Suppl. 1): Horsch A, Gross J, Jornayvaz FR et al. Diabète S83-86. gestationnel – quelles sont les approches non American Diabetes Association: Standards of me- médicales ? Rev Med Suisse 2016; 1089-1091. dical care for patients with diabetes mellitus Standards of Medical Care in Diabetes-2016: (Position Statement). Diabetes Care 2003; 26 Summary of Revisions. Diabetes Care 2016; 39 (Suppl. 1): S33-S50. Suppl 1:S4-5. American Diabetes Association. Report of the ex- Acidocetose diabétique, hyperosmol. pert committee on the diagnosis and classifica- Delaney MF, Zisman A, Kettyle WM. Diabetic ke- tion of diabetes mellitus. Diabetes Care 2003; toacidosis and hyperglycemic hyperosmolar 26 (Suppl. 1): S5-S20. nonketotic syndrome. Endocrinol Metab Clin American Diabetes Association: Treatment of hy- North Am 2000; 29: 683-705. pertension in adults with diabetes (Position American Diabetes Association. Hyperglycemic Statement). Diabetes Care 2003; 26 (Suppl. 1): crises in patients with diabetes mellitus. Diabe- S80-S82. tes Care 2001; 19: 82-90. Barnett AH. A review of basal insulins. Diabet Kitabchi AE, Umpierrez GE, Murphy MB, et al. Med 2003; 20: 873-85. Management of hyperglycemic crisies in pa- Schwab S, Stuer S, Müller B et al. Orale Antidia- tients with diabetes. Diabetes Care 2001; 24: betika heute - Substanzen, Indikationen, Per- 131-53. spektiven. Schweiz Med Forum 2005; 5: 993-9. Magee MF, Bhatt BA. Management of decompen- Amori RE, Lau J, Pittas AG. Efficacy and Safety 63 sated diabetes. Diabetic ketoacidosis and hy- mendations from the international evidence- perglycemic hyperosmolar syndrome. Crit Care based guideline for the assessment and ma- Med 2001; 17: 75-106. nagement of polycystic ovary syndrome. Hum American Diabetes Association. Hyperglycemic Reprod 2018;33:1602-18. crisis in patients with diabetes mellitus. Diabe- Diabète insipide — Diabetes insipidus tes Care 2003; 26 (Suppl. 1): S109-S117. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Miller M, Dalakos T, Moses AM et al. Recognition Hyperglycemic crises in adult patients with dia- of partial defects in antidiuretic hormone secre- betes: a consensus statement from the Ameri- tion. Ann Intern Med 1970; 73: 721-9. can Diabetes Association. Diabetes Care 2006; Vokes TJ, Robertson GL. Disorders of antidiuretic 12: 2739-48. hormone. Endocrinol Metabol North Am 1988; Kitabschi AE, Umpierrez GE, Miles JM et al. Hy- 17: 281-99. perglycemic Crises in Adult Patients with Diabe- Fujii T, Kojima S, Imanishi M, et al. Differents me- tes. Diabetes Care 2009; 32: 1335-43. chanisms of polyuria and natriuresis associated Diagnosis and Classiﬁcation of Diabetes Mellitus. with paroxysmal supraventriculair tachycardia. Diabetes Care 2014; 37 (Suppl 1); S81-S90. Am J Cardiol 1991; 68: 343-8. Standards of Medical Care in Diabetes - 2014. Blevins LS, Wand GS. Diabetes insipidus. Crit Diabetes Care 2014; 37 (Suppl 1): S14-S80. Care Med 1992; 20: 69-79. Buonocore CM, Robinson AG. The diagnosis and Syndrome des ovaires polykystiques (POCS) management of diabetes insipidus during medi- Rotterdam ESHRE/ASRM-Sponsored PCOS con- cal emergencies. Endocrinol Metab Clin North sensus workshop group. Revised 2003 consen- Am 1993; 22: 411-23. sus on diagnostic criteria and long-term health Kumar S, Berl T. Sodium. Lancet 1998; 352: 220- risks related to polycystic ovary syndrome 8. (PCOS). Hum Reprod 2004; 19: 41-7. Maghanie M, Cosi G, Genovese E, et al. Central Steering Committee of the National Institutes of diabetes insipidus in children and young adults. Health Evidence-Based Methodology Workshop N Engl J Med 2000; 343: 998-1007. on Polycystic Ovary Syndrome. Evidence- Rose BD, Post TW. Clinical physiology of acid- based Methodology Workshop on Polycystic base and electrolyte disorders, 5th edition Ovary Syndrome. Final Report. https://preven- 2001; McGraw-Hill, New York: p. 754-8. tion.nih.gov/docs/programs/pcos/FinalReport.pd Hypoglycémie f (National Institute of Health, Bethesda, MD, USA, 2012). Marks V, Teale JD. Investigation of hypoglycemia. Von Wolff M. Das PCO-Syndrom: Management in Clin Endocrinol 1996; 44: 133-6. der Praxis Differenzialdiagnostik und Therapie. Service JF. Hypoglycemic Disorders. N Engl J Gynäkologie 2012;1:9-15. Med 1995; 332: 1144-52. Dewailly D. Diagnostic criteria for PCOS: Is there Dizon AM, Kowalsky S, Hoogwerf BJ. Neurogly- a need for a rethink? Best Pract Res Clin Ob- copenic and other symptoms in patients with in- stet Gynaecol 2016; 37: 5-11. sulinoma. Am J Med 1999; 106: 307-10. Draft Summary and Recommendations of Inter- Service FJ. Classification of hypoglycemic disor- national Evidenced-Based Guideline for the As- ders. Endocrinol Metab Clin North Am 1999; 28: sessment and Management of Polycystic Ovary 501-17. Syndrome. 2018. http://pcos-cre.edu.au/wp- Sinnvolle Anwendung endokrinologischer Tests. content/uploads/2018/02/PCOS-guideline-sum- Christ-Crain M, Schild U, Müller B. Schweiz mary-and-recommendations_PC-DRAFT_FINA Med Forum 2004; 4: 1113-9. L-V2-050218-1.pdf (accessed on 28 October Hirsch IB. Insulin Analogues. N Engl J Med 2005; 2018). 352: 174-83. Aswini R, Jayapalan S. Modified Ferriman–Gall- Axe hypothalamo-hypophysaire wey Score in Hirsutism and its Association with Livanou T, Ferriman D, James VH. Recovery of Metabolic Syndrome. Int J Trichology 2017;9:7- hypothalamo-pituitary-adrenal function after 13. corticoid therapy. Lancet 1967;2: 856-9. Lie Fong S, Laven JSE, Duhamel A et al. Polycy- Esteban NV, Loughlin T, Yergey AL, et al. Daily stic ovarian morphology and the diagnosis of cortisol production rate on man determined by polycystic ovary syndrome: redefining threshold stable isotope dilution/mass spectrometry. J levels for follicle count and serum anti-Müllerian Clin Endocrinol Metabol 1991; 72: 39-45. hormone using cluster analysis. Hum Reprod Service FJ, O’Brian PC, Kao PC, et al. C-peptid 2017; 32: 1723-31. suppression test: effects of gender, age, and Casadei L, Fanisio F, Sorge RP et al. The diagno- body mass index; implications for the diagnosis sis of PCOS in young infertile women according of insulinoma. J Clin Endocrinol Metab 1992; to different diagnostic criteria: the role of serum 74: 204-10. anti Müllerian hormone. Arch Gynecol Obstet Grinspoon SK, Biller BM. Clinical review 62 : La- 2018; 298: 207-15. boratory assessment of adrenal inssufficiency. J Escobar-Morreale HF. Polycystic ovary syn- Clin Endocrinol Metabol 1994; 79: 923.31. drome: definition, aetiology, diagnosis and treat- Trainer PJ, Besser M. The Bart’s endocrine proto- ment. Nat Rev Endocrinol 2018; 14: 270-84. cols. Churchill Livingstone, 1995. Teede HJ, Misso ML, Costello MF et al. Recom- Glowniak JV, Loriaux DL. A double-blind study of 64 perioperative steroid requirements in secondary Nucl Med 2002; 32: 148-55. adrenal insufficiency. Surgery 1997; 121: 123-9. Metz DC. Endocrine Tumors of the Gastrointesti- Bangar V, Clayton RN. How reliable is the short nal Tract and Pancreas. Edinburgh: Saunders, synacthen test for the investigation of th hypo- 2003: p. 678-719. thalamic-pituitary-adrenal axis? Eur J Endocri- Moeller JE. Factors associated with progression nol 1998; 139: 580-.3 of carcinoid heart disease. N Engl J Med 2003; Vollenweider P, Waeber G. Stratégie thérapeuti- 348:1005-15. que lors d’un sevrage aux glucocorticoïdes. Öberg K, Astrup L, Eriksson B, et al. on behalf of Med Hyg 2001; 59: 366-73. the Nordic NE Tumour Group Guidelines for the Cooper M, Stewart P. Corticosteroid insufficiency management of gastroenteropancreatic neuro- in acutely ill patients. N Engl J Med 2003; 348: endocrine tumours (including bronchopulmo- 727-734. nary and thymic neoplasms). Part ii—specific ne tumour types. Acta Oncol 2004; 43: 626-36. Insuffisance surrénalienne O’Toole D, Grossman A, Gross D et al. ENETS Werbel SS, Ober KP. Acute adrenal insufficiency. Consensus Guidelines for the Standards of Endocrinol Metab Clin North Am 1993; 22: 303- Care in Neuroendocrine Tumors: Biochemical 28. Markers. Neuroendocrinology 2009;90:194-202. Howlett TA. An assessment of optimal hydrocorti- Klimstra D, Modlin I, Coppola D.: The pathologic sone replacement therapy. Clin Endocrinol classification of neuroendocrine tumors. Pan- 1997; 46: 263-8. creas 2010; 39: 707-12. Dickstein G. The assessment of the hypotha- Kocha W, Maroun J, Wong R. Consensus recom- lomo-pituitary-adrenal axis in pituitary disease: mendations for the diagnosis and management are ther short cuts? J Endocrinol Invest 2003; of well-differentiated gastroenterohepatic neuro- 26: 25-30. endocrine tumours: a revised statement from a Syndrome polyglandiulaire Canadian National Expert Group. Curr Oncol autoimmun 2010; 17: 49-64. Leshin M. Polyglandular autoimmune syndromes. Ramage JK, Ahmed A, Ardill J et al. Guidelines Am J Med Sci 1985; 290: 77. for the management of gastroenteropancreatic Neufeld M, Maclaren NK, Blizzard RM. Two types neuroendocrine (including carcinoid) tumours of autoimmune Addison's disease associated (NETs). Gut 2012; 61: 6-32. with different polyglandular autoimmune (PGA) Hypercorticisme (CUSHING) syndromes. Medicine (Baltimore) 1981; 60: 355. Liddle GW. Test of pituitary-adrenal suppressibi- lity in the diagnosis of Cushing’s syndrome. J Tumeurs neuroendocriniennes - NET Clin Endocrinol Metab 1960; 20: 1539-90. Lamberts SW. Octreotide. N Engl J Med 1996; Crapo L. Cushing’s syndrome: a review of dia- 334: 246-54. gnostic tests. Metabolism 1979; 28: 955-77. Bissonnette RT. Fatal carcinoid crisis after per- Tyrell JB, Findling JW, Aron DC, et al. An over- coutaneous fine-needle biopsy of hepatic meta- night high-dose Dexamethasone suppression stasis: case report and literature review. test for rapid differential diagnosis of Cushing’s Radiology 1990; 174: 752-2. syndrome. Ann Int Med 1986; 104: 180-6. Schupak KD. The role of radiation therapy in the Kaye TB, Crapo LC. The Cushing syndrome: an treatment of locally unresectable or metastatic update on diagnostic tests. Ann Intern Med carcinoid tumors. Int J Radiat Oncol Biol Phys 1990; 112: 434-44. 1991; 20: 489-95. Esteban NV, Loughlin T, et al. Daily cortisol pro- Gibril F. Comparative analysis of diagnostic tech- duction rate in man determined by stable dilu- niques for localization of gastrointestinal neuro- tion/mass spectrometry. J Clin Endocrinol endocrine tumors. Yale J Biol Med 1997; 70: Metab 1991; 71: 39-45. 509-22. Oelkers W. Adrenal insufficiency. N Engl J Med Modlin IM. An analysis of 8305 cases of carcinoid 1996; 335: 1206-12. tumors. Cancer 1997; 79: 813-29. Meier CA, Biller BMK. Clinical and biochemical Caplin ME, Buscombe JR, Hilson AJ, et al. Carci- evaluation of Cushing’s syndrome. Endocrinol noid tumor. Lancet 1998; 352: 799-805. Metab Clin North Am 1997; 26: 741-61. Nuttall KL, Pingree SS. The incidence of elevati- Newell-Price J, Trainer P, Besser M, et al. The ons in urine 5-hydroxyindoleacetic acid. Ann diagnosis and differential diagnosis of Cus- Clin Sci 1998; 28: 167-74. hing’s syndrome and pseudo-Cushing’s state. Pirker RA. Usefullness of chromogranin A as mar- Endocr Rev 1998; 19: 647-72. ker for detection of relapses of carcinoid tu- Simon S, Meier CA. Diagnostic du syndrome de mors. Clin Chem Lab Med 1998; 36: 837-40. Cushing. Med Hyg 2001; 59: 358-62. Wullbrand U. Growth factor receptor expression Arnaldi G, Angeli A., Atkinson AB et al. Diagnosis in human gastroenteropatic neuroendocrine tu- and Complications of Cushing’s Syndrome: A mours. Eur J Clin Invest 1998; 28: 1038-49. Consensus Statement. J Clin Endocrinol Meta- Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J bol 2003; 88: 5593-602. Med 1999; 340: 858-68. Newell-Price J, Bertagna X, Grossman AB, et al. Virgolini I. In- and Y-Dota-Ianreotide: results and Cushing's syndrome. Lancet 2006; 367: 1605- implications of the MAURITIUS trial. Semin 17. 65 Hyperaldostéronisme aldosteronism. Curr Hypertens Rep Kaplan NM. (ed). In: Kaplan NM (ed). Clinical Hy- 2010;12:342-8. pertension. Primary aldosteronism. Baltimore: Du Cailar G, Fesler P, Ribstein J, Mimran A. Die- Williams&Wilkins, 1994; 389-408. tary sodium, aldosterone, and left ventricular Young WF, Stanson AW, Thompson GB, et al. mass changes during long-term inhibition of the Role for adrenal venous sampling in primary al- renin-angiotensin system. Hypertension dosteronism. Surgery 2004;136:1227-35. 2010;56:865-70. Milliez P, Girerd X, Plouin PF et al. Evidence for Briet M, Schiffrin EL. The role of aldosterone in an increased rate of cardiovascular events in the metabolic syndrome. Curr Hypertens Rep patients with primary aldosteronism. J Am Coll 2011;13: 163-72. Cardiol 2005; 45: 1243. Phéochromocytome Mulatero P, Milan A, Fallo F, et al. Comparison of Plouin PF, et al. Le dépistage du phéochromocy- confirmatory tests for the diagnosis of primary tome: chez quels hypertendus ? Etude sémiolo- aldosteronism. J Clin Endocrinol Metab gique chez 2585 hypertendus dont 11 ayant un 2006;91:2618-23. phéochromocytome. Nouvelle Presse Méd Rossi GP, Bernini G, Caliumi C, et al. A prospec- 1981; 10: 869-72. tive study of the prevalence of primary aldoste- Feldman JM. Falsely elevated urinary excretion of ronism in 1,125 hypertensive patients. J Am catecholamines and metanephrines in patients Coll Cardiol 2006; 48:2293-300. receiving labetalol therapy. J Clin Pharmacol Fallo F, Della Mea P, Sonino N, et al. Adiponectin 1987; 27: 288-92. and insulin sensitivity in primary aldosteronism. Shapiro B, Eig LM. Management of pheochromo- Am J Hypertens 2007;20:855-61. cytoma. Endocrinol Metab Clin North Am 1989; Bernini G, Galetta F, Franzoni F, et al. Arterial 18: 443-81 stiffness, intima-media thickness and carotid ar- Bravo EL. Evolving concepts in the pathophysio- tery fibrosis in patients with primary aldostero- logy, diagnosis, and treatment of pheochromo- nism. J Hypertens 2008;26:2399-405. cytoma. Endocrine Rev 1994; 15: 356-68. Catena C, Colussi G, Nadalini E, et al. Cardiovas- Kaplan NM. (ed). In: Clinical Hypertension. Pheo- cular outcomes in patients with primary aldoste- chromocytoma. Baltimore: Williams & Wilkins, ronism after treatment. Arch Intern Med 1994; 367-87. 2008;168:80-5. Gomez F. La recherche d’un phéochromocytome Funder JW, Carey RM, Fardella C, et al. Case chez le patient hypertendu: indication et mé- detection, diagnosis, and treatment of patients thode. Med Hyg 1999; 57: 294-7. with primary aldosteronism : An endocrine society clinical practice guideline. J Clin Endocri- Tumeur neuroendocrinienne: NEN/NET/NEC nol Metab 2008;93: 3266-81. Sorbye H, et al. Predictive and prognostic factors Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular for treatment and survival in 305 patients with remodeling and duration of hypertension predict advanced gastrointestinal neuro endocrine car- outcome of adrenalectomy in primary aldostero- cinoma (WHO G3): the NORDIC NEC study. nism patients. Hypertension 2008;51:1366-71. Ann Oncol 2013; 24: 152-60. Tsioufis C, Tsiachris D, Dimitriadis K, et al. Myo- Basturk O, et al. The high-grade (WHO G3) pan- cardial and aortic stiffening in the early course creatic neuroendocrine tumor category is mor- of primary aldosteronism. Clin Cardiol phologically and biologically heterogenous and 2008;31:431-6. includes both well differentiated and poorly dif- Kempers MJ, Lenders JW, van Outheusden L, et ferentiated neoplasms. Am J Surg Pathol 2015; al. Systematic review : Diagnostic procedures 39: 683-90. to differentiate unilateral from bilateral adrenal Ramage, JK, De Herder WW, Delle Fave G et al. abnormality in primary aldosteronism. Ann In- ENETS Consensus Guidelines Update for Colo- tern Med 2009;151:329-37. rectal Neuroendocrine Neoplasms. Neuroendo- Sowers JR, Whaley-Connell A, Epstein M. Narra- crinology 2016; 103: 139-43. tive review : The emerging clinical implications Dasari A, et al. Trends in the Incidence, Preva- of the role of aldosterone in the metabolic syn- lence, and Survival Outcomes in Patients With drome and resistant hypertension. Ann Intern Neuroendocrine Tumors in the United States. Med 2009;150:776-83. JAMA Oncol 2017; 3: 1335-1342. Staermose S, Marwick TH, Gordon RD, et al. Ele- Kim, J Y, Hong SM, Ro JY, Recent updates on vated serum interleukin 6 levels in normoten- grading and classification of neuroendocrine tu- sive individuals with familial hyperaldosteronism mors. Ann Diagn Pathol 2017; 29: 11-16. type 1. Hypertension 2009;53:e31-2. Lloyd RV, Osamura RY, Klöppel G, Rosai J (Eds). Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial WHO Classification of Tumours of Endocrine dysfunction is related to aldosterone excess Organs, 4th ed, IARC Press, Lyon 2017. p.211. and raised blood pressure. Endocr J Alexander Siebenhüner A, Morell B, Burger IA et 2009;56:553-9. al. Neuroendokrine Tumoren. Schweiz Med Mulatero P, Monticone S, Bertello C, et al. Eva- Forum 2019; 19: 378-84. luation of primary aldosteronism. Curr Opin En- Klimstra DS, Kloppell G, La Rosa S, Rindi G. docrinol Diabetes Obes 2010;17:188-93. Classification of neuroendocrine neoplasms of Rossi GP. Prevalence and diagnosis of primary the digestive system. In: WHO Classification of 66 Tumours: Digestive System Tumours, 5th ed, Int 1997; 7: 390-406. WHO Classification of Tumours Editorial Board Hosking D, Chilvers CE, Christiansen C, et al. (Ed), International Agency for Research on Prevention of bone loss with alendronate in Cancer, Lyon 2019. p.16. postmenopausal women under 60 years of age. Early postmenoausal intervention cohort study Osteoporose - Ostéoporose group. N Engl J Med 1998; 338: 485-92. Gallagher JC. Pathophysiology of osteoporosis. Seibel MJ. Biochemische Marker des Knochen- Semin Nephrol 1992; 12: 109-15. stoffwechsels, klinische Wertigkeit in der Praxis. Lufkin EG, Wahner HW, O’Fallon WM, et al. Ther Umsch 1998; 55: 676-84. Treatment of postmenopausal osteoporosis with Kraenzlin ME, Rizzoli R. Abklärung der Osteopo- transdermal estrogen. Ann Intern Med 1992; rose. Schweiz Ärztezeitung 1999; 80: 536-543. 117: 1-9. Lippuner K, Casez J.-P, Jaeger Ph. L’approche Felson DT, Zhang Y, Hannan MT, et al. The effect en trois étapes du diagnostic de l’ostéoporose. of postmenopausal estrogen therapy on bone Modèle d’un screening à large échelle de density in elderly women. N Engl J Med 1993; l’ostéoporose postménopausique. Med Hyg 329: 1141-6. 1999; 57: 520-4. Meunier PJ. Is steroid-induced osteoporosis pre- Schnitzer T, Bone HG, Crepaldi G, et al. Thera- ventable ? N Engl J Med 1993; 328: 1781-2 et peutic equivalence alendronate 70 mg once- 1745-52 (Comment). weekly and alendronate 10 mg daily in the Peck WA, et al. Consensus development confe- treatment of osteoporosis Alendronate Once- rence: Diagnosis, prophylaxis, and treatment of Weekly Study Group. Aging (Milano) 2000; 12: osteoporosis. Am J Med 1993; 94: 646-50. 1-12. Assessment of fracture risk and its application to Tonino RP, Meunier PJ, Emkey R, et al. Skeletal screening for postmenopausal osteoporosis: benefits of alendronate: 7-year treatment of Synopsis of a WHO report. Osteoporosis Int postmenopausal osteoporotic women. Phase III 1994; 4: 368-81. Osteoporosis Treatment Study Group. J Clin Gambert SR, Schultz BM, Hamdy RC. Osteopo- Endocrinol Metabl 2000; 85: 3109-15. rosis. Clinical features, prevention and treat- Wirthner D, De Grandi P. Place des SERM (se- ment. Endocrinol Metab Clin North Am 1995; lective estrogen receptor modulators) dans la 24: 317-71. substitution hormonale postménopausique. Chesnut CH, et al. Alendronate treatment of the Med Hyg 2000; 58: 1677-81. postmenopausal osteoporotic woman: effect of Black DM, Steinbuch M, Palermo L et al. An As- multiple dosages on bone mass and bone re- sessment tool for predicting fracture risk in modeling. Am J Med 1995; 99: 144-52. postmenopausal women. Osteoporos Int 2001; Liberman UA, Weiss ST, Broll J, et al. Effect of 12: 519-28. oral alendronate on bone mineral density and Lindsay R, Silverman SL, Cooper C et al. Risk of the incidence of fractures on postmenopausal new vertebral fracture in the year following a osteoporosis. The Alendronate Phase III Osteo- fracture. JAMA 2001; 285: 320-3. porosis treatment Study Group. N Engl J Med NIH Consensus Developpment Panel on Osteo- 1995; 333: 1437-43. porosis Prevention, Diagnosis, and Therapy. Reginster JY, Deroisy R, Lecart MP, et al. A dou- Osteoporosis prevention, diagnosis, and the- ble-blind, placebo-controlled, dose-finding trial rapy. JAMA 2001; 285: 785-95. of intermittent nasal salmon calcitonin for pre- Meunier PJ, Roux C, Seeman E, et al. The ef- vention of postmenopausal lumbar spine bone fects of strontium ranelate on the risk of verte- loss. Am J Med 1995; 98: 452-8. bral fracture in women with postmenopausal Osteoporose: Richtlinien der Diagnostik-Präven- osteoporosis. N Engl J Med 2004; 350: 459-8. tion-Behandlung. Schweizerische Vereinigung Lawrence G. Raisz. Screening for Osteoporosis. gegen die Osteoporose SVGO; 1996. N Engl J Med 2005; 353:164-171. Ziegler R. Osteoporosis - diagnosis and therapy. Whyte MP. Paget's Disease of Bone. N Engl J Med Klin 1996; 91 (Suppl.1): 29-33. Med 2006; 355: 593-600. Dawson-Hughes B, Harris SS, Krall EA, et. al. Ef- Canalis E, Giustina A, Bilezikian JP. Mechanisms fect of calcium and vitamin D supplementation of Anabolic Therapies for Osteoporosis. N Engl on bone density in men and women 65 years of J Med 2007; 357: 357:905-916. age or older. N Engl J Med 1997; 337: 670-6. Kanis JA, Burlet N, Cooper C, Reginster J-Y, et Delmas PD, Bjarnason NH, Mitlak BH, et al. Ef- al. European guidance for the diagnosis and fects of raloxifene on bone mineral density, management of osteoporosis in postmenopau- serum cholestrerol concentrations, and uterine sal women. Osteoporos Int 2008; 19: 385–97. endometrium in postmenopausal women, N Kearns AE, Khosla S, Kostenuik P. RANKL and Engl J Med 1997; 337: 1641-7. OPG regulation of bone remodeling in health Delmas PD, Meunier PJ. The management of Pa- and disease. Endocr Rev 2008; 29: 155–92. get’s disease of bone. N Engl J Med 1997; 336: National Osteoporosis Foundation (NOF). Clinici- 558-66. an’s guide to prevention and treatment of osteo- Kanis JA, Delmas P, Burckhardt P, et al. Guideli- porosis. www nof.org. 2008. nes for diagnosis and management of osteopo- Bonjour J-P, Kraenzlin ME, Rajzbaum G, et al. rosis. The European Foundation for Ostéoporose: évaluation du risque fracturaire Osteoporosis and Bone Disease. Osteoporos absolu par le questionnaire OMSFRAX. Reprod 67 Hum Horm 2009; 12: 46–53. Ziswiler HR et al. J Bone Miner Res 2020; 35: Compston J, Cooper A, Cooper C, et al. Guideli- 1207-15. nes for the diagnosis and management of Ostéomalacie osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturi- Bingham CT, Fitzpatrick LA. NMoninvaice testing tas 2009; 62: 105–8. in the diagnosis of osteomalacia. Am J Med Cummings SR, Martin JS, McClung MR, Siris ES, 1993; 95: 519-23. Eastell R, Reid IR, et al. Denosumab for pre- Marie P, Mirav L. Ostéomalacies. In: Kuntz D vention of fractures in postmenopausal women (ed). Maladies Métaboliques Osseuses de with osteoporosis. N Engl J Med 2009; 361: l’Adulte. Médecine Sciences Flammarion. Paris; 756–65. 1996: 218-33. Dachverband Osteologie. DVO-Leitlinie 2009 zur Néoplasie endocrine multiple (NEM) Prophylaxe, Diagnostik und Therapie der Wolfe MM, Jensen RT. Zollinger-Ellison syn- Osteoporose bei Erwachsenen. www dv-osteo- drome. N Engl J Med 1987: 317: 1200-9. logie org. 2009. Pipeleers-Marichal M, Somers G, Willems G, et Kanis JA, Oden A, Johansson H, et al. FRAX® al. Gastrinomas in the duodenums of patients and its applications to clinical practice. Bone. with multiple endocrine neoplasia type 1 and 2009; 44:734–43. the Zollinger-Ellison syndrome. N Engl J Med Lewiecki EM, Watts NB. New guidelines for the 1990; 322: 723-7. prevention and treatment of osteoporosis. Jensen RT, Fraker DL. Zollinger-Ellison syn- South Med J 2009; 102: 175–9. drome. JAMA 1994; 271: 1429-35. Lippuner K, Johansson H, Kanis JA, et al. Remai- Members of Nordic Ne Tumour Group. Guidelines ning lifetime and absolute 10-year probabilities for the management of gastroenteropancreatic of osteoporotic fracture in Swiss men and neuroendocrine tumours (including bronchopul- women. Osteoporos Int 2009; 20: 1131–40. monary and thymic neoplasms). Part II—Speci- Smith MR, Egerdie B, Toriz NH, et al. Denosu- fic NE Tumour Types. Acta Oncol 2004;43: mab in men receiving androgen-deprivation the- 626-36. rapy for prostate cancer. N Engl J Med 2009; Aluri V, Dillon JS. Biochemical Testingin Neuroen- 361: 745–55. docrine Tumors. Endocrinol Metab Clin North Osteoporose: Prävention, Diagnostik und Thera- Am. 2017;46:669-677. pie. Empfehlungen 2010 Schweizerische Verei- Kleindiensta D, Plitzkoa G, Wieland Ch. Neuroen- nigung gegen Osteoporose (SVGO). www dokrine Tumoren der Lunge. Schweiz Med SVGO.ch. 2010. Forum 2016; 16: 292-8. Padhi D, Jang G, Stouch B, et al. Single-dose, Klimstra DS, Kloppell G, La Rosa S, Rindi G. placebocontrolled, randomized study of AMG Classification of neuroendocrine neoplasms of 785, a sclerostin monoclonal antibody. J Bone the digestive system. In: WHO Classification of Miner Res. 2010; epub. Tumours: Digestive System Tumours, 5th ed, Rizzoli R, Ammann P, Birkhäuser MH, et al. WHO Classification of Tumours Editorial Board Osteoporose: von der osteodensitometrischen (Ed), International Agency for Research on Diagnose zur Evaluation des absoluten Fraktur- Cancer, Lyon 2019. p.16. risikos. Schweiz Med Forum 2010; 10: 111–3. Kraenzlin ME, Meier Chr. Neue Wege in der Dia- Thyroïde gnostik und Therapie der Osteoporose. Horvath E, Majlis S, Rossi R, et al. An ultrasono- Schweiz Med Forum 2011; 11: 25-28. gram reporting system for thyroid nodules strati- NOF's Clinician's Guide to Prevention and Treat- fying cancer risk for clinical management. J Clin ment of Osteoporosis. http://nof.org/files/nof/pu- Endocrinol Metab 2009; 94: 1748-51. blic/content/file/344/upload/159.pdf, accessed November 28, 2012. Hyperthyroïdie Watts NB, Adler RA, Bilezikian JP, et al. Osteopo- Surks MI, Chopra IJ, Mariash CN, et al. American rosis in men: an Endocrine Society clinical prac- thyroid association guidelines for use of labora- tice guideline. J Clin Endocrinol Metab 2012; tory tests in thyroid disorders. JAMA 1990; 263: 97:1802. 1529-32. Lehmannn Th, Aeberli D, Häuselmann HJ. Pré- Nordin H, Galloe AM, Ladefoged SD, et al. The diction du risque fracturaire - pas uniquement effects of propranolol and verapamil on hyper- une question de densité osseuse. Forum Med thyroid heart symptoms and function, assessed Suisse 2012; 13: 913-6. by systolic time intervals. Acta Endocrinol (Co- Adler RA, El-Hajj Fuleihan G, Bauer DC et al. Ma- penh) 1993; 128: 297-300. naging Osteoporosis in Patients on Long-Term Franklyn JA. The management of hyperthyroi- Bisphosphonate Treatment: Report of a Task dism. N Engl J Med 1994; 330: 1731-8. Force of the American Society for Bone and Mi- Singer PA, Cooper DA, Levy EG, et al. Treatment neral Research. J Bone Miner Res 2016; 31: guidelines for patients with hyperthyroidism and 16-35. hypothyroidism. JAMA 1995; 273: 808-12. A Single Infusion of Zoledronate in Postmenopau- Weetman AP. Graves’ disease. N Engl J Med sal Women Following Denosumab Discontinua- 2000; 343: 1236-48. tion Results in Partial Conservation of Bone Portmann L. Approches thérapeutiques de l’hy- Mass Gains. Everts-Graber J, Reichenbach S, perthyroïdie. Med Hyg 2001; 59: 350-6. 68 Cooper DS. Subclinical Hyperthyroidism. N Engl cosis. Thyroid storm. Endocrinol Metab Clin J Med 2001; 345: 260-5. North Am 1993; 22: 263. Weetman AP. Graves’disease. N Engl J Med Porphyrie 2001; 235: 1236-48. Fajfr R, Müller B, Diem P. Hyperhyreose - Abklä- Betanocor P. Patología del metabolismo de las rung und Therapie. Schweiz Forum 2003; 5: porfirinas. In: Rodés J, et al. (eds.). El Manual 103-8. de Medicina. Masson, S.A, 1993, p: 1212-20. Surks MI, Ortiz E, Daniels GH, et al. Subclinical Fauci A, Braunwald E, (eds.) et al. In: Harrison: thyroid disease: scientific review and guidelines Principles of Internal Medicine. 1998 Mc Graw for diagnosis and management. JAMA 2004; Hill. 291: 228-38. Cholestérol - Cholesterin - Dyslipidämie Dyslipidémie - Hypercholesterinämie Hypothyroïdie Jestra JA, Kromhout D, van der Schouw YT et al. Staub JJ, Althaus BU, Engler H et al. Spectrum of Effect size estimates of lifestyle and dietary subclinical and overt hypothyroidism: effect on changes on all-cause mortality in coronary ar- thyrotropin, prolactin, and thyroid reserve, and tery disease patients: a systematic review. Cir- metabolic impact on peripheral target tissues. culation. 2005; 112: 924-34. Am J Med 1992; 92: 631-42. Reiner Z, Catapano AL, De Backer G, Graham I, Zulewski H, et al. Estimation of tissue hypothyroi- et al. ESC/EAS Guidelines for the management dism by a new clinical score: Evaluation of pa- of dyslipidaemias: the Task Force for the ma- tients with various grades of hypothyroidism nagement of dyslipidaemias of the European and controls. J Clin Endocrinol Metab 1997; 82: Society of Cardiology (ESC) and the European 771-76. Atherosclerosis Society (EAS). Eur Heart J Zulewski H, Muller B, Exer P, et al. Estimation of 2011; 32: 1769-818. tissue hypothyroidism by a new clinical score: Brun N, Rodondi N. [How to deal with familial evaluation of patients with various grades of hy- dyslipidemia in clinicalpractice?]. Rev Med pothyroidism and controls. J Clin Endocrinol Suisse 2012; 8: 494-6, 8-500. Metab 1997; 82: 771-6. Benn M, Watts GF, Tybjaerg-Hansen A, Nordest- Zulewski H, Siggelkow H, Walden C, et al. Eva- gaard BG. Familial hypercholesterolemia in the luation of procollagen III peptide as a marker of danish general population: prevalence, coro- tissue hyperthyroidism in long-term treated nary artery disease, and cholesterol-lowering women with TSH suppressive doses of thyro- medication. J Clin Endocrinol Metab. 2012; 97: xine. Exp Clin Endocrinol Diabetes 1999; 107: 3956-64. 190-4. Anderson TJ, Grégoire J, Hegele RA et al. 2012 Toft AD. Subclinical Hypothyroidism. N Engl J Update of the Canadian Cardiovascular Society Med 2001; 345: 512-6. Guidelines for the Diagnosis and Treatment of Col NF, Surks MI, Daniels GH. Subclinical thyroid Dyslipidemia for the Prevention of Cardiovascu- disease: clinical applications. JAMA 2004; 291: lar Disease in the Adult. Can J Cardiol 239-43. 2013;29:151-67. Surks MI, Ortiz E, Daniels GH et al. Subclinical Goff DC, Jr., LloydJones DM, Bennett G, Coady thyroid disease: scientific review and guidelines S, D’Agostino RB, Sr., Gibbons R, et al. 2013 for diagnosis and management. JAMA 2004; ACC/AHA Guideline on the Assessment of Car- 291: 228-38. diovascular Risk: A Report of the American Col- Thynne TR, Doogue MP. A dose of paracetamol lege of Cardiology/American Heart Association for the levothyroxine absorption test. Clin Endo- Task Force on Practice Guidelines. Circulation crinol (Oxf). 2013; 78: 968-9. November 12, 2013. Peeters RP. Subclinical Hypothyroidism. NEJM http://circ.ahajournals.org/content/early/2013/11 2017; 376: 256-65 /11/01.cir.0000437741.48606.98.citation Thyroïdite de HASHIMOTO Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and Dyan CM, Daniels GH. Chronic autoimmune thy- statin treatment on mortality risk in veterans roiditis. N Engl J Med 1996; 335: 99-107. with dyslipidaemia: a cohort study. Lancet 2013; Nodules thyroïdiens 381: 394-9. American Thyroid Association (ATA) Guidelines Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Taskforce on Thyroid Nodules and Differentia- Blum CB, Eckel RH, et al. 2013 ACC/AHA Gui- ted Thyroid Cancer, Cooper DS, Doherty GM, deline on the Treatment of Blood Cholesterol to et al. Revised American Thyroid Association Reduce Atherosclerotic Cardiovascular Risk in management guidelines for patients with thyroid Adults: A Report of the American College of nodules and differentiated thyroid cancer. Thy- Cardiology/American Heart Association Task roid 2009; 19:1167. Force on Practice Guidelines. Circulation. No- Durante C, Costante G, Lucisano G, et al. The vember 12, 2013. natural history of benign thyroid nodules. JAMA http://circ.ahajournals.org/content/early/2013/11 2015; 313: 926-35. /11/01.cir.0000437738.63853.7a.citation Ioannidis JP. More Than a Billion People Taking Crise thyréotoxique - Thyroid storm Statins? Potential Implications of the New Car- Burch HB, Wartofsky L. Life-threatening thyrotoxi- diovascular Guidelines. JAMA 2014; 311: 463- 69 4. 7. Ridker PM, Cook NR. Statins: new American gui- Calle EE, Thun MJ, Petrelli JM, et al. Body-mass delines for prevention of cardiovascular index and mortality in a prospecive cohort on disease. Lancet 2013; 382: 1762-5. U.S. adults. N Engl J Med 1999; 341: 1097- Nanchen D, von Eckardstein A., Riesen WF, et al. 1105. im Namen der Davidson MH, Hauptmann J, Di Girolamo M, et Schweizer Arbeitsgruppe Lipide und Atheroskle- al. Weight control and risk factor reduction in rose (AGLA). Cholesterin management in der obese subjects treated for 2 years with orlistat. kardiovaskulären Risikoprävention: amerikani- JAMA 1999; 281: 235-42. sche Guidelines 2013 Stellungnahme der Golay A, et al. Konsensus über die Behandlung Schweizer Arbeitsgruppe Lipide und Atheroskle- der Adipositas in der Schweiz 1999. Schweiz rose (AGLA). Schweiz Med Forum 2014; 14: Med Wschr 1999; 129 (Suppl.114): 4S-20S. 378-381. Golay A, et al. Consensus sur le traitement de Yates T, Haffner SM, Schulte PJ, et al. Associa- l’obésité en Suisse 1999. Schweiz Med Wschr tion between change in daily ambulatory activity 1999; 129 (Suppl.114): 21S-36S. and cardiovascular events in people with impai- Wirth A, Krause J. Long-term weight loss with si- red glucose tolerance (NAVIGATOR trial): a co- butramine: a randomized controlled trial. JAMA hort analysis. Lancet 2014; 383: 1059-66. 2001; 286: 1331-9. Anderson, TJ, Gr!egoire J, Pearson GJ et al. Deitel M, Shikora SA. The development of the 2016 Canadian Cardiovascular Society Guideli- surgical treatment of morbid obesity. J Am Coll nes for the Management of Dyslipidemia for the Nutr 2002; 21: 365-71. Prevention of Cardiovascular Disease in the Yanovski SZ, Yanovski JA. Obesity. N Engl J Med Adult. Can J Cardiol 2016; 32: 1263e1282. 2002; 346: 591-602. Aubert C-E., Gencer B. Rodondi N. Recomman- Pi-Sunyer X, Astrup A, Fujioka K et al. A Rando- dations de prise en charge des dyslipidémies mized, Controlled Trial of 3.0 mg of Liraglutide en 2016 en Suisse. Rev Med Suisse 2016; 12 : in Weight Management. NEJM 2015; 373: 11- 430-4. 22. Aubert C-E., Gencer B. Rodondi N. Dyslipidémies O’Brian PE, Dixon JB. Weight loss early and late au cabinet médical. Primary Care 2017; 17: complications - the international experience. Am 250-3. J Surg 2003; 184: 42S-45S. Mach F, Baigent C, Catapano AL et al. The Task Syndrome des ovaires polykystiques Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and Stein IF, Leventhal ML. Amenorrhoea associated European Atherosclerosis Society (EAS). 2019 with bilateral polycystic ovaires. Am J Obstet ESC/EAS Guidelines for the management of Gynecol 1935; 29: 181-91. dyslipidaemias: lipid modification to reduce car- Waldstreicher J. Hyperfunction of the hypothala- diovascular risk. Eur Heart J 2020; 41: 111-88. mic-pituitary axis in women with polycystic ovarian disesae: indirect evdence for partial Obésité gonodotroph desensitization. J Clin Endocrinol Ireton-Jones CS, Turner WW Jr. Actual or ideal Metab 1988; 66: 165-72. body weight: wich should be used to predict Knochenhauer E. Prevalence of the polycystic energy expenditure? J Am Diet Assoc 1991; 91: ovary syndrome in unselected black and white 193-5. women of the southeastern United States: a Physical status: the use and interpretation of an- prospective study. J Clin Endocrinol Metab thropometry: report of a WHO expert commit- 1998; 83: 3078-82. tee. WHO Tech Rep Ser 1995; 854: 1-452. Diamanti-Kandarakis E. A survey of the polycystic Bjorntorp P. Obesity. Lancet 1997; 350: 423-6. ovary syndrome in the Greek island of Lesbos: International Obesity Task Force (IOTF). Obesity: hormonal and metabolic profile. J Clin Endocri- preventing and managing the global epidemic. nol Metab 1999; 84: 4006-11. Report of a WHO consultation on obesity. Ge- Ehrmann DA. Prevalence of impaired glucose to- neva, 3-5 June, 1997 (WHO/NUT/NCD/97.2). lerance and diabetes in women with polycystic Lean ME. Silbutamine – a review of clinical effi- ovary syndrome. Diabetes care 1999; 22: 141- cacy. Int J Obes Relat Metab Disord 1997; 6. 21(Suppl. 1): S30-6; discussion S37-9. Legro RS. Prevalence and predictors of risk for Seidel JC, Rissanen AM. Time trends in the type 2 diabetes mellitus and impaired glucose worldwide prevalence of obesity. In: Bray GA, tolerance in polycystic ovary syndrome: a pro- Bouchard C, James WPT (eds.). Handbook of spective, controlled study in 254 affected obesity. New York: Marcel Dekker 1998, p. 79- women. J Clin Endocrinol Metab 1999; 84: 165- 91. 9. Sjöström L, Rissanen A, Andersen T, et al. Ran- Azziz R. Family history as a risk factor for the po- domised placebo-controlled trial of orlistat for lycystic ovary syndrome. J Pediatr Endocrinol weight loss and prevention of weight regain in Metab 2000; 13: 1303-6. obese patients. Lancet 1998; 352: 167-73. Azziz R. Troglitazone improves ovulation and hir- Stevens J, Cai J, Pamuk ER, et al. The effect of sutism in the polycystic ovary syndrome: a mul- age on the association between body-mass ticenter, double blind, placebo-controlled trial. J index and mortality. N Engl J Med 1998; 338: 1- Clin Endocrinol Metab 2001; 86: 1626-32. 70 Fogel RB. Increased prevalence of obstructive Hypercholesterinämie - Dislipidämie sleep apnea and daytime sleepness: role of in- Scandinavian Simvastatin Survival Study Group. suline resistance. J Clin Endocrinol Metab Randomized trial of cholesterol lowering in 2001; 86: 1175-80. 4444 patients with coronary heart disease: the Hardiman P. Polycystic ovary syndrome and en- scandinavian simvastatin survival study (4S). dometrial carcinoma. Lancet 2003;362:1082 / Lancet 1994; 344: 1383-9. Balen A. Polycystic ovary syndrome and can- Sacks FM, Pfeffer MA, Moye LA, et al. The effect cer. Hum Reprod Update 2001; 7: 522-5. of pravastatin on coronary events after myocar- Gopal M. The role of obesity in the increased pre- dial infarction in patients with average choleste- valence of obstructive sleep apnea syndrome in rol levels. Cholesterol and recurrrent events patients with polycystic ovary syndrome. Sleep (CARE) trial investigators. N Engl J Med 1996; Med 2002; 3: 401-4. 335: 1001-9. Glueck CJ. Incidence and treatment of metabolic Herd JA, Ballantyne CM, Farmer JA, et al. Effects syndrome in newly referred women with confir- of fluvastatin on coronary atherosclereosis in med polycystic ovarian syndrome. Metabolism patients with mild to moderate cholesterol ele- 2003; 52: 908-15. vations lipoprotein and coronary atherosclerosis Ehrmann DA. Polycystic Ovary Syndrome. N Engl study. Am J Cardiol 1997; 80: 278-86. J Med 2005; 352: 1223-36. Pyorala K, Pederson TR, Kjekshus J, et al. Cho- Syndrome métabolique lesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart Weisser B, Locher R, Vetter W. The metabolic disease. A subgroup analysis of the scandina- syndrome: common etiology fo distinct cardio- vian simvastatin survival study (4S). Diabetes vascular risk factors. Schweiz Rundsch Med Care 1997; 20: 614-20. Prax 1993; 82: 1339-43. Haffner SM. Mortality from coronary heart Zimmet P, Boyko EJ, Collier GR, et al. Etiology of disease in subjects with type 2 diabetes and in the metabolic syndrome: potential role of insulin nondiabetic subjects with and without prior resistance, leptin resistance, and other players. myocardial infarction. N Engl J Med 1998; 339: Ann NY Acad Sci 1999; 892: 25-44. 229-34. Meigs JB, Mittleman MA, Nathan DM, et al. Hype- Influence of pravastatin and plasma lipids on clini- rinsulinemia, hyperglycemia, and impaired he- cal events in the West of Scotland Cornary Pre- mostasis, The Framingham offspring study. vention Study (WOSCOPS). Circulation 1998; JAMA 2000; 283: 221-8. 97: 1440-5. Isomaa B, Almgren P, Tuomi T, et al. Cardiovas- Recommendations of the Second Joint Task cular morbidity and mortality associated with Force of European and other Societies on coro- the metabolic syndrome. Diabetes Care 2001; nary Prevention. Prevention of coronary heart 24: 683-9. disease in clinical practice. Eur Heart J 1998; Ramos F, Baglivo HP, Ramirez AJ, et al. The me- 19: 1434-1503. tabolic syndrome and related cardiovascular The long-term intervention with pravastatin in risk. Curr Hypertens Rep 2001; 3: 100-6. ischaemic disease (LIPID) study group. Preven- Ford ES, Wayne HG, Dietz WH, et al. Prevalence tion of cardiovascular events and death with of the metabolic syndrome amoung US adult. pravastatin in patients with coronary heart JAMA 2002; 287: 356-9. disease and a broad range of initial cholesterol Lakka HM, Laaksonen DE, Lakka TA, et al. The levels. N Engl J Med 1998; 339: 1349-57. metabolic syndrome and total and cardiovascu- Familial hypercholesterolaemia (FH): report of a lar disease mortality in middle-aged men. JAMA second WHO consultation, Geneva, 4 Septem- 2002; 288: 2709-16. ber 1998. World Health Organization, p. 13, National Cholesterol Education Program. Third 1998. report of the national cholesterol education pro- Société Suisse de Cardiologie, Groupe de travail gram (NCEP). Expert panel on detection, eva- Lipides et Athérosclérose. Recommandations luation, and treatment of hight blood cholesterol 1999 pour l’indication au traitement du facteur in adults (Adult Treatment Panel III). Final re- de risque " cholestérol ". Schweiz Ärztezeitung port: National Publication No.- 02-5215, sep- 1999; 80: 544-8. tember 2002 Lauer MS. Aspirin for primary prevention of coro- (www.nhlbi.nih.gov/guidelines/cholesterol/atp3f nary events. N Engl J Med 2002; 346: 1468-74. ull.pdf). And: Executive summary, National Pu- Management of dyslipidemia in adults with diabe- blication No.- 01-3670, mai 2001 tes. Diabetes Care 2002; 25: Suppl. 1: S74- (www.nhlbi.nih.gov/guidelines/cholesterol/atp3x S77. sum.pdf). National Cholesterol Education Program. Third Keller KB, Lemberg L. Obesity and the metabolic report of the national cholesterol education pro- syndrome. Am J Crit Care 2003; 12: 167-70. gram (NCEP). Expert panel on detection, eva- Meigs JB. The metabolic syndrome. BMJ 2003; luation, and treatment of hight blood cholesterol 327: 61-2. in adults (Adult Treatment Panel III). National American Diabetes association. Screening for Publication No.- 02-5215, september 2002 type 2 diabetes. Diabetes Care 2004; 27 (Suppl (www.nhlbi.nih.gov/guidelines/cholesterol/atp3f 1):S11-S14. ull.pdf). Hypercholestérolémie - Dyslipidémie Sudhop T, Lutjohann D, Kodal A, et al. Inhibition 71 of intestinal cholesterol absorption by ezetimibe diovascular risk. Eur Heart J 2020; 41: 111-88. in humans. Circulation 2002; 106: 1943-8. Riesen W, Kaiser W, Gallino A et al. Neue Sudhop T, von Bergmann K. Cholesterol absorb- ESC/EAS-Dyslipidämie- Guidelines. Schweiz tion inhibitors for the treatment of hyperchole- Med Forum 2020;20:140-8. sterolaemia. Drugs 2002; 62: 2333-7. PCSK9 De Backer G, Ambrosini E, Borch-Johnsen K, et Roth EM, McKenney JM, Hanotin C, Asset G, al. European guidelines on cardiovascular Stein EA. Atorvastatin with or without an anti- disease prevention in clinical practice. Third body to PCSK9 in primary hypercholesterole- joint task force of European and other societies mia. New Engl J Med 2012; 367: 1891-900. on cardiovascular disease prevention in clinical Vogel RA. PCSK9 inhibition : The next statin ?. J practice. Eur Heart J 2003; 24: 1601-10. Am Coll Cardiol 2012; 59: 2354-5. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Ef- Raal FJ, Honarpour N, Blom DJ, et al; TESLA In- fects of an inhibitor of cholesteryl ester transfer vestigators. Inhibition of PCSK9 with evolocu- protein on HDL cholesterol. N Engl J Med 2004; mab in homozygous familial 350: 1505-15. hypercholesterolaemia (TESLA Part B): a ran- International Diabetes Federation. The IDF con- domised, double-blind, placebo-controlled trial. sensus worldwide definition of the metabolic Lancet. 2015; 385: 341-50. syndrome. Acces sept 2005 (consensus 14 april Raal FJ, Stein EA, Dufour R, et al.; RUTHER- 2005, Berlin) y Rev Panam Salud Publica 2005; FORD-2 Investigators. PCSK9 inhibition with 18: 451-4. evolocumab (AMG 145) in heterozygous fami- The Stroke Prevention by Aggressive Reduction lial hypercholesterolaemia (RUTHERFORD-2): in Cholesterol Levels (SPARCL) Investigators a randomised, double-blind, placebo-controlled High-Dose Atorvastatin after Stroke or Transient trial. Lancet. 2015; 385:331-4. Ischemic Attack. N Engl J Med 2006; 355: 549- Raal FJ, Giugliano RP, Sabatine MS, et al. Re- 59. duction in lipoprotein(a) with PCSK9 monoclo- Barter Ph, Gotto AM, LaRosa JC, et al. HDL cho- nal antibody evolocumab (AMG 145): a pooled lesterol, very low levels of LDL cholesterol, and analysis of more than 1,300 patients in 4 phase cardiovascular events. Treating to New Targets II trials. J Am Coll Cardiol 2014; 63:1278-88. Investigators. N Engl J Med 2007; 357: 1301- 10. Nutrition Nordestgaard BG, Chapman MJ, Humphries SE, A.S.P.E.N. Board of Directrs. Guidelines for the et al. Familial hypercholesterolaemia is under- use of enteral nutrition in the adult patient. diagnosed and undertreated in the general po- JPEN 1987; 11: 435-9. pulation: guidance for clinicians to prevent Rodés J, Aguirre A, Arroyo V, et al. (eds.). Valores coronary heart disease: consensus statement nutritivos. El Manual de Medicina. Masson, of the European Atherosclerosis Society. Eur 1993, p: 3335-41. Jeart J 2013; 34: 3478-3490a. Benn M, Watts GF, Tybjærg-Hansen A et al. Mu- Hyperparathyroïdie tations causative of familial hypercholesterolae- NIH Consensus development conference state- mia: screening of 98 098 individuals from the ment: diagnosis and management of asympto- Copenhagen General Population Study estima- matic primary hyperparathyroidism. Ann Intern ted a prevalence of 1 in 217. Eur Heart J 2016; Med 1991; 114: 593-7. 37: 1384-94. Niederle B, Stamm L, Längle F, et al. Primary hy- Catapano AL, Graham I, De Backer G, Wiklund O perparathyroidism in Austria. Results of an 8- et al. 2016 ESC/EAS Guidelines for the Ma- year prospective study. World J Surg 1992; 16: nagement of Dyslipidaemias. Eur Heart J 2016; 777-83. 37: 2999-3058. Pattou F, Huglo D, Proye C. Radionuclide scan- Schöb M, Müller P, Gert Y et al. Familiäre Hyper- ning in parathyroid disease. Br J Surg 1998; 85: cholesterinämie – Diagnose und Therapie Dia- 1605-16. gnosis and Treatment of Familial Marcus R. Diagnosis and treatment of hyperpara- Hypercholesterolemia. Praxis 2018; 107: 1345- thyroidism. Rev Endocr Metab Disord 2000; 1: 53. 247-52. Grundy SM, Stone NJ, Bailey AL et al. 2018 Kearns AE, Thompson GB. Medical and surgical AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/A mangement of hyperparathyroidism. Mayo Clin GS/APhA/ASPC/NLA/PCNA Guideline on the Proc 2002; 77: 87-91. Management of Blood Cholesterol: Executive Bilezikian JP, Bandeira L, Khan A et al. Hyperpa- Summary: A Report of the American College of rathyroidism. Lancet 2018; 391; 168-78. Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circula- INFECTIOLOGIE - INFEKTIOLOGIE tion 2019; 139: e1046. Mach F, Baigent C, Catapano AL et al. The Task Méningite - Meningitis Force for the management of dyslipidaemias of Glauser MP. Recommandations pour la préven- the European Society of Cardiology (ESC) and tion de la dissémination des méningococcies. European Atherosclerosis Society (EAS). 2019 Schweiz Aerztezeitung 1982; 63: 279-81. ESC/EAS Guidelines for the management of Quagliarello VJ, Scheld WM. Bacterial meningitis: dyslipidaemias: lipid modification to reduce car- pathogenesis, pathophysiology, and progress. 72 N Engl J Med 1992; 327: 864-72. Cecil, Textbook of Medecine. W.B. Saunders Durand ML, Calderwood SB, Weber DJ, et al. Company 1992. Acute bacterial meningitis in adults: a review of Humar A, Keystone J. Evaluating fever in travel- 493 episodes. N Engl J Med 1993; 328: 21-8. lers returning from tropical countries. BMJ Lepow ML. Meningococcal vaccines. In: Plotkin 1996; 312: 953-6. SA, Mortimer EA (eds). Vaccines. 2nd edition Norman DC, et al. Fever in the elderly. Infect Dis Philadelphia: WB Saunders Company 1994, p: Clin North Am 1996; 10: 93-9. 503-15. Fauci A, Braunwald E, (eds.) et al. In: Harrison: Office fédéral de la santé publique. Maladies mé- Principles of Internal Medicine. 1998 Mc Graw ningococciques invasives en Suisse 1988- Hill. 1994. Bull OFSP 1995; 50: 5-11. Magill AJ. Fever in the returned traveler. Infect Garner JS, and the Hospital Infection Control Dis Clin North Am 1998; 12: 445-69. Practices Advisory Committee. Guideline for Fièvre d’origine indéteminée (FUO) isolation precautions in hospitals. Am J Infect Control 1996; 24: 24-52. NET: Centers for Disease Control and Prevention. Con- • www.fevertravel.ch trol and prevention of meningococcal disease • www.safetravel.ch and control and prevention of serogroup C me- Petersdorf RG, Beeson PB. Fever of unexplained nigococcal disease: evaluation and manage- origin. Medicine 1961; 40: 1-30. ment of suspected outbreaks. Jacoby GA, Swartz MN. Fever of undetermined Recommandations of the Advisory Committee origin. N Engl J Med 1973; 289: 1407-10 on Immunization Practices. MMWR 1997; 46: 1- Petersdorf RG. Fever of unknown origin. An old 21. friend revisited. Arch Intern Med 1992; 152: 21- Jafari HS, Perkins BA, Wenger JD. Control and 2. prevention of meningococcal disease: recom- Schneider-Gilg A. Unklarer Status Febrilis. Praxis mendations of the advisory committee of immu- 1986; 75: 651-5. nization practices (ACIP). MMWR 1997; 46, Cunha BA. Fever of unknown origin. Infect Dis RR-5: 1-11. Clin North Am 1996; 10: 111-27. Quagliarello VJ, Scheld WM. Treatment of bacte- Arnow PM, Flaherty JP. Fever of unknown origin. rial meningitis. N Engl J Med 1997; 336: 708- Lancet 1997; 350: 575-80. 16. Hirschmann JV. Fever of unknown origin in Aronin SI, et al. Community-acquired bacterial adults. Clin Infect Dis 1997; 24: 291-302. meningitis: risk stratification for adverse clinical Neutropénie fébrile - Neutropenie & Fieber outcome and effect of antibiotic timing. Ann In- Imunocompromised Host Society. The design, tern Med 1998; 129: 862-9. analysis and reporting of clinical trials on the Attia J, Hatala R, Cook DJ, et al. Does this adult empirical antibiotic management of the neutro- patient have acute meningitis? JAMA 1999; penic patient. J Inf Dis 1990; 161: 397-401. 282: 175-81. Cometta A, Calandra T, Gaya H, et al. Monothe- Troillet N, Rohner P, Raeber R, et al. Epidémiolo- rapy with meropenem versus combination the- gie et prévention des infections dues à Nei- rapy with ceftazidime plus amikacin as empiric sseria meningitidis. Bull Med Suisse 1999; 80: therapy tor fever in granulocytopenic patients 1375-9. with cancer. Antimicrob Agents Chemother Apicella MA, Neisseria meningitidis. In: GL, Ben- 1996; 40: 1108-15. nett JE, Dolin R (eds). Principles and practice of Hughes WT, Armstrong D, Bodey GP, et al. Gui- infectious diseases. 5th edition New York: Chur- delines from the infectious diseases society of chill Livingstone 2000. America. 1997 Guidelines for the use of antimi- Hasbun R, Abrahams J, Jekel J, et al. Computed crobial agents in neutropenic patients with un- tomography of the head before lumbar puncture explained fever. Clin Infect Dis 1997; 25: in adults with suspected meningits. N Engl J 551-73. Med 2001; 345: 1727-33. Harten P, et al. Febrile neutropenia: practical De Gans J, Van de Beek D. Dexamethasone in aspects. Med Klin 1998; 93: 598-611. adults with bacterial meningitis. N Engl J Med Kern WV, Cometta A, De Bock R, et al. Oral ver- 2002; 347: 1549-56. sus intravenous empirical antimicrobial therapy Thi Hoang Mai N, Thi Hong Chau T, Thwaites G for fever in patients with granulocytopenia who et al. Dexamethasone in Vietnamese Adoles- are receiving cancer chemotherapy. N Engl J cents and Adults with Bacterial Meningitis. N Med 1999; 341; 312-18. Engl J Med 2007; 357: 2431-40. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal État fébrile - Fieber - Status febrilis amphotericin B for empirical therapy in patients Mackowiak PA, LeMaistre CF. Drug fever: a criti- with persistent fever and neutropenia. N Engl J cal appraisal of conventional concepts. Ann In- Med 1999; 340: 764-71. tern Med 1987; 106: 728-33. Klastersky J, Paesmans M, Rubenstein EB, et al. Strickland TG. Fever in travelers. In: Strickland Te multinatioinal association for supportive care TG. (ed.): Hunnter’s Tropical Medicine. Phil- in cancer risk index: a multinational scoring sy- adelphia: WB Saunders, 1991; 1023-31. stem for identify low-risk febrile neutropenic Wyngaarden JB, Smith LH, Bennet JC. (eds.). cancer patients. J Clin Oncol 2000; 18: 3038- 73 51. Brewer MA, Edwards KM, Palmer PS, Hinson HP. Corey L, Boeckh M. Persistant fever in patients Bacille Calmette Guerin immunization in normal with neutropenia. N Engl J Med 2002; 346: 222- healthy adults. J Infect Dis 1994; 170:476-9. 4. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Hughes WT, Armstrong D, Bodey GP, et al. 2002 Burdick E, et al. Efficacy of BCG vaccine in the Guidlines for the use of antimicrobial agentes in prevention of tuberculosis. Meta-analysis of the neutropenic patients with cancer. Clin Infect Dis pubished literature. JAMA 1994; 271: 698-702. 2002; 34: 730-51. International Union Against Tuberculosis and Walsh TJ, Pappas P, Winston D, et al. Voricona- Lung Disease. Criteria for discontinuation of zole compared with piposomal amphotericin B vaccination programmes using Bacille Cal- for empirical antifungal therapy in patients with mette-Guerin (BCG) in countries with a low pre- neutropenia and persistent fever. N Engl J Med valence of tuberculosis. A statement of the 2002; 346: 225-34. International Union Against Tuberculosis and Flückiger U, Marchetti O, Bille J, et al. Treatment Lung Disease. Tuber Lung Dis 1994; 75:179- options of invasive funghal infections in adults. 80. Swiss Med Wkly 2006;136:447-463. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe Tuberculose - Tuberkulose (TB) and international migration. Report of a Euro- NET: www.who.int pean Task Force. Eur Respir J 1994; 7: 1545- NET: www.tbinfo.ch https://www.tbinfo.ch/fileadmin/user_upload/1wissenszentrum/Pu 53. blikationen/Handbuch_Tuberkulose/Handbuch_TB_DE_16_05_ Standards Committee, Canadian Thoracic So- 19.pdf ciety. Essential of tuberculosis control for the Shaw JB, Wynn-Williams N. Infectivity of pulmo- practising physician. Can Med Assoc J 1994; nary tuberculosis in relation to sputum status. 150: 1561-71. Am Rev Tuberc 1954; 69: 724-32. Schalcher C, Brändli O, Beran J, Gaze H, Howald Meijer J, Barnett GD, Kubik A, Styblo K. Identifi- H, Tschopp JM. Tuberkulintests bei Schulab- cation of sources of infection. Bull Int Union Tu- gängern in den Kantonen Bern, Neuenburg und berc 1971;45:5-50. Wallis 1992/1993. Schweiz Med Wochenschr Grzybowski S, Barnett GD, Styblo K. Contacts of 1995; 125:796-801. cases of active pulmonary tuberculosis. Bull Int World Health Organization. Global tuberculosis Union Tuberc 1975;50:90-106. programme and global programme on vaccines. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-re- Statement on BCG revaccination for the pre- lated hepatitis. Am Rev Respir Dis 1978; 117: vention of tuberculosis. WHO Wkly Epidem Rec 991-1001. 1995; 70: 229-31. Cauthen GM, Pio A, ten Dam HG. Annual risk of Association suisse contre la tuberculose et les infection. World Health Organization Document maladies pulmonaires. Lignes directrices pour 1988;WHO/TB/88.154:1-34. le traitement de la tuberculose. Bull OFSP Rieder HL, Zimmermann H, Zwahlen M, Billo NE. 1996; 16: 9-13. Epidemiologie der Tuberkulose in der Schweiz. Sudre P, Rieder H, Bassetti S, Hirschel BJ, Le- Schweiz Rundschau Med Praxis 1990; 79: 675- dergerber B, Malvy D, Swiss HIV Cohort Study. 9. Infection VIH, tuberculose et test tuberculinique Association suisse contre la tuberculose et les en Suisse. Schweiz Med Wochenschr 1996; maladies pulmonaires. Lignes directrices pour 126: 2007-12. la chimiothérapie préventive de l’infection tuber- White NJ. The treatment of malaria. N Engl J Med culeuse. Bull OFSP 1991; 23: 38-9. 1996; 335:800-6. Snider DE Jr, Caras GJ. Isoniazid-associated he- Richtlinien für den Tuberkulintest. Bull BAG patitis deaths: a review of available information. 1997:13-14. Am Rev Respir Dis 1992; 145:494-7. Association suisse contre la tuberculose et les Winters R.A., Murray H.W. Malaria - The Mime maladies pulmonaires ASTP Société suisse de Revisited: Fifteen More Years of Experience at pneumologie SSP. Lignes directrices concer- a New York City Teaching Hospital. The Ameri- nant le test tuberculinique. Bull OFSP 1997; 16: can Journal of Medicine. 1992; 93: 243-6. 13-14. Veen J. Microepidemics of tuberculosis: the Behr MA, Hopewell PC, Paz A, Kawamura LM, stone-in-the-pond principle. Tuber Lung Dis Schecter GF, Small PM. Predictive value of 1992;73:73- 6. contact investigation for identifying recent trans- Association suisse contre la tuberculose et les mission of mycobacterium tuberculosis. Am J maladies pulmonaires. Lignes directrices con- Respir Crit Care Med 1998; 158: 465-9. cernant la prévention de la tuberculose dans le Maher D, Chaulet P, Spinaci S, Harries A. Global cadre professionnel. Bull OFSP 1993; annexe Tuberculosis Programme World Health Organi- 3: 31-6. zation Geneva, Switzerland, 1998, p 1-81.[http: Iseman MD. Treatment of multidrug-resistant tu- //www.who.int] berculosis. N Engl J Med 1993; 329: 784-791. Markwalder K., Hatz C. Malaria-Therapie 1998. American Thoracic Society, CDC and Prevention. Schweiz Med Wochenschr 1998; 128: 1313-27. Treatment of tuberculosis and tubercuolosis in- Trnka L, Dankova D, Zitova J, et al. Survey of fection in adults and children. Am J Respir Crit BCG vaccination policy in Europe: 1994-96. Care Med 1994; 149: 1359-74. Bull World Health Organ 1998; 76:85-91. 74 Standards Committee (Tuberculo sis), Canadian ximab, a tumor necrosis factor alpha-neutrali- Thoracic Society. Canadian tuberculosis stan- zing agent. N Engl J Med 2001; 345: 1098-104. dards. 3rd ed. Ottawa: Canadian Lung Associa- Lalvani A, Pathan AA, McShane H, et al. Rapid tion, 1998. detection of Mycobacterium tuberculosis infec- Soccal PM, Rochat Th. Diagnostic de tubercu- tion by enumeration of antigen-specific T cells. lose. Med Hyg 1998; 56: 2336-41. Am J Respir Crit Care Med 2001; 163: 824-8. Bundesamt für Gesundheit. Infektionskrankheiten Lalvani A, Pathan AA, Durkan H, et al. Enhanced in der Schweiz 1997. Tuberkulose. Bull contact tracing and spatial tracking of mycobac- BAG/OFSP 1999; 34-7. terium tuberculosis infection by enumeration of ERS TASK FORCE.Tuberculosis management in antigen-specific T cells. Lancet 2001; 357: Europe.Eur Respir J 1999; 14: 978-92. 2017-21. Havlir DV, Barnes PF. Tuberculosis in patients Rieder HL. Risk of travel-associated tuberculosis. with human imunodeficiency virus infection. N Clin Infect Dis 2001; 33: 1393-6. Engl J Med 1999;340:367-73. World Health Organization. BCG in immunization Del Castillo OD, Penafiel CM, Alvarez GF, Soto programmes. Wkly Epidem Rec 2001;76:33-9. Campos JG, Calderon OE, et al. Investigation Broekmans JF, Migliori GB, Rieder HL, Lees J, of tuberculosis contacts in a nonhospital pneu- Ruutu P, et al. European framework for tubercu- mology practice. Eur.J Clin Microbiol Infect Dis losis control and elimination in countries with a 1999; 18: 790-5. low incidence. Recommendations of the World American Thoracic Society, Centers for Disease Health Organization (WHO), International Union Control and Prevention. Targeted tuberculin te- Against Tuberculosis and Lung Disease (IU- sting and treatment of latent tuberculosis infec- ATLD) and Royal Netherlands Tuberculosis As- tion. Am J Respir Crit Care Med 2000; 161: sociation (KNCV) Working Group. Eur Respir J S221-S247. 2002; 19: 765-75. American Thoracic Society, CDC and prevention. Wang L, Turner MO, Elwood RK, Schulzer M, Diagnostic standards and classification of tuber- FitzGerald JM. A meta-analysis of the effect of culosis in adults and children. Am J Resp Crit bacille Calmette Guerin vaccination on tubercu- Care Med 2000; 161: 1376-95. lin skin test measurements. Thorax Hopewell PC. Targeting tuberculosis prevention. 2002;57:804-9. Am J Respir Crit Care Med 2000; 162: 2017-8. American Thoracic Society, CDC, and infectious Centers for Disease Control and Prevention. Ta- disease of America. Treatment of tuberculosis. geted tuberculin testing and treatment of latent MMWR 2003; 52 (N° RR-11). tuberculosis infection. MMWR 2000; 49 (N° RR- Barnes PF, Cave MD. Molecular epidemiology of 6). tuberculosis. N Engl J Med 2003; 349: 1149-56. Chin DP, Crane CM, Diul MY, Sun SJ, Agraz R, et Lalvani A. Spotting latent infection: the path to al. Spread of mycobacterium tuberculosis in a better tuberculosis control Thorax 2003; community implementing recommended ele- 58:916-8. ments of tuberculosis control. JAMA 2000; 283: Pai M, Riley LW, Colford JM. Interferon-g assays 2968-74. in the immunodiagnosis of tuberculosis: a sy- Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwa- stematic review. Lancet Infect Dis 2004;4:761- hara RJ, Wilce MA, Nguyen CH. Outcomes of 76. contact investigations of infectious tuberculosis Whitty CJ, Lalloo D, Ustianowski A. Malaria: an patients. Am J Respir.Crit Care Med. 2000; 162: update on treatment of adults in non-endemic 2033-8. countries. BMJ 2006; 333: 241-5. Rieder HL. Epidemiologic basis of tuberculosis Genton B. Malaria: Prophylaxe und Therapie - ist control. 1 ed. International Union Against Tuber- die Mefloquin-Ära vorbei? Schweiz Med Forum culosis and Lung Disease, Paris, 1999; 1-162. 2001; 1: 337-44. Bundesamt für Gesundheit. Tuberkulose in der Erkens CG, Kamphorst M, Abubakar I, et al. Tu- Schweiz: 1995 bis 1998. Bull BAG/OFSP berculosis contact investigation in low preva- 2000;1:8-11. lence countries: a European consensus. Eur World Health Organisation. Severe Falciparum Respir J 2010; 36: 925-49. Malaria. Trans R Soc Trop Med Hyg 2000; 94 Nahid P, Dorman SE, Alipanah N, et al. Official (S1): 1-90. American Thoracic Society / Centers for American Thoracic Society, Centers for Disease Disease Control and Prevention / Infectious Control and Prevention. Update: fatal and se- Diseases Society of America clinical practice vere liver injuries associated with rifampin and guidelines: treatment of drug-susceptible tuber- pyrazinamide for latent tuberculosis infection, culosis. Clin Infect Dis 2016; 63: 853-67. and revisions in American Thoracic World Health Organization. Guidelines for treat- Society/CDC recommendations - United States ment of drug-susceptible tuberculosis and pa- 2001. Am J Respir Crit Care Med 2001; 164: tient care, 2017 update. WHO / HTM / TB / 1319-20. 2017.05 Hatz C. Clinical Treatment of Malaria in Returned Bernhard S, Büttcher M, Heininger U, et al. Gui- Travelers. In: Schlagenhauf P. (Hrsg). Travelers' dance for testing and preventing infections and Malaria. BC Decker, Hamilton - London 2001; updating immunisations in asymptomatic refu- 431-45. gee children and adolescents in Switzerland. Keane J, et al. Tuberculosis associated with infli- Paediatrica 2016; 27: 1-8. 75 World Health Organization. Rapid communica- Steere AC. Lyme disease. N Engl J Med 2001; tion: key changes to treatment of multidrug and 345: 115-125. rifampicin-resistant tuberculosis (MDR / RR- Kaplan RF,Trevino RP, Johnson GM, et al. Cogni- TB). WHO / CDS / TB / 2018.18 tive function in post-treatment Lyme disease: World Health Organization. Global tuberculosis Do additional antibiotics help ? Neurology 2003; report 2018. World Health Organization Docu- 60: 1916-22. ment 2018; WHO / CDS / TB / 2018.20 Krupp LB, Hyman LG, Grimson R, et al. Study World Health Organization. WHO treatment gui- and treatment of post-Lyme disease (STOP- delines for isoniazid-resistant tuberculosis. Sup- LD): A randomized double masked clinical trial. plement to the WHO treatment guidelines for Neurology 2003; 60: 1923-30. drug-resistant tuberculosis. WHO / CDS / TB / Wormser GP, Ramanthan R, Nowakowski J, et al. 2018.7 Duration of antibotic therapy for early Lyme disease. A randomized, double-blind, placebo- Borréliose (LYME-disease) controlled trial. Ann Intern Med 2003: 138: 697- Steere AC, Batsford WP, Weinberg M, et al. Lyme 704. carditis: cardiac abnormalities of Lyme disease. Evison J, Aebi C, Franciolo P et al. Borréliose de Ann Intern Med 1980; 93: 8-16. Lyme. Rev Med Suisse 2006; 2: 919-24 (1 Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme part). et 925.34 (2nd part) et 935-40 (third part). disease - a tick-borne spirochetosis ? Science Lienhard R. Quelle est l’utilité de la sérologie de 1982; 216: 1317-9. Lyme? Rev Med Suisse 2015; 11: 1830-4. Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-96. Salmonellose Logigan EL, Kaplan RF, Steere AC. Chronic neu- Aserkoff B, Bennett JV. Effect of antibiotic therapy rologic manifestations of Lyme disease. N Engl in acute salmonellosis on the fecal excretion of J Med 1990; 323:1438-44. salmonellae. N Engl J Med 1969; 281: 636-40. Rahn DW. Lyme disease: clinical manifestations, Goldberg MB, Rubin RH. The spectrum of salmo- diagnosis, and treatment. Semin Arthritis nella infection. Infect Dis Clin North Am 1988; 2: Rheum 1991; 20: 201-18. 571-98. Rahn DW, Malawista SE. Lyme disease. Ann In- Wistrom J, Jertborn M, Ekwall E, et al. Empiric tern Med 1991; 114: 472-81. treatment of acute diarrheal disease with norflo- Fallon BA, et al. Lyme disease: a neuropsychia- xacin: a randomized placebo contolled study. tric illness. Am J Psychiatry 1994; 151:1571-83. Swedish study group. Ann Intern Med 1992; Stanek G, O'Connell S, Cimmino M, et al. Euro- 117: 202-8. pean Union Concerted Action on Risk Assess- Rowe B, Ward LR, Threlfall EJ. Multidrug-resi- ment in Lyme Borreliosis: Clinical case stant Salmonella typhi: a worldwide epidemic. definitions for Lyme borreliosis. Wien Klin Wo- Clin Infect Dis 1997; 24 (Suppl.1): S106-9. chenschr 1996; 108: 741-7. Mandell GL. Principles and Practice of Infectious Centers for Disease Control and Prevention. diseases. 5th edition Churchill Livingstone. Case definitions for infectious conditions under 2000. public health surveillance. MMWR Recomm Oehri I, Frei R, Sponagel L et al. Salmonellosen. Rep 1997; 46: 1-55. Schweiz Med Forum 2005; 5: 1000-7. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftria- Endocardite xone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Von Reyn CF, Levy BS, Arbeit RD, et al. Infective Engl J Med 1997; 337: 289-94. endocarditis: an analysis based on strict case Tugwell P, Dennis D, Weinstein A, et al. Labora- definitions. Ann Intern Med 1981; 94: 505-18. tory evaluation in the diagnosis of Lyme die- Durack DT, Lukes AS, Bright DK, et al. New crite- sease. Ann Intern Med 1997; 127: 1109-23. ria for diagnosis of infective endocarditis: utiliza- Nahimana I, Praz G, Francioli P. Borréliose de tion of specific echocardiographic findings. Am Lyme: actualités. Rev Med Suisse Rom 2000; J Med 1994; 96: 200-9. 120: 31-7. Wilson WR, Karchmer AW, Dajani AS, et al. Anti- Wormser GP, Nadelman RB, Dattwyler RJ, et al. biotic treatment of adults with infective endocar- Practice guidelines for the treatment of Lyme ditis due to streptococci, enterococci, disease. Clin Infect Dis 2000; 31 (Suppl. 1): S1- staphyloccci and HACEK microorganisms. 14. JAMA 1995; 274: 1706-13. Klempner MS, Hu LT, Evans J, et al.Two control- Dajani AS, Taubert KA, Wilson W, et al. Preven- led trials of antibiotic treatment in patients with tion of bacterial endocarditis. Recommendati- persistent symptoms and a history of Lyme ons by the American Heart Association. JAMA disease. N Engl J Med 2001; 345: 85-92. 1997; 277:1794-1801. Nadelman RB, Nowakowski J, Fish D, et al. Pro- Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis phylaxis with single-dose Doxycycline for the and management of infective endocarditis and prevention of Lyme disease after an Ixodes sca- its complications. Circulation 1998; 98: 2936- pularis tick bite. N Engl J Med 2001; 345: 79- 48. 84. Little J. The American Heart Association’s guideli- Shapiro AE. Doxycylcine for tick bites - nor for nes for the prevention of bacterial endocarditis: everyone. N Engl J Med 2001; 345: 133-4. a critical review. Gen Dent 1998; 46: 508-15. 76 Moreillon P, for the Swiss working group for endo- Falagas ME, Bliziotis IA. Quinolones for Treat- carditis prophylaxis. Schweiz Med Wochenschr ment of Human Brucellosis: Critical Review of 2000; 130: 1013-26. the Evidence from Microbiological and Clinical Mylonakis E, Calderwood SB. Infective endocar- Studies. Antimicrob Agents Chemother 2006; ditis in adults. N Engl J Med 2001; 345: 1318- 50: 22-23. 30. Roushan MRH, Mohraz M, Hajiahmadi M, et al. Efficacy of Gentamicin plus Doxycycline versus Legionella pneumophila Streptomycin plus Doxycycline in the Treatment Fraser DW, Tsai TR, Orenstein W, et al: Legion- of Brucellosis in Humans. Clinical Infectious naires’ disease: description of an epidemic of Diseases 2006; 42: 1075-80. pneumonia, N Engl J Med 1977; 297: 1189-97. Edelstein PH. Legionnaires’ disease. Clin Infect Maladie de griffes de chat Dis 1993; 16: 741-9. Holley HP. Successful treatment of cat-scratch Plouffe JF, File TM, Breimann RF. Reevaluation disease with ciprofloxacin. JAMA 1991; 265: of the difinition of Legionnaire’s disesase: use 1563-5. of the urinary antigen assay. Clin Infect Dis Margileth AM. Antibiotic therapy for cat-scratch 1995; 20: 1286-91. disease: clinical study of therapeutic outcome in Stout JE, Yu VL. Legionellosis. N Engl J Med 268 patients and a review of th literature. Pe- 1997; 337: 682-7. diatr Infect Dis J 1992; 11: 474-8. Gilbert DN, Moellering RC, Sande MA. The Sand- Bass JW, Freitas BC, Freitas AD. Prospective ford Guide to antimicrobial therapy; 2003. randomized double -blind placebo-controlled evaluation of azithromycin for treatment of cat- Listéria monocytogenes scratch disease. Pediatr Infect Dis J 1998; 17: Bula CJ, Bille J, Glauser MP. An epidemic of 447-52. food-borne Listeriosis in western Switzerland: Chia JK, Nakata MM, Lami JL, et al. Azithromycin description of 57 cases involving adults. Clin In- for the treatment of cat-scratch disease. Clin In- fect Dis 1995; 20: 66-72. fect Dis 1998; 26: 193-4. Sizthwick FS, Purich DL. Intracellular pathogenesis of Listeriosis. N Engl J Med 1996; 334: 770- Morsure d’animaux et d’humains - 6. Bisswunden Calder JAM. Listeria meningitis in adults. Lancet Stucker FJ, Shaw GY, Boyd S, et al. Management 1997; 350: 307. of animal and human bites in the head and Dalten CG, Austin CC, Sobel J, et al. An outbreak neck. Arch Otorlaryngol Head Neck Surg 1990; of gastroenteritis and fever due to Listeria mo- 116: 789-93. nocytogenes in milk. N Engl J Med 1997; 336: Weber DH, Ganson AR. Infections resulting from 100-5. animal bites. Infect Dis Clin North Am 1991; 5: Lorber B. Listeriosis. Clin Infect Dis 1997; 24: 1- 663-80. 11. Goldstein EJC. Bite wounds and infection. Clin In- Schuchat A, Robinson K, Wenger JD, et al. Bac- fect Dis 1992; 14: 633-8. terial meningitis in the United States in 1995. N Klein NC, Cunha BA. Pastorella multocida pneu- Engl J Med 1997; 337: 970-6. monia. Semin Respir Infect 1997; 12: 54-6. Mylonakis E, Hohmann EL, Calderwood SB. Cen- Fleisher GR. The management of bite wounds. tral nervous system infection with Listeria mo- NEJM 1999; 340:138-40. nocytogenes. 33 years' experience at a general Talan DA, Citron DM, Abrahamian FM, et al. Bac- hospital and review of 776 episodes from the li- teriologic analysis of infected doc and cat bites. terature. Medicine (Baltimore). 1998; 77: 313- N Engl J Med 1999; 340: 85-92. 36.vioe Medeiros I, Saconato H. Antibiotic prophylaxis for Lorber B. Listeria monocytogenes. In: Principles mammalian bites. Cochrane Database Syst and Practice of Infectious Diseases. 5th ed. Rev 2001; 2: CD001738. Mandell GL, et al. Churchill Livingstone, Phil- Green BT, Ramsey KM, Nolan PE. Pasteurella adelphia 2000; p. 2208. multocida meningitis: case report and review of Mylonakis E, Paliou M, Hohmann EL, et al. Liste- the last 11 years. Scand J Infect Dis 2002; 34: riosis during pregnancy: a case series and re- 213-7. view of 222 cases. Medicine (Baltimore) 2002; Gilbert DN, Moellering RC, Sande MA. The Sand- 81: 260-9. ford Guide to antimicrobial therapy; 2003. HOf H. An update on the medical management of Broder J, Jerrardd D, Olshaker J, et al. Low risk listeriosis. Expert Opin Pharmacother 2004; 5: of infection in selected human bites treated wit- 1727-35. hout antibiotics. Am J Emerg Med 2004; 22: 10- Ooi ST, Lorber B. Gastroenteritis due to Listeria 13. monocytogenes. Clin Infect Dis 2005; 40: 1327- Taplitz RA. Managing bite wounds: current re- 32. commended antibiotics for treatment and pro- Brouwer MC, van de Beek D, Heckenberg SG. phylaxis. Postgrad Med 2004; 116: 49-59. Community-acquired Listeria monocytogenes Prä- und postexpositionelle Tollwutprophylaxe meningitis in adults. Clin Infect Dis 2006; 43: beim Menschen. Schweizerische Bundesamt 1233-8. für Gesundheitswesen 01.07.2004. Oehler RL, Velez AP, Mizrachi M et al. Bite-rela- Brucellose ted and septic syndromes caused by cats and 77 dogs. Lancet Infect Dis 2009; 9: 439-47. Mulligan ME, et al. Methicillin-resistant Staphyloc- Eigenmann K, Vogt M. Was tun bei Bissverletzun- cus aureus: a consenus review of the microbio- gen? Schweiz Med Forum 2015; 15: 172-6. logy, pathogenesis, and epidemiology with implications for prevention and management. Clostridium difficile Am J Med 1993; 94: 313-28. Kelly CP, Pothoulakis C, LaMont JT. Clostridium Sanford MD, Widmer AF et al. Efficient detection difficile colitis. N Engl J Med 1994; 330: 257-62. and long-term persistence of carriage of methi- Blossom DB, McDonald CL. The Challenges cillin-resistant S. aureus. Clin Infect Dis 1994; Posed by Reemerging Clostridium difficile In- 19: 1123-8. fection. Clin Infect Dis 2007; 45: 222-7. Working party Report: Revised guidelines for the Neal MD, Alverdy JC, Hall DE, et al. Diverting control of methicillin-resistant Staphylococcus loop ileostomy and colonic lavage: An alterna- aureus infection in hospital. J of Hosp Infection tive to total abdominal colectomy for the treat- 1998; 39: 253-90. ment of severe, complicated Clostridium difficile Mandell, Douglas, and Bennett’s. Principles and associated disease. Ann Surg 2011;254:423-7; Practice of infectious diseases. Churchill Living- discussion 427-9. stone 5th ed, 2000. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomi- Oliveira DC, Tomasz A, de Lencastre H. Secrets cin versus vancomycin for Clostridium difficile of success of a human pathogen: molecular infection. NEJM 2011; 364: 422-31. evolution of pandemic clones of methicillin-resi- Cornely OA. Current and emerging management stant Staphylococcus aureus. Lancet Infect Dis. options for Clostridium difficile infection: What is 2002; 2: 180-9. the role of fidaxomicin? Clin Microbiol Infect Wunderlingk RG, Rello J, Cammarata SK, et al. 2012;18 (Suppl. 6):28-35 Linezolid vs vancomycin: analysis of the dou- Cohen SH, Gerding ND, Johnson S, et al. Clinical ble-blind studies of patients with methicillin-resi- practice guidelines for Clostridium difficile infec- stant Staphycococcus aureus nosocomial tion in adults: 2010 update by the Society for pneumonia. Chest 2003; 124: 1789-97. Healthcare Epidemiology of America (SHEA) Lee MC, Rios AM, Aten MF, et al. Management and the Infectious Diseases Society of America and outcome of children with skin and soft tis- (IDSA). Infect Control Hosp Epidemiol 2010; 31: sue abscesses caused by communty-acquired 431-55. methicillin-reistant Staphylococcus aureus. Pe- Smits LP, Bouter KE, de Vos WM, et al. Thera- diatr Infect Des J 2004; 23: 123-7. peutic potential of fecal microbiota transplanta- Harbarth S, Francois P, Schrenzel J et al. Com- tion. Gastroenterology 2013; 145: 946-53. munity-associated methilcillin-resistant Stra- van Nood E, Vrieze A, Nieuwdorp M, et al. Duo- phylcoccus aureus. Emerg Infect Dis 2005; 11: denal infusion of donor feces for recurrent Clo- 962-5. stridium difficile. NEJM 2013; 368: 407-15. Zimmerli W. Infektiologie: Der ambulant erwor- Debast SB, Bauer MP, Kuijper EJ, and The Com- bene methicillinresistente Staphylcoccus au- mittee European Society of Clinical Microbio- reus (CA-MRSA). Schweiz Med Forum 2005; 5: logy and 1285-7. Infectious Diseases (ESCMID): Update of the Gorwitz RJ, Jernigan DB, Powers HJ, et al. Stra- treatment guidance document for Clostridium tegies for clinical management of MRSA in the difficile infection (CDI). Clin Microbiol Infect community: summary of an experts’ meeting 2014;20(Suppl. 2): 1-26. convened by the CDC. March 2006. Gié O, Clerc D, Giulieri S et al. Prise en charge www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_Exp de la colite à Clostridium difficile. Rev Med MtgStrategies.pdf Suisse 2014; 10: 1309-13. Daum RS. Skin an doft-itssue infections caused Syphilis by Methicillin-resistant Staphylcoccus aureus. N Larsen SA, Steiner BM, Rudolph AH. Laboratory Engl J Med 2007; 357: 380-90. diagnosis and interpretation of tests for syphilis. Malaria (paludisme) Clin Microbiol Rev 1995; 8: 1-21. INTERNET: Young H. Syphilis. Serology. Dermatol Clin. 1998; - www.safetravel.ch and NET: cdc.com 16: 691-8. - www.sti-ch (= schweiz. Tropeninstitut). Notfall- Peeling RW, Ye H. Diagnostic tools for preventing nummer: 061/284.81.44 and managing maternal and congenital syphilis: - www.hc-sc.gc.ca/pphb-dgspsp/publicat/ccdr- an overview. Bulletin of the World Health Or- rmtc/97vol23/23s5/index_f.html ganization 2004; 82: 439-46. Markwalder K., Hatz C. Malaria-Therapie 1998. Itin P, Bosshard PP, Toutous Trellu L, Schmidt AJ, Schweiz Med Wochenschr 1998; 128: 13-27. Vernazza P, Tarr Ph et al. Syphilis: Diagnostik Warrell DA, Molyneux ME, Beales PF. Severe und Behandlung. Schweiz Med Forum and complicated malaria. WHO malaria action 2015;15:459. programme. Trans R Soc Trop Med Hyg 1990; MRSA / MSSA -- SASM / SARM 84 (Suppl. 2): 1-65. Boyce JM. Methicillin-resistant Staphylococucs Winters R.A., Murray H.W. Malaria - The Mime aureus. Detection, epidemiology, and control Revisited: Fifteen More Years of Experience at measures. Infect Dis Clin North Am 1989; 3: a New York City Teaching Hospital. The Ameri- 901-13. can Journal of Medicine. 1992; 93: 243-6. 78 Gilles HM, Warrel DA. Bruce-Chwatt’s Essential Owens DK, Holodniy M, Garber AM, et al. Poly- of Malariology,. Edward Arnold, 1993. merase chain reaction for the diagnosis of HIV Recommendations canadiennes pour la préven- infection in adults. A meta-analysis with recom- tion et le traitement du paludisme (malaria) mendations for clinical practice and study de- chez les voyageurs internationaux 1995. Re- sign. Ann Intern Med 1996; 124: 803-15. levé des maladies transmissibles au Canada, Bush MP, Satten GA. Time course of viremia and RMTC 1995, volume 21S3, octobre. antibody seroconversion following human im- Swenson JE, MacLean JD, Gyorkos TW, et al. munodeficiency virus exposure. Am J Med Imported malaria. Clinical presentation and ex- 1997; 102: 117-26. amination of symptomatic travelers. Arch Intern Office fédéral de la santé publique (OFSP). Med 1995; 155: 861-8. 22.12.1997. Office fédéral de la santé publique, Division Epi- Bulletin de l’Office fédéral de la santé publique démiologie et maladies infectieuses - Guide (OFSP). Expositions à du sang en milieu pro- méthodologique des maladies transmissibles - fessionnel et traitement prophylactique post-ex- Janvier 1996. positionnel en Suisse jusqu'à fin 1996. Bulletin White NJ. The treatment of malaria. N Engl J Med de l’OFSP 1998; 27: 14-19. 1996; 335: 800-6. CDC: Public health service guidelines for the ma- Recommandations canadiennes pour la préven- nagement of health-care worker exposures to tion et le traitement du paludisme (malaria) HIV and recommendations for postexposure chez les voyageurs internationaux 1997. Re- prophylaxis. MMWR 1998; 47: 1-31. levé des maladies transmissibles au Canada, Hirschel B, Kaiser L. (eds.). In: Le Sida. Guide du RMTC (www.hc-sc.gc.ca/pphb-dgspsp/publi- praticien - Diagnostic, traitement, prise en cat/ccdr-rmtc/97vol23/23s5/index_f.html). charge. M&H, 1998. Warrell DA. Cerebral malaria: clinical features, Jost M et al. Prévention des maladies infectieu- pathophysiology and treatment. Ann Trop Med ses transmises par voie sanguine dans le sec- Parasitol 1997; 91: 875-84. teur sanitaire. SUVA 1998; 2869/30.f. Newton CR, Taylor TE, Whitten RO. Pathophysio- Bulletin de l’Office fédéral de la santé publique logy of fatal falciparum malaria in African chil- (OFSP). Nouveautés dans le diagnostic de l’in- dren. Am Trop Med Hyg 1998; 58: 673-83. fection par le VIH et complément au " concept Genton B. Tests rapides pour le diagnostic des de test VIH ". OFSP 1998; 29 novembre 1999. maladies tropicales. Med Hyg 1999; 57: 1120-6. 1999 USPHS/IDSA guidelines for the prevention Warrell DA. The management of severe malaria. of opportunistic infections in persons infected Parasitology 1999; 41: 287-94. with Human Immunodeficiency Virus. Mandell GL. Principles and Practice of Infectious USPHS/IDSA Prevention of Opportunistic Infec- diseases. 5th edtition Churchill Livingstone tions Working Group. Infectious Diseases So- 2000. ciety of American. Ann Intern Med 1999; 131: World Health Organisation. Severe Falciparum 873-908. Malaria. Trans R Soc Trop Med Hyg 2000; 94 1999 USPHS/IDSA guidelines for the prevention (Sl): 1-90 of opportunistic infections in persons infected Genton B. Malaria: Prophylaxe und Therapie - Ist with human immunodeficiency virus. U.S. Pu- die Mefloquin-Aera vorbei? Schweiz Med blic Health Service (USPHS) and Infectious Forum 2001; 1: 337-44. Diseases Society of America (IDSA). MMWR Hatz C. Clinical Treatment of Malaria in Returned 1999; 48 (RR-10): 1-59, 61-6. Travelers. In: Schlagenhauf P. (Hrsg). Travelers' Bürgisser P, Spertini F. Test de diagnostic et de Malaria. BC Decker, Hamilton - London 2001; suivi de l’infection par le VIH: progrès récents. 431-445. Med Hyg 1999; 57: 867-71. D’Acremont V et al. Treatment of imported mala- Ledergerber B, Egger M, Erard V, et al. AIDS-re- ria in an ambulatory setting: prospective study. lated opportunistic illnesses occurring after in- BMJ. 2002; 324: 875–7. itiation of potent antiretroviral therapy: the D'Acremont V, Burnand B, Ambresin AE, Genton Swiss HIV Cohort Study. JAMA 1999; 282: B. Practice guidelines for evaluation of fever in 2220-6. returning travelers and migrants. J.Travel Med. Rime Dubey B, Telenti A, Francioli P. Prise en 2003;10:S25-S52. charge des expositions professionnelles à du Whitty CJ, Lalloo D, Ustianowski A. Malaria: an sang ou à d’autres liquides biologiques conta- update on treatment of adults in non-endemic minés par les hépatites B et C et le VIH. Rev countries. BMJ 2006; 333: 241-5. Med Suisse Rom 1999; 119: 587-92. Carpenter CC, Cooper DA, Fischl MA, et al. Anti- SIDA / AIDS, virostatiques retroviral therapy in adults: updated recommen- Société canadienne (1-800-499-1986) dations of the International AIDS Society-USA INTERNET: Panel. JAMA 2000; 283: 381-90. • www.cdnaids.ca Sulkowski MS, Thomas DL, Chaisson RE, Moore • www.hivnet.ch Krawczynski K, Alter MJ, Tankersley DL, et al. Ef- RD. Hepatotoxicity associated with antiretroviral fect of immune globulin on the prevention of ex- therapy in adults infected with human immuno- perimental hepatitis C virus infection. J Infect deficiency virus and the role of hepatitis C or B Dis 1996; 173: 822-8. virus infection. JAMA 2000; 283: 74-80. Whitcup SM. Cytomegalovirus retinitis in the era 79 of highly active antiretroviral therapy. JAMA 2003; 345: 2293-303. 2000; 283: 653-7. Benson CA, Kaplan JE, Masur H, Pau A, Holmes 1999 USPHS/IDSA Guidelines for the prevention KK. Treating opportunistic infections among of opportunistic infections in persons infected HIV-infected adults and adolescents: recom- with HIV: part I. Prevention of exposure. Am mendations from CDC, the National Institutes of Fam Physician 2000; 61: 163-74. Health, and the HIV Medicine Association/Infec- 1999 USPHS/IDSA Guidelines for the Prevention tious Diseases Society of America. MMWR Re- of Opportunistic Infections in Persons Infected comm Rep 2004; 53: 1-112. with HIV: Part II. Prevention of the first episode Gulick RM, J. Ribaudo HJ, Shikuma CM et al. Tri- of disease. U.S. Department of Health and ple-Nucleoside Regimens versus Efavirenz- Human Services, Public Health Service, Cen- Containing Regimens for the Initial Treatment of ters for Disease Control and Prevention. U.S. HIV-1 Infection. New Engl J Med 2004; 350: Public Health Service/Infectious Diseases So- 1850-61. ciety of America. Am Fam Physician 2000; 61: Hammer SM, Saag MS, Schechter M, et al. Treat- 441-2, 445-9, 453-4. ment for adult HIV infection: 2006 recommen- 1999 USPHS/IDSA Guidelines for the prevention dations of the International AIDS Society-USA of opportunistic infections in persons infected panel. JAMA 2006; 296: 827-43. with HIV: Part III. Prevention of disease recur- Herpès: HSV, VZV-Zoster, EBV, CMV rence. United States Public Health Service/In- fectious Diseases Society of America. Am Fam Corey L, Nahmias AJ, Guinan ME, et al. A trial of Physician 2000; 61: 771-8, 780, 785. topical acyclovir in genital herpes simplex virus Bassetti S, Battegay M, Sudre P. Access to anti- infections. NEJM 1982; 306: 1313-9. retroviral therapy. JAMA 2000; 283: 883-4; dis- Ragozzino MW, Melton LJ, III, Kurland LT, Chu cussion 884. CP, Perry HO. Population-based study of her- Flepp M, Jost J, Hirschel B, et al. Subkomission pes zoster and its sequelae. Medicine (Balti- Klinik (SKK) der Eidg. Kommission für AIDS- more) 1982; 61: 310-6. Fragen (EKAF): Empfehlungen zur antiretrovi- Andersson J, Ernberg I. Management of Epstein- ralen HIV-Therapie 2001. Bulletin, des Barr vius infections. Am J Med 1988;85:107-15. Bundesamtes für Gesundheit 2000; 51: 994- Haake DA, Zakowski PC, Haake DL, et al. Early 1000. treatment with acyclovir for varicella pneumonia Gallant JE. Strategies for long-term success in in otherwise healthy adults: retrospective con- the treatment of HIV infection. JAMA 2000; 283: trolled study and review. Rev Infect Dis 1990; 1329-34. 12: 788-98. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. An- OrenI, Sobel JD. Human herpesvirus type 6: re- tiretroviral drug resistance testing in adult HIV-1 view. Clin Infect Dis 1992; 14: 741-6. infection: recommendations of an International Reusser P, Gambertoglio JG, Lilleby K, et al. AIDS Society-USA Panel. JAMA 2000; 283: Phase I-II trial of foscarnet for prevention of cy- 2417-26. tomegalovirus infection in autologous and allo- Kovacs JA, Masur H. Prophylaxis against oppor- genic marrow transplant recipients. J Infect Dis tunistic infections in patients with human immu- 1992; 166: 303-310. nodeficiency virus infection. N Engl J Med Wallach MR, et al. Treatment of adult varicella 2000; 342: 1416-29. with oral acyclovir. A randomized placebo-con- Ledergerber B, Egger M, Telenti A. AIDS-Related trolled trial. Ann Intern Med 1992; 117: 358-63. opportunistic illness and potent antiretroviral Rooney JF, et al. Oral acyclovir to suppress fre- therapy. JAMA 2000; 283: 2653-4. quently recurrent herpes labialis: A double-blind Furrer H. Behandlung und Prävention der wichtig- placebo-controlled trial. Ann Intern Med 1993; sten HIV-assoziierten Infektionen. Schweiz Med 118: 268-72. Forum 2001; 1: 605-12. Wood MJ, et al. A randomized trial of acyclovir for Tillmann HL, Heiken H, Knapik-Botor A, et al. In- 7 days or 21 days with and without predniso- fection with GB virus reduced mortality amoung lone for treatment of acute herpes zoster. N HIV-infected patients. N Engl J Med 2001; 345: Engl J Med 1994; 330: 896-900. 715-24. Kost RG, Strauss St. Postherpetic neuralgia – pa- Updated U.S. Public Health Service Guidelines thogenesis, treatment and prevention. N Engl J for the management of occupational exposures Med 1996; 335: 32-42. to HBV, HCV and HIV and recommenations for Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclo- postexposure prophylaxis. MMWR 2001; 58 vir with and without prednisone for the treat- (RR-11): 1-52. ment of herpes zoster. A randomized, Xiang J, Wunschmann S, Diekema D, et al. Effect placebo-controlled trial. Ann Intern Med 1996; of coinfection with GB virus C on survival 125: 831-2. amoung patients with HIV infection. N Engl J Jackson JL, Gibbons R, Meyer G, et al. The ef- Med 2001; 345: 707-14. fect of treating herpes zoster with oral acyclovir Guidelines for the use of antiretroviral agents in in preventing postherpetic neuralgia. A meta- HIV-1-infected adults. MMWR 2003; july 14. analysis. Arch Intern Med 1997; 157: 909-12. Robbins GK, De Gruttola V, Shafer RW et al. Reitano M, Tyring S, Lang W, et al. Valaciclovir Comparison of sequential three-drug regimens for the suppression of recurrent genital herpes as initial therapy for HIV-1 infection. N Engl J M simplex virus infection: a large-scale dose 80 range-finding study. J Infect Dis 1998; 178: 603- Clin Proc 1992; 67: 910-2. 10. Robert-Gangneux F, Dardé ML. Epidemiology Rowbotham M, Harden N, Stacey B. Gabapentin and diagnostic strategies for toxoplasmosis. for the treatment of postherpetic neuralgia. Clin Microbiol Rev 2012; 25: 264-96. JAMA, 1998; 280: 1837-42. Anonyme. Concept suisse de test VIH : récapitu- Whitley RJ, Kimberlin DW, Roizman B. Herpes latif actualisé. Bulletin OFSP 2013;6:6-14. simplex virus. Clin Infect Dis 1998; 26: 541-55. Valin N. Conduite à tenir devant un syndrome Reusser P. Management of viral infections. In: mononucléosique. EMC Maladies infectieuses Klastersky J, Schimpff SC, Senn H-J, eds. Sup- 2014; 11: 1-5. portive care in cancer: A handbook for oncolo- Lennon P, Crotty M, Fenton JE. Infectious mono- gists. 2nd ed. New York: Marcel Dekker, 1999: nucleosis. BMJ 2015; 350: h1825. 87-112. De Paor M, O'Brien K, Fahey T, et al. Antiviral Cathomas G. Human herpes virus 8: a new virus agents for infectious mononucleosis (glandular disclosis its face. Virchows Arch 2000; 436: fever). Cochrane Database Syst Rev 195-206. 2016;12:CD011487. Furuta Y, Ohtaniu F, Kawabata H, et al. High pre- Dumoulin A, Eyer M. Causes fréquentes de mo- valence of varciella-zoster virus reactivation in nonucléose infectieus. Rev Med Suisse 2018 ; herpes simplex virus-seronegative patients with 14 : 1799-802. acute peripheral facial palsy. Clin Infect Dis Sonderegger J, Karrer U, Huber B et al. In- 2000; 30: 529-33. fektiöse Mononukleose: Update für die Praxis. Helgason S, Petursson G, Gudmundsson S, Si- Praxis 2021 in press. gurdsson JA. Prevalence of postherpetic neur- Tétanos algia after a first episode of herpes zoster: prospective study with long term follow up. BMJ NET: www.bag.admin.ch 2000; 321: 794-6. Ahmadsyah I, Salim A. Treatment of tetanus: an Reusser P. Antiviral therapy: Current opinions and open study to compare the efficacy of procaine challenges. Schweiz Med Wschr 2000; 130: penicillin and metronidazole. Br Med J 1985; 101-12. 291: 648-50. Schmader K. Herpes zoster in older adults. Clin Sun KO, Chan YW, Cheung RT, et al. Manage- Infect Dis 2001; 32: 1481-6. ment of tetanus: a review of 18 cases. J R Soc Wald A, Langenberg AG, Link K, et al. Effect of Med 1994; 87: 135-7. condoms on reducting the transmission of her- Sanford J. Tetanus – Forgotten but not gone. N pes simplex virus type 2 from men to women. Engl J Med 1995; 332: 812. JAMA 2001; 285: 3100-6. Mandell GL. Principles and Practice of Infectious Gnann JW, Whiteley. Herpes Zoster. N Engl J diseases. 5th edition Churchill Livingstone. Med 2002; 347: 340-6. 2000. Raschilas F, Wolff M, Delatour F, et al. Outcome Rage of and prognostic factors for herpes simplex en- Centers for Disease Control and Prevention. cephalitis in adults patients: results of a multi- Human rabies prevention - United States, 1999. center study. Clin Infect Dis 2002; 35: 254-60. Recommendations fo the advisory committee Hjalgrim H, Askling J, Rostgaard K, et al. Charac- on immunization practices (ACIP). Morb Mortal teristics of Hodgkin’s lymphoma after infectious Wkly Rep 1998; 48 (RR-1): 1-21. mononucleosis, N Engl J Med 2003; 349: 1324- 32. Diphthérie Swiss Herpes Management Forum. Schweizer Wilson AP. Treatment of infection caused by toxi- Empfehlungen für das Management des Her- genic and non-toxigenic strains of Corynebacte- pes genitalis und Herpes-simplex-Virus Infek- rium diphtheriae. J Antimicrob Chemoth 1995; tion des Neugeborenen. Schweiz Ärztezeitung 35: 717-20. 2005; 86: 780-92. Vaccins: Meylan P, Kempf W, Gerber S, et al. Recomman- dations suisses pour la prise en charge des in- Grippe fections dues au virus de la varicelle-zoster. Tétanos Forum Med Suisse 2007; 7: 895-905. Pneumocoque Lautenschlager S. Herpes-simplex-Infektionen Hépatites der Haut. Schweiz Med Forum 2013; 13:703-8. NET: www.cdc.gov/disease/flu/weekly.htm Buvelot H, Lebowitz D, Huttner B. et al. Infection NET: www.influenza.ch (centre de grippe national, Genève) par le virus Varicella zoster chez l’adulte : au- delà du zona ? Rev Med Suisse 2016; 12: 738- INFLUENZA 43. Nichol KL, Margolis KL, Wuorenma J, et al. The Surber J, Hunziker M, Navarria I et al. Genitalher- efficacy and cost effectiveness of vaccination pes – Update 2020 für die Praxis. Primary Hosp against influenza among elderly persons living Care – Allg Innere Med 2020; 20: 100-104. in the community. N Engl J Med 1994; 331: 778-84. EPSTEIN-BARR virus - Mononukleose Nichol KL, Lind A, Margolis KL, et al. The effecti- Aldrete JS. Spontaneous rupture of the spleen in veness of vaccination against influenza in heal- patients with infectious mononucleosis. Mayo thy, working adults. N Engl J Med 1995; 333: 81 889-93. 19) From Publicly Reported Confirmed Cases: Recommendations pour la prévention de la Estimation and Application. Ann Intern Med grippe. Office fédéral de la santé publique. Bul- 2020; 172: 577-82. letin OFSP, Suppl. XIII, août 1996. Leismann DE, Ronner L, Pinotti R et al. Cytokine Magnenat JL. Vaccins anti-grippal et anti-pneu- elevation in severe and critical COVID-19: a mococcique chez la personne âgée. Med Hyg rapid systematic review, meta-analysis, and 1997; 55: 977-80. comparison with other inflammatory syndromes Bulletin de l’OFSP. Une nouvelle possibilité de Lancet https://doi.org/10.1016/S2213- traiter les infections par le virus grippal. Bulletin 2600(20)30404-5 44/99, OFSP 1 novembre 1999. Li L, Zhang W, Hu Y et al. Effect of Convalescent Bundesamt für Gesundheit, Arbeitsgruppe Influ- Plasma Therapy on Time to Clinical Improve- enza, Schweizerische Kommission für Impffra- ment in Patients With Severe and Life-threate- gen. Empfehlung zur Grippeprävention, in: ning COVID-19: A Randomized Clinical Trial. Bundesamt für Gesundheit, ed. Infektionskrank- JAMA 2020; 324: 460-470. heiten. Diagnose und Bekämpfung. Bern: Bun- Petrilli Ch, Jones SA, Yang J et al. Factors asso- desamt für Gesundheit, Suppl. XIII; 2000. ciated with hospital admission and critical ill- Wenzel RP. Expanding the treatment options for ness among 5279 people with coronavirus influenza. JAMA 2000; 283: 1057-9. disease 2019 in New York City: prospective co- Bundesamt für Gesundheit, Arbeitsgruppe Influ- hort study. BMJ 2020;369:m1966. enza, Schweizerische Kommission für Impffra- Wang B, Ruobao L, Zhong L et al. Does comorbi- gen. Empfehlung zur Grippeprävention, in: dity increase the risk of patients with COVID-19: Bundesamt für Gesundheit, ed. Infektionskrank- evidence from meta-analysis. Aging 2020; 12: heiten. Diagnose und Bekämpfung. Bern: Bun- 6049-57. desamt für Gesundheit, Suppl. XIII; Wang D, Hu B, Hu C et al. Clinical Characteri- 2000.European Influenza Surveillance Scheme. stics of 138 Hospitalized Patients With 2019 Low and decreasing levels of influenza activity Novel Coronavirus-Infected Pneumonia in in Europe. 15 April 2005: 151. Wuhan, China. JAMA 2020; 323:1061-1069 Brief der EKIF an die Kantonsärzte vom 14. Juni Wong HYF, Lam HYS, Ho-Tung Fong A et al. Fre- 2006 quency and Distribution of Chest Radiographic EVM statement: Influenza vaccine supply for the Findings in Patients Positive for COVID-19. Ra- 2006/7 season: low yield of recommended diology 2020; 296: E72-E78. strain may lead to delivery delays. 9. Juni 2006 Pan Y, Zhang D, Yang P et al. Viral load of SARS- World Health Organization. Recommended com- CoV-2 in clinical samples. Lancet Infect Dis position of influenza virus vaccines for use in 2020; 20: 411-412 the 2006-2007 influenza season. Weekly epide- RECOVERY Collaborative Group. Dexametha- miological record No.9, 2006; 81: 82. sone in Hospitalized Patients with Covid-19 - COVID-19 Preliminary Report. NEJM 2020 July 17, DOI: 10.1056/NEJMoa2021436. Morgan RJM, Williams F, Wright MM. An early warning scoring system for detecting develo- TETANOS ping critical illness. Clin Intens Care 1997; 8: Weinstein L. Tetanus. N Engl J Med 1974; 289: 100. 1293-6. Beigel JH, Tomashek KM, Dodd LE et al. Remde- Centers for disease control. Diphtheria, tetanus, sivir for the Treatment of Covid-19 — Final Re- and pertussis; recommendations for vaccine se port NEJM 2020 Oct 8;NEJMoa2007764 and other preventive measures: recommendati- Cochrane Database Syst Rev. 2020;9:CD013639. ons of the immunization practices advisory Epub 2020 Sep 30. committee (ACIP). MMWR 1991; 40: 1-28. Goyal P, Choi JJ, Pinheiro L e al. Clinical Charac- PNEUMOCOQUE teristics of Covid-19 in New York City. NEJM Butler JC, Breimann RF, Campbell JF, et al. 2020; 382: 2372-2374. Pneumococcal polysaccharide vaccine efficacy. He J, GuoY, Mao R et al. Proportion of asympto- An evaluation of current recommendations. matic coronavirus disease 2019: A systematic JAMA 1993; 270: 1826-31. review and meta-analysis. J Med Virol 2020 Jul Farr BM, Johnston L, Cobb DK, et al. Preventing 21;10.1002/jmv.26326 pneumoccal bacteriemia in patients at risk. Re-

sults of a matched case-controle study. Arch In- Ilaria Liguoro I, Pilotto C, Bonanni M et al. SARS- tern Med 1995; 155: 2336-40. COV-2 infection in children and newborns: a sy- Konradsen HB. Quantity and avidity of pneumo- stematic review. Eur J Pediatr 2020; 179: coccal antibodies before and up to 5 years after 1029-46. pneumococcal vaccination of elderly persons. Kucirka LM, Lauer SA, Laeyendecker O et al. Va- Clin Infect Dis 1995; 21: 616-20. riation in False-Negative Rate of Reverse Magnenat JL. Vaccins anti-grippal et anti-pneu- Transcriptase Polymerase Chain Reaction- mococcique chez la personne âgée. Med Hyg Based SARS-CoV-2 Tests by Time Since Expo- 1997; 55: 977-80. sure. Ann Intern Med 2020; 173: 262-267. Nuorti PJ, Butler JC, Breiman RF. Prevention of Lauer SA, Grantz KH, Bi Q et al. The Incubation pneumococcal disease: recommendations of Period of Coronavirus Disease 2019 (COVID- the advisory committee on immunization practi- 82 ces (ACIP). MMWR 1997; 46, RR-8: 1-24. Fisher JF, Newman CL, Sobel JD. Yeast in the Ketterer JP, Rochat Th. Vaccin anti-pneumococci- urine: solutions for a budding problem. Clin In- que. Med Hyg 1999; 57: 2329-33. fect Dis 1995; 20: 183-9. Mühlemann K, Francioli P, et al. Prévention des Nguyen MH, Peacock JE Jr, Tanner DC, et al. infections à pneumocoques par la vaccination. Therapeutic appoaches in patients with candi- Schweiz Aerztezeitung 2000; 81: 561-7. demia. Evaluation in a multicenter, prospective, Prevention and control of influenza: Recommen- observational study. Arch Intern Med 1995; 155: dations of the advisory committee on immuniza- 2429-35. tion practices (ACIP). MMWR 2000; 49, RR-03: Witt MD, Lewis RJ, Larsen RA, et al. Identification 1-38. of patients with acute aids-associated cryptococcal meningitis who can be effectively treated Pharyngite aiguë / RAA with fluconazole: the role of antifungal suscepti- NET: www.idsociety.org bility testing. Clin Infect Dis 1996; 22: 322-8. Gerber MA. Comparison of throat cultures and Edwards JE, et al. International conference for rapid strep tests for diagnosis of streptococcal the development of a consensus on the ma- pharyngitis. Pediatr Infect Dis J 1989; 8: 820-4. nagement and prevention of severe candidal in- Guidelines for the diagnosis of rheumatic fever. fections. Clin Infect Dis 1997; 25: 43-59. Jones Criteria, 1992 update. Special Writing Sobel JD. Vaginitis. N Engl J Med 1997; 337: Group of the Committee on Rheumatic Fever, 1896-1903. Endocarditis, and Kawasaki Disease of the Van der Horst CM, Saag MS, Cloud GA, et al. Council on Cardiovascular Disease in the Treatment of cryptococcal meningitis associa- Young of the American Heart Association. JAMA ted with the acquired immunodeficiency syn- 1992; 268: 2069. drome. N Engl J Med 1997; 337: 15-21. Djani AS, Ayoub E, Bierman FZ, et al. Guidelines Denning DW. Invasive aspergillosis. Clin Infect for the diagnosis of rheumatic fever: Jones cri- Dis. 1998; 26: 781-5. teria, updated 1993. Circulation 1993; 87: 302- Walsh TJ, Hiemenz JW, Seibel NL, et al. Ampho- 7. tericin B lipid complex for invasive fungal infecti- Bisno AL, Gerber MA, Gwaltney JM, et al. Dia- ons: analysis of safety and efficacy in 556 gnosis and management of group A streptococ- cases. Clin Infect Dis 1998; 26: 1383-96. cal pharyngitis; A practice guideline. Clin Infect Francis P, Walsh TJ. Evolving role of flucytosine Dis 1997; 25: 574-583. in immunocompromized patients: new insights Nadal D, Weber R. Diagnose und Therapie der into safety, pharmacokinetics and antifungal akuten Tonsillo-pharyngitis durch Gruppe A therapy. Clin Infect Dis 1999; 16: 1-9. beta-hämolysierende Streptokokken. Schweiz Walsh TJ, Finberg RW, Arndt C, et al. Liposomal Ärztezeitung 1999; 80: 599-601; version fran- amphotericin B for empirical therapy in patients çaise p: 602-4. with persistent fever and neutropenia. N Engl J Zwart S, Sachs AP, Ruijs GJ, et al. Penicillin for Med 1999; 340: 764-71. acute sore throat: randomised double blind trial Fisher JF. Candiduia: when and how to treat it. of seven das versus three days treatment or Curr Infect Dis Rep 2000; 2: 523-30. placebo in adults. BMJ 2000; 320: 150-4. Rex JH, Walsh TJ, Sobel JD, et al. Practice gui- Bisno AL, Gerber MA, Gwaltney JM, et al. Prac- delines for the treatment of candidiasis. Clin In- tice guidelines for the diagnosis and manage- fect Dis 2000; 30: 662-78. ment of group A streptococcal pharyngitis. Clin Lundstrom T, Sobel J. Nosocomial candiduria: a Infect Dis 2002; 25: 113-25. review. Clin Infect Dis 2001; 32: 1602-7. Ferrieri P, Jones Criteria Working Group. Procee- Mora-Duarte J et al. Comparison of Caspofungin dings of the Jones Criteria workshop. Circula- and Amphotericin B for invasive Candidiasis. tion 2002; 106: 2521. New Engl J Med 2002; 347: 2020-9. Gilbert DN, Moellering RC, Sande MA. The Sand- Kullberg BJ, Pappas P, Ruhnke M et al. Voricona- ford Guide to antimicrobial therapy; 2003. zole compared with a strategy of amphotericin Gewitz MH, Baltimore RS, Tani LY, Sable CA et B followed by fluconazole of candidaemia in al. Revision of the Jones Criteria for the diagno- non-neutropenic patients. Abstract O245, 14th sis of acute rheumatic fever in the era of Dopp- ECCMID, Prague, May 1-4, 2004 ler echocardiography: a scientific statement from the American Heart Association. Circula- Infection urinaire — HWI (Harnwegsinfekt) Pyélonéphrite — Pyelonephritis tion 2015; 131: 1806-18. Prostatite/Épididymite Candidose Prostatitis/Epididymitis Graybill JR, Vasquez J, Darouiche RO, et al. Warren JW, Tenney JH, Hoopes JM, et al. A pro- Randomized trial of itraconazole oral solution spective microbiologic study of bacteriuria in for oropharyngeal candidiasis in hiv/aids pa- patients with chronic indwelling urethral cathe- tients. Am J Med 1988; 104: 33-9. ters. J Infect Dis 1982; 146: 719-23. Rex JH, Bennett JE, Sugar AM, et al. A randomi- Wong ES, McKevitt M, Running K, et al. Manage- zed trial comparing fluconazole with amphoteri- ment of recurrent urinary tract infections with cin B for the treatment of candidemia in patients patient-administered single-dose therapy. Ann without neutropenia. N Engl J Med 1994; 331: Intern Med 1985; 102: 302-7. 1325-30. Schaeffer AJ. Catheter-associated bacteriuria. Urol Clin North Am 1986; 13: 735-47. 83 Warren JW. Catheter-associated urinary tract in- rison of Levofloxacin 750 mg Once-Daily for fections. Infect Dis Clin North Am 1987; 1: 823- Five Days With Ciprofloxacin 400/500 mg 54. Twice-Daily for 10 Days for the Treatment of Pezzlo M. Detection of urinary tract infections by Complicated Urinary Tract Infections and Acute rapid methods. Clin Microbiol Rev 1988; 2: 268- Pyelonephritis. Urology 2008; 17-22. © 2008 El- 80. sevier Inc. Dickinson GM, Bisno AL. Infections associated Splénectomie with indwelling devices: concept of pathogenesis; infection associated with intravascular devi- Ruben FL, Hankins WA, Zeigler Z. Antibody re- ces. Antimicrob Agents Chemother 1989; 33: sponses to menigococcal polysaccharide vac- 597-607. cine in adults without a spleen. N Engl J Med Lipsky BA. Urinary tract infections in men: epide- 1983; 76: 115-21. miology, pathophysiology, diagnosis, and treat- McMullin M. Johnston G. Long term management ment. Ann Intern Med 1989; 110: 138-50. of patients after splenectomy. BMJ 1993; 307: Stapleton A, Latham RH, Johnson C, Stamm WE. 1372-3. Postcoital antimicrobial prophylaxis for recur- Waghorn DJ. Prevention of post-splenectomy rent urinary tract infection: a randomized, dou- sepsis. Lancet 1993; 341: 248. ble-blind, placebo-controlled trial. JAMA 1990; British committee for standard in haematolgoy, 264: 703-6. clinical haematology task force. Guidelines for Pappas PG. Laboratory in the diagnosis and ma- the prevention and treatment of infection in pa- nagement of urinary tract infections. Med Clin tients with an absent or dysfunctional spleen. North Am 1991; 75: 313-25. BMJ 1996; 312: 430-4. Humbert G. French consensus on antibiotherapy Genne D. Recommandations pour la prévention of urinary tract infections. The French Society et le traitement des infections chez les patients for Infectious Diseases. Infection 1992; 20 splénectomisés ou souffrant d’une rate non (Suppl 3): S171-2. fonctionnelle. Med Hyg 2001; 59: 2306-10. Neu HC. Urinary tract infections. Am J Med 1992; Anthrax 92(Suppl.4A): 63S-70S. INTERNET: http://www.bt.cdc.gov. Rubin RH, Shapiro ED, Andriole VT, et al. Evalua- La Force FM. Anthrax. Clin Infect Dis 1994; 19: tion of new anti-infective drugs for the treatment 1009-14. of urinary tract infection. Clin Infect Dis 1992; Centers for Disease Control, and Prevention. Bio- 15 (Suppl.1): S216-S27. terrorism alleging use of anthrax and interim Stamm WE, Hooton TM. Management of urinary guidelines for management: United States, tract infections in adults. N Engl J Med 1993; 1998. Morb Mortal Wkly Rep 1999; 48: 69-74. 329: 1328-34. Dixom TC, Meselson M, Guillemin J, et al. An- Hatton J, Hughes M, Raymond Ch. Management thrax. N Engl J Med 1999; 341: 815-26. of bacterial urinary tract infections in adults. Ann Inglesby TV, Henderson DA, Bartlett JG, et al. An- Pharmacother. 1994; 28: 1264-72. thrax as a biological and public health manage- Lipsky BA. Prostatitis and urinary tract infection in ment. Working group on civilian biodefense. men: what's new; what's true? Am J Med 1999; JAMA 1999; 283: 1735-45. [Erratum: JAMA 106: 327-34. 2000; 283: 1963] Rex JH, Walsh TJ, Sobel JD, et al. Practice gui- Shafazand S, Doyle R, Ruoss S, et al. Inhalatio- delines for the treatment of candidiasis. Clin In- nal Anthrax. Epidemiology, Diagnosis, and Ma- fect Dis 2000; 30: 662-78. nagement. Chest 1999; 116: 1369-76. Tambyah PA, Maki DG. Catheter-associated uri- Swartz AN. Recognition and management of an- nary tract infection is rarely symptomatic: a pro- thrax - an update. N Engl J Med 2001; 345: spective study of 1,497 catheterized patients. 1621-6. Arch Intern Med 2000; 160: 678-82. Gilbert DN, Moellering RC, Sande MA. The Sand- Infection de cathéter ford Guide to antimicrobial therapy; 2003. Bryant JK, Strand CL. Reliability of blood cultures Hooton TM, Scholes D, Gupta K et al. Amoxicillin- collected from intravascular catheter versus Clavulanate vs Ciprofloxacin for the Treatment veinpuncture. Am J Clin Pathol 1987; 88: 113-6. of Uncomplicated Cystitis in Women. A Rando- Mansfield PF, Hohn DC, Fornage BD, et al. Com- mized Trial. JAMA 2005; 293: 949-955. plications and failures of subclavian-vein cathe- Mandell, Douglas, Bennett’s Principles and Prac- terization. N Engl J Med 1994; 331: 1735-8. tices of Infectious Diseases. Sixth Edition 2005. Raad I. Intravascular-catheter-related infections. Nicolle LE, Bradley S, Colgan R, et al. American Lancet 1998; 351: 893-8. guidelines for the diagnois and treatment of McKinley S, Mackenzie A, Finfer S, et al. Inci- asymptomatic bacteriuria in adults. Clin Infect dence and predictors of central vnous catheter Dis 2005;40: 643-54. related infection in intenive care patients. Ana- Naber KG, Bishop MC, Bjerklund-Johansen TE et esth Intensive Care 1999; 27: 164-9. al. Guidelines on The Management of Urinary Mermel LA, Farr BM, Sherertz RJ, Raad II, et al. and Male Genital Tract Infections. European As- Guidelines for the management of intravascular sociation of Urology 2006. catheter-related infections. Clin Infect Dis 2001; Janet Peterson, Simrati Kaul, Mohammed Khas- 32: 1249-72. hab et al. A Double-Blind, Randomized Compa- Merrer J, De Jonghe B, Golliot F, et al. Complica- 84 tions of femoral and subclavian venous cathete- Switzerland. Epidemiology and Infection 2012; rization in critically ill patients. JAMA 2001; 286: 141: 1953. 700-7. Papp JR, Schachter J, Gaydos CA, Van Der Pol O’Grady NP, Alexander m, Dellinger EP, et al. B. Recommendations for the Laboratory-Based Guidelines for prevention of intravascular cathe- Detection of Chlamydia trachomatis and Nei- ter-related infections. Clin Infect Dis 2002; 35: sseria gonorrhoeae – 2014. MMWR – Recom- 1281-307. mendations and Reports 2014; 63: 1–19. O'Grady NP, Alexander M, Dellinger EP, et al. Bally F, Quach A, Greub G, et al. Opportunistic te- Guidelines for the prevention of intravascular sting for urogenital infection with Chlamydia tra- catheter-related infections. Centers for Disease chomatis in south-western Switzerland, 2012: a Control and Prevention. MMWR Recomm Rep feasibility study. Euro Surveill 2015; 20: 21051. 2002; 51(RR-10): 1-29. Geisler WM, Uniyal A, Lee JY, et al. Azithromycin McGee DC, Gould MK. Preventing complications versus Doxycycline for Urogenital Chlamydia of central venous catheterization. N Engl J Med trachomatis Infection. N Engl J Med 2015; 373: 2003; 348: 1123-33. 2512–21. Lanjouw E, Ouburg S, de Vries HJ, Stary A, Rad- Ostéomyélite cliffe K, Unemo M. 2015 European guideline on Waldvogel FA, Vasey H. Osteomyelitis: the past the management of Chlamydia trachomatis in- decade. N Engl J Med 1980; 303: 360-70. fections. Int J STD AIDS 2015; 27: 333–48. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Moore MS, Golden MR, Scholes D, Kerani RP. Med 1997; 336; 999-1007. Assessing Trends in Chlamydia Positivity and Fernandez M, Carrol CL, Baker CJ. Discitis and Gonorrhea Incidence and Their Associations vertebral osteomyelitis in children: a 18-year re- With the Incidence of Pelvic Inflammatory view. Pediatrics 2000; 105: 1299-304. Disease and Ectopic Pregnancy in Washington McHenry MC, Easley KA, Locker GA. Vertebral State, 1988–2010. Sex Transm Dis 2015; 43: osteomyelitis: long term outcome for 253 pa- 2–8. tients from 7 Cleavland-area hospitals. Clin In- Nwokolo NC, Dragovic B, Patel S, Tong CYW, fect Dis 2002; 34: 1342-50. Barker G, Radcliffe K. 2015 UK national guide- Gilbert DN, Moellering RC, Sande MA. The Sand- line for the management of infection with Chla- ford Guide to antimicrobial therapy; 2003. mydia trachomatis. Int J STD AIDS 2015; 27: Lee MV, Minotti A. Acute vertebral osteomyelitis. 251–67. N Engl J Med 2003; 349: 2525. Prevention ECDC. Scientific advice: Guidance on Tice AD, Hoaglund PA, Shoultz DA. Outcomes of chlamydia control in Europe. 2015. osteomyelitis amoung patients treated with out- https://ecdc.europa.eu/sites/portal/files/media/e patient parenteral antimicrobial therapy. Am J n/publications/Publications/chlamydia-control- Med 2003; 114: 723-8. europe-guidance.pdf Chlamydia trachomatis Workowski KA, Bolan GA. Sexually transmitted Kälin U, Lauper U, Lautenschlager S. Urethritis. diseases treatment guidelines, 2015. MMWR Erregerspektrum, Abklärung und Therapie Teil Recomm Rep 2015; 64: 1–137. 1. Swiss Med Forum 2009; 9: 101–4. Bundesamt für Gesundheit BAG. HIV, Syphilis, Kälin U, Lauper U, Lautenschlager S. Urethritis. Gonorrhoe und Chlamydiose in der Schweiz im Erregerspektrum, Abklärung und Therapie Teil Jahr 2015: eine epidemiologische Übersicht. 2. Swiss Med Forum 2009; 9: 121–4. BAG Bulletin 2016; 12-3. Oakeshott P, Kerry S, Aghaizu A, et al. Randomi- Dize L, Barnes P, Barnes M, et al. Performance of sed controlled trial of screening for Chlamydia self-collected penile-meatal swabs compared to trachomatis to prevent pelvic inflammatory clinician-collected urethral swabs for the detec- disease: the POPI (prevention of pelvic infection of Chlamydia trachomatis, Neisseria gonor- tion) trial. BMJ. 2010;340:c1642. rhoeae, Trichomonas vaginalis, and Bundesamt für Gesundheit BAG – 2011. Sex Mycoplasma genitalium by nucleic acid amplifi- unter Männern: Für eine bessere sexuelle Ge- cation assays. Diagn Microbiol Infect Dis 2016; sundheit 2012. 86: 131–5. https://www.bag.admin.ch/bag/de/home/ser- Price MJ, Ades AE, Soldan K, et al. The natural vice/publikationen/broschueren/publikationen- history of Chlamydia trachomatis infection in uebertragbare-krankheiten/maenner-sex.html women: a multi-parameter evidence synthesis. Dize L, Agreda P, Quinn N, Barnes MR, Hsieh Y- Health Technol Assess 2016; 20: 1–250. H, Gaydos CA. Comparison of self-obtained pe- Berry L, Stanley B. Comparison of self-collected nile-meatal swabs to urine for the detection of meatal swabs with urine specimens for the dia- C. trachomatis, N. gonorrhoeae and T. vagina- gnosis of Chlamydia trachomatis and Neisseria lis. Sex Transm Infect 2012; 89: 305–7. gonorrhoeae in men. J Med Microbiol 2017; 66: Rekart ML, Gilbert M, Meza R, et al. Chlamydia 134–6. public health programs and the epidemiology of Notter J, Frey Tirri B, Bally F et al. Sexuell über- pelvic inflammatory disease and ectopic preg- tragene Infektionen mit Chlamydia trachomatis. nancy. J Infect Dis 2012; 207: 30–8. Schweiz Med Forum 2017; 11: 705-711. Testing for Chlamydia trachomatis: time trends in positivity rates in the canton of Basel-Stadt, HÉMATOLOGIE - Hämatologie INTERNET: www.2bib.ch/hemato.pdf 85 Schmidt PM: Bases physiopathologiques en hé- Transfusions sanguines matologie générale, v. 8.0, 2005 Consensus conference: perioperative red blood Anémie - Anämie — Eisenmangelanämie cell transfusion. JAMA 1988; 260: 2700-3. Ganzoni AM. Eisen-Dextran intravenös: therapeu- American College of Physicians. Practice strate- tische und experimentelle Möglichkeiten. gies for elective red blood cell transfusion. Ann Schweiz Med Wochenschr 1970; 100: 301-3. Intern Med 1992; 116: 403-6. Healton B, Savage D, Brust JCM et al. Neurologic Expert Working Group. Guidelines for red blood aspects of cobalamin deficiency. Medicine cell and plasma transfusions for adults and chil- 1991; 70: 229-44. dren. Can med Assoc J 1997; 156 (Suppl 11): Guyatt GH, Oxman AD, Ali M, et al. Laboratory S1-24. diagnosis of iron-deficiency anemia: on over- Hebert PC, Wells G, Martin C, et al. Canadian view. J Gen Intern Med 1992; 7: 145-53. survey of transfusion practices in critically ill pa- Lee R, et al (eds). Clinical hematology. 1993, Lea tients. Crit Care Med 1998; 26: 482-7. & Febiger. Ely EW, Bernard GR. Transfusions in critically ill Stalder M. Une anémie peut en cacher une autre. patientes. N Engl J Med 1999; 340 .467-8. Rev Med Suisse Rom 19193; 113: 1019-23. Goodnough LT, Brecher ME, Kanter MH et al. Beris P, Tobler A. Diagnostic de l’anémie. Med Transfusion medicine - blood transfusion. N Hyg 1997; 55: 1812-6. Engl J Med 1999; 340: 438-47. Ruedin P. Traitement de l’anémie liée à l’insuffi- Hebert PC, Wells G, Blajcjam MA, et al. Transfu- sance rénale chronique. Med Hyg 1998; 56: sion requirements in critical care: a multicentre 2081-4. randomized controlled clinical trial. N Engl J Olivieri NF. The beta-thalassemias. N Engl J Med Med 1999 ;340: 409-17. 1999; 341: 99-109. [Erratum: N Engl J Med Goodnough LT, Bach RG. Anemia, Transfusion, 1999; 341: 1407]. and mortality. N Engl J Med 2001; 345: 1272-4. Bernini LF, Harteveld CL. Alpha-thalassaemia. Wu WC, Rathore SS, Wang Y, et al. Blood trans- Baillieres Clin Haematol 1998; 11: 53-90. fusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 230-6. Fer - Eisen Agence française de sécurité sanitaire des pro- Working group on fortification of salt with iron: duits de santé. Transfusion de globules rouges Use of common salt fortified with iron in the homologues: produits, indications, alternatives. control and prevention of anemia – a collabora- Méthode générale et recommandations. Trans- tive study. Am J Clin Nutr 1982; 35: 1442. fusion clinique et biologiques 2002; 9: 333-56. Crosby WH, O’Neil-Cutting MA. A small-dose iron Nguyen BV, Bota DP, Melot C, et al. Time course tolerance test as an indicator of mild iron defi- of hemoglobin concentrations in nonbleeding in- ciency. JAMA 1984; 251: 1986-7. tensive care unit patients. Crit Care Med 2003; Wallach J. Interpretation of Diagnostic Tests. Little 31: 406-10. Brown, 1996. Chiaroni J, Legrand D, Dettori I, Ferrera V. Hoffman R. Hematology Basic Principles & Prac- Analysis of ABO discrepancies occurring in 35 tice. Mosby 1999, p: 417. French hospitals. Transfusion 2004; 44: 860-4. Brecher ME, Hay SM. Bacterial contamination of Surcharge en fer - Eisenüberlastung blood components. Clin Microbiol Rev 2005; 18: Kirk, P., et al., Cardiac T2* magnetic resonance 195-204. for prediction of cardiac complications in thalas- Goodnough LT. Risks of blood transfusion. Anes- semia major. Circulation 2009; 120: 1961-8. thesiol Clin North America 2005; 23: 241-52. Wood, J.C., Guidelines for quantifying iron over- Toy P, Popovsky M, Abraham E, et al. Transfu- load. Hematology Am Soc Hematol Educ Pro- sion-related acute lung injury: Definition and re- gram 2014. 2014: 210-5. view. Critical Care Medicine 2005; 33: 721-6. Ogilvie, C., et al., Improved detection of hereditary haemochromatosis. J Clin Pathol 2015; 68: Myélome multiple, MGUS 218-21. Durie BG, Salmon SE. A clinical staging system Coates, T.D., et al., Management of iron overload for multiple myeloma. Correlation of measured in hemoglobinopathies: what is the appropriate myeloma cell mass with presenting clinical fea- target iron level? Ann N Y Acad Sci 2016; 1368: tures, response to treatment and survival. Can- 95-106. cer 1975; 36: 842-54. Cullis, J.O., et al., Investigation and management Durie BG. Staging and kinetics of multiple mye- of a raised serum ferritin. Br J Haematol 2018; loma. Sem Oncol 1986; 13: 300-9. 181: 331-340. Kyle RA. Multiple myeloma. An update on diagno- Fitzsimons, E.J., et al., Diagnosis and therapy of sis and management. Acta Oncol 1990; 29: 1-8. genetic haemochromatosis (review and 2017 Durie BGM. Staging and kinetics of multiple mye- update). Br J Haematol 2018; 181: 293-303. loma. In: Wiernik Ph, et al. (eds.). Neoplastic diseases of the blood. New York, NY, Churchill Électrophorèse (protéines) Livingstone 1991, p: 439-52. Merino J. Patología del metabolismo de las pro- Kyle RA. Diagnostic criteria of multiple myeloma. teínas y los aminoácidos. In: Rodés J, et. al. Hematol Oncol Clin North Am 1992; 6: 347-58. (eds.). El Manual de Medicina. Masson, 1993. Riedel DA, Pottern LM. The epidemiology of mul- p: 1193-6. tiple myeloma. Hematol Oncol Clin North Am, 86 1992; 6: 225-47. Kyle RA, Therneau TM, Rajkumar SV, et al. Pre- Bladé J. Gammapatías monoclonales. In: Rodés valence of monoclonal gammopathy of undeter- J, et. al. (eds.). El Manual de Medicina. Mas- mined significance. N Engl J Med 2006; 354: son, S.A, 1993. p: 1834. 1362-9. Kyle RA. «Benign» monoclonal gammopathy - Polycythaemia vera (VAQUEZ-OSLER) after 20 to 35 years of follow-up. Myo Clin Proc 1993; 68: 26-36. Silverstein MN, Petitt RM, Solberg LA Jr, et al. Roux C, Ravaud P, Cohen-Solal M, et al. Biolo- Anagrelide: a new drug for threating thrombocy- gic, histologic and densitometric effects of oral tosis. N Engl J Med 1988; 318: 1292-4. risedronate on bone in patients with multiple Cervantes F. Eritrocitosis y policitemia. In: Rodés myeloma. Bone 1993; 15: 41-9. J, et. al. (eds.). El Manual de Medicina. Mas- Kyle RA. Monoclonal gammopathy of undeter- son, S.A, 1993. p: 1776-80. mined significance. Blood Rev 1994; 8: 135-41. Rognon R, Piguet D, Mégevand M, Kaeser P. Po- Sukpanichnant S, Cousar JB, Leelasiri A, et al. lyglobulies secondaires: le rôle de l’érythropoié- Diagnostic criteria and histologic grading in mul- tine. Rev Med Suisse Rom 1993; 113: 865-71. tiple myeloma: histologic and immunohistologic Pearson TC, Messinezy M. The Diagnostic Crite- analysis of 176 cases with clinical correlation. ria of Polycythaemia Rubra Vera. Leukemia and Hum Pathol 1994; 25: 308-18. Lymphoma 1996; 22 (Suppl. 1): 87-93. Bataille R, Harousseau JL. Multiple myeloma. N Michiels JJ, Juvonen E. Proposal for revised dia- Engl J Med 1997; 336: 1657-64. gnostic criteria of essential thrombocythemia Zulian GB. Multiple myeloma: clinical evaluation and polycythemia vera by the Thrombocythe- of plasma cell lymphoproliferative disorders and mia Vera Study Group. Semin Thromb Hemost initial management. Semin Hematol 1997; 1997; 23: 339-47. 34(Suppl.1): 29-39. Petitt RM, Silverstein MN, Petrone ME. Anagre- Major PP, Lipton A, Berenson J, et al. Oral lide for control of thrombocythemia in polycythe- bisphosphonates: a review of clinical use in pa- mia and other myeloproliferative disorders. tients with bone metastases. Cancer 2000; 88: Semin Hematol 1997; 34: 51-4. 6-14. Messinezy M, Pearson TC. Diagnosis of Polycy- Katzmann JA, Clark RJ, Abraham RS, et al. thaemia. J Clin Pathol 1998; 51: 1-4. Serum reference intervals and diagnostic ran- Landolfi R, Marchiolo R, Kutti J, et al. Efficacy ges for free kappa and free lambda immunoglo- and safety on low-dose Asprin in polycythemia bulin light chains: relative sensitivity for vera. N Engl J Med 2004; 350: 114-24. detection of monoclonal light chains. Clin Chem Thrombocytose essentielle 2002; 48: 1437-44. Michiels JJ, Juvonen E. Proposal for revised dia- Kyle RA, Therneau TM, Rajkumar SV, et al. A gnostic criteria of essential thrombocythemia long-term study of prognosis in monoclonal and polycythemia vera by the Thrombocythe- gammopathy of undetermined significance. N mia Vera Study Group. Semin Thromb Hemost Engl J Med 2002; 346: 564-9. 1997; 23: 339-47. The International Myeloma Working Group. Crite- Thiele J, Kvasnicka HM. Chronic myeloprolifera- ria for the classification of monoclonal gammo- tive disorders. The new WHO classification. Pa- pathies, multiple myeloma and related disorder: thologe 2001; 22: 429-43. report of the International Myeloma Working Harrison CN, Path MRC, Campbell PJ et al. Hy- Group. Br J Hematol 2003, 121:749-57. droxyurea Compared with Anagrelide in High- Child JA, Gareth JM, Faith ED, et al. High-dose Risk Essential Thrombocythemia. N Engl J Med chemotherapy with hematopoietic stem-cell res- 2005; 353:33-45. cue for multiple myeloma. N Engl J Med 2003; Tefferi A, Thiele J, Orazi A, Kvasnicka HM et al. 348: 1875-83. Proposals and rationale for revision of the International Myeloma Working Group. Criteria for World Health Organization diagnostic criteria for the classification of monoclonal gammopathies, polycythemia vera, essential thrombocythemia, multiple myeloma and related disorders: a re- and primary myelofibrosis: recommendations port of the International Myeloma Working from an ad hoc international expert panel. Group. Br J Haematol 2003; 121: 749-57. Blood 2007; 8 may. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Long-term follow- Thromobozytopenie — Thrombozytose up of 241 patients with monoclonal gammopa- Thrombopénie — Thrombocytose thy of undetermined significance: the original Fauci A, Braunwald E, (eds.) et al. In: Harrison: Mayo Clinic series 25 years later. Mayo Clin Principles of Internal Medicine. 1998 Mc Graw Proc 2004; 79: 859-66. Hill. Greipp PhR, San Miguel J, Durie BGM et al. In- Arepally GM, Ortel TL. Heparin-induced thrombo- ternational Staging System for Multiple Mye- cytopenia. N Engl J Med 2006: 355: 809-17. loma. J of Clin Oncology 2005; 3: 3412-20. Aster RH, Bougie D. Drug-induced immune Rajkumar SV, Kyle RA, Therneau TM, et al. thrombocytopenia. N Engl J Med 2007; 357: Serum free light chain ratio is an independent 580-7. risk factor for progression in monoclonal gam- Warkentin TE, Pai M, Linkins LA. Direct oral anti- mopathy of undetermined significance. Blood coagulants for treatment of HIT: update of Ha- 2005; 106: 812-17. milton experience and literature review. Blood 87 2017 31; 130:1104-1113. ced thrombocytopenia. J Transl Sci 2015; 1: 37- Provan D et al. Updated international consensus 42. report on the investigation and management of Iluonakhamhe E, Ibekwe O, Samuel S, Zakaria A. primary immune thrombocytopenia. Blood Adv Plasmapheresis may be an option in urgent ma- 2019, 3: 3780-3817 nagement of heparin-induced thrombocytopenia in the setting of acute intracerebral hemor- Thrombotische Mikroangiopathie, Thrombo- tisch thrombozytopenische Purpura rhage. Neurocrit Care. 2015; 22:140-5. Linkins LA et al.: Combination of 4Ts score and Kremer Hovinga JA, Coppo P. Lämmle B., Moake PF4/H-PaGIA for diagnosis and management of JL, Miyata T, Vanhoorelbeke K. Thrombotic heparin-induced thrombocytopenia: prospective thrombocytopenic purpura. Nat Rev Dis Primers cohort study. Blood 2015; 126: 597-603. 2017;3:17020 Tardy-Poncet B, Nguyen P, Thiranos JC, Mo- Thrombopénie induite par l’héparine (TIH) range PE, Biron-Andreani C, Gruel Y, et al. Ar- Arepally GM. Heparin-induced thrombocytopenia. gatroban in the management of Blood. 2017;129(21):2864-72. heparin-induced thrombocytopenia: a multicen- Warkentin TE, Kelton JG. Temporal aspects of ter clinical trial. Crit Care 2015; 19: 396. heparin-induced thrombocytopenia. NEJM Thachil J, falanga A, levi M, liebman H, Di nisio M. Manage- 2001; 344: 1286-92. ment of cancer-associated disseminated intravascular Warkentin TE, Kelton JG. Delayed-onset heparin- coagulation: guidance from the SSC of the ISTH. J induced thrombocytopenia and thrombosis. Ann Thromb Haemost 2015; 13: 671-5. Intern Med 2001; 35: 502-6. Tvito A, Bakchoul T, Rowe JM, Greinacher A, Lubenow N, Kempf R, Eichner A, Eichler P, Carls- Ganzel C. Severe and persistent heparin-indu- son LE, Greinacher A. Heparin-induced throm- ced thrombocytopenia despite fondaparinux bocytopenia: temporal pattern of treatment. Am J Hematol 2015; 90: 675-8. thrombocytopenia in relation to initial use or Levi M. Management of cancer-associated disseminated in- reexposure to heparin. Chest 2002; 122: 37-42. travascular coagulation. Thromb Res 2016; 140 Suppl 1: Warkentin TE. Heparin induced thrombocytope- S66-70. nia: pathogenesis and management. Br J Hae- Nagler M, Bakchoul T: Clinical and laboratory matology 2003; 121: 535-55. tests for the diagnosis of heparin-induced Pouplard C, May MA, Regina S, Marchand M, thrombocytopenia. Thromb Haemost 2016; 116: Fusciardi J, Gruel Y. Changes in platelet count 823-34. after cardiac surgery can effectively predict the Nagler M, et al. Diagnostic value of immunoas- development of pathogenic heparin-dependent says for heparin-induced thrombocytopenia: a antibodies. Br J Haematol 2005; 128: 837-41. systematic review and meta-analysis. Blood Warkentin TE. Heparin-induced thrombocytope- 2016; 127: 546-57. nia: pathogenesis and management. Br J Hae- Falanga A, Russo l, Milesi V et al. Mechanisms and risk fac- matol 2003; 121: 535-55. tors of thrombosis in cancer. Crit Rev Oncol Hematol Levine RL, Hursting MJ, McCollum D. Argatroban 2017; 118: 79-83. therapy in heparin-induced thrombocytopenia Lei BZ, Shatzel JJ, Sendowski M. Rapid and du- with hepatic dysfunction. Chest 2006; 129: rable response to intravenous immunoglobulin 1167-75. in delayed heparin-induced thrombocytopenia: Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler a case report. Transfusion 2017; 57: 919-23. P, Greinacher A. Evaluation of pretest clinical Padmanabhan A, Jones CG, Pechauer SM et al. score (4 T's) for the diagnosis of heparin-indu- IVIg for Treatment of Severe Refractory Hepa- ced thrombocytopenia in two clinical settings. J rin-Induced Thrombocytopenia. Chest 2017; Thrombosis and Haemostasis 2006; 4: 759- 152: 478-85. 765. Warkentin TE, Pai M, Linkins LA. Direct oral anti- Levi M. Disseminated intravascular coagulation in coagulants for treatment of HIT: update of Ha- cancer patients. Best Pract Res Clin Haematol milton experience and literature review. Blood 2009; 22: 129-36. 2017 31; 130: 1104-1113. Shepherd MF, Jacobsen JM, Rosborough TK. Ar- Coagulation sanguine gatroban therapy using enzymatic anti-factor IIa Van Wynsberghe D, Noback CR, Carola R. monitoring. The Annals of pharmacotherapy (eds.). Human Anatomy and Physiology. 2011; 45: 422-3. McGraw-Hill, 1995. Tun NM, Bo ZM, Ahluwalia M, Guevara E, Villani Wallach J. Interpretation of Diagnostic Tests. Little GM. A rare case of intracerebral hemorrhage Brown, 1996. complicating heparin-induced thrombocytopenia Gavillet M, Angelillo-Scherrer A.Quantification of with thrombosis: a clinical dilemma ameliorated the anticoagulatory effect of novel anticoagu- by novel use of plasmapheresis. Int J Hematol lants and management of emergencies. Cardio- 2012; 96: 513-5. vasc Med 2012; 15: 170-9. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med 2013; 8: Hémophilie, 23-32. Maladie de Von WILLEBRAND Colucci G, Nagler M, Klaus N, Conte T, Giabbani Sadler JE, Davie EW. Hemophilia A, hemophilia E, Alberio L. Practical guidelines for argatroban B, and von Willebrand’s disease. In: The mole- and bivalirudine in patients with heparin-indu- 88 cular basis of blood diseases. G Stamatoyano- 7. poulis et al (eds.). Philadelphia, Saunders 1987; Boneu B. Disseminated intravascular coagulation. p: 575-630. Etiology, diagnosis. Rev Prat 1997; 47:215-8. Beutler E, Lichtmann MA, Coller TJ, et al. (eds.). Levi M, Ten Cate H. Current concepts: dissemina- In: Williams Hematology, Fifth Edition 1995, ted intravascular coagulation. N Engl J Med McGraw Hill, p: 1413-29, and p: 1458-80. 1999; 341: 586-92. Pier MM. Treatment of von Willebrand's Disease. Erez O, Mastrolia SA, Thachil J. Disseminated in- N Engl N Med 2004; 351: 683-94. travascular coagulation in pregnancy: insights Sadler JE, Budde U, Eikenboom JCJ et al. Up- in pathophysiology, diagnosis and manage- date on the pathophysiology and classification ment. Am J Obstet Gynecol 2015; 213: 452-63. of von Willebrand disease: a report of the Sub- Erez O. Disseminated intravascular coagulation committee on von Willebrand Factor. J Thromb in pregnancy – Clinical phenotypes and diagno- Haemost 2006;4:2103-14. stic scores. Thrombosis Research 2017; James PD, Connell NT, Ameer B et al. ASH ISTH 151(Suppl. 1): S56–S60. NHF WFH 2021 guidelines on the diagnosis of Thrombophilie von Willebrand disease. Blood Adv 2021; 5: Syndrome anti-phospholipides 280-300. Asherson RA, Chan JKH, Harris EN, et al. Anti- Purpura (voir «INVESTI-MÉD) cardiolipin antibody, recurrent thrombosis, and Kitchens CS. The purpuric disorders. Semin Warfarin withdrawal. Ann Rheum Dis 1985; 44: Thromb Hemost 1984; 10: 173-89. 823-5. Hoffbrand AV. Petit JE. Essential Haematology. Hughes GRV, Harris NN, Gharavi AE. The anti- Blackwell Scientific Publications, 1993. cardiolipine syndrome. J Rheum 1986; 13: 486- George JN, El-Harake MA, Raskob GE. Chronic 9. idiopathic thrombocytopenic purpura. N Engl J Mackworth-Young CG, Loizou S, Walport MJ. Pri- Med 1994, 331: 1207-11. mary antiphospholipid syndrome: features of Varet B. Le livre de l'interne: hématologie. Méde- patients with raised anticardiolipin antibodies cine-Sciences. Flammarion, 1997. and no other disorder. Ann Rheum Dis 1989; Eldor A. Thrombotic thrombocytopenic purpura: 48: 362-7. diagnosis, pathogenesis and modern therapy. Brandt TJ, Triplett DA, Alving B, et al. Criteria for Baillière's Clinical Haematology, 1998; 11: 475- the diagnosis of lupus anticoagulants: an up- 95. date. Thromb Haemost 1995; 74: 1185-90. Fauci A, Braunwald E, (eds.) et al. In: Harrison: Khamashta MA, Cuadrado MJ, Mujic F, et al. The Principles of Internal Medicine. 1998 Mc Graw management of thrombosis in the antiphospho- Hill. lipid-antibody syndrome. N Engl J Med 1995; Gillis S, Eldor A. Immune thrombocytopenic pur- 332: 993-7. pura in adults: clinical aspects. Baillière's Clini- Ginsberg JS, Wells PS, Brill-Edwards P, et al. An- cal Haematology, 1998; 11: 361-72. tiphospholipid antibodies and venous thrombo- Provan D, Chisholm M, Duncombe AS, et al. Ox- embolism. Blood 1995; 10: 3685-91. ford Handbook of Clinical Haematology, Oxford Cavenagh JD, Colvin BT. Guidelines for the ma- University Press, 1998. nagement of thrombophilia. Postgrad Med J Pallister CJ. Haematology (Biomedical Sciences 1996; 72: 87-94. Explained). Butterworth-Heinemann, 1999. Price DT, Ridjer PM. Factor V Leiden mutation Cines DB, Blanchette VS. Immune thrombocyto- and the risks for thromboembolic disease: a cli- penic purpura. N Engl J Med 2002; 346: 995- nical perspective. Ann Intern Med 1997; 127: 1008. 895-903. Cheng Y, Wong RSM, Soo YOY, et al. Initial treat- Wilson WA, Gharavi AE, Koike T, et al. Internatio- ment of immune thrombocytopenic purpura with nal consensus statement on preliminary classifi- high-dose dexamethasone. N Engl J Med 2002; cation criteria for definite antiphospholipid 349: 831-6. syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11. CIVD - DIC Disseminierte intravasale Gerinn. Graves M. Antiphospholipid antibodies and Colman R, Robboy S, Minna J. Disseminated in- thrombosis. Lancet 1999; 353: 1348-53. travascular coagulation (DIC): an approach. Am Levine JS, Branch DW, Rauch J. The antiphos- J Med 1972; 52: 679-87. pholipid syndrome. N Engl J Med. 2002; 346: Fenstein D. Diagnosis and management of disse- 752-63. minated intravascular coagulation: the role of Crowther MA, Ginsberg JS, Math JJ, et al. A com- heparin therapy. Blood 1982; 60: 284-7. parison of two intensities of warfarin for the pre- Bick RL. Disseminated intravascular coagulation. vention of recurrent thrombosis in patients with Hem Onc Clin North Am 1992; 6: 1259-81. antiphospholipid antibody syndrome. N Engl J Williams E. Disseminated intravascular coagula- Med 2003; 349: 1133-8. tion. In: Loscalzo J, Schafer A (eds.). Thrombo- Weitz JI, Lensing AWA, Prins MH et al. Rivaroxa- sis and hemorrhage. Blackwell Science 1994, ban or Aspirin for Extended Treatment of Ve- pp. 921-44. nous Thromboembolism. N Engl J Med. 2017; Baglin T. Disseminated intravascular coagulation: 376: 1211-22. diagnosis and treatment. BMJ 1996; 312: 683- Hémopathies malignes 89 INTERNET: www.2bib.ch/hemato.pdf Oncologie - Onkologie Schmidt PM: Bases physiopathologiques en hé- matologie générale, v. 8.0, 2005 (p. 94-152 et www.cancer.gov/cancertopics 166) Cancer colo-rectal Jaffe ES, Harris NL, Stein H, et al (ed.). Tumors Van Gossum A, Miguel Munoz Navas M, Fernan- of haematopoietics and lymphoid tissues. World dez-Urien I, et al. Capsule Endoscopy versus Health Organization classification of tumors. Colonoscopy for the Detection of Polyps and Pathology and genetics. IARC Press, 2001 (351 Cancer. N Engl J Med 2009; 361: 264-70. pages). CA mammaire Syndromes myélodysplasiques (SMD) ces références sont en cours Aul C, Gattermann N and Schneider W. Age-related incidence and other epidemiological Schilddrüsen-CA aspects of myelodysplastic syndromes. British Haugen BR, Alexander EK, Bible KC et al. 2015 journal of haematology 1992; 82: 358-367. American Thyroid Association Management 1992/10/01. Guidelines for Adult Patients with Thyroid Nodu- Myélofibrose les and Differentiated Thyroid Cancer The Ame- rican Thyroid Association Guidelines Task Force Tefferi A. Myelofibrosis with myeloid metaplasia. on Thyroid Nodules and Differentiated Thyroid NEJM 2000; 342: 1255-65. Cancer. Thyroid 2016; 26: 1-133. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol 2005; 42: 248-58. Cancer des testicules - Hodentumor Mehta J, Wang H, Iqbal SU, et al. Epidemiology International Germ Cell Consensus Classification: of myeloproliferative neoplasms in the United a prognostic factor-based staging system for States. Leukemia & lymphoma 2014; 55: 595- metastatic germ cell cancers. International 600. Germ Cell Cancer Collaborative Group. J Clin Tefferi A. Primary myelofibrosis: 2014 update on Oncol 1997; 15:594-603. diagnosis, risk-stratification, and management. American journal of hematology 2014; 89: 915- Lymphome HODGKIN et non-HODGKIN 925. Rosenberg SA. Validity of the Ann Arbor staging Tefferi A and Vainchenker W. Myeloproliferative classification for the non-Hodgkin's lymphomas. neoplasms: molecular pathophysiology, essen- Cancer Treat Rep 1977; 61: 1023-7. tial clinical understanding, and treatment strate- A predictive model for aggressive non-Hodgkin's gies. Journal of clinical oncology: official journal lymphoma. The International Non-Hodgkin's of the American Society of Clinical Oncology Lymphoma Prognostic Factors Project. N Engl J 2011; 29: 573-82. Med 1993; 329: 987-94. Drépanocytose (anémie falciforme) Chronisch lymphastische Leukämie (CLL) Platt OS, Thorington BD, Brambilla DJ, et al. Pain Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, in sickle cell disease: rates and risk factors. N A.D., Levy, R.N., Pasternack, B.S.. Clinical sta- Engl J Med 1991; 325: 11-6. ging of chronic lymphocytic leukemia. Blood Brookoff D, Polomano R. Treating sickle cell pain 1975; 46: 219-234. like cancer pain. Ann Intern Med 1992; 116: Binet, JL, Leporrier M, Dighiero G et al. A Clinical 364-8. statging system for chronic lymphocytic leuke- Wayne AS, Kevy SV, Nathan DG. Transfusion mia. Cancer 1977; 40: 855-864. management of sickle cell disease. Blood 1993; Binet, J.L., et al., A new prognostic classification 81: 1109-23. of chronic lymphocytic leukemia derived from a Carache S, Terrin ML, Moore RD, et al. Effect of multivariate survival analysis. Cancer 1981; 48: hydroxyurea on the frequency of painful crises 198-206. in sickle cell anemia. N Engl J Med 1995; 332: CA prostatique - Prostata-CA 1317-22. D'Amico AV, Whittington R, Malkowicz SB et al. Vichinsky EP, Haberkern CM, Neumayr L, et al. A Biochemical outcome after radical prostatec- comparison of concervative and aggressive tomy, external beam radiation therapy, or inter- transfusion regimens in the perioperative ma- stitial radiation therapy for clinically localized nagement of sickle cell diseas. N Engl J Med prostate cancer. JAMA 1998; 280: 969-74. 1995; 333: 206-13. Stuart MJ, Setty BN. Sickle cell acute chest syn- Syndrome veine cave supérieure drome: pathogenesis and rationale for treat- Wilson LD, Detterbeck FC, Yahalom J. Clinical ment. Blood 1999; 94: 1555-60. practice. Superior vena cava syndrome with Ballas SK. Sickle cell disease: current clinical ma- malignant causes. N Engl J Med 2007; 356: nagement. Semin Hematol 2001; 38: 307-14. 1862-9. Stuart MJ, Setty BN. Acute ches syndrome of sickle cell disease: new light on an old problem. Gliome Curr Opin Hematol 2001; 8: 111-22. Brouland JP, Hottinger AF. Nouvelle classification Ballas SK. Sickle cell anaemia: progress in patho- OMS 2016 des gliomes : quels changements ? genesis and treatment. Drugs 2002; 62: 1143- Rev Med Suisse 2017; 13: 1805-9. 72. WHO Classification of Tumours of the Central 90 Nervous System, 4th ed, Louis DN, Ohgaki H, tology 2002; 204: 50-55. Wiestler OD, Cavenee WK (Eds), IARC, Lyon Williams H. New treatment for atopic dermatitis. 2016. BMJ 2003; 324: 1533-4. Leung DY, Bieber T. Atopic dermatitis. Lancet Melanom - Mélanome 2003; 361: 151-60. Grob JJ, Bonerandi JJ. The «ugly duckling» sign: Hanfin JM, Cooper KD, Ho VC et al. Guidelines of identification of the common characteristics of care fot atopic dermatitis, developed in caccor- nevi in an individual as a basis for melanoma dance with the AAD. J Am Acad Dermatol 2004; screening. Arch Dermatol 1998; 134: 103-4. 50: 391-404. Abbasi NR, Shaw HM, Rigel DS, et al. Early dia- Illi S, von Mutius E, Lau S, et al. The natiral gnosis of cutaneous melanoma: revisiting the course of atopic dermatitis from birth to age 7 ABCD criteria. JAMA 2004;2 92: 2771-76. years and the association with asthma. J Allery Gershenwald JE, Scolyer R, Hess KR et al. Mela- Clin Immunol 2004; 113: 925-31. noma staging: Evidence-based changes in the Luger TA, Tahfa M, Folwster-Holst R, et al. Long-- American Joint Committee on Cancer eighth term safety and dolerability of priecrolimus edition cancer staging manual. CA Cancer J cream 0.1 % and topical corticosteroids in Clin 2017; 67: 472-92. adults with modrate to severe aotpic dermatitis. J Dermatol Treat 2004; 15:169-78. DERMATOLOGIE National Institute for Clinical Excellence. Final ap- Textbook praisal determination: tacrolimus and pimecroli- Saurat JH. Dermatologie et maladies sexuelle- mus for atopic eczema. ment transmissibles. Masson 1999. www.nice.org.uk/pdf/P&T_FAD.pdf www.kopflaus.ch Williams HC. Atopic dermatitis. N Engl J Med Lebwohl M. et al. Therapy for head lice based on 2005; 352: 2314-24. life cycle, resistance, and safety considerations. Gale Pediatrics 2007; 119: 965-74. Delisle BR. La gale humaine. Le Médecin du Livedo reticularis Québec 1998; 33, 59-60. Frances C, Niang S, Laffitte E, et al. Dermatolo- Bigby M. A systematic review of the treatment of gic manifestations of the antiphospholipid syn- scabies. Arch Dermatol 2000; 136: 387-9. drome: two hundred consecutive cases. Arthritis Del Giudice P. Ivermectin in scabies. Curr Opin Rheum 2005; 52: 1785-93. Infect Dis 2002; 15: 123-6. Gibbs MB, English JC, Zirwas MJ. Livedo reticu- Elston DM. Controversies concerning the treat- laris: an update. J Am Acad Dermatol 2005; 52: menet of lice and scabies. J Am Acad Dermatol 1009-19. 2002; 46: 794-6. Herrero C, Guilabert A, Mascaro-Galy JM. Dia- Leone PA. Scabies and pediculosis pubis: an up- gnosis and treatment of livedo reticularis on the date of treatment regimens and general review. legs. Actas Dermosifiliogr 2008; 99: 598-607. Clin Infect Dis 2007; 44 (Suppl 3): S153-9. Kroshinsky D, Stone JH, Bloch DB, Sepehr A. Psoriasis Case records of the Massachusetts General Hospital. Case 5-2009. A 47-year-old woman Greaves MW, Weinstein GD. Treatment of psoria- with a rash and numbness and pain in the legs. sis. N Engl J Med 1995; 332: 581-9. NEJM 2009; 360: 711-20. Nickoloff BJ, Wrone-Smith T. Superantigens, au- Coattrenec Y, Terrani I, Spoerl D. Le livedo : phy- toantigens, and pathogenic T cells in psoriasis. siopathologie et diagnostic. Rev Med Suisse J Invest Dermatol 1998; 110: 459-60. 2018 ; 14 : 746-50. Drew GS. Psoriasis. Prim Care 2000; 27: 385- 406. Dermatite atopique=Eczéma atopique Ashcroft DM, Li Wan Po A, Griffiths CE. Thera- Hannifin J.M et al. Acta Dermatovener 1980; 92: peutic strategies for psoriasis. J Clin Pharm 44. Ther. 2000; 25: 1-10. Williams H.C, Jburney PG, Hay RJ et al. The U.K. Granstein RD. New treatments for psoriasis. N working Party’s diagnositc criteria for atopic Engl J Med 2001; 345: 284-7. dermatitis. Br J Dermatol 1994; 131: 383-96. Heydendael VMR, Spuls P, Cpmeer RC, et al. Lucky AW, Leach AD, Laskarzewski P et al. Use Methotrexate versus cyclosprine in moderate- of an emollient as a steroid-sparing agent in the te-severe chronic plaque psoriasis. N Engl J treatment of mild to moderate atopic dermatitis Med 2003; 349: 658-65. in children. Pediatr Dermatol 1997; 14: 321-4. Leonardi CL, Powers JL, Matheson RT, et al. Eta- Kang S, Lucky AW, Pariser D, et al. Long-term nercept as monotherapy in patients with psoria- safety and efficacy of tacrolimus ointment for sis. N Engl J Med 2003; 349: 2014-22. the treatment of atopic dermatitis in children. J Lowes MA, Bowcock AM, Krueger JG. Pathoge- Am Acad Dermatol 2001; 44 (Suppl 1):S58-64. nesis and therapy of psoriasis. Nature 2007; Devillers, ACA, de Waard-van der Spek F.B., Mul- 445: 866-73. der PGH et al. Treatment of Refractory Atopic Stern RS. Psoralen and ultraviolet a ligt therapy Dermatitis Using «Wet-Wrap» Dressings and for psorisis. N Engl J Med 2007; 357: 682-90. Diluted Corticosteroids: Results of Standardized Erysipèle (cellulite) - fasciite Treatment in both Children and Adults. Derma- Leppard BJ, Seal DV, Colman G, et al. The value 91 of bacteriology and serology in the diagnosis of rol 2001; 128: 167-71. cellulite end erysipelas. Br J Dermatol 1985; Prurit 112: 559-67. Hook EW 3d, Hooton TM, Horton CA, et al. Mi- Hagermark O, Wahlgren CF. Treatment itch. crobiologic evaluation of cutaneous cellulitis in Semin Dermatol 1995; 14: 320-5. adults. Arch Intern Med 1986; 146: 295-7. Kantor GR, Bernhard JD. Investigation of the pru- Duvanel T, Auckenthaler R, Rohner P, et al. ritic patient in daily practice. Semin Dermatol Quantitative cultures of biopsy specimens from 1995; 14: 290-6. cutaneous cellulitis. Arch Intern Med 1989; 149: Yosipovitch G, David M. The diagnostic and the- 239-6. rapeutic approach to idiopathic generalized pru- Chartier C, Grosshans E. Erysipelas. Int J Der- ritus. Int J Dermatol 1999; 38: 881-7. matol 1990; 29: 459-67. Krajnik M, Zylicz Z. Understanding pruritus in sy- Sjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. stemic disease. J Pain Symptom Manage 2001; Antibiotic prophylaxis in recurrent erysipelas. In- 21: 151-68. fection 1993; 21: 390-3. Vitiligo Bisno AL, Stevens DL. Streptococcal infections of WEB: American Academy of Dermatology (Ed). skin and soft tissues. N Engl J Med 1996; 334: Public Resources, Patient Education - Vitiligo, 240-5. American Academy of Dermatology. [Consulté Eriksson B, Jorup-Ronstrom C, Karkkonen K, et le 1er décembre 2003]. www.aad.org/pam- al. Erysipelas: clinical and bacteriologic spec- phlets/Vitiligo.html trum and serological aspects. Clin Infect Dis Kragballe K. Vitamin D3 analogues. Dermatol 1996; 23: 1091-8. Clin 1995; 13: 835-9. Dan M, Heller K, Shapira I, et al. Incidence of ery- Kieffer MA. Topical vitamin D analogs. Dermatol sipelas following venectomy for coronary artery Nurs 2004; 16: 89-90, 93, 100. bapass surgery. Infection 1987; 15: 107-8. Berneburg M, Rocken M, Benedix F. Photothe- Mertz KR, Baddur LM, Bell JL, et asl. Brest cellu- rapy with narrowband vs broadband UVB. Acta litis following breast conservation therapy: a Derm Venereol 2005; 85: 98-108. novel complication of medical progress. Clin In- Grimes PE. New insights and new therapies in vi- fect Dis 1998; 26: 481-6. tiligo. JAMA 2005; 293: 730-5. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk Kostovic K, Pasic A. New treatment modalities for factors for erysipelas of the leg (cellulitis): case- vitiligo: focus on topical immunomodulators. control study. BMJ 1999 ;318: 1591-4. Drugs 2005; 65: 447-9. Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with Pemphigoïde bulleuse - Pemphigus cellulites. Clin Infect Dis 1999; 29: 1483-8. Nousari HC, Anhalt GJ. Pemphigus and bullous Mandell GL. Principles and Practice of Infectious pemphigoid. Lancet 1999; 345: 667-75. diseases. 5th edition. Churchill Livingstone Joly P, Roujeau JC, Benichou J, et al. A compari- 2000. son of oral and topical corticosteroids in pa- Gottlieb T, Atkins BL, Shaw DR Soft tissue, bone tients with bullous pemphigoid. N Engl J Med and joint infections. Med J Aust 2002; 176: 609- 2002; 346: 321-7. 15. Bystrin JC, Rudolph JL. Pemphigus. Lance 2005; Bassetti St, Itin P, Flückiger U. Primäre bakterielle 366 :61-73. Hautinfektion. Schweiz Med Forum 2003; 35: Ehrenberger-Lang A, Leisner A, Rhyner M, et al. 819-7. Bullöse Erkrankung mit hoher Letalität. Forum Stevens DL et al. Practice guidelines for the dia- 2006; 6: 945-6. gnosis and management of skin and soft-tissue Joly P, Mouquet H, Rojeau J-C, etl al. A single infections. Clin Infect Dis 2005;41: 1373-406. cycle of rituximab for the treatment of severe Stevens DL, Bisno AL, Chambers HF et al. Prac- pemphigus. N Engl J Med 2003; 197: 545-52. tice guidelines for the diagnosis and manage- Diaz LA. Rituximab and pemphigus - a therapeu- ment of skin and soft tissue infections: 2014 tic advance. N Engl J Med 2007: 357: 605-9. update by the infectious diseases society of America. Clin Infect Dis 2014; 59: 147-59. Toxidermies Martinez M, Peponis Th, Hage A et al. The Role Roujeau JC, Stern RS. Severe adverse cutane- of Computed Tomography in the Diagnosis of ous reactions to drugs. N Engl J Med 1994; Necrotizing Soft Tissue Infections. World J Surg 331: 1272-85. (2018) 42:82-87. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic Érythème noueux epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science Bohn S, Buchner S, Itin P. Erythema nodosum: 1998; 282: 490-3. 112 cases. epidemiology, clinical aspects and Bastuji-Garin S, Fouchard N, Bertocchi M, et al. histopathology. Schweiz Med Wochenschr SCORTEN: a severity-of-illness score for toxic 1998; 1288: 85. epidermal necrolysis. J Invest Dermatol 2000; Cribier B, Caille A, Heidi E, et al. Erythema nodo- 115: 149-53. sum and associated disease. A study of 129 Prins C, Kerdel FA, Padilla RS, et al. Treatment of cases. Int J Dermatol 1998; 37: 667-72. toxic epidermal necrolysis with high-dose intra- Petit A. Erythema nodosum. Ann Dermatol Vene- venous immunoglobulins: multicenter retrospec- 92 tive analysis of 48 consecutive cases. Arch Der- JAMA 2007;297:1478-88. matol 2003; 139: 26-32. Mathews CJ, Weston VC, Jones A, et al. Bacte- Trent JT, Kirsner RS, Romanelli Pet al. Analysis rial septic arthritis in adults. Lancet 2010; 375: of intravenous immunoglobulin for the treatment 846-55. of toxic epidermal necrolysis using SCORTEN: Carpenter CR, Schuur JD, Everett WW et al. Evi- The University of Miami Experience. Arch Der- dence-based diagnostics: adult septic arthritis. matol 2003; 139:39-43. Acad Emerg Med 2011;18:781-96.

RHUMATOLOGIE Ponction articulaire Thumboo J, O’Duffy JD. A prospective study of INTERNET: the safety of joint and soft tissue aspirations www.arthritis.ca and injections in patients taking warfarin so- www.rheuma-net.ch dium. Arthritis Rheum 1989; 41: 736-9. Textbooks Yood RA. Use of gloves for rheumatologic proce- Colvin RB, Bhan AK, McCluskey RT (eds.). Dia- dures. Arthritis Rheum 1994: 36: 575. gnostic Immunopathology. Raven Press 1995. Lemaire V, charbonnier B, Gruel Y, et al. Antiagré- Frank MM, Austen KF, Claman HN, Unanue ER gants, anticoagulants et infiltrations: comment (eds.). Samter’s Immunologic Disease. Little faire? Rev Rhum 2002; 69: 8-11. Brown 1995. Kahn MF, Peltier A, Meyer O, Piette JC (eds.). In: Arthrite rhumatoïde Maladies et syndromes systémiques. Paris: Arnett FC, Edworthy SM, Bloch DA et al. The Flammarion Médecine-Sciences, 1999. American Rheumatism Association 1987 revi- Fox RI. Sjogren’s syndrome: Current therapies sed criteria for the classification of rheumatoid remain inadequate for a common disease. Ex- arthritis. Arthritis Rheum 1988; 31: 315-24. pert Opin Invest Drugs 2000; 9: 207-16. Weaver A, Caldwell J, Olsen N. et al. Treatemt of PM Villiger, Seitz M. Rheumatologie in Kürze. active rheumatoid arthritis with leflunomide Thieme Verlag 2006. compared to placebo or methotrexate. Arthrits Arthrite/septique - Arthritis septische Rheum 1998; 41: S131. Smolen JS, Kalden JR, Scott DL, et al. Efficacy Gottlieb NL, Riskin WG. Complications of local and safety of leflunomide compared with pla- corticosteroid injections. JAMA 1980; 243:1547- cebo and sulphasalazine in active rheumatoid 8. arthritis: a double blind, randomised, multicen- Goldenberg DL, Reed Jl. Bacterial arthritis. N ter trial. Lancet 1999; 353: 259-66. Engl J Med 1985; 312: 764-71. Villiger PM, Brühlmann P. Rheumatoide Arthritis. Gächter A. Der Gelenkinfekt. Inform Arzt 1985; In: Alexander K, et al (eds). Thiemes Innere 5:5-43. Medizin. Stuttgart. Thieme Verlag, 1999, pp Baker DG, Schumacher HR. Acute monoarthritis. 1622-31. N Engl J Med 1993; 329: 1013-20. Schellekens GA, Visser H, de Jong BA, et al. The American College of Rheumatology ad hoc com- diagnostic properties of rheumatoid arthritis an- mittee on clinical guidelines. Guidelines for the tibodies recognizing a cyclic citrullinated pep- initial evaluation of the adult patient with acute tide. Arthtitis Rheum 2000; 43: 1901-2. musculo-skeletal symptoms. Arthritis Rheum Van der Heijde DMFM. Radiographic imaging: the 1996; 39: 1-8. «gold standard» for assessment of disease pro- Schumacher HR Jr. Synovial fluid analysis and gression in rheumatoid arthritis. Rheumatology synovial biopsy. In: Kelley ED Jr, Ruddy S, 2000; 39 (Suppl 1): 9-16. Sledge CB, (eds.). Textbook of rheumatology: Tremblay JL, Morin F. La polyarthrite rhumatoïde pp 609-25. Philadelphia, W.B. Saunders 1997. (PAR). Le Rhumatologue 2002; 3: 1-8. Stutz G, Kuster MS, Kleinstuck F et al. Arthrosco- American College of Rheumatology Subcommit- pic management of septic arthritis; stages of in- tee on Rheumatoid Arthritis Guidelines. Guideli- fection and results. Knee Surf Sports Taumatol nes for the management oif rheumatoid Arthrosc 2000; 8: 270-4. arthritis. Arthritis Rheum 2002; 46: 328-46. Gächter A. Der Gelenkinfekt. Inform Arzt 1985; Kremer JM, Westhovens R, Leon M, et al. Treat- 5:5-43. ment of rheumatoid arthritis by selective inhibi- Stutz G, Kuster MS, Kleinstuck F et al. Arthrosco- tion of T-celle activation with fusion protein CTL pic management of septic arthritis; stages of in- A4Ig. N Engl J Med 2003; 349: 1907-15. fection and results. Knee Surf Sports Taumatol Olsen NJ, Stein CM. New drugs for rheumatoid Arthrosc 2000; 8: 270-4 arthritis. N Engl J Med 2004; 350: 2167-79. Stutz G, Gächter A. Diagnosis and stage-related therapiy of joints infectinos. Unfallchirurg 2001; Lombalgies 104; 682-6. Bogduk N, McGuirk B. Medical management of Buchs N, Vischer TL. Que faire lors d’une arthrite acute and chronic low back pain. An evidence- d’apparition récente? Le triage par le labora- based approach.Amsterdam: Elsevier, 2002. toire et l’imagerie. Med Hyg 1999; 57: 595-600. Goupille P, Mulleman D, Paintaud G et al. Can Theiler R. Arthrose. Schweiz Med Forum 2002: sciatica induced by disc herniation be treated 23: 555-61. with tumor necrosis factor alpha blockade? Ar- Margaretten ME, Kohlwes J, Moore D, Bent S. thritis Rheum 2007; 56: 3887-95. Does this adult patient have septic arthritis? Younes M, Bejia I, Aguir Z, et al. Prevalence and 93 risk factors of disk-related sciatica in an urban 2007; 25: 407-18. population in Tunisia. Joint Bone Spine 2006; Katz JN, Harris MB. Clinical practice. Lumbar spi- 73: 538-42. nal stenosis. NEJM 2008; 358: 818-25. Bouhassira D, Lanteri-Minet M, Attal N et al. Pre- Watters WC, 3rd, Baisden J, Gilbert TJ, et al. De- valence of chronic pain with neuropathic cha- generative lumbar spinal stenosis: an evidence- racteristics in the general population. Pain based clinical guideline for the diagnosis and 2008; 136: 380-7. treatment of degenerative lumbar spinal steno- Genevay St, Gabay C. Syndrome radiculaire par sis. Spine J 2008; 8: 305-10. hernie discale lombaire. Rev Med Suisse 2009; Conn A, Buenaventura RM, Datta S, Abdi S, 5: 577-81. Diwan S. Systematic review of caudal epidural Guzman J, Haldeman S, Carroll LJ et al. Clinical injections in the management of chronic low practice implications of the Bone and Joint De- back pain. Pain Physician 2009; 12: 109-35. cade 2000-2010 Task Force on Neck Pain and Siebert E, Pruss H, Klingebiel R, Failli V, Einhaupl Its Associated Disorders: from concepts and fin- KM, Schwab JM. Lumbar spinal stenosis: syn- dings to recommendations. Spine (Phila Pa drome, diagnostics and treatment. Nat Rev 1976) 2008; 33 (4 Suppl): S199. Neurol 2009; 5: 392-403. Haldeman S, Carroll L, Cassidy JD et al. The Kalichman L, Cole R, Kim DH, et al. Spinal steno- Bone and Joint Decade 2000–2010. Task Force sis prevalence and association with symptoms: on Neck Pain and Its Associated Disorders. the Framingham Study. Spine J 2009; 9: 545- Executive Summary. 2008, Lippincott Williams 50. & Wilkins: SPINE Volume 33, Number 4S, S5- Genevay S, Atlas SJ. Lumbar spinal stenosis. S7. Best Pract Res Clin Rheumatol 2010; 24: 253- Hill JC, Whitehurst DGT, Lewis M et al. Compari- 65. son of stratified primary care management for Suri P, Rainville J, Kalichman L, Katz JN. Does low back pain with current best practice (STarT this older adult with lower extremity pain have Back): a randomised controlled trial. Lancet the clinical syndrome of lumbar spinal stenosis 2011; 378: 1560-71. ? JAMA 2010; 304: 2628-36. Genevay S, Chevallier-Ruggeri P, Faundez A. Kovacs FM, Urrutia G, Alarcon JD. Surgery ver- Canal lombaire étroit: clinique, physiopathologie sus conservative treatment for symptomatic et traitement. Rev Med Suisse 2012; 8: 585-9. lumbar spinal stenosis : A systematic review of Cohen SP. Epidemiology, diagnosis, and treat- randomized controlled trials. Spine (Phila Pa ment of neck pain. Mayo Clin Proc 2015; 90: 1976) 2011; 36: E1335-51. 284. Radcliff KE, Rihn J, Hilibrand A, et al. Does the La Cour P, Petersen M. Effects of mindfulness duration of symptoms in patients with spinal meditation on chronic pain: a randomized con- stenosis and degenerative spondylolisthesis af- trolled trial. Pain Med 2015; 16: 641-5. fect outcomes?: analysis of the Spine Outco- Hilton L, Hempel S, Ewing BA et al. Mindfulness mes Research Trial. Spine (Phila Pa 1976) Meditation for Chronic Pain: Systematic Review 2011;36: 2197-210. and Meta-analysis. Ann Behav Med 2017; 51: Genevay S, Chevallier-Ruggeri P, Faundez A. 199-213. Canal lombaire étroit: clinique, physiopathologie Genevay St, Courvoisier DS, Konstantinou K et et traitement. Rev Med Suisse 2012; 8: 585-9. al. Clinical classification criteria for radicular de Schepper EI, Overdevest GM, Suri P, et al. pain caused by lumbar disc herniation: the radi- Diagnosis of lumbar spinal stenosis: an updated cular pain caused by disc herniation (RAPIDH) systematic review of the accuracy of diagnostic criteria. Spine Journal 2017; 17: 1464-71. tests. Spine (Phila Pa 1976) 2013; 38: E469-81. Juch JN, Maas ET, Osteolo RWJG et al. Effect of Ishimoto Y, Yoshimura N, Muraki S, et al. Asso- Radiofrequency Denervation on Pain Intensity ciations between radiographic lumbar spinal among Patients With Chronic Low Back Pain stenosis and clinical symptoms in the general The Mint Randomized Clinical Trials. JAMA population: the Wakayama Spine Study. Osteo- 2017; 318:68-81. arthritis Cartilage 2013; 21: 783-8. Genevay St, Courvoisier DS, Konstantinou K et Burgstaller JM, Schuffler PJ, Buhmann JM, et al. al. Clinical classification criteria for neurogenic Is There an Association Between Pain and Ma- claudication caused by lumbar spinal stenosis. gnetic Resonance Imaging Parameters in Pa- The N-CLASS criteria. Spine Journal 2018 (In tients With Lumbar Spinal Stenosis? Spine press). (Phila Pa 1976) 2016; 41: E1053-62. Forsth P, Olafsson G, Carlsson T, et al. A Rando- Canal lombaire étroit mized, Controlled Trial of Fusion Surgery for Katz JN, Dalgas M, Stucki G, et al. Degenerative Lumbar Spinal Stenosis. NEJM 2016; 374: lumbar spinal stenosis. Diagnostic value of the 1413-23. history and physical examination. Arthritis Tomkins-Lane C, Melloh M, Lurie J, et al. ISSLS Rheum 1995; 38: 1236-41. Prize Winner: Consensus on the Clinical Dia- Lohman CM, Tallroth K, Kettunen JA, Lindgren gnosis of Lumbar Spinal Stenosis: Results of an KA. Comparison of radiologic signs and clinical International Delphi Study. Spine (Phila Pa symptoms of spinal stenosis. Spine 2006; 31: 1976). 2016; 41: 1239-46. 1834-40. Aichmair A, Burgstaller JM, Schwenkglenks M, et Chad DA. Lumbar spinal stenosis. Neurol Clin al. Cost-effectiveness of conservative versus 94 surgical treatment strategies of lumbar spinal terature. J Rheumatol 1987; 14: 1139-46. stenosis in the Swiss setting: analysis of the Bywaters EG. Still’s disease in the adult. Ann prospective multicenter Lumbar Stenosis Out- Rheum Dis 1971; 30: 121-33. come Study (LSOS). Eur Spine J 2017; 26: Cush JJ, Medsger TA, Christy WC, et al. Adult- 501-9. onset Still’s disease. Clinical course and out- Bakhsheshian J, Mehta VA, Liu JC. Current Dia- come. Arthritis Rheum 1987; 30: 186-94. gnosis and Management of Cervical Spondylo- Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A. tic Myelopathy. Global Spine J 2017; 7:572-86. Evaluation of serum ferritin as a marker for Machado GC, Ferreira PH, Harris IA, et al. Effec- adult Still’s disease activity. Ann Rheum Dis tiveness of surgery for lumbar spinal stenosis: a 1992; 51: 683-5. systematic review and meta-analysis. PLoS Yamagushi M, Ohta A, Tsunematsu T, et al. Preli- One 2015; 10: e0122800. minary criteria for classification of adult Still's disease. J Rheumatol 1992; 19: 424-30. Cervicalgies Van Reeth C, Le Moel G, Lasne Y et al. Serum Alafifi T, Kern R, Fehlings M. Clinical and MRI ferritin and isoferritins are tools for diagnosis of predictors of outcome after surgical intervention active adult Still's disease. J Rheumatol 1994; for cervical spondylotic myelopathy. J Neuroi- 21: 890-5. maging 2007; 17: 315-22. Zenagui D, De Coninck JP. Atypical presentation Furlan JC, Kalsi-Ryan S, Kailaya-Vasan A, et al. of adult Still’s disease mimicking acute bacterial Functional and clinical outcomes following sur- endocarditis. Eur Heart J 1995; 16: 1448-50. gical treatment in patients with cervical spondy- Akritidis N, Giannakakis I, Giouglis T. Ferritin le- lotic myelopathy: A prospective study of 81 vels and response to treatment in patients with cases. J Neurosurg Spine 2011; 14: 348-55. Adult Still’s disease. J Rheumatol 1996; 23: Faundez A, Genevay St. Canal cervical étroit : 201-2. diagnostic et traitement. Rev Med Suisse 2012; Kumakura S, Ishikura H, Munemasa S, Adachi T, 8: 1383-8. et al. Adult onset Still’s disease associated he- Côté P, Wong JJ, Sutton D. Management of neck mophagocytosis. J Rheumatol 1997; 24: 1645- pain and associated disorders: A clinical prac- 7. tice guideline from the Ontario Protocol for Traf- Nguyen K, Weisman M. Severe sore throat as a fic Injury Management (OPTIMa) Collaboration. presenting symptom of adult onset Still’s Eur Spine J 2016; 25: 2000-22. disease: a case series and review of the litera- Kjaer P, Kongsted A, Hartvigsen J. National clini- ture. J Rheumatol 1997; 24: 592-7. cal guidelines for non-surgical treatment of pa- Klippel J, Dieppe P. Rheumatology. 2nd ed. Lon- tients with recent onset neck pain or cervical don: Mosby International; 1998. radiculopathy. Eur Spine J 2017; 26: 2242-57. Cavagna L, Caporali R, Epis O, et al. Infliximab in Canal cervical étroit the treatment of adult Still’s disease refractory Faundez A, Genevay St. Canal cervical étroit : to conventional therapy. Clin Exp Rheumatol diagnostic et traitement. Rev Med Suisse 2012; 2001; 19: 329-32. 8: 1383-8. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Côté P, Wong JJ, Sutton D. Management of neck et al. Diagnostic value of ferritinand glycosyla- pain and associated disorders: A clinical prac- ted ferritin in adult onset Still’s disease. J Rheu- tice guideline from the Ontario Protocol for Traf- matol 2001; 28: 322-8. fic Injury Management (OPTIMa) Collaboration. Fautrel B, Zing E, Goldmard J-L, et al. Proposal Eur Spine J 2016; 25: 2000-22. for a New Set of Classification Criteria for Adult- Kjaer P, Kongsted A, Hartvigsen J. National clini- Onset Still Disease. Medicine 2002; 1: 194-200. cal guidelines for non-surgical treatment of pa- Scirè CA, Cavagna L, Perotti C, et al. Diagnostic tients with recent onset neck pain or cervical value of procalcitonin measurement in febrile radiculopathy. Eur Spine J 2017; 26: 2242-57. patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006; 24: 123-8. Cauda equina syndrom - Church LD, Cook GP, McDermott MF. Primer : In- Syndrome de la queue de cheval flammasomes and interleukin 1beta in inflam- REF:  matory disorders. Nat Clin Pract Rheumatol http://campus.neurochirurgie.fr/IMG/pdf/231_sq 2008; 4: 34-42. c.pdf Kontzias A, Efthimiou P. Adult-onset Still’s Loblaw DA, Mitera G, Ford M, Laperriere NJ . A disease : Pathogenesis, clinical manifestations 2011 updated systematic review and clinical and therapeutic advances. Drugs 2008; 68: practice guideline for the management of mali- 319-37. gnant extradural spinal cord compression. Int J Ribi C. Maladie de Still de l’adulte. Rev Med Radiat Oncol Biol Phys 2012; 84: 312-7. Suisse 2008; 4: 1039-44. Maladie de STILL de l’adulte Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al.: Adult-onset Still’s disease. Autoimmun Rev Cush JJ, Medsger TA, Christy WC, et al. Adult- 2014; 13: 708-222. onset Still’s disease. Clinical course and out- Jamilloux Y, Gerfaud-Valentin M, Martinon F et come. Arthritis Rheum 1987; 30: 186-94. al.: Pathogenesis of adult-onset Still’s disease: Ohta A, Yamaguchi M, Kaneoka H, et al. Adult new insights from the juvenile counterpart. Im- Still’s disease: review of 228 cases from the li- munol Res 2015; 61: 53–62. 95 Sfriso P, Priori R, Valesini G et al. Adult-onset 361-8. Still’s disease: an Italian multicentre retrospec- Picozzi M, Weber M, Frey RA, et al. Spondylar- tive observational study of manifestations and thrite ankylosante (maladie de Bechterew). treatments in 245 patients. Clin Rheumatol Forum Med Suisse 2002; 10: 232-7. 2016; 35: 1683-89. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylo- Spondyloarthropathies (SPA) sing spondylitis: do we need new criteria? Ar- Amor B, Dougados M, Mijiyawa. Critères de clas- thritis Rheum 2005; 52: 1000-8 sification des spondylarthropathies. Rev Rhum Weber U, Kissling O. Morbus Bechterew - neue 1990; 57: 85-9 Therapien, offene Fragen. Schweiz Med Forum Amor B, Dougados M, Listrat V, et al. Evaluation 2006; 6: 163-71. of the Amor criteria for spondylarthitis and Euro- Rudwaleit M, van der Heijde D, Landewé R et al. pean Spondylarthritis Study Group (ESSG). A The Assessment of SpondyloArthritis Internatio- cross-sectional analysis of 2,228 patients. Ann nal Society classification criteria for peripheral Med Intern (Paris) 1991; 142: 85-9. spondyloarthritis and for spondyloarthritis in ge- Dougados M, van der Linden S, Juhlin R, et al. neral. Ann Rheum Dis 2011; 70: 25-31. The European Spondyloarthropathy Study Van den Berg R, de Hooge M, Rudwaleit M, et al. Group preliminary criteria for the classification ASAS modification of the Berlin algorithm for of spondylarthropathy. Arthritis Rheum 1991; diagnosing axial spondyloarthritis: results from 34: 1218-27. the SPondyloArthritis Caught Early (SPACE)- Maksymowych WP, Chou CT, Russell AS. Mat- cohort and from the Assessment of SpondyloAr- ching prevalence of peripheral arthritis and thritis international Society (ASAS)-cohort. Ann acute anterior uveitis in individuals with ankylo- Rheum Dis 2013; 72: 1646-53. sing spondylitis. Ann Rheum Dis 1995; 54: 128- 30. Myopathie inflammatoire idiopathique Gordman JD, Sack KE, Davis JC, et al. Treat- Mariampillai K, Granger B, Guiguet M et al. Une ment of ankylosing spondylitis by inhibition of nouvelle classification des myopathies inflam- tumor necrosis factor alpha. N Engl J Med matoires idiopathiques basée sur des manife- 2002; 346: 1349-56. stations cliniques et les anticorps spécifiques Gladman TD, Helliwell P, Marchesoni A, et al. des myosites. CASPAR Study Group. Classification criteria for https://doi.org/10.1016/j.revmed.2017.10.356 psoriatic arthritis: development of new criteria Schmidt J. Current Classification and Manage- from a large international study. Arthritis Rheum ment of Inflammatory Myopathies. J Neuromus- 2006; 54: 2665-73. cul Dis 2018; 5: 109-29. Rudwaleit M, Metter A, Listing J et al. Inflamma- Lundberg IE, de Visser M, Werth VP. Classifica- tory back pain in ankylosing spondylitis: a reas- tion of myositis. Nat Rev Rheumatol. 2018;14: sessment of the clinical history for application 269-278. as classification and diagnostic criteria. Arthritis Polymyosite - Dermatomyosite Rheum 2006; 54: 569-78. Tanimoto K, Nakano K, Kano S, et al: Classifica- Zochling J, van der Heijde D, Dougados M, tion criteria for pllymyositis and dermatomyosi- Braun. Current evidence for the management of tis. J Rheumatol 1995; 22: 668-74. ankylosing spondylitis: a systematic literature Mixed connective tissue disease review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Alarcon-Segovia D, Villarreal M. Classification Rheum Dis 2006; 65: 423-32. and diagnostic criteria for mixed connective tis- Gladman DD, Mease PJ, Strand , et al. Consen- sue disease. In: Kasukawa R, Sharp GC, eds. sus on a core set of domains for psoriatic arthri- Mixed Connective Tissue Disease and Anti-nu- tis. J Rheumatol 2007; 34: 1167-70. clear Antibodies. Amsterdam, Netherlands: Ex- Rudwaleit M, van der Heijde D, Landewé R et al. cerpta Media; 1987:33-40. International The Assessment of SpondyloArthritis Internatio- Congress Series No. 719. nal Society classification criteria for peripheral Amigues JM, Cantagrel A, Abbal M, et al. Compa- spondyloarthritis and for spondyloarthritis in ge- rative study of 4 diagnosis criteria sets for neral. Ann Rheum Dis 2011; 70: 25-31. mixed connective tissue diseases in patients Van den Berg R, de Hooge M, Rudwaleit M, et al. with anti-RNP antibodies. J Rheumatol 1996; ASAS modification of the Berlin algorithm for 23: 2055-62. diagnosing axial spondyloarthritis: results from Kahn MF, Appelboom T. Syndrome de Sharp. In: the SPondyloArthritis Caught Early (SPACE)- Kahn MF, et al. Ed. Les maladies systémiques, cohort and from the Assessment of SpondyloAr- 3rd ed Paris; Flammarion 1991: 545-56. thritis international Society (ASAS)-cohort. Ann SJÖGREN Rheum Dis 2013; 72: 1646-53. Vitali C, Bombardieri S, Moutsopoulos HM et al. Spondylarthrite ankylosante - and the European Community Study Group on BECHTEREW Diagnostic Criteria for Sjögren's Syndrome, incl. Van der Linden S, Valkenburg HA, Cats A. Eva- Manthorpe R. Assessment of the European luation of diagnostic criteria for ankylosing classification criteria for Sjögren's syndrome in spondylitis. A proposal for modification of the a series of clinically defined cases: results of a New York criteria. Arthritis Rheum 1984; 27: prospective multicentre study. Ann Rheum Dis 96 1996; 55: 116-21. ruricaemic agents with fenofibrate and/or losar- R Manthorpe. Sjögren's syndrome criteria. Ann tan on uric acid metabolism. Ann Rheum Dis Rheum Dis 2002; 61: 482-4. 2003; 52: 572. Vitali C, Bombardieri S, Jonsson R, et al. Classifi- Khanna D, Fitzgerald JD, Khanna PP et al. 2012 cation criteria for Sjögren's syndrome: a revised American College of Rheumatology guidelines version of the European criteria proposed by for management of gout. Part 1: systematic the American-European Consensus Group. Ann nonpharmacologic and pharmacologic thera- Rheum Dis 2002; 61: 554–8. peutic approaches to hyperuricemia. Arthritis Seror R, Ravaud Ph, Bowman S et al. EULAR Care Res 2012; 64: 1431-46. Sjogren's syndrome disease activity index: de- Keenan RT. Safety of urate-lowering therapies: velopment of a consensus systemic disease ac- managing the risks to gain the benefits. Rheum tivity index for primary Sjogren's syndrome. Ann Dis Clin North Am 2012; 38: 663-80. Rheum Dis 2010; 69: 1103-1109. Stamp LK, Taylor WJ, Jones PB et al. Starting Shiboski CH, et al. 2016 American College of dose is a risk factor for allopurinol hypersensiti- Rheumatology/European League Against Rheu- vity syndrome: a proposed safe starting dose of matism classification criteria for primary Sjo- allopurinol. Arthritis Rheum 2012; 64: 2529-36. gren’s syndrome: A consensus and data-driven Stamp LK, Taylor WJ, Jones PB, Dockerty JL, methodology involving three international pa- Drake J et al. Starting dose is a risk factor for tient cohorts. Ann Rheum Dis 2017; 76: 9-16. allopurinol hypersensitivity syndrome: a propo- Liapi A, Horisberger A, Spertini F et al. Syndrome sed safe starting dose of allopurinol. Arthritis de Sjögren : quand le suspecter et comment le Rheum. 2012; 64: 2529-36. confirmer? Rev Med Suisse 2016; 12: 698-702. Moi JHY, Sriranganathan MK, Edwards CJ, Buch- Aeby M, Maurer B, Distler O. Le syndrome de binder R: Lifestyle interventions for acute gout. Sjögren primaire, une maladie systémique: par- Cochrane Database Syst Rev 2013;1 1: tie 1. Swiss Med Forum 2017; 17: 1027-1038. CD010519. Aeby M, Maurer B, Distler O. Le syndrome de Duskin-Bitan H, Cohen E, Goldberg E et al. The Sjögren primaire, une maladie systémique: par- degree of asymptomatic hyperuricemia and the tie 2. Swiss Med Forum 2017; 17: 1063-1066. risk of gout. A retrospective analysis of a large cohort. Clin Rheumatol 2014; 33: 549-53. Liquide synovial - Synovialflüssigkeit Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet Cohen AS et al. Synovial Fluid. In: Laboratory 2016; 388: 2039-52. Diagnosis in the Rheumatic Disease, 2nd edi- Forster A, Krebs A. Kristallkrankheiten (Teil 1): tion, 1975. Gicht. Swiss Med Forum 2017;17:387-390. Krey PR, Bailen DA. Synovial fluid leukocytosis. Richette P, Doherty M, Pascual E et al. 2016 up- Am J Med 1979; 67: 436-42. dated EULAR evidence-based recommendati- Eisenberg JM, et al. Usefulness of synovial fluid ons for the management of gout. Ann Rheum analysis in the evaluation of joint effusions. Use Dis 2017; 76: 29-42. of threshold analysis and likelihood ratios to as- Shekelle PG, Newberry SJ, FitzGerald JD et al. sess a diagnostic test. Arch Intern Med 1984; Management of Gout: A Systematic Review in 144: 715-9. Support of an American College of Physicians Shmerling RH, Delbanco TL. Synovial fluid tests. Clinical Practice Guideline. Ann Intern Med What should be ordered? JAMA 1990; 264: 2017; 166: 37-51. 1009-14. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 Goutte - Gicht American College of Rheumatology guideline Wallace SL, Robinson H, Masi AT, et al. Prelimi- for the management of gout. Arthritis Care Res nary criteria for the classification of the acute (Hoboken) 2020; 72: 744-760. arthritis of primary gout. Arthritis Rheum 1977; Fibromyalgie-Syndrom 20: 895-900. Goldenberg DL. Diagnostic and therapeutic chal- Emmerson BT. The management of gout. N Engl langes of fibromyalgia. Hosp Pract 1989; Sep- J Med 1996; 334: 445-51. tember 30: 39-52. Rana SS, Giuliani MJ, Oddis CV, et al. Acute Wolfe F, Smythe HA, Yunus MB, et al. The ameri- onset of colchicine myoneuropathy in cardiac can college of rheumatology 1990 criteria for transplant recipients: case studies of three pa- the classification of fibromyalgia. Arthritis tients. Clin Neurol Neurosurg 1997; 99: 266-70. Rheum, 1990; 33: 160-72. Cohen MG, Emmerson BT. Gout. In: Rheumato- Wolfe F, Hawley DJ and Wilson K. The preva- logy. Klippel JH, Dieppe PA (eds.). Mosby Phil- lence and meaning of fatigue in rheumatic adelphia, 1998, p: 8.14.1-14. disease. J.Rheumatol 1996 ;23: 1407-17. Minghelli G, Seydoux C, Goy JJ, et al. Uricosuric White KP, Speechley M, Harth M. The London Fi- effect of the angiotensin II receptor antagonist bromyalgia Epidemiology Study: comparing the losartan in heart transplant recipients. Trans- demographic and clinical characteristics in 100 plantation 1998; 66: 268–71. random community cases of fibromyalgia ver- Bardin, T. Fenofibrate and losartan. Ann Rheum sus controls. J.Rheumatol 1999; 26: 1577-85. Dis 2003; 62: 497-498. Kivimaki M, Leino-Arjas P, Virtanen M, et al. Work Takahashi S, Moriwaki Y, Yamamoto T, et al. Ef- stress and incidence of newly diagnosed fibro- fects of combination treatment using anti-hype- myalgia: prospective cohort study. J Psycho- 97 som Res 2004; 57: 417-22. 2007; 7: 81-6. Yunus MB. Fibromyalgia and overlapping disor- Bursite ders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: Schumacher HR Jr. Synovial fluid analysis and 339-56. synovial biopsy. In: Kelley ED Jr, Ruddy S, Wang C, Schmid CH, Rones R, et al. A randomi- Sledge CB, (eds.). Textbook of rheumatology. zed trial of tai chi for fibromyalgia. NEJM 2010; Philadelphia, W.B. Saunders 1997. 363: 74354. Algodystrophie SUDECK - Wolfe F, Clauw DJ, Fitzcharles MA, et al. The CRPCS Komplexes regionalses American College of Rheumatology preliminary Schermzsyndrom diagnostic criteria for fibromyalgia and measu- Sudeck P. Über die akute (reflektorische) Kno- rement of symptom severity. Arthritis Care Res chenatrophie nach Entzündungen und Verlet- 2010; 62: 600-10. zungen an den Extremitäten und ihre klinischen Davidson JR, Crawford C, Ives JA and Jonas Erscheinungen. Fortschr Gebiete Roentgenstr WB. Homeopathic treatments in psychiatry: a 1901; 5: 277-93. systematic review of randomized placebo-con- Kozin F, Genant HK, Beckerman C, et al. The re- trolled studies. J.Clin Psychiatry 2011; 72: 795- flex sympathetic dystrophy syndrome II. Roent- 805. genographic and scintigraphic evidence of Häuser W, Kosseva M, Üceyler N, et al. Emotio- bilaterality and of periarticular accentuation. Am nal, physical, and sexual abuse in fibromyalgia J Med 1976; 60: 332-38. syndrome: a systematic review with meta-ana- Merskey H, Bogduk N. Complex regional pain lysis. Arthritis Care Res 2011; 63: 808-20. syndromes: classification of chronic pain. Des- Verra ML, Angst F, Beck T, et al. Horticultural the- criptions of chronic pain syndromes and definiti- rapy for patients with chronic musculoskeletal ons of pain terms. Seattle: IASP Press 1994; pain: results of a pilot study. Altern Ther Health 40-3. Med 2012; 18: 42-50. Stanton-Hicks M, Janic W, Hassenbusch S, et al. Aeschlimann AG, Bachmann ST, Cedraschi C et Reflex sympathetic dystrophy: changing con- al. Syndrome fibromyalgique: nouvelles concepts and taxonomy. Pain 1995; 63: 127-33. naissances relatives au diagnostic et au traite- Todorovic-Tirnanic M, Obradovic V, Han R, et. al. ment. Partie 1: tableau clinique, contexte de Diagnostic approach to reflex sympathetic dys- survenue et évolution. Forum Med Suisse 2013; trophy after fracture: radiography or bone scinti- 13: 517-21. graphy? Eur J Nucl Med 1995; 22: 1187-93. Aeschlimann AG, Bachmann ST, Cedraschi C et Adami S, Fossaluzza V, Gatti D, et al. al. Fibromyalgie-Syndrom: neue Erkenntnisse Bisphosphonate therapy of reflex sympathetic zu Diagnostik und Therapie Teil 2: Praktisches dystrophy syndrome. Ann Rheum Dis 1997; 56: Vorgehen bei Abklärung und Behandlung. 201-4. Schweiz Med Forum 2013; 13: 541-43. Zollinger PE, Tuinebreijer WE, Kreis RW, et al. C Sommer, Alten R, Bär KJ et al. Drug Therapy of Effect of vitamin C on frequency of reflex sym- Fibromyalgia Syndrome : Updated Guidelines pathetic dystrophy in wrist fractures: a randomi- 2017 and Overview of Systematic Review Arti- sed trial. Lancet 1999; 354: 2025-8. cles Schmerz 2017; 31: 274-284. van Hilten BJ, van de Beek WJ, Hoff JI, et al. In- Schiltenwolf M, Eidmann U, Köllner V et al. Multi- trathecal baclofen for the treatment of dystonia modal therapy of fibromyalgia syndrome : Up- in patients with reflex sympathetic dystrophy. N dated guidelines 2017 and overview of Engl J Med 2000; 343 .625-30. systematic review articles. Schmerz 2017; 31: Kemler MA, Barendse GA, van Kleef M, et al. 285-288. Spinal cord stimulation in patients with chronic Syndrome du tunnel carpien reflex sympathetic dystrophy. N Engl J Med 2000; 343: 618-24. Kaplan SJ, Glickel SZ, Eaton RG. Predictive fac- Schwartzmann R, Popescu A. Reflex sympathetic tors in the non-surgical treatment of carpal tun- dystrophy. Curr Rheumatol Rep 2002; 4: 165-9. nel syndrome. J Hand Surg 1990; 15: 108. van de Beek WJT, Schwartzman RJ, van Nes SI, Périarthropathie huméroscapulaire et al. Diagnostic criteria used in studies of reflex Hawkins RJ, Kennedy JC. Impingement syn- sympathetic dystrophy. Neurology 2002; 58: drome in athletes. Am J Sports Med 1980; 8: 522-6. 151-8. Harden RN, Bruehl S, Perez RSGM, et al. Valida- Hedtmann A, Fett H. So-called humeroscapular tion of proposed diagnostic criteria (the “Buda- periarthropathy-calssification and analysis pest Criteria”) for Complex Regional Pain based on 1266 cases. Z Orthop Ihre Grenzgeb Syndrome. Pain 2010; 150: 268-74. 1989; 127: 643-9. Roh YH, Lee BK, Noh JH, et al. Factors associa- Sher JS, Uribe JW, Posada A, et al. Abnormal fin- ted with complex regional pain syndrome type I dings on magnetic resonance images of asym- in patients with surgically treated distal radius ptomatic shoulders. J Bone Joint Surg Am fracture. Arch Orthop Trauma Surg 2014;1775- 1995; 77: 10-5. 81. Würgler CC, Sheikh R, Jost B et al . Periarthropa- Harnik MA, Streitberger K, Brunner F et al. Kom- thia humeroscapularis. Schweiz Med Forum plexes regionales Schmerzsyndrom (CRPS) – Teil 1. Schweiz Med Forum 2021; 21: 209-213. 98 Ostéonécrose aseptique amyloidosis. N Engl J Med 2003: 349: 583-96. Manking HJ. Nontraumatic necrosis of bone. N Dember LM, Hawkins PN, BP.C. Hazenberg et al. Engl J Med 1992; 326: 1473-9. Eprodisate for the Treatment of Renal Disease Chang C, Greenspan A, Gershwin ME. Osteone- in AA Amyloidosis. N Engl J Med 2007; 356: crosis: current perspectives on pathogenesis 2349-60. and treatment. Semin Arthritis Rheum 1993; 23: Jaccard A, Moreau Ph, Leblond V, et al. High- 47-69. Dose Melphalan versus Melphalan plus Dexa- Mirzai R, Chang C, Greenspan A, et al. Avascular methasone for AL Amyloidosis, N Engl J Med necrosis. Compr Ther 1998; 24: 251-5. 2007; 357: 1083-93. Mirzai R, Chang C, Greenspan A, et al. The pa- Auto-anticorps - Autoantikörper thogenesis of osteonecrosis and the relations- Tan EM, Robinson CA, Nakamura RM, et al. hips to corticosteroids. J Asthme 1999; 36: ANA’s in systemic rheumatic disease: Diagno- 77-95. stic significance. Postgrad Med 1985; 78: 141- Glesby MJ, Hoover DR, Vaamonde CM. Osteone- 2, 145-8. crosis in patients with human immunodeficiency Love PE, Santoro SA. Antiphospholipid antibo- virus: a case-control study. J Infect Dis 2001; dies: Anticardiolipin and the lupus anticoagulant 184: 519-23. in systemic lupus erythematosus (SLE) and in Miller KD, Masur H, Jones EC, et al. High preva- non-SLE disorders. Ann Intern Med 1990; 112: lence of osteonecrosis of the femoral head in 682- 98. HIV-infected adults. Ann Intern Med 2002; 137: Wallach J. Interpretation of Diagnostic Tests. Little 17-25. Brown, 1996. Paranéoplasie - Paraneoplasisches Syndrom Collagénose/connectivite/Vasculites John WJ, et al. (eds.). Paraneoplastic syndromes. Kollagenose - Vaskulitis In: Cancer. Principles and Practice of Oncology. Jennette JC, Falk RJ, Andrassi K, et al. Nomen- De Vita VT. Lippincott-Raven 1997, p: 2397- clature of systemic vasculitides. Proposal of an 2422. international consensus conference. Arthritis Darnell RB, Posner JB. Paraneoplastic syndro- Rheum 1994; 37: 187-92. mes involving the nervous system. N Engl J Hunder G. Vasculitis: diagnosis and therapy. Am Med 2003; 349: 1543-54. J Med 1996; 100 (Suppl. 2A): 37S-45S. Amyloïdose Lie JT. Classification of histopathological specificity of systemic vasculitis. In: Ansell BM, Bacon Hill GS, Morel-Maroger L, Mery JP, et al. Renal PA, Lie JT (eds). The vasculitides. London: lesions in multiple myeloma: the relationship to Chapman & Hall, 1996; 26-36. associated proteine abnormalities. Am J Kidney Jennette JC, Falk RJ. Small-vessel vasculitis. N Dis 1983; 2: 423-38. Engl J Med 1997; 337: 1512-23. Bukbaum JN, Chuba JV, Hellman GC, et al. Mo- Olivieri J, Chizzolini C, Dayer JM. Vasculites: Un noclonal immunoglobuline deposition disease: défi pour le clinicien. Med Hyg 1998; 56: 398- light chain and light and heavy chain deposition 402. diseases and their relation to light chain amyloi- Michel B, Brühlmann P. Kollagenosen und Vasku- dosis. Clinical features, immunopathology, and litiden. In: Flasnoecker M, (ed.). Thiemes Innere molecular analysis. Ann Intern Med 1990; 112: Medizin: TIM. Georg Thieme Verlag, New York, 455-64. Stuttgart 1999, p. 1632-51. Solomon A, Weiss DT, Kattine AA, et al. Nephro- Hoffman GS. Classification of systemic vasculiti- toxic potential of Bence Jones proteins. N Engl des. Clin Exp Rheumatol 1998; 16: 111-5. J Med 1991; 324: 1845-51. Gross WL, Trabandt A, Reinhold-Keller E. Dia- Holmgren G, Ericzon BG, Groth CG, et al. Clinical gnosis and evaluation of vasculitis. Rheumato- improvement and amyloid regression after liver logy 2000; 39: 245-52. transplantation in hereditary transthyretin amy- Weyand CM, Goronzy JJ. Medium- and large- loidosis. Lancet 1993; 341: 1113-6. vessel vasculitis. N Engl J Med 2003; 349: 160- Skinner M, Lewis WD, Jones LA, et al. Liver 9. transplantation as a treatment for familial amy- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revi- loidotic polyneuropathy. Ann Intern Med 1994; sed International Chapel Hill Consensus Confe- 120: 133-4. rence Nomenclature of Vasculitides. Arthritis Falk RH, Comenzo RL, Skinner M. The systemic Rheum 2013; 65:1. amyloidoses. N Engl J Med 1997; 337: 898- Walsh M, Merkel PA, Peh CA et al. Plasma ex- 909. change and glucocorticoid dosing in the treat- Kyle RA, Gertz MA, Greipp PR, et al. A trial of ment of anti-neutrophil cytoplasm antibody three regimens for primary amyloidosis: colchi- associated vasculitis (PEXIVAS): protocol for a cine alone. melphalan and prednison, and randomized controlled trial. Trials 2013; 14: 14- melphalane, prednisone, and colchicine, N Engl 73. J Med 1997; 336: 1202-7. Kushwaha SS, Fallen JT, Foster V. Restrictive Phénomène de RAYNAUD cardiomyopathy. N Engl J Med 1997; 336: 267- Allen EV, Brown GE. Raynaud’s disease: a critical 76. view of minimal requisities for diagnosis. Am J Merlini G, Belloti V. Molecular mechanisms of Med Sci 1932; 183: 187-200. 99 Kluken N, Rabe E. Clinical picture and treatment Kowal-Bielecka O, Fransen J, Avouac J e al. Up- of the Raynaud syndrome of the upper extre- date of EULAR recommendations for the treat- mity. Phlebologie 1987; 40: 447-54. ment of systemic sclerosis. Ann Rheum Dis Lally EV. Raynaud’s phenomenon. Curr Opin 2017; 76: 1327-39. Rheumatol 1992; 4: 825-36. Périartérite noueuse (PAN) LeRoy EC, Medsger TA Jr. Raynaud’s phenomenon: a proposal for classification. Clin Exp Lightfoot RW, Michel AB, Bloch DA, et al. The Rheumato 1992; 10: 485-8. American College of Rheumatology 1990 crite- Bolster MB, Maricq HR, Leff RL. Office evaluta- ria for the classification of polyarteriitis nodosa. tion and treatment of Raynaud’s phenomenon. Arthritis Rheum 1990; 33: 1088-93. Cleve Clin J Med 1995; 62: 51-61. Syndrome de TAKAYASU Roussin A. Raynaud’s phenomonon. Therapeutic Arend WP, Michel BA, Bloch DA, et al. The Ame- choices. 3ème édition. Association des pharma- rican College of Rheumatology 1990 criteria for ciens du Canada, 2000, chap. 33, p. 285. the classification of Takayasu arteriitis. Arthritis Block JA, Sequeira W. Raynaud’s phenomenon. Rheum 1990; 33: 1129-34. Lancet 2001; 357: 2042-48. Villiger PM. Large-vessel vasculitis-giant cell and Roussin A. Le phénomène de Raynaud. Mythes Takayasu arteritis [Article in German] Internist et réalités. Le Clinicien Nov 2001; 85-95. (Berl). 2019 Oct;60(10):1059-1073. doi: Wigley FM. Raynaud’s phenomenon. N Engl J 10.1007/s00108-019-00666-2 Med 2002; 347: 1001-8. IgA-Vaskulitis (HENOCH-SCHÖNLEIN) Sclérose systémique - Systemische Sklerose Mills JA, Michel BA, Cloch DA, et al , The Ameri- Steen VD, Medsger TA, Rodnan GP. D-Penicilla- can College of Rheumatology 1990: Criteria for mine therapy in progressive systemic sclerosis the classification of Henoch-Schönlein purpura. (scleroderma): a retrospective analysis. Ann In- Arhtritis Rheum 1990; 33: 1114-21. tern Med 1982; 97 :652-9. Leroy EC, Black C, Fleischmajer R, et al. Sclero- Vasculite leucocytoclasique derma (systemic sclerosis): classification, sub- Calabrese LH, Michel BA, Bloch DA, et al. The setus, and pathogenesis. J Rheumatol 1988; American College of Rheumatology 1990 crite- 15: 202-5. ria for the classification of hypersensitivity vas- Steen VD, Costantino JP, Shapiro AP, et al. Out- culitis. Arthritis Rheum 1990; 33: 1108-13. come of renal crisis in systemic sclerosis: rela- Maladie de BUERGER tion to availability of angiotensin converting (Thrombangéite oblitérante) enzyme (ACE) inhibitors. Ann Intern Med 1990; 113 :352-7. Mozes M, Cahansky G, Deutsch V, et al. The As- Medsger TA. Treatment of systemic sclerosis. sociation of arteriosclerosis and Buerger’s Ann Rheum Dis 1991; 50 (Suppl 4): 877-86. disease: a clinical and radiological study. J Car- Pope J. Treatment of systemic sclerosis. Curr diovasc Surg 1970; 11: 52-7. Opin Rheumatol 1993; 5: 792-801. Shionoya S. Diagnostic criteria of Buerger’s Sandusky SB, McGuire L, Smith MT, Wigley FM, disease. Int J Cardiol 1998; 66(Suppl.): 243e5. Haythornthwaite JA. Fatigue: an overlooked de- Maladie de BEHçET terminant of physical function in scleroderma. International study group for Behçet’s disease. Rheumatology (Oxford) 2009;48:165. Criteria for diagnosis of Behçet’s disease. Lan- Roustit M, Blaise S, Allanore Y, Carpentier PH, cet 1990; 335: 1078-80. Caglayan E, Cracowski JL. Phosphodiesterase- Sakane T, Takeno M, Suzuki N, et al. Behcet’s 5 inhibitors for the treatment of secondary Ray- disease. NEJM 1999; 341: 1284-91. naud's phenomenon: systematic review and Gabay C. Syndrome de Behçet. Rev Med Suisse meta-analysis of randomised trials. Ann Rheum 2008; 4: 728-33. Dis. 2013; 72: 1696-99. The International Criteria for Behçet's Disease van den Hoogen F, Khanna D, Fransen J et al. (ICBD): A Collaborative Study of 27 Countries EULAR/ACR. 2013 classification criteria for sy- on the Sensitivity and Specificity of the New Cri- stemic sclerosis: an American college of rheu- teria. J Eur Acad Dermatol Venereol 2014; 28: matology/European league against rheumatism 338-47. collaborative initiative. Ann Ann Rheum Dis Villiger RA, Stefanski AL, Grobéty V, Adler S, Villi- 2013; 72: 1747-55. ger PM. Behçet’s syndrome: clinical presenta- Khanna D, Distler JHW, Sandner P, Distler O. tion and prevalence in Switzerland. Swiss Med Emerging strategies for treatment of systemic Wkly. 2019;149:w20072. https://smw.ch/arti- sclerosis. Journal of Scleroderma and Related cle/doi/smw.2019.20072 Disorders 2016; 1: 186-93. Schoenfeld SR, Choi HK, Sayre EC et al. Risk of Syndrome de CHURG-STRAUSS Pulmonary Embolism and Deep Venous Throm- = Granulomatose éosinophilique avev polyangiite (EGPA) bosis in Systemic Sclerosis: A General Popula- tion-Based Study. Arthritis Care Res 2016; 68: Churg J, Strauss L. Allergic granulomatosis, aller- 246-53. gic angiitis, and periarteritis nodosa. Am J Pa- Da D. Sclérose systémique. Forum Médical thol 1951; 27: 277-94. Suisse 2017; 17: 808-15. Franco J, Artes MJ. Pulmonary eosinophilia asso- 100 ciated with montelukast. Thorax 1999; 54: 558- European League Against Rheumatism/Ameri- 60. can College of Rheumatology Classification Cri- Green RL, Vayonis AG: Churg-Strauss syndrome teria for Systemic Lupus Erythematosus. after zafirlukast in two patients not receiving sy- Arthritis Rheumatol 2019; 71: 1400-1412. stemic steroid treatment. Lancet 1999; 353: Artérite temporale (HORTON-Arteriitis) / 725-6. Risenzellarteriitis (RZA) Guillevin L, Lhote F, Gayraud M: Prognostic fac- und Polymyalgia rheumatica (PMR) tors in polyarteritis nodosa and Churg-Strauss Bird HA, Esselinckx W, Dixon AS, et al. An eva- syndrome. A prospective study in 342 patients. luation of criteria for polymyalgia rheumatica. Medicine (Baltimore) 1996; 75: 17-28. Ann Rheum Dis 1979; 38: 434-9. Jennette JC, Falk RJ, Andrassy K. Nomenclature Chuang TY, Hunder GG, Ilstrup DM, et al. Poly- of systemic vasculitides. Proposal of an interna- myalgia rheumatica: a 10-year epidemiology tional consensus conference. Arthritis Rheum and clinical study. Ann Intern Med 1982; 97: 1994; 37: 187-92. 672-80. Masi AT, Hunder GG, Lie JT. The American Col- Healey LA. Long-term follow-up of polymyalgia lege of Rheumatology 1990 criteria for the clas- rheumatica: evidence for synovitis. Semin Ar- sification of Churg-Strauss syndrome (allergic thritis Rheum 1984; 13: 322-8. granulomatosis and angiitis). Arthritis Rheum Delecoeuillerie G, Joly P, Cohen de Lara A, et al. 1990; 33: 1094-100. Polymyalgia rheumatica and temporal arteritis: Tuggey JM, Hosker HS. Churg-Strauss syndrome a retrospective analysis of prognostic features associated with montelukast therapy. Thorax and different corticosteroid regimens. (11 years 2000; 55: 805-6. of survey of 210 patients). Ann Rheum Dis Wechsler ME, Finn D, Gunawardena D: Churg- 1988; 47: 733-9. Strauss syndrome in patients receiving monte- Hunder GG, Bloch DA, Michel BA, et al. The lukast as treatment for asthma. Chest 2000; American College of Rheumatology 1990 crite- 117: 708-13. ria for the diagnosis of giant cell arteritis. Arthri- Guillevin L, Pagnoux C, Seror R, et al. The Five- tis Rheum 1990; 33: 1122-8. Factor Score revisited: assessment of progno- Evans JM, O’Fallon WM, Hunder GG. Increased ses of systemic necrotizing vasculitides based incidence of aortic aneurysm and dissection in on the French Vasculitis Study Group (FVSG) giant cell (temporal) arteritis. Ann Intern Med cohort. Medicine (Baltimore) 2011; 90:19. 1995; 122: 502-7. MCTD Salvarani C, Gabriel SE, O’Fallon WM, et al. Epi- Kahn MF, Appelboom T. Syndrom de Sharp. In: demiology of polymyalgia rheumatica in Olm- Les maladies systemiques, 3rd, Kahn MF, Pel- sted Coutry, Minnesota, 1970-1991. Arthritis tier AP, Meyer O, Piette JC (Eds), Flammarion, Rheum 1995; 38: 369-73. Paris 1991. p.545. Salvarani C, Gabriel SE, O'Fallon WM, et al. The Alarcón-Segovia D, Cardiel MH. Comparison bet- incidence of giant cell arteritis in Olmsted ween 3 diagnostic criteria for mixed connective County, Minnesota: apparent fluctuations in a tissue disease. Study of 593 patients. J Rheu- cyclic pattern. Ann Intern Med 1995; 123: 192. matol 1989;16:328-34. Schmidt WA, Kraft HE, Vorpahl K et al. Color duplex ultrasonography in the diagnosis of tempo- Lupus érythémateux disséminé (LED) ral arteritis. N Engl J Med 1997; 337: 1336-42. Tan EM, et al. The 1982 reviesed criteria for the Saag KG, Emkey R, Schnitzer TJ, et al. Alendro- classification of systemic lupus erythematosus. nate for the prevention and treatment of gluco- Arthritis Rheum 1982; 25: 1271-7. corticoid-induced osteoporosis. N Engl J Med Hess E. Drug related-lupus. N Engl J Med 1988; 1998; 339: 292-9. 318: 1460-2. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et Love PE, Santoro SA. Antiphospholipid antibo- al.: Visual manifestations of giant cell arteritis. dies: Anticardiolipin and the lupus anticoagulant Trends and clinical spectrum in 161 patients. in systemic lupus erythematosus (SLE) and in Medicine 2000; 79: 283-92. non-SLE disorders. Ann Intern Med 1990; 112: Martinez-Taboada VM, Rodriguez-Valverde V. Po- 682- 98. lymyalgia rheumatica with normal erythrocyte Colvin RB, Bhan AK, McCluskey RT (eds.). Dia- sedimentation rate: clinical aspects. Clin Exp gnostic Immunopathology. Raven Press 1995. Rheumatol 2000; 4 (Suppl. 20): S34-37. Frank MM, Austen KF, Claman HN, Unanue ER Gerster J.-CH. Polymyalgia rheumatica et mala- (eds.). Samter’s Immunologic Disease. Little die de Horton. Med Hyg 2001; 59: 609-12. Brown 1995. Salvarani C, Cantini F, Boiardi L, et al. Polymyal- Hochberg M. Updating the American College of gia rheumatica and giant -cell arteritis. N Engl J Rheumatolgy revised criteria for the classifica- Med 2002; 347; 261-71. tion of systemic lupus erythematosus. Arthritis Rahman W, Rahman FZ: Giant cell (temporal) ar- 1997; 40: 1725-34. teritis: an overview and update. Surv Ophthal- Piette J-Ch, Le Thi Huong D, Amoura Z. Traite- mol 2005; 50: 415-28. ment du lupus érythémateux systémique. Med Mazlumzadeh M, Hunder GG, Easley KA et al. Hyg 1999; 57: 908-15. Treatment of giant cell arteritis using induction Aringer M, Costenbader K, Daikh D et al. 2019 therapy with high-dose glucocorticoids: a dou- 101 ble-blind, placebo-controlled, randomized pro- 18: 654-60. spective clinical trial. Arthritis Rheum 2006; 54: 3310. ORL — HNO Ness T, Auw-Hadrich C, Schmidt D: Temporal arteritis (giant cell arteritis). Clinical picture, histo- Acouphènes - Tinnitus logy, and treatment. Ophthalmologe 2006; 103: Luxon LM. Tinnitus: its causes, diagnosis, and 296-301. treatment. BMJ. 1993;306:1490–1491. Dasgupta B, Cimmino MA, Maradit Kremers H et Nondahl DM, Cruickshanks KJ, Wiley TL et al. al. 2012 provisional classification criteria for po- Prevalence and 5-year incidence of tinnitus lymyalgia rheumatica: a European League among older adults: the Epidemiology of Hea- Against Rheumatism/American College of ring Loss Study. J Am Acad Audiol 2002; 13: Rheumatology collaborative initiative. Arthritis 323-31. Rheum 2012; 64: 943-54 und Ann Rheum Dis Byung In Han, Ho Won Lee, Tae You Kim et al. 2012; 71: 484-92. Tinnitus: Characteristics, Causes, Mechanisms, Christian Dejaco C, Singh YP, Perel P et al. A Eu- and Treatments. J Clin Neurol. 2009; 5: 11-19. ropean League Against Rheumatism/American Tunkel DE, Bauer CA, Sun GH, et al. Clinical College of Rheumatology Collaborative Initia- practice guideline: tinnitus. Otolaryngol Head tive. 2015 Recommendations for the Manage- Neck Surg 2014; 151: Suppl: S1-S40. ment of Polymyalgia Rheumatica. Ann Rheum Manche SK, Madhavi J, Meganadh KR, Jyothy A. Dis 2015; 74: 1799-807. Association of tinnitus and hearing loss in otolo- Villiger PM. Large-vessel vasculitis-giant cell and gical disorders: a decade-long epidemiological Takayasu arteritis [Article in German] Internist study in a South Indian population. Braz J Otor- (Berl). 2019 Oct;60(10):1059-1073. hinolaryngol 2016; 82: 643-9. Bauer C.A. Tinnitus. NEJM 2018; 378:1224-1231. Granulomatose avec polyangéitite (GPA) (anciemment/früher WEGENER) Rhinosinusitis - Sinusitie Nölle B, Specks U, Lüdemann J, et al. Anticyto- Fokkens WJ, Lund WJ, Hopkins C et al. Rhino- plasmic autoantibodies: their immunodiagnostic logy. European Position Paper on Rhinosinusi- value in Wgener’s granulomatosis. Ann Intern tis and Nasal Polyps 2020. 2020; 58(Suppl Med 1989; 111: 28-40. S29)1-464. Leavitt RY, Fauci AS, Bloch DA, et al. The Ameri- can College of Rheumatology 1990 criteria for Epistaxis the classification of Wegener's granulomatosis. Becker, Walter: Hals-Nasen-Ohren-Heilkunde. Arthritis Rheum 1990; 33: 1101-7. Stuttgart; New York: Thieme 1989 Hoffman GS, Kerr GS, Leavitt RY. Wegener gra- Naumann, Hans-Heinz, Scherer, Hans Hermann nulomatosis: an analysis of 158 patients. Ann (Hrsg.): Differentialdiagnostik in der Hals- Intern Med 1992; 116: 488-98. Nasen-Ohrenheilkunde. Stuttgart; New York: Weir A, Lipman M, Congleton J. Co-trimoxazole Thieme, 1998 in Wegener’s granulomatosis. N Engl J Med Strutz, Jürgen; Mann Wolf (Hrsg.): Praxis der 1996; 335: 1769-70. HNO-Heilkunde, Kopf- und Halschirurgie. Stutt- De Groot K, Gross WL. Wegener’s granulomato- gart; New York: Thieme, 2001 sis: disease course, assessment of activity and Vertiges, nystagmus - Schwindel/Nystagmus extent and treatment. Lupus 1998; 7: 285-91. Coquoz E. Le vertige et le praticien. Rev Med Syndrome de GOODPASTURE Suisse Rom 1993; 113: 999-1002. Rees AJ. Goodpasture’s syndrome. In: Lichten- Liard P. et al. (ed.). Les vertiges. Karger 1993. stein LM, Fauci AS. (eds). Current Therapy in Vibert D, Teppa H, Häusler R. Le traitement médi- Allergy, Immunology, and Rheumatology.Mosby, camenteux des vertiges. Rev Med Suisse Rom 1996. p: 120-6. 1993; 113: 685-8. Vibert D. Le traitement physiothérapeutique des Cryoglobulinémie - Kryoglobulinämie vertiges. Rev Med Suisse Rom 1993; 113: 689- Ramos-Casals M, Stone JH, Cid MC, et al.The 91. cryoglobulinaemias. Lancet. 2012; 379: 348-60. Hotson JR, Baloh RW. Acute vestibular syn- Tendinopathie Achilles - rupture du tendon drome. N Engl J Med 1998; 339: 680-5. Minor LD. Superior canal dehiscence syndrome. Neumayer F, Mouhsine E, Arlettaz Y, et al. A new Am J Otol 2000; 21: 9-19. conservative-dynamic treatment for the acute Brandt T. Vertigo, dizziness and falls in the el- ruptured Achilles tendon. Arch Orthop Trauma derly. In: Vertigo. its multisensory syndromes, Surg 2010; 130: 363-8. London: Springer-Verlag 1999: 385-92. Neumayer F, Crevoisier X, Assal M. Diagnostic et Fontana PE, Zekry D, Gold G. Vertiges: De la traitement de la rupture du tendon d’Achille. plainte au diagnostic. Med Hyg 1999; 57: 2221- Rev Med Suisse 2012; 8: 1490-95. 7. Hitz M, Meier S, Huber M. Die ansatzferne Tendi- Marill KA, Walsh MJ, Nelson BK. Intravenous lo- nopathieder Achillessehne. Schweiz Med razepam versus dimenhydrinate for treatment Forum 2018; 18: 654-60. of vertigo in the emergeny department: a rando- Hitz M, Meier S, Huber M. La tendinopathie achil- mized clinical trial. Ann Emerg Med 2000; 36: léenne corporéale. Suisse Med Forum 2018; 310-9. 102 Irving C, Richman P, Kaiafas C, et al. Intramuscu- Semont A. Le vertige paroxystique bénin. In: Le lar droperidol versus intramulscular dimenhydri- traitement des troubles vestibulaires. Mémoire. nate for the treatment of acute peripheral Bibliothèque nationale de Paris, 1984. vertigo in the emergency department: a rando- Zumstein V, Reglin F. Nystagmus positionnel. In: mized clinical trial. Acad Emerg Med 2002; 9: Les vertiges. Zumstein V, Regli F. 1990; p: 15- 650-3. 16. Baloh RW. Vestibular neuritis. N Engl J Med Herdmann SJ, Tusa RJ, Zee DS et al. Single 2003; 348: 1027-32. treatment approaches to benign paroxysmal po- Neuhauser, H. K. Epidemiology of vertigo. Curr sitional vertigo. Arch Otolaryngol Head Neck Opin Neurol 2007; 20: 40-46. Surg 1993; 119:450-454. Kattah JC, Talkad AV, Wang DZ et al.: HINTS to Epley JM. Particle repositioning for benign parox- diagnose stroke in the acute vestibular syn- ysmal positional vertigo. Otolaryngol Clin North drome: three-step bedside oculomotor exami- Am 1996; 29: 323-31. nation more sensitive than early MRI Serafini G, Palmieri AMR, Simincelli C. Benign diffusion-weighted imaging. Stroke 2009; 40: paroxysmal positional vertigo of posterior semi- 3504-10. circular canal: Results in 160 cases treated with Tarnutzer AA, Berkowitz AL, Robinson KA, et al.: Semont’s maneuver. Ann Otol Rhinol Laryngol Does my dizzy patient have a stroke? A syste- 1996; 105: 770-775. matic review of bedside diagnosis in acute ve- Furman JM, Cass SP. Primary care: Benigne pa- stibular syndrome. CMAJ 2011;183:E571-92. roxysmal positional vertigo. N Engl J Med 1999; Tarnutzer AA, Berkowitz AL, Robinson KA, et al.: 341; 1590-6. Does my dizzy patient have a stroke? A syste- von Brevern M, Lempert T. Benigner paroxysma- matic review of bedside diagnosis in acute ve- ler Lagerungsschwindel. Nervenarzt 2004; 75: stibular syndrome. CMAJ 2011;-183:-E571Y92. 1027-36. Newman-Toker DE, Saber Tehrani AS, Mantokou- Maladie WALLENBERG dis G et al.: Quantitative video-oculography to help diagnose stroke in acute vertigo and dizzi- Frumkin LR, Baloh RW. Wallenberg’s syndrome ness: toward an ECG for the eyes. Stroke 2013; following a neck manipulaiton. Neurology 1990; 44: 1158Y61. 40: 611-5. Saber Tehrani AS, Kattah JC, Mantokoudis G et Rigueiro-Veloso MT, Pego-Reigosa R, Branas- al.: Small strokes causing severe vertigo: fre- Fernandez-F, et al. Wallenberg syndrome: a re- quency of false-negative MRIs and nonlacunar view of 25 cases. Rev Neurol 1997; 25: 1561-4. mechanisms. Neurology 2014; 83: 169-73. Dinichert A, Rufenacht DA, Tribolet N. Dissecting Guyot J-P. La neuro-otologie pour le praticien. aneurysms of the posterior inferior verebellar Rev Med Suisse 2015; 11: 249-50. artery: report of four cases and review of the li- Mantokoudis G, Tehrani AS., Wozniak A .et al.: terature. J Clin Neurosci 2000; 7: 151-20. VOR gain by head impulse video-oculography Maladie de Ménière differentiates acute vestibular neuritis from Ménière P. Pathologie auriculaire: mémoire sur stroke.Otol Neurotol 2015 36:457-65. les lésions de l’oreille interne donnant lieu à des Zamaro E, Vibert D, Caversaccio M, Mantokoudis symptôme de congestion cérébrale apoplecti- G. «HINTS» bei akutem Schwindel: peripher forme. Gaz Med Pars 1861; 16: 597-601. oder zentral? Schweiz Med Forum 2016; 16: Saeed SR. Diagnosis and treatment of Ménière’s 21-23. disease. B MJ 1998; 316: 368-72. FL. Wuyts, V. Van Rompaey, LK Maes. «SO STO- Lopez-Escamez JA, Carey J, Chung WH, Goebel NED»: Common Sense Approach of the Dizzy JA, Magnusson M, Mandala M, Newman-Toker Patient. Front Surg 2016; 3: 32. DE, Strupp M, Suzuki M, Trabalzini F, Bisdorff Névralgie du trijumeaux A. Diagnostic criteria for Menière's disease. J Headache Classification Committee of the Inter- Vest Res 2015; 25:1-7. national Headache Society (IHS) The Interna- Déficit cochléo-vestibulaire aigu tional Classification of Headache Disorders, 3rd Wilson WR, Byl FM, Laird N. The efficacy of ste- edition. Cephalalgia 2018; 38:1-211. roids in the treatment of idiopathic sudden hea- Vertige positionnel paroxystique bénin ring loss. A double-blind clinical study. Arch Beigner positioneller Lagerungsschwindel Otolaryngol 1980; 106: 772-6. BPLS Hotson JR, Baloh RW. Acute vestibular syn- Dix MR, Hallpike CS. The pathology, symptoma- drome. N Engl J Med 1998; 339: 680-5. tology and diagnosis of certain disorders of the Ogawa K, Takei S, Inoue Y, Kanzaki J. Effect of vestibular system. Proc R Soc Med 1952; 45: prostaglandin E1 on idiopathic sudden sensori- 341-54. neural hearing loss: a double-blinded clinical Semont A, Freyss G, Witte E. Vertiges position- study. Otol Neurotol 2002; 23: 665-8. nels paroxystiques bénins et manœuvre libéra- Suzuki H, Furukawa M, Kumagai M et al. Defibri- toire. Ann Otolaryngol (Paris) 1980; 1096: nogenation therapy for idiopathic sudden sen- 473-6. sorineural hearing loss in comparison with Semont A, Freyss G, Vitte E. Curing the BPPV high-dose steroid therapy. Acta Otolaryngol with a liberatory maneuver. Adv Otorhinolaryn- 2003; 123: 46-50. gol 1988; 42: 290-293. 103 Épiglottite rium in the emergency department - a pilot Carey MJ. Epiglottitis in adults. Am J Emerg Med study on the feasibility of a new algorithm for 1996; 14: 421-4. use in older emergency department patients: Hebert PC, Ducic Y, Boisvert D, et al. Adult epi- the modified Confusion Assessment Method for glottitis in a canadian setting. Laryngoscope the Emergency Department (mCAM-ED). 1998; 108: 64-9. Scand J Trauma Resusc Emerg Med 2014; 22: Nakamura H, Tanaka H, Matsuda A, et al. Acute 19. epiglottitis: a review of 80 patients. J Lanryngol Hasemann W, Grossmann FF, Stalder R et al. Otol 2001; 5: 31-4. Screening and detection of delirium in older ED Templier F, Lentz T, Tazarourte K, et al. Benefit of patients: performance of the modified Confu- pharmaceutical anti-oedematous treatment in sion Assessment Method for the Emergency acute adult epiglottitis. Ann Fr Anesth Reanim Department (mCAM-ED). A two-step tool. Intern 2004; 23: 1003-6. Emerg Med 2018; 13: 915-922. Simon M, Cour M, Argaud L. Épiglottites aiguës Troubles neurocognitifs sévères de l’adulte Severe Adult Acute Epiglotti- Neurokognitive Störung (früher Demenz) tis. Réanimation 2016; 25: S62-S68. Hughes CP, Berg L, Danziger WL et al. A new cli- Rhinosinusite nical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72. Hamory BH, Sande MA, Sydnor A, et al. Etiology Inouye SK, van Dyk CH, Alessi CA. Clarifying and antimicrobial therapy of acute maxillary si- Confusion: The Confusion Assessment Method. nusitis. J Infect Dis 1979; 139: 197-202. Ann Intern Med 1990; 113: 941-8. Berg O, Carenfelt C. Rystedt G, et al. Occurrence Bennett DA, Wilson RS, Gilley DW et al. Clinical of asymptomatic sinusitis in common cold and diagnosis of Binswanger’s dieseas. J Neuro- other acute ENT-infections. Rhinology 1986; 24: surg Psychiatry 1991; 54: 1122-3. 223-5. American Psychiatric Association Diagnostic and Gwaltney JM, Phillips CD, Miller RD, et al. Com- Statistical Manual, 4th edition, APA Press, Wa- puted tomographic study of the common cold. N shington DC, 1994. Engl J Med 1994; 330: 25.30. Canadian study of health and aging working Gwaltney JM. Acute community-acquired sinusi- group. Canadian study of health and aging: tis. Clin Infect Dis 1996; 23: 1209-25. study methods and prevalence of dementia. Puhakka T, Makela MJ, Alanen A, et al. Sinusitis Can Med Assoc J 1994; 150: 899-913. in the common cold. J Allergy Clin Immunol. Cummings JL, Mega MS, Gray K et al. The neu- 1998 ;102: 403-8. ropsychiatric inventory: Comprehensive assess- Hickner JM, Bartlett JG, Besser RE, et al. Princi- ment of psychopathology in dementia. ples of appropriate antibiotic use for acute rhi- Neurology 1994; 44: 2308-14. nosinusitis in adults: background. Ann Intern Rosen J, Burgio L, Kollar M, et al. A user-friendly Med 2001; 134: 498-505. instrument for rating agitation in dementia pa- Gilbert DN, Moellering RC, Sande MA. The Sand- tients. Am J Geriatr Psychiatry 1994; 2: 52-9. ford Guide to antimicrobial therapy; 2003. Giannakopoulos P, et al. Démences et détériora- Piccirillo JF. Acute Bacterial Sinusitis. New Engl J tion. Pathologie Médicale. Masson, 1995; 2: Med 2004; 351: 902-10. 405-17. Fokkens WJ, Lund VJ, Mullol J et al. EPOS Giannakopoulos P, et al. Confusion mentale. Pa- 2012: European position paper on rhinosinusitis thologie Médicale. Masson, 1995; 2: 418-28. and nasal polyps 2012. A summary for otorhino- Polvikoski T, Sulkava R, Haltia M, et al. Apoliporo- laryngologists. Rhinology 2012; 50:1-12. tein E, Dementia , and cortical deposition of Rosenfeld RM Piccirillo JF, Chandrasekhar SS et beta-amyloid protein: N Engl J Med 1995; 333: al. Clinical practice guideline (update): adult si- 1242-7. nusitis. Otolaryngol Head Neck Surg 2015; 152 Diagnostisches und statistisches Manual psychi- (2 Suppl): S1-S39. scher Störungen DSM-IV. Göttingen: Hogrefe- PSYCHIATRIE - Geriatrie Verlag; 1996. McKeith LG, Galasko D, Kosaka K, et al. Consen- Delir (Delirium) sus guidelines for the clinincal and pathologic diagnosis of dementia with Lewy bodies (DLB): Kahn RL, Goldfarb AI, Pollack M, Peck A: Brief Report of the consortium on DLB international objective measures for the determination of workshop. Neurology 1996; 47: 113-24. mental status in the aged. Am J Psychiatry Snowdon DA, Greiner LH, Mortimer JA, et al. 1960; 117: 326-328. Brain infarction and the clinical expression of

Alzheimer disease. The Nun Study. JAMA 1997; Thomas C, Kreisel SH, Oster P et al. Diagnosing 277: 813-7. delirium in older hospitalized adults with de- Hock C, Müller-Spahn F. Verwirrtheitszustände im mentia: adapting the confusion assessment me- Alter. Schweiz Rundsch Med Prax 1999; 88: thod to international classification of diseases, 998-1006. tenth revision, diagnostic criteria. J Am Geriatr Inouye SK, Bogardus ST, Charpentier PA, et al. A Soc 2012; 60: 1471-7. multicomponent intervention to prevent delirium Grossmann FF, Hasemann W, Graber A et al. in hospitalized older patients. N Engl J Med Screening, detection and management of deli- 104 1999; 340: 669-76. heimer's disease: recommendations from the Tariot PN, Erb R, Podgorski CA, et al. Efficacy National Institute on Aging-Alzheimer's Associa- and tolerability of carbamazepine for agitation tion workgroups on diagnostic guidelines for and aggression in dementia. Am J Psychiatry Alzheimer's disease. Alzheimers Dement 2011; 1998; 155: 54-61. 7: 270-9. Moroney JT, Tang MX, Berglund L, et al. Low- McKhann GM, Knopman DS, Chertkow H et al. density lipoprotein cholesterol and the risk of The diagnosis of dementia due to Alzheimer's dementia with stroke. JAMA 1999; 282: 254-60. disease: recommendations from the National Ott A, Stolk RP, van Harskamp F, et al. Diabetes Institute on Aging-Alzheimer's Association work- mellitus and the risk of dementia: The Rotter- groups on diagnostic guidelines for Alzheimer's dam Study. Neurology 1999; 53: 1937-42. disease. Alzheimers Dement 2011; 7: 263-9. Gifford DR, Holloway RG, Vickrey BG: Systema- Sperling RA, Aisen PS, Beckett LA et al. Toward tic review of clinical prediction rules for neuroi- defining the preclinical stages of Alzheimer's maging in the evaluation of dementia. Arch disease: recommendations from the National Intern Med 2000; 160: 2855-62. Institute on Aging-Alzheimer's Association work- Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes groups on diagnostic guidelines for Alzheimer's associated with cognitive impairment and cogni- disease. Alzheimers Dement 2011; 7: 280-92. tive decline amoung older women? Study of Chester JG, Beth Harrington M, Rudolph JL. Se- osteoporotic fractures research group. Arch In- rial administration of a modified Richmond Agi- tern Med 2000; 160: 174-80. tation and Sedation Scale for delirium Sisco F, Taurel M, Lafont V, et al. Troubles du screening. Br J HospMed 2012; 7: 450-3. comportement chez les sujets déments en insti- Gold G, Fazio L, Hua Stolz J. Evaluation du com- tution: évaluation à partir de l'inventaire Neuro- portement en milieu somatique: utilisation d’une psychiatrique pour les équipes soignantes. méthode simple et fiable. Rev Med Suisse L'Année Gérontologique 2000; 14: 151-71. 2012; 8: 2119-21. Seshadri S, Beiser A, Selhub J, et al. Plasma ho- Soto ME, Andrieu S, Villars H, et al. Improving mocysteine as a risk factor for dementia and care of older adults with dementia : Description Alzheimer’s disease. N Engl J Med 2002; 346: of 6299 hospitalizations over 11 years. J Am 476-83. Med Dir Assoc 2012; 13: 486.e1-6. Verghese J, Lipton RB, Hall CB, et al. Abnorma- Cummings JL, Dubois B, Molinuevo JL et al. In- lity of gait as a predictor factor of non-Alzhei- ternational Work Group criteria for the diagnosis mer’s dementia. N Engl J Med 2002; 347: of Alzheimer disease. Med Clin North Am 2013; 1761-8. 97: 363-8. Ely EW, Truman B, Shintani A, et al. Monitoring American Psychiatric Association. Diagnostic and sedation status over time in ICU patients: relia- Statistical Manual of Mental Disorders, Fifth bility and validity of the Richmond Agitation-Se- Edition. Arlington, VA, American Psychiatric As- dation Scale (RASS). JAMA 2003; 289: sociation 2013. 2983-91. Dubois B, Hampel H, Feldman HH. Preclinical Reisberg B, doddy R, Stöffler A, et al. Memantine Alzheimer's disease: Definition, natural history, in moderate-to-severe Alzheimer’s disease. N and diagnostic criteria. Alzheimers Dement Engl J Med 2003; 348: 1331-41. 2016; 12: 292-323. Wancata J, Windhaber J, Krautgartner M, et al. Petersen RC, Lopez O, Armstrong MJ et al. Prac- The consequences of non-cognitive symptoms tice guideline update summary: Mild cognitive of dementia in medical hospital departments. Int impairment: Report of the Guideline Develop- J Psychiatry Med 2003; 33: 257-1. ment, Dissemination, and Implementation Sub- Tarrot PN, Farlow; R. Frossberg FT, et al. Me- committee of the American Academy of mantine treatment in patients with moderate to Neurology. Neurology 2018; 90: 126-135. severe Alzheimer disease alredy revecing do- De Roeck EE, De Deyn PP, Dierckx E et al. Brief nepezil. KAMA 2004; 291: 317-24. cognitive screening instruments for early detec- Nasreddine ZS, Phillips NA, Bédirian V et al. The tion of Alzheimer’s disease: a systematic re- Montreal Cognitive Assessment, MoCA: a brief view. Alzheimers Res Ther 2019; 11: 21. screening tool for mild cognitive impairment. J Neuropsychologisches Assessment Am Geriatr Soc 2005; 53: 695-9. Folstein MF, Folstein SE, McHugh PR. Mini-men- American Academy of Clinical Neuropsychology tal state: A practical method for grading the co- (AACN) practice guidelines for neuropsycholo- gnitive state of patients for the clinician. J gical assessment and consultation. Clin Neuro- Psychiatr Res 1975; 12: 189-198. psychol 2007; 21: 209-31. Nasreddine ZS, Phillips NA, Bédirian V et al. The Dubois B, Feldman HH, Jacova C et al. Research Montreal Cognitive Assessment, MoCA: a brief criteria for the diagnosis of Alzheimer's disease: screening tool for mild cognitive impairment. J revising the NINCDS-ADRDA criteria. Lancet Am Geriatr Soc 2005; 53: 695-9. Neurol 2007; 6: 734-46. American Academy of Clinical Neuropsychology Dubois B, Picard G, Sarazin M. Early detection of (AACN) practice guidelines for neuropsycholo- Alzheimer's disease: new diagnostic criteria. gical assessment and consultation. Clin Neuro- Dialogues Clin Neurosci 2009; 11:135-9. psychol 2007; 21: 209-31. Albert MS, DeKosky ST, Dickson D et al. The dia- Petersen RC, Lopez O, Armstrong MJ et al. Prac- gnosis of mild cognitive impairment due to Alz- 105 tice guideline update summary: Mild cognitive sedation status over time in ICU patients: relia- impairment: Report of the Guideline Develop- bility and validity of the Richmond Agitation-Se- ment, Dissemination, and Implementation Sub- dation Scale (RASS). JAMA 2003; 289: committee of the American Academy of 2983-91. Neurology. Neurology 2018; 90: 126-135. Mini-mental state (FOLSTEIN) MoCA-Test© Folstein MF, Folstein SE, McHugh PR. «Mini- Nasreddine ZS, Phillips NA, Bédirian V et al. The mental state»: a practical method for grading Montreal Cognitive Assessment, MoCA: a brief the cognitive state of patients for the clinician. J screening tool for mild cognitive impairment. J Psych Res 1975; 12: 189-98. Am Geriatr Soc 2005; 53: 695-9. État dépressiv, trbl. panique MMS (Mini-mental state Test) CIM-10/ICD-10: Classification internationale des Folstein MF, Folstein SE, McHugh PR. Mini-men- troubles mentaux et des troubles du comporte- tal state: A practical method for grading the co- ment. Organisation Mondiale de la Santé, Ge- gnitive state of patients for the clinician. J nève, Paris, Masson, 1-305, 1993. Psychiatr Res 1975; 12: 189-198. Hirschfeld RM. Guidelines for the longterm treat- Delirium tremens ment of depression. J Clin Psych 1994; Lipowski ZJ. Transient cognitive disorders (deli- 55(Suppl.): 61-9. rium, acute confusional states) in the elderly. DSM-IV: Manuel diagnostique et statistique des Am J Psychatry 1983; 140: 1426-36. troubles mentaux. Traduction française coor- Erkinjuntti T, et al. Dementia among medical inpa- donnée par Guelfi JD, Paris, Masson, 1-1008, tients: evaluation of 2000 consecutive admissi- 1996. ons. Arch Intern Med 1986; 146: 1923-6. Culpepper L. Escitalopram: a new SSRI for the Lipowski ZL. Delirium in the elderly patient. N treatment of depression in primary care. Pri- Engl J Med 1989; 320: 578-82. mary Care Companion J Clin Psychiatry 2002; CIM-10/ICD-10: Classification internationale des 4: 209-14. troubles mentaux et des troubles du comporte- Maladie d’ALZHEIMER ment. Organisation Mondiale de la Santé, Ge- McKhann G, Drachman D, Folstein M, et al. Clini- nève, Paris, Masson, 1993, p: 1-305. cal diagnosis of Alzheimer’s disease. Neurology Brust JC. Agitation and delirium. In: Bogousslav- 1984; 34: 939-44. sky J, Caplan L, (eds.). Stroke syndromes. Evans DA, Funkenstein HH, Albert MS, et al. Pre- Cambridge: Cambridge Univ Press 1995: 134- valence of Alzheimer’s disease in a community 9. population of older persons: higher than previo- DSM-IV: Manuel diagnostique et statistique des usly reported. JAMA 1989; 262: 2551-6. troubles mentaux. Traduction française coor- Reisberg B, Schneider, Doody R, et al. Clinical donnée par Guelfi JD, Paris, Masson, 1-1008, global measures of dementia: position paper 1996. from the International Work Group on Harmoni- Ghika J. Delirium chez la personne âgée. Med zation of Dementia Drug Guidelines. Alzheimer Hyg 1997; 55: 1037-41. Dis Assoc Disord 1997; 11 (Suppl.3): S8-S18. Winterthaler G, Ferrero F, Bertschy G. Syndrome Giacobini E. Cholinergic foundations of Alzhei- de sevrage: alcool, médicaments, drogues. In: mer’s disease therapy. J Physiol Paris 1998; Restellini A, et al. (éds.). Urgences Médicales. 92: 283-7. Editions Médecine et Hygiène, 1997, p: 455-60. Mayeux R, Sano M. Treatment of Alzheimer’s Young J, Inouye SK. Delirium in older people. disease. N Engl J Med 1999; 341: 1670-9. BMJ 2007; 334: 842-6. Zekry D, Fontana P, Laszlo A. La prise en charge Maldonado JR, Sher Y, Das S. et al. Prospective médicamenteuse de la maladie d’Alzheimer. Validation Study of the Prediction of Alcohol Med Hyg 1999; 57: 2210-4. Withdrawal Severity Scale (PAWSS) in Medi- Seshadri S, Beiser A, Selhub J, et al. Plasma Ho- cally Ill Inpatients: A New Scale for the Predic- mocysteine as a risk factor for dementia and tion of Complicated Alcohol Withdrawal Alzheimer’s disease. N Engl J Med 2002; 346: Syndrome. Alcohol and Alcoholism 2015; 50: 476-83. 509-18. McKhann GM, Knopman DS, Chertkow H et al. Wood E, MD, Albarqouni L, Tkachuk S et al. Will The diagnosis of dementia due to Alzheimer's This Hospitalized Patient Develop Severe Alco- disease: recommendations from the National holWithdrawal Syndrome? The Rational Clinical Institute on Aging-Alzheimer's Association work- Examination Systematic Review. JAMA 2018; groups on diagnostic guidelines for Alzheimer's 320: 825-33. disease. Alzheimers Dement. 2011; 7: 263-9. Confusion Assessment Method (CAM) DSM-5, Manuel diagnostique et statistique des Inouye SK, Bogardus ST, Charpentier PA, et al. A troubles mentaux. American Psychiatric Asso- multicomponent intervention to prevent delirium ciation. Diagnostic and Statistical Manual of in hospitalized older patients. N Engl J Med Mental Disorders, Fifth Edition (DSM-5), Ameri- 1999; 340: 669-76. can Psychiatric Association, Arlington, VA 2013. Chute de la personne âgée - Sturz im Alter Richmond Scale Ely EW, Truman B, Shintani A, et al. Monitoring Podsiadlo D, Richardson S. Tire Timed «Up & 106 Go»: A test of basic functional mobility for frail tensive Care Med 1980; 6: 243-4. elderly persons. Am Geriatr Soc 1991,39:142-8. Scrimshaw NS. Criteria for valid nitrogen balance Duncan PW, Studenski S, Chandler S et al. measurement of protein requirements. Eur J Functional reach: predictive validity in a sample Clin Nutr 1996; 50 (Suppl 1): S196-7. of elderly male veterans. J Gerontol A Biol Sci Calcium Med Sci 1992; 47: M93-98. Baraff LJ, Della Penna R, Williams N et al. Prac- Messaï E, (ed.). In: Guide des chiffres et formules tice Guideline for the ED management of falls in utiles en pratique médicale. Arnette Blackwell, community dwelling elder persons. Ann Emerg 1995, p: 38. Med 1997; 30: 480-9. Chlore: déficit Sloan JP. Protocols in primary care geriatrics. 2d Brimioulle S Vincent JL, Dufaye P, et al. Hydro- ed. New York: Springer, 1997 chloric acid infusion for treatment of metabolic Tinetti ME, Baker DI, Dutcher J, Vincent JE, Ro- alkalosis: effects on acid-base balance and oxy- zett RT. Reducing the risk of falls among older genation. Crit Care Med 1985; 13: 738-42. adults in the community. Berkeley, CA: Peace- able Kingdom Press, 1997. Clairance (créatinine, eau libre, Hb), Man-Son-Hing M, Nichol G, Lau A et al. Choosing osmolalité Antithrombotic Therapy for Elderly Patients Smith HW. The kidney: structure and function in With Atrial Fibrillation Who Are at Risk for Falls. health and disease. Oxford University Press, New Arch Intern Med. 1999;159:677-85. York 1951, 231-238. American Geriatrics Society, British Geriatrics So- Cockcrof DW, Gault MH. Prediction of creatinine ciety and American Academy of Orthopaedic clearance from serum creatinine. Nephron Surgeons Panel on Fall Prevention. Guidelines 1976; 16: 31-41. for the Prevention of Falls in older Persons. J National Kidney Foundation (NFK) Kidney Americ Geriatric Soc 2001: 49: 664-72. Disease Outcome Quality Initiative (K/DOQI) Masud T. Morris RO. Epidemiology of falls. Age Advisory Board. K/DOQI clinical practice guide- and Ageing 2001; 30-S4: 3-7. lines for chronic kidney disease: evaluation, Rubenstein LZ, Powers CM, MacLean CH. Qua- classification, and stratification. Am J Kidney lity Indicators for the Management and Preven- Dis 2002; 39 (Suppl. 2): S1-S246. tion of Falls and Mobility Problems in vulnerable Cameron J, Greger R. Renal function and testing elders. Ann Int Med. 2001; 135(8): 686-93. of function, in AM Davidson, JS Cameron, JP Wettstein A, Conzelmann M, Heiss HW (Hrsg). Grunfeld, et al., Oxford texbook of clinical ne- Checkliste Geriatrie. Georg Thieme Verlag phrology. Oxford University Press Oxford 1998, Stuttgart New York 2001. 39-69. Ensrud KE, Blackwell TL, Mangione CM et al. Rahn KH, Heidenreich S, Bruckner D. How to as- Central nervous system-active medications and sess glomerular function and damage in hu- risk for falls in older women. J Am Geriatr Soc mans. J Hypertens 1999: p. 309-317. 2002; 50: 1629-37. Fer Grob D, Stuck AE. Der Sturz im Alter. In: Medizi- Working group on fortification of salt with iron: nische Notfälle. Thieme 2003; 439-47. Use of common salt fortified with iron in the Man-Son-Hing M, Laupacis A. Anticoagulant-Re- control and prevention of anemia – a collabora- lated Bleeding in Older Persons With Atrial Fi- tive study. Am J Clin Nutr 1982; 35: 1442. brillation. Arch Intern Med 2003; 163: 1580-86. Crosby WH, O’Neil-Cutting MA. A small-dose iron Chang JT, Morton SC, Rubenstein LZ et al. Inter- tolerance test as inidcator of mild iron defi- ventions for the prevention of falls in older ciency. JAMA 1984; 251: 1986-7. adults: systematic review and meta-analysis of Lee R, et al. (eds.). Clinical hematology. 1993, randomised clinical trials. BMJ 2004; 328: Lea & Febiger. 680.FORMULES Wallach J. Interpretation of Diagnostic Tests. Little Éthanol — Alcool Brown, 1996. Ruedin P. Traitement de l’anémie liée à l’insuffi- Jennet B, Gleave J, Wilson P. Brain death in sance rénale chronique. Med Hyg 1998; 56: three neurosurgical units. BMJ 1981; 282: 533- 2081-4. 9. Purssell RA, Pudek M, Brubacher J, et al. Deri- Glycémie et HbA1c vaiton and validation of a fromula to calculate Peters AL, Davidson MB, Schriger DL, et al. A cli- the contribution of the osmolal gap. Ann Emerg nical aprproach tor the diagnosis of diabetes Med 2001; 38: 653-9. mellitus: an analysis using glycated hemoglobin Bilan azoté levels. JAMA 1996; 276: 1246-52. Lee HA, et al. A method of determining daily nitro- Gradient: albumine sérum-ascite gen requirements. Postgrad Med J 1975; 51: Reynolds TB, Ito S, Iwatsuki S. Measurement of 441-5. portal pressure and its clinical application. Am J Protein and energy requirements: a joint Med 1970; 49: 649-57. FAO/WHO memorandum. Bull World Health Runyon BA. Care of patients with ascites. N Engl Organ 1979; 57: 65-79. J Med 1994; 330: 337-42. Park GR. Rapid calculation of nitrogen losses. In- LDL-Cholestérol 107 Friedewald WT, Levy RL, Fredrickson DS. Esti- 2007; 7: 765-9. mation of the concentration of low density lipoprotein cholesterol in plasma without the use of RADIOLOGIE the preparative ultracentrifuge. Clinical Chemi- NET: www.MRIsafety.com stry 1972; 18: 499-502. TEXTBOOK: Meire H, Cosgrove D, Dewburg K, Recommendations of the Second Joint Task et al. (ed.). Clinical ultrasound, a comprehen- Force of European and other Societies on coro- sive text. Churchill Livingstone 2001. nary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; Échographie, échocardiographie 19: 1434-1503. Gladisch R. (ed.). Praxis der abdominellen Ultra- schalldiagnostik. Schlatter, 1992. Osmolalité Coady MA, Rizzo JA, Hammond GL, et al. What Truniger B, Briner V. Troubles du bilan acqueux. is the appropriate size criterion for resection of Forum Med Suisse 2001; N° 1:779-83. thoracic aortic aneurysms? J Thorax Cardio- PARKLAND vasc Surg 1997; 1113: 476-91. Scheulen JJ, Munster AM. The Parkland formula Deuzat M. (ed.). Ultatrasonographie vasculaire in patient with burns and ihhalation injury. J diagnostic. Viogt, 1991. Trauma 1982; 22: 869-71. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318- Poids idéal, indice de la masse corporelle 30. Bray GA, et al. Evaluation of the obese patient. Anévrisme aortique JAMA 1976; 235: 1447. Juvonene T, Ergin MA, Galla JD, et al. Prospec- Physical status: the use and interpretation of an- tive study of the natural history of thoracic aortic thropometry: report of a WHO expert commit- aneurysms. Ann Thorac Surg 1997; 63: 1533- tee. WHO Tech Rep Ser 1995; 854: 1-452. 45. International Obesity Task Force (IOTF). Obesity: Patel HJ, Deeb GM. Ascending and arch aorta. preventing and managing the global epidemic. Pathology, natural history and treatment. Circu- Report of a WHO consultation on obesity. Ge- lation 2008; 118: 188-95. neva, 3-5 June, 1997 (WHO/NUT/NCD/97.2). Calle EE, Thun MJ, Petrelli JM, et al. Body-mass Radiographie standard, thorax index and mortality in a prospecive cohort on Fleischner FG, Udis SW. Dilatation of the azygos U.S. adults. N Engl J Med 1999; 341: 1097- veins, a roentgen sign of venous engorgement. 1105. Am J Roentgenol 1952; 67: 659-75. Pression artérielle moyenne Chang CH. The normal roentgenographic measu- Hall JB, Schmidt GA, Wood LDH, (eds.). Princi- rement of the right descending pulmonary ar- ples of critical care. McGraw-Hill,1998. tery. Am J Roentgenol 1962; 87: 929-35. Felson B. (ed.). Principles of chest roentgenology. Sodium: déficit, natrémie corrigée, Saunders 1974. fraction d’extraction Conrardy PA, Goodman LR, Lainge F, et al. Alte- Steffes MW, Freier EF. A simple and precise me- ration of endotracheal tube position: flexion and thod of determining true sodium, potassium and extension of the nekc. Crit Care Med 1976; 4: chloride concentrations in hyperlipemia. J Lab 7-12. Clin Med 1976; 88: 683-88. Bismuth V, Bléry M, Rémy J, et al. Traité de ra- Oh MS, Carroll HJ. Regulation of intracellular and diodiagnostic. Tome IV. Appareil pulmonaire et extracellular volume. In: Arieff AI, DeFronzo RA médiastin. Masson, 1977. (eds.). Fluid, electrolyte, and acid-base disor- Vasile N. (ed.). I.R.M. corps entier. Vigot, 1988. ders. 2nd edition New York: Churchill Living- Rich S, Chomka E, Hasara L, et al. The preva- stone, 1995; 1-28. lence of pulmonary hypertension in the United Vitesse de sédimentation States. Adult population estimates obtained Gilbertsen VA. Erythrocyte sedimentation rates in from measurements of chest roentgenograms older patients. Postgrad Med 1965; 38: A44- from the NHANES II Survey. Chest 1989; 96: A52. 236-41. Bottiger LE, Svedberg CA. Normal erythrocyte Remy J, Caodeville R, Coussement A. Le pou- sedimentation rate and age. Br Med J 1967; 2: mon pathologique. Atlas de sémiologie radiolo- 85-7. gique. Arnet. Paris, 1990. Miller A, Green M, Robinson D. Simple rule for Bernadac P, Anthoine D, Hennequin L, et al. Pou- calculating normal erythrocyte sedimentation mon cardiaque. Editions techniques. Encyl Med rate. Br Med J 1983: 2: 266. Chir (Paris-France). Radiodiagnostic Cœur- Bedell SE, et al. Erythrocyte sedimentation rate. Poumon- Larynx, 32489R10, 1991. Am J Med 1985; 78: 1001-9. Armstrong P, Wastie ML. (eds.). Diagnostic Ima- Sox HC, Liang MH. The erythrocyte sedimenta- ging. Blackwell, 1994. tion rate. Gudelines for rational use. Ann Intern Armstrong P, Wilson AG, Dee P, et al. (eds). Ima- Med 1986; 104: 515-23. ging of diseases of the chest. Mosby 2000. Lessung HP, Delmenico S. Une vitesse de sédi- Muller N, Fraser R, Colman N, et al. Radiologic mentation augmentée. Schweiz Med Forum diagnosis of diseases of the chest. WB Saun- 108 ders, 2001. 1995; 63: 65-76. Hanks GW, de Conno F, Ventafridda V, et al. Mor- Divers phine in cancer pain: modes of administration. Steens RD, Summers QA, Tarala RA. Pulmonary BJM, 1996; 312: 823-26. alveolar proteinosis in association with Fan- Levy MH. Pharmacologic treatment of cancer coni’s anemia and psoriasis. A possible com- pain. N Engl J Med 1996; 335: 1124-32. mon pathogentic mechanism. Chest 1992; 102: McQuay HJ, Tramèr M, Nye BA, et al. A systema- 637-8. tic review of antdepressants in neuropathic Eisenberg RL, Margulis AR (eds.). In: Radiology: pain. Pain 1996; 68: 217-27. What to order when. Lippincott – Raven, 1996. Rosner H, Rubin L, Kestenbaum A et al. Gaba- Bonow RO et al. ACC/AHA guidelines for the ma- pentin adjunctiv therapy in neuropathic pain nagement of patients with valvular heart states. Clin J Pain 1996; 12: 56-8. disease. Circulation 1998; 98: 1949-84. Also Manfredi PL, et al. (ed). Comprehensive medical published in: J Heart Valve Dis 1998 ; 7: 672- management: Opioid analgesia. In: Parris WCV, 707 and JACC 1998; 32: 1486-588. (ed). Cancer Pain Management: Principles and Webb R, Muller N, Naidich DP. (ed.). High-resolu- Practice, Butterworth-Heinemann, 1997, p: 49- tion CT of the lung. Lippincott Wiliams 2001. 63. Shellock FG, Crues JV. Commentary: MR safety Rosenberg JM, Harrell C, Ristic H, et al. The ef- and the american college of radiology white fect of gabapentin on neuropathic pain. Clin J paper. Am J Roentgenol 2002; 178: 1349-52. Pain, 1997; 13: 251-55. Nodule pulmonaire solitaire Tudela LL, et al. Protocolo de cuidados paliativos Cummings SR, Lillington GA, Richard RJ. Esti- en atención primaria. Formación medica conti- mating the probability of malignancy in solitary nua, 1997, p. 23. pulmonary nodules: a Bayesian approach. Am Backonja M, Beydoun A, Edwards KR, et al. Ga- Rev Respir Dis 1986; 134: 449-52. bapentin for the symptomatic treatment of pain- Swensen SJ, Silverstein MD, Edell ES, et al. Soli- ful neuropathy in patients with diabetes mellitus. tary pulmonary nodules: clinical prediction JAMA, 1998; 280: 1831-36. model versus physicians. Mayo clin Proc 1999; Hewitt DJ, Portenoy RK. Adjuvant drugs for neu- 74: 319-29. ropathics cancer pain. In: Portenoy RK, Bruera Henschke CI, Yankelevitz D, Westcott J, et al. E (eds.). Topics in Palliative Care. Oxford Uni- Work-up of the solitrary pulmonary nodule. Ra- versity Press, New York Oxford 1998, p: 41-62. diology 2000; 215: (Suppl.) 607-9. Collège des médecins du Québec. Traitement de Ost D, Fein AM, Feinsilver SH. The solitary pul- la douleur: le point sur l’utilisation des narcoti- monary nodule. N Engl J Med 2003; 348: 2535- ques. QMC, décembre 1998. 42. Grond St, Radbruch L, Meuser Th, et al. Assess- ment and treatment of neuropahtic cancer pain Douleurs, Opioïdes following WHO guidelines. Pain; 1999; 79: 15- 20. NET: Portenoy RK, Lesage P. Management of cancer • www.douleur.ch pain. Lancet 1999; 353: 1695-1700. • www.palliative.org Woolf CJ, Mannion RJ. Neuropathic pain: aetio- • www.palliative.info logy, symptoms, mecanisms, and management. • www.doloplus.com Lancet 1999; 353: 1959-64. Twycross RG. Control of pain. J R Coll Physici- Cavigelli A, Dietz V. Poststationäre Nachsorge bei ans Lond 1984; 18: 32-9. Querschnittgelähmten: ausgewählte internisti- Foley KM. The treatment of cancer pain. N Engl J sche Aspekte. Schweiz Med Wochenschr 2000; Med 1985; 313: 84-95. 130: 851-60. World Health Organization (WHO). Cancer Pain Guay DPR. Adjunctive agents in the management Relief and Palliative Care: Report of a WHO Ex- of chronic pain. Pharmacotherapy 2001; 21: pert Committee. Geneva: WHO, 1986. 1070-81. Wall PD, Melzack R. (eds.). Textbook of Pain. Association des pharmaciens des établissements Churchill Livingstone, 1989. de santé du Québec. Guide pratique des soins Kunz KM, Thesien JA, Schroeder ME. Severe palliatifs. 3ième édition 2002. episodic pain: management with subligual su- Breibat W, Chandler S, Eagel B, et al. An alterna- fentanil. J Pain Symptom Manage 1993; 8: 189- tive algorithm for dosing transdermal fentanyl 90. for cancer-relatet pain. Oncology 2000;14: 695- Koo D, Hall E, Motson R et al. Palliation of mali- 705. Discussion 705, 709-17. gnant intestinal obstruction using octreotide. Pereira J, Lawsor P, Vigano A, et al. Equianalge- Eur J Cancer 1994; 30A: 375-6. sic dose rations for opioids. A critical review and Mercadante S, Lodi F, Sapio M et al. Long-term proposals for long-term dosing. J Pain Sym- ketamine subcutaneous continous infusion in ptom Manage 2001; 22; 672-87. neuropathic cancer pain. J Pain Symptom Ma- Bouhassira D, Attal N, Fermanian J et al. Deve- nage 1995; 10: 564-8. lopment and validation of the Neuropathic Pain Zech DFJ, Grond S, Lynch J, et al. Validation of Symptom Inventory. Pain 2004; 108: 248‐57. World Health Organization guidelines for cancer Mason L, Moore RA, Derry S, et al. Systematic pain relief: 10-year prospective study. Pain review of topical acpsaicin for the treatment of 109 chronic pain. BMJ 2004; 328: 991. Lieber MM. Pharmacologic therapy for prosta- Bouhassira D, Attal N, Alchaar H et al. Compari- tism. Mayo Clin Proc 1998; 73: 590-6. son of pain syndromes associated with nervous Carter HB, Partin AW. Diagnosis and staging of or somatic lesions and development of a new prostate cancer. Campbell’s Urology. Walsh PC, neuropathic pain diagnostic questionnaire Retik AB, Vaughan ED, et al (eds.). WB Saun- (DN4). Pain 2005; 114: 29-36. ders 1998; 3: 2519. Gilron I, Bailey JM, Tu D, et al. Morphine, Gaba- Lowe FC, Roehrborn CG, Robertson C, et al. pentin, or Their Combination for Neuropathic Meta-analysis of clinical trials of Permixon® Pain. N Engl J Med 2005; 352: 1324-34. (abstract). J Urol 1998; 159: 257. Fiellin DA, Pantalon MV, Chawarski MC, et al. Carter HB, Pearson JD. Prostate-specific antigen Counseling plus Buprenorphine–Naloxone testing for early diagnosis of prostate cancer: Maintenance Therapy for Opioid Dependence. formulation of guidelines. Urology 1999; 54: N Engl J Med 2006; 355: 365-74. 780-6. Treede RD, Jensen TS, Campbell JN, et al. Neu- Kranse R, Beemsterboer P, Rietbergen J, et al. ropathic pain: redefinition and a grading system Predictors for biopsy outcome in the European for clinical and research purposes. Neurology Randomized Study of Screening for Prostate 2008; 70: 1630-5. Cancer (Rottedam region). Prostate 1999; 39: Haanpää M, Treede RD. Diagnosis and classifi- 316-22. cation of neuropathic pain. Pain: Clin Updates Lowe FC, Fagelman E. Phytotherapy in the treat- 2010;XVIII;7. ment of benign prostatic hyperplasia: an up- Wiese AD, Griffin MR, Schaffner W et al. Opioid date. Urology 1999; 53: 671-8. Analgesic Use and Risk for Invasive Pneumo- Vallancien G. Alpha-blockers in benign prostatic coccal Diseases: A Nested Case-Control Study. hyperplasia. Urology 1999; 54: 773-5. Ann Intern Med 2018; 168: 396-404. Iselin C. Antigène spécifique de la prostate (PSA): quelle utilité clinique? Med Hyg 2000; Ophtalmologie 58: 1795-6. Barry MJ. Prostate-specific-antigen testing for Glaucome à angle fermé early diagnosis of prostate cancer. N Engl J Asbury T, ,Vaughan D, Riordan-Eva P, (eds.). Ge- Med 2001; 344: 1373-7. neral opthalmology. Appleton & Lange, 1999. Thompson IM, Goodman PJ, Tangen CM, et al. Trobe JD. (ed.). The physician’s guide to eye The influence of Finasteride on the develop- care. American Academy of Opthalmology, ment of prostate cancer. N Engl J Med 2003; 2000. 349: 215-24. Nelson WG, De Marzo AM, Isaacs WB. Prostate Décollement de la rétine cancer. N Engl J Med 2003; 349: 366-81. Asbury T, ,Vaughan D, Riordan-Eva P, (eds.). Ge- Punglia RS, D’Amico A, Catalona WJ, et al. Effect neral opthalmology. Appleton & Lange, 1999. of verification bias on screening for prostate Trobe JD. (ed.). The physician’s guide to eye cancer by measurement of protate-specific anti- care. American Academy of Opthalmology, gen. N Engl J Med 2003; 349: 335-42. 2000. Hyperactivité vésicale Urologie Van Kerrebroeck P, Serment G, Dreher E. Clinical efficacy and safety of tolterodin compared to Prostate. Hyperplasie prost. bénigne oxybutynin in patients with overactive bladder. Berry SJ, Coffey DS, Walsh PC et al. The deve- Neurourol Urodyn 1997; 16: 478-9. lopment of human benign prostatic hyperplasia Ouslander JG. Management of overactive blad- with age. J Urol 1984; 132; 474-79. der. N Engl J Med 2004; 350: 786-99. Chapple CR. Selective a1-adrenoceptor antago- Incontinence urinaire nists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129- Hannestad YS , Rortveit G, Sandvik H, A commu- 67. nity-based epidemiological survey of female uri- Bosch JL, Hop WC, Kirkels WJ, Schröder FH. naryJ Clin Epidemiol. 2000; 53: 1150-7. The International Prostate Symptom Score in a Abrams P et al. The standardisation of termino- community-based sample of men between 55 logy of lower urinary tract function: report from and 74 years of age: prevalence and correlation the Standardisation Sub-committee of the Inter- of symptoms with age, prostate volume, flow national Continence Society. Neurourol Urodyn rate and residual urine volume. Br J Urol 1995; 2002; 21: 167-78. 75: 622-30. Hunskaar S1, Burgio K, Diokno A, Epidemiology Lepor H, Williford WO, Barry MJ, et al. The effi- and natural history of urinary incontinence in cacy of terazosin, finasteride or both in benign women; Urology 2003; 62(4 Suppl 1): 16-23. prostatic hyperplasia. N Engl J Med 1996; 335: Brown JS, Bradley CS, Subak LL: Diagnostic 533-9. Aspects of Incontinence Study (DAISy) Re- Smith DS, Catalona WJ, Herschman JD. Longitu- search Group Ann Intern Med 2006; 16;144: dinal screening for prostate cancer with pro- 715-23. state specific-antigen. JAMA 1996; 276: Hunskaar S et al. The prevalence of urinary in- 1309-15. continence in women in four European coun- 110 tries. BJU Int 2004; 93: 324 -30. morbidity and mortality in 442 pregnancies with Anger JT et al. The prevalence of urinary inconti- hemolysis, elevated liver enzymes, and low pla- nence among community dwelling adult telets (HELLP syndrome). Am J Obstet Gynecol women: results from the National Health and 1993; 169: 1000. Nutrition Examination Survey. J Urol 2006; 175: Hypertension artérielle et grossesse 601-4. Haab F, et al. Terminologie des troubles fonction- Galery E. Hypertension in pregnancy: practical nels du bas appareil urinaire, adaptation fran- managment recommendations. Drugs 1995; 49: çaise de la terminologie de l’International 555-62. Continence Society Pelv Perineol 2006 ;1: 196- Sibai BM. Treatment of hypertension in pregnant 206. woman. N Engl J Med 1996; 335: 257-65. Harris SS et al. Care seeking and treatment for Heleva ME, Burrows RF, Smith J, et al. Report of urinary incontinence in a diverse population. J the canadian hypertension society consensus Urol 2007; 177: 680-4. conference: 1. Definitions, evaluations and clas- Liapis A, Bakas P, Creatsas G. Long-term efficacy sification of hypertensive disorders in preg- of tension-free vaginal tape in the management nancy. Can Med Assoc J 1997; 157: 715-25. of stress urinary incontinence in women: effi- Moutquin JM, Garner PR, Burrows RF, et al. Re- cacy at 5- and 7-year follow-up. Int Urogynecol port of the canadian consensus conference: 2. J Pelvic Floor Dysfunct 2008; 19: 1509-12. Nonpharmacologic management and preven- Nygaard I, Barber MD, Burgio KL Prevalence of tion of hypertensive disorders in pregnancy. symptomatic pelvic floor disorders in US Can Med Assoc J 1997; 157: 907-19. women. JAMA 2008; 17; 300: 1311-6. Rey E, LeLorier J, Burgess E, et al. Report of the Ward RM et al. The impact of multichannel urody- canadian hypertension society consensus con- namics upon treatment recommendations for ference: 3. pharmacologic treatment of hyper- female urinary incontinence. Int Urogynecol I J tensive disorders in pregnancy. Can Med Assoc Pelvic Floor Dysfunct 2008; 19: 1235-41. J 1997; 157: 1245-54. Hauth JC, Ewell MG, Levine RJ et al. Pregnancy Torsion testiculaire outcomes in healthy nulliparas who developed Schalamon J, Ainoedhofer H, Schleef J, et al. Ma- hypertension. Calcium for Preeclampsia Pre- nagement of acute scrotum in children - the im- vention Study Group.Obstet Gynecol 2000; pact of Doppler ultrasound. J Pediatr Surg 95:24. 2006; 41: 1377-80. Buchbinder A, Sibai BM, Caritis S et al. Adverse perinatal outcomes are significantly higher in GYNECOLOGIE severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186: Prééclampsie, HELLP-Syndrome 66. White WB. Management of hypertension during Sibai BM. Diagnosis and management of gesta- lactation. Hypertension 1984; 6: 297-300. tional hypertension and preeclampsia. Obstet Sibai BM, Mabie WC, Shamsa F, et al. A compari- Gynecol 2003; 102: 181. son of no medication versus methyldopa or la- American College of Obstetricians and Gynecolo- betalol in chronic hypertension during gists, Task Force on Hypertension in Preg- pregnancy. Am J Obstet Gynecol 1990; 162: nancy. Hypertension in pregnancy. Report of 960-7. the American College of Obstetricians and Gy- Paran E, Holzberg G, Mazor M, et al. Beta-adre- necologists’Task Force on Hypertension in nergic blocking agents in the treatment of preg- Pregnancy. Obstet Gynecol 2013; 122: 1122. nancy-induced hypertension. Int J Clin Pharmacol Ther 1995; 33: 119-23. LABORATOIRE ET NORMES Hohlfeld P, Marty F, De Grandi P, et al. Le livre de Textbooks l’interne obstétrique. Médecine-Sciences Flam- Berkow R. The Merck Manual of diagnosis and marion 1998. therapy. 16th ed. Merck & Co. Inc, 1992. Sibai BM. Treatment of hypertension in pregnant Jacobs DS, Demott, Grady, et al. Laboratory Test women. N Engl J Med 2000; 335: 257-65. Handbook. 4th ed. Lexi-Comp, Inc., 1996. Umans JG, Lindheimer MD. Antihypertensive Dufour R. Clinical of laboratory data. A practical treatment. In: Hypertensive disorders in preg- guide. Lippincott Williams & Wilkins, 1998. nancy. Lindheimer MD, et al (eds.). Appleton & Wallach J. Interpretation of Diagnostic Tests. 7th Lange, Stamford 1999; p. 581-604. ed. Lippincott Williams & Wilkins, 2000. Vogt B, Mohaupt M. Traitement de l’hypertension: Braunwald E, Fauci, Kasper, et al. Harrison’s 15th ciblé sur le vieillard et la femme enceinte. editions. Principles of International Medicine. Forum 2001; 22: 571-5. Mc Graw-Hill, 2001. Hypertension in pregnancy: Report of the Ameri- Young DS. Effects of drugs on clinical laboratory can College of Obstetricians and Gynecologists' tests. 5th ed. AACC Press, 2000. Task Force on Hypertension in Pregnancy. Ob- Young DS. Effects of disease on clinical labora- stet Gynecol 2013; 122:1122. tory tests. 4th ed. AACC Press, 2001. HELLP-Syndrome Laposata M. Laboratory medicine. Clinical patho- Sibai BM, Ramadan MK, Usta I et al. Maternal logy in the practice of medicine. ASCP Press, 2002. 111 Acide folique Hess OM, Suter T, Mohacsi P. Editorial: Medika- Schnyder G, Roffi M, Pin R, et al. Decreased rate mentöse Therapie der Herinsuffizienz. J Kardiol of coronary restenosis after lowering of plasma 2002; 9: 167-8. homcysteine levels. N Engl J Med 2001; 335: Maisel A. B-type natriuretic peptide measure- 1593-1600. ments in diagnosing congestive heart failure in the dyspneic emergency department patient. ALT, AST Rev Cardiovasc Med 2002; 3 (Suppl. 4): S10-7. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - Morrison LK, Harrison A, Krishnaswamy P, et al. an indicator of alcoholic lver disease. Dig Dis Utility of a rapid B-natriuretic peptide assay in Sci 1979; 24: 835-8. differentiating congestive heart failure from lung Rej R. Aminotransferases in disease. Clin lab disease in patients presenting with dyspnea. J Med 1989 ;9: 667-87. Am Coll Cardiol 2002; 39: 202-9. Pratt DS, Kaplan MM. Evaluation of abnormal Hohl CM, Mitelman BY, Wyer P, et al. Should liver-enzyme results in asymptomatic patients. emergency physicians use B-type natriuretic N Engl J Med 2000 ;342: 1266-71. peptide testing in patients with unexplained Lee WM. Drug-induced hepatotoxicity. N Engl J dyspnea? Can J Emerg Med 2003; 5: 166-8. Med 2003: 349: 474-85. Kuster GM, Tanner H, Printzen G, Suter TM, et al. B-type natriuretic peptide for diagnosis and ANA treatment of congestive heart failure. Swiss Tan EM, Feltkamp TE, Smolen JS, Butcher B, med wkly 2003; 133: 623-8. Dawkins R, Fritzler MJ, et al. Range of antinu- Mueller Ch, Scholer A, Laule-Kilian K, et al. Use clear antibodies in «healthy» individuals. Arthri- of B-type natriuretic peptide in the evaluation tis Rheum 1997; 40: 1601-11. and management of acute dyspnea. N Engl J Solomon DH, Kavanaugh AJ, Schur PH, Ameri- Med 2004; 350: 647-54. can College of Rheumatology Ad Hoc. Commit- tee on Immunologic Testing Guidelines. Bilirubine Evidence-based guidelines for the use of immu- Beck K. Icterus. Schattauer. Stuttgart 1968. nologic tests: antinuclear antibody testing. Ar- CK-MB thritis Rheum 2002; 47: 434. Lassoued K, Coppo P, Gouilleux-Gruart V. Place Ong L, Reiser P, et al. Left ventricular function des anticorps antinucléaires en pratique clini- and rapid release of creatine kinase MB in que? Réanimation. 2005;14:651-6. acute myocardial infarction. N Engl J Med 1983; Petitpierre S, Aubert V, Leimgruber A, Spertini F, 309: 1-6. Bart P- A. Utilité de la recherche des autoanti- Schifferli J. Intérêt clinique des isoenzymes de la corps dans la pratique quotidienne. Rev Med créatine kinase. Praxis 1983; 18: 605-8. Suisse 2009; 5: 823-31. Lee T, Goldman L. Serum enzyme assays in the Agmon-Levin N, Damoiseaux J, Kallenberg C et diagnosis of acute myocardial infacrtion. Ann In- al. International recommendations for the as- tern Med 1986; 105: 221-33. sessment of autoantibodies to cellular antigens Lee TH, et al. Ruling-out acute myocardial in- referred to as anti-nuclear antibodies. Ann farction. A prospective multicenter validation of Rheum Dis 2014;73:17-23. a 12 hour strategy for patients at low risk. N Chan EK, Damoiseaux J, Carballo OG, Conrad K, Engl J Med 1991; 324: 1239-46. de Melo Cruvinel W, Francescantonio PL et al. CRP (C-réactive protéine) Report of the First International Consensus on Wallach J. Interpretation of Diagnostic Tests. Little Standardized Nomenclature of Antinuclear Anti- Brown, 1996. body HEp-2 Cell Patterns 2014–2015. Front Im- Fauci A, Braunwald E, (eds.) et al. In: Harrison: munol 2015; 6: 412. Principles of Internal Medicine. 1998 Mc Graw BNP Hill. Cheng, V, Kazanagra J. A Rapid Bedside Test for Ridker PM. Clinical application of C-reactive pro- B-Type peptide predicts treatment outcomes in tein for cardiovascular disease detection and patients admitted for decompensated heart fai- prevention. Circulation 2003; 107: 360-9. lure: a pilot study. Am Coll Cardiol 2001; 37: Danesh J, Wheeler JG, Hirschfield GM, et al. C- 386-91. reactive protein and markers of inflammation in Dao Q, Krishnaswamy P, Kazanegra R, et al.: Uti- the prediction of coronary heart disease. N Engl lity of B-Type natriuretic peptide in the diagnosis J Med 2004; 350: 1387-97. of congestive heart failure in an urgent-care set- Butler CC, Gillespie D, White P et al. C-Reactive ting, J Am Coll Cardiol 2001; 37: 379-85. Protein Testing to Guide Antibiotic Prescribing Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role for COPD Exacerbations. NEJM 2019; 381: of brain natriuretic peptide in risk stratification of 111-20. patients with congestive heart failure. J Am Coll D-dimères Cardiol 2001; 38; 1934-41. Perrier A, Desmarais S, Miron MJ, et al. Non-in- Maisel AS, Krishnaswamy P, Nowak RM, et al. vasive diagnosis of venous thromboembolism in Rapid measurement of B-type natriuretic pep- outpatients including clinical probability, D- tide in the emergency diagnosis of heart failure. dimer and ultrasonography. Lancet 1999; 353: N Engl J Med, 2001; 347, 161-7. 190-5. 112 Kearon C, Ginsberg JS, Douketis J, et al. Ma- known primary tumor. Semin Oncol 1993; 20: nagement of suspected deep venous thrombo- 251-60. sis in outpatients by using clinical assessment Lovis C. Les marqueurs tumoraux. Med Hyg and D-dimer testing. Ann Intern Med 2001; 135: 1995; 53: 1038-48. 108-11. Oxygène Ferritine O’Donohue WJ. Home oxygen therapy. Clin Adams PC, Barton JC. A diagnostic approach to Chest Med 1997; 18: 535-45. hyperferritinemia with a non-elevated transferrin Hall JB, Schmidt GA, Wood LDH, (eds.). Princi- saturation. J Hepatol 2011; 55: 453-58. ples of critical care. McGraw-Hill, 1998. Saglini V, Brissot P. Hyperferritinémie – Algo- Rochat Th. Oxygénothérapie au long cours à do- rithme. Rev Med Suisse 2012; 8: 1135-7. micile. Med Hyg 1998; 56: 2312-4. Anderhub AP, Bloch K, Breitenbüchler A, et al. Li- Hémoglobine glycosilée (HbA1c) gnes directriches 2006 pour l’oxygénothérapie The diabetes control and complications trial re- de longue durée à domicile. Forum Med Suisse search group. The effect of intensive treatment 2007; 7: 87-90. of diabetes on the development and progression of long-term complications in insulin de- Potassium pendent diabetes mellitus. N Engl J Med 1993; Whang R, Whang DD, Ryan MP. Refractory po- 329: 977-86. tassium deficiency. Arch Intern Med 1992; 152: UK Prospective diabetes study (UKPDS) group. 40-45. Intensive blood-glucose control with sulfonylu- Cohn JN, Kowey PR, Whelton PK, et al. New reas or insulin compared with conventional Guidelines for potassium replacement in clinical treatment and risk of complications in patints practice. Arch Intern Med 2000; 160: 2429-36. with type 2 diabetes. UKPDS group. Lancet Pancytopénie 1998; 352: 837-53. Philippe J. L’hémoglobine glyquée (HbA1c). Med Fauci A, Braunwald E, (eds.) et al. In: Harrison: Hyg 2000; 58: 1800-1. Principles of Internal Medicine. 1998 Mc Graw Hill. Natriurétique peptide Phosphatase alcaline Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic pep- Wallach J. Interpretation of Diagnostic Tests. Little tide in the emergency diagnosis of heart failure. Brown, 1996. N Engl J Med 2002; 347: 161-7. Troponines Homocyst(é)ine Antman EM, Tanasijevic MJ, Thompson B, et al. Nygard O, Nordrehaug JE, Refsum H, et al. Cardiac-specific troponin I levels to predict the Plasma homocysteine levels and mortality in risk of mortality on patients with acute coronary patients with coronary artery disease. N Engl J syndromes. N Engl J Med 1996; 335: 1342-9. Med 1997; 337: 230-6. Wallach J. Interpretation of Diagnostic Tests. Little Maghadasian MH, McManus BM, Frohlich JJ. Ho- Brown, 1996. mocyst(e)ine and coronary artery disease. Arch Hamm CW, Goldmann BU, Heeschen C, et al. Intern Med 1997; 157: 2299-2308. Emergency room triage of patients with acute Welch GN, Loscalzo J. Homocysteine and athe- chest pain by means of rapid testing for cardiac rothrombosis. N Engl J Med 1998; 338: 1042- troponin T or troponin I. N Engl J Med 1997; 50. 337: 1648-53. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, et Missow E, Calzolari C, Pau B. Circulating cardiac al. Interaction between the G20210A mutation troponin I in severe congestive heart failure. of the prothrombin gene and oral contraceptive Circulation 1997; 96: 2953-8. use in deep vein thrombosis. Arterioscler Smith SC, Ladenson JH, Mason JW, et al. Eleva- Thromb Vasc Biol 1999; 19: 700-3. tions of cardiac troponin I associated with myo- Hankey GJ, Eikelboom JW. Homocysteine and carditis: experimental and clinical correlates. vascular disease. Lancet 1999; 345: 407-13. Circulation 1997; 95: 163-8. Schnyder G, Roffi M, Pin R, et al. Decreased rate Hamm CW, Braunwald E. A classification of uns- of coronary restenosis after lowering of plasma table angina revisited. Circulation 2000; 102: homcysteine levels. N Engl J Med 2001; 335: 118-22. 1593-1600. Goldberg RJ, Spencer FA, Fox KA, et al. Prehos- Seshadri S, Beiser A, Selhub J, et al. Plasma Ho- pital delay in patients with acute coronary syn- mocysteine as a risk factor for dementia and dromes (from the Global Registry of Acute Alzheimer’s disease. N Engl J Med 2002; 346: Coronary Events [GRACE]). Am J Cardiol 2009; 476-83. 103: 598–603. Keller T, Zeller T, Peetz D, et al. Sensitive tropo- Marqueurs tumoraux nin I assay in early diagnosis of acute myocar- Bates S. Clinical applications of serum tumor dial infarction. N Engl J Med. 2009; 361: markers. Ann Int Med 1991; 115: 632-8. 868–877. Raymond W, Norton RE, Norton SE. Use of biolo- Reichlin T, Hochholzer W, Bassetti S, et al. Early gical markers in the diagnosis of cancer of un- diagnosis of myocardial infarction with sensitive 113 cardiac troponin assays. N Engl J Med 2009; Anderson PO, Knoben JE, Troutman WG (eds). 361: 858-67. Handbook of clinical drug data. Appleton & Bandstein N, Ljung R, Johansson M, Holzmann Lange1999. MJ. Undetectable highsensitivity cardiac tropo- Compendium des produits et spécialités pharma- nin T level in the emergency department and ceutiques (CPS). Association des pharmaciens risk of myocardial infarction. J Am Coll Cardiol du Canada, 2003. 2014; 63: 2569-78. Lacy CG, Armstrong LL, Lance LL (eds.). Drug in- Klinkenberg LJ, van Dijk JW, Tan FE, vet al. Cir- formation handbook. Lexi-Comp Inc 2002. culating cardiac troponin T exhibits a diurnal Antibiotiques - Antibiotika rhythm. J Am Coll Cardiol 2014; 63: 1788–95. Sherwood MW, Kristin Newby L. High-sensitivity Roger M, St-Antoie P, Coutlee F. Vancomycin-re- troponin assays: evidence, indications, and rea- sistant enterococci in health care facilities. N sonable use. J Am Heart Assoc 2014; Engl J Med 2001 ;345: 768-9. 3:e000403. Gilbert DN, Moellering RC, Sande MA. The Sand- Müller Ch, Kaufmann U, von Eckardsteinc A et al. ford Guide to antimicrobial therapy; 2003. Recommandation relative au changement Allergie aux bêtalactames d’unité de mesure pour la troponine cardiaque. Weiss ME, Adkinson NF. Immediate hypersensiti- Swiss Med Forum 2015; 15: 852-853. vity reactions to penicillin and related antibio- Segraves JM, Frishman WH. Highly Sensitive tics. Clin Allergy 1988; 18: 515-40. Cardiac Troponin Assays. Cardiology in Review Shephered GM. allergy to b-lactames antibiotics. 2015;23: 282-289. Immunol Alllergy Clin North Am 1991; 11: 611- VDRL 33. Anderson JA. Allergic reactions to drugs and bio- Peeling RW, Ye H. Diagnostic tools for preventing logical agents. JAMA 1992; 268: 2845-57. and managing maternal and congenital syphilis: Lin RY. A perspective on penicillin allergy. Arch In- an overview. Bulletin of the World Health Or- tern Med 1992; 152: 930-7. ganization 2004; 82: 439-46. Segreti J, Trenholme GM, Levin S. Antibiotic the- Itin P, Bosshard PP, Toutous Trellu L, Schmidt AJ, rapy in the allergic patient. Med Clin North Am Vernazza P, Tarr Ph et al. Syphilis: Diagnostik 1995; 79: 935-42. und Behandlung. Schweiz Med Forum 2015;15:459 Anticoagulation - Antikoagulantien Vitesse de sédimentation (VS) Cole MS, et al. Coumarin necrosis - a review of the litterature. Surgery 1988; 103: 271-7. Gilbertsen VA. Erythrocyte sedimentation rates in Smith P, Arneson H, Holme I. The effect of warfa- older patients. Postgrad Med 1965; 38: A44- rin on mortality and reinfarction. N Engl J Med A52. 1990; 323: 147-52. Bottiger LE, Svedberg CA. Normal erythrocyte Hirsh J. Oral anticoagulant drugs. N Engl J Med sedimentation rate and age. Br Med J 1967; 2: 1991; 324: 1865-75. 85-7. Hirsh J, Levine MN. Low molecular weight hepa- Bedell SE, et al. Erythrocyte sedimentation rate. rin. Blood 1992; 79: 1-17. Am J Med 1985; 78: 1001-9. Aster RH. Heparin-induced thrombocytopenia Sox HC, Liang MH. The erythrocyte sedimenta- and thrombosis. N Engl J Med 1995; 332: 1374- tion rate. Gudelines for rational use. Ann Intern 6. Med 1986; 104: 515-23. Cannegieter SC, Rosendaal FR, Wintzen AR, et Laboratoire: unités SI traditionnelles al. Optimal oral anticoagulant therapy in pa- Young DS. Standardized reporting of laboratory tients with mechanical heart valves. N Engl J data. N Engl J Med 1974; 290: 368-73. Med 1995; 333: 11-7. Le SI pour les professions de la santé. Genève Warkentin TE, Levine MN, Hirsh J, et al. Heparin- OMS, 1978. induced thrombocytopenia in patients treated SI-Einheiten in der Medizin. Herbert Lippertt. with low-molecular-weight heparin or unfractio- Urban & Schwarzenberg, München/ Wien/ Balti- nated heparin. N Engl J Med 1995; 332: 1330- more, 1978. 5. Lundberg GD, Iverson C, Radulescu G. Now read Weitz JI. Low-molecular-weight heparins. N Engl this: the SI units are here. JAMA 1986; 255: J Med 1997; 337: 688-98. [Erratum: N Engl J 2329-39. Med 1997; 337: 1567]. Young DS. Implementation of SI units for clinical Fifth consensus conference on antithrombotic laboratory data. Ann Intern Med 1987; 106: 114- therapy (1998): summary recommendations. 29. Chest 1998; 114 (Suppl.): 439S-769S. Recommendations of the Second Joint Task PHARMACOLOGIE CLINIQUE Force of European and other Societies on coro- Klinische Pharmakologie nary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; Chernow B (ed). Essential of Critical Care Phar- 19: 1434-1503. macology. Wiliams & Wilkins, 1989. Kelton JG. The clinical management of heparin- Goodman & Gilman’s The Pharmacological basis induced thrombocytopenia. Semin Haematol of therapeutics. McGrawHill, 1997. 1999; 36(Suppl.1): 17-21. 114 Raible MD. Hematologic complications of hepa- in non-insuline dependant diabetes mellitus. N rin-induced thrombocytopenia. Semin Haematol Engl J Med 1995; 333: 550-4. 1999; 25(Suppl.1): 17-21. UK Prospective Diabetes Study (UKPDS) Group. Walenga JM, Jeske WP, Wood JJ, et al. Labora- Effect of intensive blood-glucose control with tory tests for heparin-induced Thrombocytope- metformin on complications in over-weight pa- nia: a multicenter study. Semin Haematol 1999; tients with type 2 diabetes (UKPDS 34). Lancet 36(Suppl.1): 22-8. 1998; 352: 854-65. Verstraete M, Prentice CR, Samama M, et al. A Barman Balfour JA, Plosker GL. Rosiglitazone. European view on the North American fifth con- Drugs 1999; 57: 921-30. sensus on antithrombotic therapy. Chest 2000; Dormandy JA, Charbonnel B, Eckland DJ, et. al. 117: 1755-70. Secondary prevention of macrovasculair events Hirsh J. New anticoagulants. Am Heart J 2001; in patients with type 2 diabetes in the PROac- 142 (2 Suppl.): S3-8. tive Study: A randomized controlled trial. Lancet Sixth ACCP Consensus Conference on anti- 2005; 366: 1279-89. thrombotic therapy. Chest 2001; 119 (Suppl. 1): Erdmann E, Charbonnel B, Wilcox RG, et al. Pio- 1S-336S. glitazone in patients with type 2 diabetes and Dager WE, White RH. Treatment of heparin-indu- preexisting cardiovasculaar disease: date form ced thrombocytopenia. Ann Pharmacother the PROactive study. Diabetes Care 20072007; 2002; 36: 489-503. july 31. Chong BH. Heparin-induced thrombocytopenia. J Home PhD, Pocock SJ, Beck-Nielsen H et al. Ro- Thromb Haemost 2003; 1:1471-8. siglitazone Evaluated for Cardiovascular Outco- Verma AK, Levine M, Shalansky SJ, et al. Fre- mes — An Interim Analysis. N Engl J Med 2007; quency of heparin-induced thrombocytopenia in 357: 28-38. critical care patients. Pharmacotherapy 2003; Antiépileptiques -Antieptileptika 23:745-53. Warkentin TE, Heddle NM. Laboratory diagnosis McCormack M., Alfirevic BA.A, Bourgeois St. et of immune heparin-induced thrombocytopenia. al. HLA-A*3101 and Carbamazepine-Induced Curr Hematol Rep 2003; 2:148-57. Hypersensitivity Reactions in Europeans. N Vespa PM. Oral anticoagulants and the risk of in- Engl J Med 2011;364:1134-1143. tracranial hemorrhage. JAMA 2014; 312: 2562- Antihistaminiques -Antihistaminika 3. Desager JP, Horsmans Y. Pharmacokinetic-phar- Antidépresseurs - Antidepressiva macodynamic relationships of H1-antihistami- Calanca A, Bryois C, Buclin T. (eds.). Vade- nes. Clin Pharmacokinet 1995; 28: 419-32. mecum de thérapeutique psychiatrique. Editi- Antihypertenseurs -Antihyperensiva ons Médecine & Hygiène, 1997. Taira N. Differences in cardiovascular profile Woggon B. (ed.). Behandlung mit Psychophar- amoung calcium antagonists. Am J Cardiol maka. Verlag Huber, 1998. 1987; 59: 24B-29B. Syndrome sérotoninergique The fifth report of the joint national committee on Serotoninsyndrom detection, evaluation, and treatment of high Dunkley EJ, Isbister GK, Sibbritt D et al. The blood pressure. Arch Intern Med 1993; 153: Hunter Serotonin Toxicity Criteria: simple and 154-83. accurate diagnostic decision rules for serotonin Lüscher TF, Cosentino F. The classification of cal- toxicity. QJM 2003; 96: 635-42. cium antagonists and their selection in the treat- Chassot M, Livio F, Buclin Th et al. Syndrome sé- ment of hypertension. Drugs 1998; 55: 509-17. rotoninergique : mise au point et revue des cas Abernethy DR, Schwartz JB. Drug therapy: Cal- annoncés en Suisse. Rev Med Suisse 2012; 8: cium-antagonist drugs. N Engl J Med 1999; 2086-90. 341: 1447-57. Birkenhäger WH, Leeuw PW. Non-peptide angio- Antiémétiques -Antiemeitka tensin type 1 receptor antagonists in the treat- ASHP therapeutic guidelines on the pharmacolo- ment of hypertension. J Hypertens 1999; 17: gic management of nausea and vomiting in 873-81. adult and pediatric patients receiving chemothe- Burnett JC. Vasopeptidase inhibition: a new con- rapy or radiation therapy or undergoing surgery. cept in blood pressure management. J Hyper- Am J Health-Syst Pharm 1998; 56: 729-64. tens 1999; 17(Suppl.1): 37-43. Yusuf S et al. Effects of an angiotensin-conver- Antidiabétiques oraux - Orale Antidiabetika ting-enzyme inhibitor, Ramipril, on death from Gerich JE. Oral hypoglycémic agents. N Engl J cardiovascular events in high-risk patients. N Med 1989; 321: 1231-45. Engl J Med 2000; 342,145-53. Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM sujects. Diabe- AINS/Aspirine - NSAR/ASPIRIN® tes Care 1994; 17: 142-5. Settipane GA. Adverse reactions to aspirin and DeFronzo RA, et al. Efficacy of metformin in pa- related drugs. Arch Intern Med 1981; 141: 328- tients with non-insuline dependant diabetes 32. mellitus. N Engl J Med 1995; 333: 541-9. Slepian IF, Mathews KP, McLean JA. Aspirin-sen- Stumvoll M, et al. Metabolic effect of metformine sitive asthma. Chest 1985; 87: 386-91. 115 Duc J, Pécaud A. A propos d’un cas d’arrêt respi- Risks of agranulocytosis and aplastic anemia. A ratoire. Intolérance à l’aspirine et aux anti-in- first report of their relation to drug use with spe- flammatoires non stéroïdiens. Med Hyg 1988; cial reference to analgesics. The International 46: 705-9. Agranulocytosis and Aplastic Anemia Study. Fries JF, et al. Identification of patients at risk for JAMA 1986; 256: 1749-57. gastropathy associated with NSAID use. J Stamer UM, Gundert-Remy U, Biermann E, et al. Rheumatol 1990; 17 (Suppl. 20): 12-19. Metamizol: Überlegungen zum Monitoring zur Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin frühzeitigen Diagnose einer Agranulozytose. use and reduced risk of fatal colon cancer. N Schmerz 2017; 31: 5-13. Engl J Med 1991; 325: 1593-6. Aspirine® - Prévention primaire Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; Jill Belch et al. The prevention of progression of 44: 643-53. arterial disease and diabetes (POPADAD) trial: Bronner LL, Kanter DS, Manson JE. Primary pre- factorial randomised placebo controlled trial of vention of stroke. N Engl J Med 1995; 333: aspirin and antioxidants in patients with diabe- 1392-1400. tes and asymptomatic peripheral arterial Bakowsky VS, Hanly JG. Complications of non- disease - BMJ; 2008; 337. steroidal antiinflammatory drug gastropathy and Rothwell PM, Price JF, Fowkes Nelson MR, Reid use of gastric cytoprotection: experience at a CM, Ames DA et al. Feasibility of conducting a tertiary care health centre. J Rheumatol 1999; primary prevention trial of low-dose aspirin for 26: 1557-63. major adverse cardiovascular events in older Hawkey CJ. Cox-2 inhibitors. Lancet 1999; 353: people in Australia: results from the ASPirin in 307-14. Reducing Events in the Elderly (ASPREE) pilot Caspi D, Lubart E, Graff E, et al. The effect of study. Med J Aust 2008;189:105-9. et al. Short- mini-dose aspirin on renal function and uric acid term effects of daily aspirin on cancer inci- handling in elderly patients. Arthritis Rheum dence, mortality, and non-vascular death: 2000; 43: 103-8. analysis of the time course of risks and benefits Everts B, Währborg P, Hedner. COX-2-specific in- in 51 randomised controlled trials. Lancet 2012; hibitors - the emergence of a new class of anal- 379: 1602-12. gesic and anti-inflammatory drugs. Clin Guirguis-Blake JM, Evans CV, Senger CA, Rheumatol 2000; 19: 331-43. O'Connor EA, Whitlock EP. Aspirin for the Pri- FitzGerald GA, Patrono C. The coxibs, selective mary Prevention of Cardiovascular Events: A inhibitors of cycloocygenase-2. N Engl J Med Systematic Evidence Review for the U.S. Pre- 2001; 345: 433-42. ventive Services Task Force. Ann Intern Med. Stevenson DD, Sanchez-Borges M, Szczeklik A. 2016; 164: 804-13. Classification of allergic and pseudoallergic re- Patrignani P, Patrono C. Aspirin and Cancer. J actions to drugs that inhibit cyclooxygenase en- Am Coll Cardiol 2016; 68: 967-76. zymes. Ann Allergy Asthma Immunol 2001; 87: Whitlock EP, Burda BU, Williams SB, et al. Blee- 177-80. ding Risks With Aspirin Use for Primary Preven- Chandrasekharan NV, Dai H, Roos KL, et al. tion in Adults: A Systematic Review for the U.S. COX-3, a cyclooxygenase-1 variant inhibited by Preventive Services Task Force. Ann Intern acetaminophen and other analgesic/antipyrectic Med. 2016; 164: 826-35. drugs: cloning, structure, and expression. Proc Cole BF, Logan RF, Halabi S et al. Aspirin for the Natl Acad Sci USA 2002; 99: 13926-31. chemoprevention of colorectal adenomas: U.S. Preventive Services Task Force (Chair: Berg meta-analysis of the randomized trials. J Natl AO). Aspirin for the prevention of cardiovascular Cancer Inst 2009; 101: 256-66. events: recommendation and rationale. Ann In- Bowman L. et al. ASCEND: A Study of Cardiovas- tern Med 2002; 136: 157-60. cular Events iN Diabetes: Characteristics of a August P. Initial treatment of hypertension. N Engl randomized trial of aspirin and of omega-3 fatty J Med 2003; 348: 610-17. acid supplementation in 15,480 people with dia- Sandler RS, Halabi S, Baron JA, et al. A randomi- betes; Am Heart J 2018; 198: 135-144. zed trial of aspirin to prevent colorectal adeno- Effects of aspirin on risks of vascular events and mas in patients with previous colorectal cancer. cancer according to bodyweight and dose: ana- N Engl J Med 2003; 348: 883-90. lysis of individual patient data from randomised Baron JA, Cole BF, Sandler RS, et al. A randomi- trials. Lancet 2018; 392: 387-399. doi: zed trieal of aspirin to prevent colorectal adeno- 10.1016/S0140-6736(18)31133-4. mas. N Engl J Med 2003; 348: 891-9. Gaziano JM, Brotons C, Coppolecchia R et al. Gum PA, Kottke-Marchant K, Welsh PA, et al. A Use of aspirin to reduce risk of initial vascular prospective, blinded determination of the natu- events in patients at moderate risk of cardiovas- ral history of aspirin resistance amoung stable cular disease (ARRIVE): a randomised, double- patients with cardiovascular disease. J Am Coll blind, placebo-controlled trial. [Lancet 2018. pii: Cardiol 2003; 41: 961-5. S0140-6736(18)31924-X] Ridker, PM, Nancy R. Cook, and I-Min Lee, et al. Arnett DK, Blumenthal RS, Albert MA et al. 2019 A randomized trial of low-dose aspirin in the pri- ACC/AHA Guideline on the Primary Prevention mary prevention of cardiovascular disease in of Cardiovascular Disease. A Report of the women. N Engl J Med 2005; 352: 1293-1304. American College of Cardiology/American 116 Heart Association Task Force on Clinical Prac- and safety of alirocumab in reducing lipids and tice Guidelines. Circulation 2019; 140: e596– cardiovascular events. N Engl J Med 2015; e646. DOI: 10.1161/CIR.0000000000000678 372:1489. Sabatine MS, Giugliano RP, Wiviott SD, et al. Effi- NSAR Überempfindlichkeit cacy and safety of evolocumab in reducing li- Arnett DK, Blumenthal RS, Albert MA et al. 2019 pids and cardiovascular events. N Engl J Med ACC/AHA Guideline on the Primary Prevention 2015; 372:1500. of Cardiovascular Disease. A Report of the American College of Cardiology/American Diurétiques - Diuretika Heart Association Task Force on Clinical Prac- Jacobson HR. Diuretics. Mecanisms of action and tice Guidelines. Circulation 2019; 140: e596– uses. Hosp Pract 1987; December: 129-56. e646. DOI: 10.1161/CIR.0000000000000678 Chernow B (ed). Essential of Critical Care Phar- White AA, Stevenson DD. Aspirin-Exacerbated macology. Wiliams & Wilkins, 1989. RespiratoryDisease. NEJM 2018; 379: 1060-70. Brater DC. Diuretic therapy. N Engl J Med 1998; Kowalski ML, Asero R, Bavbek S et al. Classifica- 339: 387-95. tion and practical approach to the diagnosis and Hypnotiques management of hypersensitivity to nonsteroidal Greenblatt DJ, Shader RI, Abernethy DR. Current anti-inflammatory drugs. Allergy 2013; 68: status of benzodiazepines (First of two parts). N 1219-32. Engl J Med 1983; 309: 354-8. Wedi B. Aktuelle Diagnostik der NSAR-Überemp- Greenblatt DJ, Shader RI, Abernethy DR. Current findlichkeit. Allergo J 2017; 26: 204-11. status of benzodiazepines (Second of two Warner TD, Mitchell JA. Cyclooxygenases: new parts). N Engl J Med 1983; 309: 410-6. forms, new inhibitors, and lessons from the cli- Calanca A, Bryois C, Buclin T. (eds.). Vade- nic. FASEB J 2004; 18: 790-804. mecum de thérapeutique psychiatrique. Editi- Ballmer-Weber B. Analgetikaunverträglichkeit: In- ons Médecine & Hygiène, 1997. toleranz oder Allergie? Therapeutische Um- schau 2019; 76: 23-27. Magnésium https://doi.org/10.1024/0040-5930/a001053 Reinhart RA. Magnesium metabolism. A review P2Y12 Hemmer with special reference to the relationship between intracellular content and serum levels. Sibbing D, Kastrati A, Berger PB. Pre-treatment Arch Intern Med 1988; 48: 2415-20. with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? Eur Heart J 2016; Neuroleptiques - Neuroleptika 37: 1284-1295. Kapsambelis V, Gekiere C, Ginestet D. Classifi- Cholestérol, hypolipémiants cation clinique des neuroleptiques. Étude critique et perspectives actuelles. Encéphale 1990; Société Suisse de Cardiologie, Groupe de travail 16: 60-70. Lipides et Athérosclérose. Recommandations Pabis DJ, Stanislav SW. Pharmacotherapy of 1999 pour l’indication au traitement du facteur agressive behaviour. Ann Pharmacother 1996; de risque «cholestérol». Schweiz Ärztezeitung 30: 278-87. 1999; 80: 544-8. Calanca A, Bryois C, Buclin T. (eds.). Vade- Davidson MH, McGarry T, Bettis R, et al. Ezeti- mecum de thérapeutique psychiatrique. Editi- mibe coadminstred with simvastatin in patients ons Médecine & Hygiène, 1997. with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34. Grossesse et médicaments/lacatation Gupta EK, Ito MK. The first in a novel class of se- Kunz J, Schreiner WE. In: Pharmakotherapie lective cholesterol-absorption inhibitors. Heart während der Schwangerschaft und Stillperiode. Dis 2002; 4: 399-404. 1. Aufl. Thieme Verlag Stuttgart, New York, Sudhop T, Lutjohann D, Kodal A, et al. Inhibition 1982. of intestinal chlesterol absorption by ezetimibe Knoben JE, Anderson PO. Handbook of Clinical in humans. Circulation 2002; 106: 1943-8. Drug Data. 7th ed. Hamilton Press 1993; Ander- Cortisone - Kortison son P. Drug use during breastfeeding. Clin Pharm. 1991; 10: 596-624. Haynes RC, Murad F. Adrenocortical steroids. In: Briggs GG, Freeman RK, Yaffe SJ. (eds.). In: Goodman-Gilman A, et al. (eds.). The pharma- Drugs in pregnancy and lactation. Williams & cological basis of therapeutics. Macmillan, New Wilkins 1994. York, 1985. Sibai BM. Treatment of hypertension in pregnant Keenan GF. Management of complicications of women. N Engl J Med 1996; 335: 257-65. glucocorticoid therapy. Chest 1997; 18: 507-20. Cloherty JP, Stark AR 1997. Manual of neonatal McEvoy CE, Niewoehner DE. Adverse effects of care, 4th edn. Little, Brown & Co Boston. coricosteroid therapy for COPD. A critical re- Delaloye J-F, De Grandi P, Vial Y, Hohlfeld P. view. Chest 1997; 111: 732-43. (eds.). In: Médicaments, Grossesse et lactation. Israel E, Banerjee TR, Fitzmaurice GM , et al. Ef- Editions Médecine & Hygyène, Genève, 1997. fekt of inhaled glucocorticoids on bone densitiy Koren G, Pastuszak A, Ito S. Drugs in pregnancy. in premenopausal women. N Engl J Med 2001; N Engl J Med 1998; 338: 1128-37. 345: 941-7. Robinson JG, Farnier M, Krempf M, et al. Efficacy Midazolam 117 Shapiro BA, Warren J, Egol AB, et al. Practice Use of procalcitonin to shorten antibiotic treat- parameters for intravenous analgesia and seda- ment duration in septic patients : A randomized tion for adult patients in the intensive care unit: trial. Am J Respir Crit Care Med 2008; 177: an executive summary. Crit Care Med 1995; 23: 498-505. 1596-600. Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to anti- Cytochrome P450 - CYP 450 biotics in intensive care units (PRORATA trial): www.infomed.ch/pharma-kritik/pk21d-98.html a multicentre randomised controlled trial. Lan- www.hospitalist.net/highligh.htm cet 2010; 375: 463-74. Richelson E. Pharmacokinetic drug interactions of Schuetz P, Muller B, Christ-Crain M, et al. Procal- new antidepressants: a review of the effects on citonin to initiate or discontinue antibiotics in the metabolism of other drugs. Mayo Clin Proc acute respiratory tract infections. Cochrane Da- 1997; 72: 835-47. tabase Syst Rev 2012;9:CD007498. Michalets EL. Clinically significant cytochrome P- Luong Ba K, Harbarth S, Carballo S. Procalcito- 450 drug interactions. Pharmacotherapy 1998; nine: doser ou ne pas doser? Rev Med Suisse 18: 84-112. 2013; 9: 1881-5. Desmeules J, Bonnabry P, Dayer P. Hepatic me- Huang DT, Yealy DM, Filbin MR et al. Procalcito- tabolism of drugs. In: Bircher J, et al. (eds.). Ox- nin-Guided Use of Antibiotics for Lower Respi- ford textbook of clinical hepatology. Oxford ratory Tract Infection. NEJM 2018; 379:236-49. University Press, 1999. Oestreicher KM, Desmeules J, Piguet V, et al. In- Psychiatrie - Geriatrie teractions médicamenteuses: le rôle des cyto- chromes P450. Med Hyg 1999; 57: 793-800. Saisonale Depression (SAD) Obach RS. Inhibition of human cytochrome P450 Eastman CI, Young MA, Fogg LF, Liu L, Meaden enzymes by constituents of St-John’s Wort, an PM. Bright light treatment of winter depression: herbal preparation used in the treatment of de- a placebo-controlled trial. Arch Gen Psychiatry pression. J Pharmacol Exp Ther 2000; 294: 88- 1998; 55: 883-9. 95. Terman M, Terman JS. Controlled trial of naturali- Taketomo CK et al. Cytochrom P-450 enzymes stic dawn simulation and negative air ionization and drug metabolism. In: Pediatric dosage for seasonal affective disorder. Am J Psychiatry handbook. 8th edition 2001-2001: 1076-84. 2006; 163: 2126-33. Bonnabry P, Sievering J, Leemann T, et al. Quan- Lam RW, Levitan RD, Levitt AJ, et al. American titative drug interactions prediction system (Q- Psychiatric Association, 168th Annual Meeting, DIPS): a dynamic computer-based method to Toronto, Canada, May 2015. New research po- assist in the choice oc clinically relevant in vivo ster session 2, number 52. studies. Clin Pharmacokinet 2001; 40: 631-40. Ahya SN, Flood K, Paranjothi S. (eds.). The Wa- shington Manual of Medical Therapeutics. Lip- GYNÄKOLOGIE pincott Williams & Wilkins, 2001, p: 590-607. Compendium des produits et spécialités pharma- Präeklampsie ceutiques (CPS) 2003. American College of Obstetricians and Gynecolo- Bisphosphonates (cf. Ostéoporose) gists, Task Force on Hypertension in Preg- Watts NB, Harris ST, Genant HK, et al. Intermit- nancy. Hypertension in pregnancy. Report of tent cyclical etidronate treatment of postmeno- the American College of Obstetricians and Gy- pausal osteroporisis, N Engl J Med 1990; 323: necologists' Task Force on Hypertension in 73-9. Pregnancy. Obstet Gynecol 2013; 122: 1122- Miller PD, Watts NB, Licata AA, et al. Cyclical eti- 1131. dronate in the treatment of postmenopausal Tranquilli AL, Brown MA, Zeeman GG, Dekker G, osteopororis; efficacity and safety after 7 years Sibai BM: The definition of severe and early- of treatment. Am J Med 1997; 103: 468-76. onset preeclampsia. Statements from the Inter- Russel RFF. Rogers MG. Bisphosphonates: from national Society for the Study of Hypertension the laboratory to the clinic and back again. in Pregnancy (ISSHP). Pregnancy Hypertens Bone 1999; 25: 97-106. 2013; 3: 44-47. Tonino RP, Meunier PF, Emkey R, et al. Skeletal Tranquilli AL, Dekker G, Magee L, et al.: The clas- benefits of alendronate: 7-years treatment of sification, diagnosis and management of the hy- postmenopausal osteoporotic women. J Clin pertensive disorders of pregnancy: A revised Endocrinol Metabl 2000; 85: 3109-15. statement from the ISSHP. Pregnancy Hyper- tens 2014; 4: 97-104. Procalcitonine Stephan et al.: S1-Leitlinie Hypertensive Schwan- Christ-Crain M, Jaccard-Stolz D, Bingisser R, et gerschaftserkrankungen: Diagnostik und Thera- al. Effect of procalcitonin-guided treatment on pie. Deutsche Gesellschaft für Gynäkologie und antibiotic use and outcome in lower respiratory Geburtshilfe (DGGG). Stand: 1. Dezember tract infections : Cluster-randomised, single- 2013. blinded intervention trial. Lancet 2004; 363: Schäffer L. Präeklampsie: neue Definitionen. Pra- 600-7. xis 2018; 107: 1333-7. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Rolnik DL, Wright D, Poon LC, et al.: Aspirin ver- 118 sus placebo in pregnancies at high risk for pre- Rathore SS, Wang Y, Krumholz HM. Sex-based term preeclampsia. NEJM 2017; 377: 613-622. differences in the effect of digoxin for the treat- Brown MA, Magee LA, Kenny LC et al. on behalf ment of heart failure. N Engl J Med 2002; 347: of the International Society for the Study of Hy- 1403-11. pertension in Pregnancy (ISSHP). The hyper- Milrinone tensive disorders of pregnancy: ISSHP classification, diagnosis & management recom- Colucci WS, Wright RF, Jaski BE et al. Milrinone mendations for international practice. Hyperten- and dobutamine in severe heart failure: differing sion 2018; 72: 24-43. hemodynamic effects and induvidual patient responsiveness. Circulation 1986; 73: III 175-83. MEDICAMENTS - BREVIERE Mehra MR, Ventura HO, Kapoor C et al. Safety and clinical utility of long-term intravenous milri- NET: http://jml.georgetown.edu/jepts/pharmaco- none in advanced heart failure. Am J Cardiol logy 1997; 80: 61-4. Textbooks Packer M, Carver JR, Rodeheffer RJ et al. Effect Chernow B (ed). Essential of Critical Care Phar- of oral milrinone on mortality in severe chronic macology. Wiliams & Wilkins, 1989. heart failure. N Engl J Med 1988; 318: 358-75. Goodman & Gilman’s The Pharmacological basis Stevenson LW. Inotropic therapy for heart failure. of therapeutics. McGrawHill, 1997. N Engl J Med 1998; 339: 1848-50. Morant J, Ruppanner H, (eds.). Arzneimittel Kom- Yamani HM, Haji SA, Starling RC et al. Compari- pendium der Schweiz 2001. Documed 2002. son of dobutamine-based and milrinone-based Canadian Pharmacists Association. Compendium therapy for advanced decompensated conge- of pharmaceuticals and specialities - CPS 2002. stive heart failure: hemodynamic efficacy clini- Amiodarone cal outcome, and economic impact. Am Heart J Mason JW. Amiodarone. N Engl J Med 1987; 2001; 142: 998-1002. 316: 455-66. Hunt SA, Baker DW, Chin MH et al. ACC/AHA Martin WJ, Resenow EC. Amiodarone pulmonary guidelines for the evaluation and management toxicity. Recognition and pathogenesis (Part 1). of chronic heart failure in the adult. J Am Car- Chest 1988; 93: 1067-75. diol 2001; 38: 2101-13 (also in: Circulation Sunderji R, Kanji Z, Gin K. Pulmonary effects of 2001; 104: 2996-3007.) low dose amiodarone: a review of the risks and Midazolam recommendations for surveillance. Can J Car- Shapiro BA, Warren J, Egol AB, et al. Practice diol 2000; 16: 1435-40. parameters for intravenous analgesia and seda- Amlodipin tion for adult patients in the intensive care unit: Bhatia V, Mittal A, Parida A et al. Amlodipine indu- an executive summary. Crit Care Med 1995; 23: ced gingival hyperplasia: a rare entity. Int J Car- 1596-600. diol 2007; 122: 23-24. Vasopressine (ADH) Agratroban Argenziano M, Choudhri AF, Oz MC, et al. A pro- McKeage K, Polsker GL. Drugs 2001; 611: 515- spective randomized trial of arginine vasopres- 22; discussion 523-4. sin in the treatment of vasodilatory schock after left ventricular assist device placement. Cricula- Clopidogrel tion 1997; 96 (Suppl): II-286-90. A randomised, blinded, trial of clopidogrel versus Landry DW, Levin HR, Gallant EM, et al. Vaso- aspirin in patients at risk of ischaemic events pressin deficiency contributes to the vasodilata- (CAPRIE). CAPRIE Steering Committee. Lan- tion of septic schock. Circulation 1997; 95: cet 1996; 348: 1329-39. 1122-5. Sharis PJ, Cannon CP, Loscalzo J. The antiplate- Schrier RW, Cadnapaphornchai MA, Umenishi F. let effects of ticlopidine and clopidogrel. Ann In- Water-losing and water-retaining states: role of tern Med 1998; 129: 394-405. water channels and vasopressin receptor ant- Harding SA, Boon NA, Flapan AD. Antiplatelet agonist. Heart Dis 2001; 3: 210-4. treatment in unstable angina: aspirin, clopido- Annane D, Sebille V, Charpentier C, et al. Effect grel, glycoprotein IIb/IIIa, or all three? Heart of treatment with low doses of hydrocortisone 2002; 88 .11-4. and fludrocotisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71. Digoxine Chen P. Vasopressin: new uses in critical care. Smith TW. Digitalis: mecanisms of action and cli- Am J Sci 2002; 324: 146-54. nical use. N Engl J Med 1988; 318: 358-65. Patel BM, Chittock DR, Russel JA, et al. Benefi- The Digitalis Investigation Group. The efffect of cal effects of short-term vasopressin infusion digoxin on mortality and morbidity in patients during severe septic schock. Anesthesiology with heart failure. N Engl J Med 1997; 336: 525- 2002; 96: 576-82 33. Levi D, Kenchaiah S, Larson MG, et al. Long - INTOXICATIONS term trends in the incidence of and survival with heart faulure. N Engl J Med 2002; 347: 1397- - Centre anti-poison du Québec: Tél: 1-800-563- 1402. 5060; ou (418) 656-8090. 119 - Textbook: Tintinalli, Rothstein & Krome (ed.). multi-dose activated charcoal in the treatment Emergency medicine, a comprehensive study of acute poisoning. J Toxicol Clin Toxicol 1999; guide. 5th edition. 37: 731-51. - Bulletin toxicologique (avril 1999): Olson KR. (ed.). Posionning and drug overdoses. www.ctq.qc.ca/avril99.pdf 3rd edition. Appleton & Lange, Stanford CT Done AK. Salicylate intoxication: significance of 1999. salicylate in blood in cases of acute ingestion. Guidelines 2000 for cardiopulmonary Resuscita- Pediatrics 1960; 26: 800-7. tion and Emergency Cardiovascular Care. Part Rumack BH, Matthew H. Acetaminophen poiso- 8: advanced challengers in resuscitation section ning and toxicity. Pediatrics 1975; 55: 871-6. 2: Toxicology in ECC. Circulation 2000 ; 102 Rumack BH, Peterson RC, Koch GG, et al. Ace- (Suppl. 1): I223-8. taminophen overdose. 662 cases with evalua- Woo OF, Mueller PD, Olson KR, et al. Shorter du- tion of oral acetylcysteine treatment. Arch Intern ration of oral N-acetylcysteine therapy for acute Med 1981; 141: 380-5. acetaminophen overdose. Ann Emerg Med Cohen L, Kitzes R. Magnesium sulfate and digita- 2000; 35: 363-8. lis-toxic arrhythmias. JAMA 1983; 249: 2808-10. Lange RA, Hillis L. Cardiovascular complications Schwartz JA, Koenigsberg MD. Naloxone-indu- of cocaine use. N Engl J Med 2001; 345: 351-8. ced pulmonary edema. Ann Emerg Med 1987; Meier-Abt PJ, Kupferschmidt H. Dekontamination 16: 1294-6. und wichtigste Antidota. Schweiz Med Forum Maio RF, Gaukel B, Freeman B. Intralingual injec- 2001; 1: 402-5. tion for narcotic-induced respiratory depression. Albertson TE, Dawson A, de Latorre F, et al. Tox- Ann Emerg Med 1987; 16: 572-3. ACLS: Toxicologic-oriented advanced cardiac Smilkstein MJ, Knapp GL, Kulig KW, et al. Effi- life support. Ann Emerg Med 2001; 37 (4. cacy of oral N-acetylcysteine in the treatment of Suppl.): S78-90. acetaminophen overdose. Analysis of the natio- Wallace CI, Dargan PI, Jones AL. Paracetamol nal multicenter study (1976 to 1985). N Engl J overdose: an evidence based flowchart to guide Med 1988; 319: 1557-62. management. Emerg Med J 2002; 19: 202-5. Hollander JE. The management of cocaine-asso- Weber JE, Shofer FS, Larkin GL, et al. Validation ciated myocardial ischemia. N Engl J Med of a brief observation period for patients with 1995; 333: 1267-72. cocaine-associated chest pain. N Engl J Med Liebelt EL, Francis PD, Woolf AD. ECG lead aVR 2003; 348: 510-7. versus QRS interval in predicting seizures and Weaver LK, Valentine KJ, Hopkins RO. Carbon arrhythmias in acute tricyclic antidepressant to- Monoxide Poisoning. Risk Factors for Cognitive xicity. Ann Emerg Med 1995; 26: 195-201. Sequelae and the Role of Hyperbaric Oxygen. Thom SR, Taber RL, Mendiguren II, et al. De- Am J Respir Crit Care Med 2007 ; 176 : 491-7. layed neurological sequelae after carbon mon- Siegal DM, Curnutte JT, Connolly SJ, et al. Ande- oxide poisonning: prevention by treatment with xanet alfa for the reversal of factor Xa inhibitor hyperbaric oxygen. Ann of Emerg Med 1995; activity. N Engl J Med 2015; 373: 2413-2424. 25: 474-80. Kind B, Krähenbühl S, Wyss PA et al. Dosierung OPHTALMOLOGIE von N-Acetylcystein bei akuter Vergiftung mit Azuara-Blanco A, Burr J, Ramsay C et al.Effecti- Paracetamol. Schweiz Rdschau Med Praxis veness of early lens extraction for the treatment 1996; 85: 935-8. of primary angle-closure glaucoma (EAGLE): a Ellenhorn MJ. (ed.). Ellenhorn’s Medical Toxico- randomised controlled trial. Lancet 2016; logy. Williams & Wilkins, 1997. 388:1389-1397 Seyffart G. (ed.). Poison index. The treatment of acute intoxication. 4. Edition, Pabst science pu- Fahrzeiugfahreinigung blishers, 1997. Buser M, Christen St, Schär B et al. Fahreignung Goldfrank LR, et al. (eds.). Goldfranks’s Toxicolo- und kardiovaskuläre Erkrankungen: gemein- gic Emergencies. 6th edition, Appleton & same Richtlinien der Schweizerischen Gesell- Lange, Stanford 1998. schaft für Kardiologie und der Schweizerischen Hirsh J. Reversal of the anticoagulant effects of Gesellschaft für Rechtsmedizin. Cardiovasc warfarin by vitamin K1. Chest 1998; 114: 1505- Med. 2019;22:w02023 8.

Lekin JB, Palouceck FP. (eds.). Poisoning & Toxi-

cology Compendium. Lexi-Comp, Hudson OH 1998. American Academy of Clinical Toxicology (AACT), European Association of Poisons Centers and Clinical Toxicologists (EAPCCT): Position statements: gut decontamination. J Toxicol Clin Toxi- col 1997; 35: 695-762. American Academy of Clinical Toxicology (AACT), European Association of Poisons Centres and Clinical Toxicologists (EAPCCT): Position statements and practice guidelines on the use of 120